All our publications are maintained in a Zotero library. To request access, please click here.
Jump to year
Search all IeDEA publications
2775998
GXCKG69T
100
date
desc
toplevel
1
2023
2775998
GXCKG69T
2023
items
1
0
date
desc
https://www.iedea.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22instance%22%3A%22zotpress-c7bc851178afa477c8cea0dde2e7e005%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22SIC596PA%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dantuluri%20et%20al.%22%2C%22parsedDate%22%3A%222023-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDantuluri%2C%20M.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERubin%2C%20L.%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EManabe%2C%20Y.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMoore%2C%20R.%20D.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAlthoff%2C%20K.%20N.%3C%5C%2Fspan%3E%20%282023%29.%20Selection%20of%20cognitive%20impairment%20screening%20tools%20for%20longitudinal%20implementation%20in%20an%20HIV%20clinical%20care%20setting.%20%3Ci%3EAIDS%20Care%3C%5C%2Fi%3E%2C%20%3Ci%3E35%3C%5C%2Fi%3E%20%2810%29%2C%20S.%201619%26%23x2013%3B1627.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2023.2165614%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2023.2165614%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Selection%20of%20cognitive%20impairment%20screening%20tools%20for%20longitudinal%20implementation%20in%20an%20HIV%20clinical%20care%20setting%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Dantuluri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20H.%22%2C%22lastName%22%3A%22Rubin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20C.%22%2C%22lastName%22%3A%22Manabe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%5D%2C%22abstractNote%22%3A%22To%20address%20and%20slow%20the%20increasing%20burden%20of%20cognitive%20impairment%20in%20people%20surviving%20to%20older%20ages%20with%20HIV%20requires%20longitudinal%20monitoring%20of%20cognition.%20We%20conducted%20a%20structured%20literature%20review%20to%20identify%20peer-reviewed%20studies%20employing%20validated%20cognitive%20impairment%20screening%20tools%20in%20adult%20populations%20of%20people%20with%20HIV.%20We%20identified%20three%20key%20criteria%20for%20selection%20and%20ranking%20of%20a%20tool%3A%20%28a%29%20strength%20of%20validity%20of%20the%20tool%3B%20%28b%29%20acceptability%20and%20feasibility%20of%20the%20tool%3B%20%28c%29%20ownership%20of%20the%20data%20from%20the%20assessment.%20From%20our%20structured%20review%20of%20105%2C%2029%20studies%20met%20our%20inclusion%20criteria%2C%20within%20which%2010%20cognitive%20impairment%20screening%20measurement%20tools%20were%20validated%20in%20a%20population%20of%20people%20with%20HIV.%20The%20BRACE%2C%20NeuroScreen%20and%20NCAD%20tools%20were%20ranked%20highly%20when%20compared%20with%20the%20other%20seven%20tools.%20Additionally%2C%20patient%20population%20and%20clinical%20setting%20characteristics%20%28such%20as%20availability%20of%20quiet%20space%2C%20timing%20of%20assessment%2C%20security%20of%20electronic%20resources%2C%20and%20ease%20of%20linkage%20to%20electronic%20health%20records%29%20were%20included%20in%20our%20framework%20for%20selection%20of%20tools.%20Numerous%20validated%20cognitive%20impairment%20screening%20tools%20are%20available%20to%20monitor%20for%20cognitive%20changes%20in%20the%20HIV%20clinical%20care%20setting%2C%20detecting%20opportunities%20for%20earlier%20intervention%20to%20reduce%20cognitive%20decline%20and%20preserve%20quality%20of%20life.%22%2C%22date%22%3A%22Oct%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F09540121.2023.2165614%22%2C%22ISSN%22%3A%221360-0451%20%28Electronic%29%200954-0121%20%28Print%29%200954-0121%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A27%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22W2HVK3BT%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bocage%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBocage%2C%20A.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoelho%2C%20L.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELake%2C%20J.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EClark%2C%20J.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETorres%2C%20T.%20S.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20The%20Impact%20of%20COVID-19%20on%20HIV%20Care%20in%20Rio%20de%20Janeiro%2C%20Brazil%202019-2021%3A%20Disparities%20by%20Age%20and%20Gender.%20%3Ci%3EAIDS%20Behav%3C%5C%2Fi%3E%2C%20%3Ci%3E27%3C%5C%2Fi%3E%20%288%29%2C%20S.%202629%26%23x2013%3B2641.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-023-03988-3%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-023-03988-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Impact%20of%20COVID-19%20on%20HIV%20Care%20in%20Rio%20de%20Janeiro%2C%20Brazil%202019-2021%3A%20Disparities%20by%20Age%20and%20Gender%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20E.%22%2C%22lastName%22%3A%22Bocage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20E.%22%2C%22lastName%22%3A%22Coelho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Lake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Clark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20S.%22%2C%22lastName%22%3A%22Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20M.%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20W.%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20I.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%5D%2C%22abstractNote%22%3A%22We%20evaluated%20COVID-19%27s%20impact%20on%20HIV%20care%20indicators%20among%20INI%5C%2FFIOCRUZ%27s%20HIV%20Clinical%20Cohort%20in%20Rio%20de%20Janeiro%2C%20Brazil%3A%20%281%29%20Adequate%20care%20visits%3A%20two%20visits%20%3E%5C%2F%3D%2090%20days%20apart%3B%20%282%29%20Adequate%20viral%20load%20monitoring%3A%20%3E%5C%2F%3D%202%20viral%20load%20results%20%3E%5C%2F%3D%2090%20days%20apart%3B%20%283%29%20Consistent%20viral%20suppression%3A%20all%20viral%20loads%20%3C%2040%20copies%5C%2FmL%3B%20and%20%284%29%20ART%20medication%20possession%20ratio%20%28MPR%29%20%3E%5C%2F%3D%2095%25.%20Chi-square%20tests%20compared%20the%20fraction%20of%20participants%20meeting%20each%20indicator%20per%20period%3A%20pre-pandemic%20%283%5C%2F1%5C%2F2019-2%5C%2F29%5C%2F2020%29%20and%20post-pandemic%20%283%5C%2F1%5C%2F2020-2%5C%2F28%5C%2F2021%29.%20Logistic%20regression%20models%20were%20used%20to%20assess%20disparities%20in%20adequate%20care%20visits.%20Among%20906%20participants%2C%20care%20visits%20and%20viral%20load%20monitoring%20decreased%20pre-pandemic%20to%20post-pandemic%3A%2077.0-55.1%25%20and%2036.6-11.6%25%20%28both%20p%20%3C%200.001%29%2C%20respectively.%20The%20optimal%20MPR%20rate%20improved%20from%2025.5%20to%2040.0%25%20%28p%20%3C%200.001%29.%20Post-pandemic%20period%20%28aOR%200.33%2C%20CI%200.28-0.40%29%2C%20transgender%20women%20%28aOR%200.34%2C%20CI%200.22-0.53%29%2C%20and%20those%20aged%2018-24%20years%20%28aOR%200.67%2C%20CI%200.45-0.97%29%20had%20lower%20odds%20of%20adequate%20care%20visits.%20COVID-19%20disrupted%20care%20access%20disproportionately%20for%20transgender%20women%20and%20younger%20participants.%22%2C%22date%22%3A%22Aug%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10461-023-03988-3%22%2C%22ISSN%22%3A%221573-3254%20%28Electronic%29%201090-7165%20%28Print%29%201090-7165%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A49%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22FKSXKEEB%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhou%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-14%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZhou%2C%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBakoyannis%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZhang%2C%20Y.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYiannoutsos%2C%20C.%20T.%3C%5C%2Fspan%3E%20%282023%29.%20Semiparametric%20marginal%20regression%20for%20clustered%20competing%20risks%20data%20with%20missing%20cause%20of%20failure.%20%3Ci%3EBiostatistics%3C%5C%2Fi%3E%2C%20%3Ci%3E24%3C%5C%2Fi%3E%20%283%29%2C%20S.%20795%26%23x2013%3B810.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbiostatistics%5C%2Fkxac012%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbiostatistics%5C%2Fkxac012%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Semiparametric%20marginal%20regression%20for%20clustered%20competing%20risks%20data%20with%20missing%20cause%20of%20failure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Bakoyannis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%5D%2C%22abstractNote%22%3A%22Clustered%20competing%20risks%20data%20are%20commonly%20encountered%20in%20multicenter%20studies.%20The%20analysis%20of%20such%20data%20is%20often%20complicated%20due%20to%20informative%20cluster%20size%20%28ICS%29%2C%20a%20situation%20where%20the%20outcomes%20under%20study%20are%20associated%20with%20the%20size%20of%20the%20cluster.%20In%20addition%2C%20the%20cause%20of%20failure%20is%20frequently%20incompletely%20observed%20in%20real-world%20settings.%20To%20the%20best%20of%20our%20knowledge%2C%20there%20is%20no%20methodology%20for%20population-averaged%20analysis%20with%20clustered%20competing%20risks%20data%20with%20an%20ICS%20and%20missing%20causes%20of%20failure.%20To%20address%20this%20problem%2C%20we%20consider%20the%20semiparametric%20marginal%20proportional%20cause-specific%20hazards%20model%20and%20propose%20a%20maximum%20partial%20pseudolikelihood%20estimator%20under%20a%20missing%20at%20random%20assumption.%20To%20make%20the%20latter%20assumption%20more%20plausible%20in%20practice%2C%20we%20allow%20for%20auxiliary%20variables%20that%20may%20be%20related%20to%20the%20probability%20of%20missingness.%20The%20proposed%20method%20does%20not%20impose%20assumptions%20regarding%20the%20within-cluster%20dependence%20and%20allows%20for%20ICS.%20The%20asymptotic%20properties%20of%20the%20proposed%20estimators%20for%20both%20regression%20coefficients%20and%20infinite-dimensional%20parameters%2C%20such%20as%20the%20marginal%20cumulative%20incidence%20functions%2C%20are%20rigorously%20established.%20Simulation%20studies%20show%20that%20the%20proposed%20method%20performs%20well%20and%20that%20methods%20that%20ignore%20the%20within-cluster%20dependence%20and%20the%20ICS%20lead%20to%20invalid%20inferences.%20The%20proposed%20method%20is%20applied%20to%20competing%20risks%20data%20from%20a%20large%20multicenter%20HIV%20study%20in%20sub-Saharan%20Africa%20where%20a%20significant%20portion%20of%20causes%20of%20failure%20is%20missing.%22%2C%22date%22%3A%22Jul%2014%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fbiostatistics%5C%2Fkxac012%22%2C%22ISSN%22%3A%221468-4357%20%28Electronic%29%201465-4644%20%28Print%29%201465-4644%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A27%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22T3Z9FQFK%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Siedentop%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESiedentop%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKachalov%2C%20V.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWitzany%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEgger%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKouyos%2C%20R.%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20The%20effect%20of%20combining%20antibiotics%20on%20resistance%3A%20A%20systematic%20review%20and%20meta-analysis.%20%3Ci%3EMedRxiv%3C%5C%2Fi%3E%2C%20S.%202023.07.10.23292374.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2023.07.10.23292374%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2023.07.10.23292374%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20effect%20of%20combining%20antibiotics%20on%20resistance%3A%20A%20systematic%20review%20and%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Siedentop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20N.%22%2C%22lastName%22%3A%22Kachalov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Witzany%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Kouyos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bonhoeffer%22%7D%5D%2C%22abstractNote%22%3A%22When%20and%20under%20which%20conditions%20antibiotic%20combination%20therapy%20decelerates%20rather%20than%20accelerates%20resistance%20evolution%20is%20not%20well%20understood.%20We%20examined%20the%20effect%20of%20combining%20antibiotics%20on%20within-patient%20resistance%20development%20across%20various%20bacterial%20pathogens%20and%20antibiotics.%20We%20searched%20CENTRAL%2C%20EMBASE%20and%20PubMed%20for%20%28quasi%29-randomised%20controlled%20trials%20%28RCTs%29%20published%20from%20database%20inception%20to%20November%2024%20%28th%29%20%2C%202022.%20Trials%20comparing%20antibiotic%20treatments%20with%20different%20numbers%20of%20antibiotics%20were%20included.%20A%20patient%20was%20considered%20to%20have%20acquired%20resistance%20if%2C%20at%20the%20follow-up%20culture%2C%20a%20resistant%20bacterium%20was%20detected%20that%20had%20not%20been%20present%20in%20the%20baseline%20culture.%20We%20combined%20results%20using%20a%20random%20effects%20model%20and%20performed%20meta-regression%20and%20stratified%20analyses.%20The%20trials%27%20risk%20of%20bias%20was%20assessed%20with%20the%20Cochrane%20tool.%2042%20trials%20were%20eligible%20and%2029%2C%20including%205054%20patients%2C%20were%20qualified%20for%20statistical%20analysis.%20In%20most%20trials%2C%20resistance%20development%20was%20not%20the%20primary%20outcome%20and%20studies%20lacked%20power.%20The%20combined%20odds%20ratio%20%28OR%29%20for%20the%20acquisition%20of%20resistance%20comparing%20the%20group%20with%20the%20higher%20number%20of%20antibiotics%20with%20the%20comparison%20group%20was%201.23%20%2895%25%20CI%200.68-2.25%29%2C%20with%20substantial%20between-study%20heterogeneity%20%28%20I%20%282%29%20%3D77%25%29.%20We%20identified%20tentative%20evidence%20for%20potential%20beneficial%20or%20detrimental%20effects%20of%20antibiotic%20combination%20therapy%20for%20specific%20pathogens%20or%20medical%20conditions.%20The%20evidence%20for%20combining%20a%20higher%20number%20of%20antibiotics%20compared%20to%20fewer%20from%20RCTs%20is%20scarce%20and%20overall%2C%20is%20compatible%20with%20both%20benefit%20or%20harm.%20Trials%20powered%20to%20detect%20differences%20in%20resistance%20development%20or%20well-designed%20observational%20studies%20are%20required%20to%20clarify%20the%20impact%20of%20combination%20therapy%20on%20resistance.%20SIGNIFICANCE%20STATEMENT%3A%20Antimicrobial%20resistance%20is%20a%20threat%20to%20human%20health.%20Antibiotic%20combinations%20potentially%20reduce%20resistance.%20However%2C%20conflicting%20data%20exists%20on%20its%20effectiveness.%20To%20test%20the%20effect%20of%20antibiotic%20combination%20therapy%20on%20resistance%2C%20we%20conducted%20a%20meta-analysis%20of%20clinical%20evidence%2C%20comparing%20higher%20and%20lower%20numbers%20of%20antibiotics%20across%20various%20bacterial%20infections%20and%20antibiotic%20combinations.%20We%20update%20and%20expand%20on%20previous%20work%20that%20focused%20on%20specific%20infections%20and%20antibiotic%20combinations.%20Overall%2C%20we%20found%20no%20statistical%20evidence%20for%20a%20difference%20in%20the%20risk%20of%20resistance%20acquisition%20due%20to%20lack%20of%20power.%20Thus%2C%20despite%20the%20increasing%20threat%20of%20antibiotic%20resistance%2C%20it%20remains%20unresolved%20whether%20combination%20therapy%20de-%20or%20accelerates%20resistance%20evolution%20of%20bacterial%20pathogens%20beyond%20the%20well-known%20conditions%20where%20combination%20therapy%20is%20the%20standard%20of%20care.%22%2C%22date%22%3A%22Jul%2012%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2023.07.10.23292374%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A30%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22GGX2LKGQ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thomadakis%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EThomadakis%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYiannoutsos%2C%20C.%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPantazis%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDiero%2C%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMwangi%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20The%20Effect%20of%20HIV%20Treatment%20Interruption%20on%20Subsequent%20Immunological%20Response.%20%3Ci%3EAm%20J%20Epidemiol%3C%5C%2Fi%3E%2C%20%3Ci%3E192%3C%5C%2Fi%3E%20%287%29%2C%20S.%201181%26%23x2013%3B1191.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwad076%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwad076%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Effect%20of%20HIV%20Treatment%20Interruption%20on%20Subsequent%20Immunological%20Response%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Thomadakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Pantazis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mwangi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20S.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Touloumi%22%7D%5D%2C%22abstractNote%22%3A%22Recovery%20of%20CD4-positive%20T%20lymphocyte%20count%20after%20initiation%20of%20antiretroviral%20therapy%20%28ART%29%20has%20been%20thoroughly%20examined%20among%20people%20with%20human%20immunodeficiency%20virus%20infection.%20However%2C%20immunological%20response%20after%20restart%20of%20ART%20following%20care%20interruption%20is%20less%20well%20studied.%20We%20compared%20CD4%20cell-count%20trends%20before%20disengagement%20from%20care%20and%20after%20ART%20reinitiation.%20Data%20were%20obtained%20from%20the%20East%20Africa%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Collaboration%20%282001-2011%3B%20n%20%3D%2062%2C534%29.%20CD4%20cell-count%20trends%20before%20disengagement%2C%20during%20disengagement%2C%20and%20after%20ART%20reinitiation%20were%20simultaneously%20estimated%20through%20a%20linear%20mixed%20model%20with%202%20subject-specific%20knots%20placed%20at%20the%20times%20of%20disengagement%20and%20treatment%20reinitiation.%20We%20also%20estimated%20CD4%20trends%20conditional%20on%20the%20baseline%20CD4%20value.%20A%20total%20of%2010%2C961%20patients%20returned%20to%20care%20after%20disengagement%20from%20care%2C%20with%20the%20median%20gap%20in%20care%20being%202.7%20%28interquartile%20range%2C%202.1-5.4%29%20months.%20Our%20model%20showed%20that%20CD4%20cell-count%20increases%20after%20ART%20reinitiation%20were%20much%20slower%20than%20those%20before%20disengagement.%20Assuming%20that%20disengagement%20from%20care%20occurred%2012%20months%20after%20ART%20initiation%20and%20a%203-month%20treatment%20gap%2C%20CD4%20counts%20measured%20at%203%20years%20since%20ART%20initiation%20would%20be%20lower%20by%2036.5%20cells%5C%2FmuL%20than%20those%20obtained%20under%20no%20disengagement.%20Given%20that%20poorer%20CD4%20restoration%20is%20associated%20with%20increased%20mortality%5C%2Fmorbidity%2C%20specific%20interventions%20targeted%20at%20better%20retention%20in%20care%20are%20urgently%20required.%22%2C%22date%22%3A%22Jul%207%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Faje%5C%2Fkwad076%22%2C%22ISSN%22%3A%221476-6256%20%28Electronic%29%200002-9262%20%28Print%29%200002-9262%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A30%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22QAUT66D2%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ingle%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIngle%2C%20S.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMiro%2C%20J.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMay%2C%20M.%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECain%2C%20L.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESchwimmer%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Early%20Antiretroviral%20Therapy%20Not%20Associated%20With%20Higher%20Cryptococcal%20Meningitis%20Mortality%20in%20People%20With%20Human%20Immunodeficiency%20Virus%20in%20High-Income%20Countries%3A%20An%20International%20Collaborative%20Cohort%20Study.%20%3Ci%3EClin%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E77%3C%5C%2Fi%3E%20%281%29%2C%20S.%2064%26%23x2013%3B73.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad122%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad122%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Early%20Antiretroviral%20Therapy%20Not%20Associated%20With%20Higher%20Cryptococcal%20Meningitis%20Mortality%20in%20People%20With%20Human%20Immunodeficiency%20Virus%20in%20High-Income%20Countries%3A%20An%20International%20Collaborative%20Cohort%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20M.%22%2C%22lastName%22%3A%22Ingle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Miro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20T.%22%2C%22lastName%22%3A%22May%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20E.%22%2C%22lastName%22%3A%22Cain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Schwimmer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Zangerle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Sambatakou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cazanave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Reiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Brandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20C.%22%2C%22lastName%22%3A%22Bucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Sabin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Vidal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Obel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mocroft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Wittkop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22d%27Arminio%20Monforte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Torti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Mussini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Furrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Konopnicki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Teira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20S.%22%2C%22lastName%22%3A%22Saag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20M.%22%2C%22lastName%22%3A%22Crane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Jacobson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20C.%22%2C%22lastName%22%3A%22Mathews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Geng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Eron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kroch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%20C.%22%2C%22lastName%22%3A%22Sterne%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Randomized%20controlled%20trials%20%28RCTs%29%20from%20low-%20and%20middle-income%20settings%20suggested%20that%20early%20initiation%20of%20antiretroviral%20therapy%20%28ART%29%20leads%20to%20higher%20mortality%20rates%20among%20people%20with%20HIV%20%28PWH%29%20who%20present%20with%20cryptococcal%20meningitis%20%28CM%29.%20There%20is%20limited%20information%20about%20the%20impact%20of%20ART%20timing%20on%20mortality%20rates%20in%20similar%20people%20in%20high-income%20settings.%20METHODS%3A%20Data%20on%20ART-naive%20PWH%20with%20CM%20diagnosed%20from%201994%20to%202012%20from%20Europe%5C%2FNorth%20America%20were%20pooled%20from%20the%20COHERE%2C%20NA-ACCORD%2C%20and%20CNICS%20HIV%20cohort%20collaborations.%20Follow-up%20was%20considered%20to%20span%20from%20the%20date%20of%20CM%20diagnosis%20to%20earliest%20of%20the%20following%3A%20death%2C%20last%20follow-up%2C%20or%206%20months.%20We%20used%20marginal%20structural%20models%20to%20mimic%20an%20RCT%20comparing%20the%20effects%20of%20early%20%28within%2014%20days%20of%20CM%29%20and%20late%20%2814-56%20days%20after%20CM%29%20ART%20on%20all-cause%20mortality%2C%20adjusting%20for%20potential%20confounders.%20RESULTS%3A%20Of%20190%20participants%20identified%2C%2033%20%2817%25%29%20died%20within%206%20months.%20At%20CM%20diagnosis%2C%20their%20median%20age%20%28interquartile%20range%29%20was%2038%20%2833-44%29%20years%3B%20the%20median%20CD4%2B%20T-cell%20count%2C%2019%5C%2FmuL%20%2810-56%5C%2FmuL%29%3B%20and%20median%20HIV%20viral%20load%2C%205.3%20%284.9-5.6%29%20log10%20copies%5C%2FmL.%20Most%20participants%20%28n%20%3D%20157%20%5B83%25%5D%29%20were%20male%2C%20and%20145%20%2876%25%29%20started%20ART.%20Mimicking%20an%20RCT%2C%20with%20190%20people%20in%20each%20group%2C%20there%20were%2013%20deaths%20among%20participants%20with%20an%20early%20ART%20regimen%20and%2020%20deaths%20among%20those%20with%20a%20late%20ART%20regimen.%20The%20crude%20and%20adjusted%20hazard%20ratios%20comparing%20late%20with%20early%20ART%20were%201.28%20%2895%25%20confidence%20interval%2C%20.64-2.56%29%20and%201.40%20%28.66-2.95%29%2C%20respectively.%20CONCLUSIONS%3A%20We%20found%20little%20evidence%20that%20early%20ART%20was%20associated%20with%20higher%20mortality%20rates%20among%20PWH%20presenting%20with%20CM%20in%20high-income%20settings%2C%20although%20confidence%20intervals%20were%20wide.%22%2C%22date%22%3A%22Jul%205%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad122%22%2C%22ISSN%22%3A%221537-6591%20%28Electronic%29%201058-4838%20%28Print%29%201058-4838%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22RS75ZUAW%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marincowitz%20et%20al.%22%2C%22parsedDate%22%3A%222023-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarincowitz%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESbaffi%2C%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHasan%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHodkinson%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcAlpine%2C%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20External%20validation%20of%20triage%20tools%20for%20adults%20with%20suspected%20COVID-19%20in%20a%20middle-income%20setting%3A%20an%20observational%20cohort%20study.%20%3Ci%3EEmerg%20Med%20J%3C%5C%2Fi%3E%2C%20%3Ci%3E40%3C%5C%2Fi%3E%20%287%29%2C%20S.%20509%26%23x2013%3B517.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Femermed-2022-212827%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Femermed-2022-212827%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22External%20validation%20of%20triage%20tools%20for%20adults%20with%20suspected%20COVID-19%20in%20a%20middle-income%20setting%3A%20an%20observational%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Marincowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Sbaffi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Hasan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Hodkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22McAlpine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Fuller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Goodacre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20A.%22%2C%22lastName%22%3A%22Bath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Omer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Wallis%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tools%20proposed%20to%20triage%20ED%20acuity%20in%20suspected%20COVID-19%20were%20derived%20and%20validated%20in%20higher%20income%20settings%20during%20early%20waves%20of%20the%20pandemic.%20We%20estimated%20the%20accuracy%20of%20seven%20risk-stratification%20tools%20recommended%20to%20predict%20severe%20illness%20in%20the%20Western%20Cape%2C%20South%20Africa.%20METHODS%3A%20An%20observational%20cohort%20study%20using%20routinely%20collected%20data%20from%20EDs%20across%20the%20Western%20Cape%2C%20from%2027%20August%202020%20to%2011%20March%202022%2C%20was%20conducted%20to%20assess%20the%20performance%20of%20the%20PRIEST%20%28Pandemic%20Respiratory%20Infection%20Emergency%20System%20Triage%29%20tool%2C%20NEWS2%20%28National%20Early%20Warning%20Score%2C%20version%202%29%2C%20TEWS%20%28Triage%20Early%20Warning%20Score%29%2C%20the%20WHO%20algorithm%2C%20CRB-65%2C%20Quick%20COVID-19%20Severity%20Index%20and%20PMEWS%20%28Pandemic%20Medical%20Early%20Warning%20Score%29%20in%20suspected%20COVID-19.%20The%20primary%20outcome%20was%20intubation%20or%20non-invasive%20ventilation%2C%20death%20or%20intensive%20care%20unit%20admission%20at%2030%20days.%20RESULTS%3A%20Of%20the%20446%20084%20patients%2C%2015%20397%20%283.45%25%2C%2095%25%20CI%2034%25%20to%2035.1%25%29%20experienced%20the%20primary%20outcome.%20Clinical%20decision-making%20for%20inpatient%20admission%20achieved%20a%20sensitivity%20of%200.77%20%2895%25%20CI%200.76%20to%200.78%29%2C%20specificity%20of%200.88%20%2895%25%20CI%200.87%20to%200.88%29%20and%20the%20negative%20predictive%20value%20%28NPV%29%20of%200.99%20%2895%25%20CI%200.99%20to%200.99%29.%20NEWS2%2C%20PMEWS%20and%20PRIEST%20scores%20achieved%20good%20estimated%20discrimination%20%28C-statistic%200.79%20to%200.82%29%20and%20identified%20patients%20at%20risk%20of%20adverse%20outcomes%20at%20recommended%20cut-offs%20with%20moderate%20sensitivity%20%28%3E0.8%29%20and%20specificity%20ranging%20from%200.41%20to%200.64.%20Use%20of%20the%20tools%20at%20recommended%20thresholds%20would%20have%20more%20than%20doubled%20admissions%2C%20with%20only%20a%200.01%25%20reduction%20in%20false%20negative%20triage.%20CONCLUSION%3A%20No%20risk%20score%20outperformed%20existing%20clinical%20decision-making%20in%20determining%20the%20need%20for%20inpatient%20admission%20based%20on%20prediction%20of%20the%20primary%20outcome%20in%20this%20setting.%20Use%20of%20the%20PRIEST%20score%20at%20a%20threshold%20of%20one%20point%20higher%20than%20the%20previously%20recommended%20best%20approximated%20existing%20clinical%20accuracy.%22%2C%22date%22%3A%22Jul%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Femermed-2022-212827%22%2C%22ISSN%22%3A%221472-0213%20%28Electronic%29%201472-0205%20%28Print%29%201472-0205%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A45%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22VGIYGH2M%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Person%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-16%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPerson%2C%20A.%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECrabtree-Ramirez%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKim%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVeloso%2C%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMaruri%2C%20F.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Cryptococcal%20Meningitis%20and%20Clinical%20Outcomes%20in%20Persons%20With%20Human%20Immunodeficiency%20Virus%3A%20A%20Global%20View.%20%3Ci%3EClin%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E76%3C%5C%2Fi%3E%20%2812%29%2C%20S.%202116%26%23x2013%3B2125.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad076%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad076%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cryptococcal%20Meningitis%20and%20Clinical%20Outcomes%20in%20Persons%20With%20Human%20Immunodeficiency%20Virus%3A%20A%20Global%20View%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20K.%22%2C%22lastName%22%3A%22Person%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22John%20Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Imran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Van%20Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Nalitya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Cryptococcal%20meningitis%20%28CM%29%20is%20a%20major%20cause%20of%20morbidity%20and%20mortality%20in%20persons%20with%20human%20immunodeficiency%20virus%20%28HIV%3B%20PWH%29.%20Little%20is%20known%20about%20CM%20outcomes%20and%20availability%20of%20diagnostic%20and%20treatment%20modalities%20globally.%20METHODS%3A%20In%20this%20retrospective%20cohort%20study%2C%20we%20investigated%20CM%20incidence%20and%20all-cause%20mortality%20in%20PWH%20in%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20cohort%20from%201996%20to%202017.%20We%20estimated%20incidence%20using%20quasi-Poisson%20models%20adjusted%20for%20sex%2C%20age%2C%20calendar%20year%2C%20CD4%20cell%20count%20%28CD4%29%2C%20and%20antiretroviral%20therapy%20%28ART%29%20status.%20Mortality%20after%20CM%20diagnosis%20was%20examined%20using%20multivariable%20Cox%20models.%20A%20site%20survey%20from%202017%20assessed%20availability%20of%20CM%20diagnostic%20and%20treatment%20modalities.%20RESULTS%3A%20Among%20518%20852%20PWH%2C%20there%20were%203857%20cases%20of%20CM%20with%20an%20estimated%20incidence%20of%201.54%20per%201000%20person-years.%20Mortality%20over%20a%20median%20of%202.6%20years%20of%20post-CM%20diagnosis%20follow-up%20was%2031.6%25%2C%20with%2029%25%20lost%20to%20follow-up.%20In%20total%2C%202478%20%2864%25%29%20were%20diagnosed%20with%20CM%20after%20ART%20start%20with%20a%20median%20of%20253%20days%20from%20ART%20start%20to%20CM%20diagnosis.%20Older%20age%20%28hazard%20%5BHR%5D%2C%201.31%20for%2050%20vs%2035%20years%29%2C%20lower%20CD4%20%28HR%2C%201.15%20for%20200%20vs%20350%20cells%5C%2Fmm3%29%2C%20and%20earlier%20year%20of%20CM%20diagnosis%20%28HR%2C%200.51%20for%202015%20vs%202000%29%20were%20associated%20with%20higher%20mortality.%20Of%2089%20sites%2C%2034%25%20reported%20access%20to%20amphotericin%20B%3B%2012%25%20had%20access%20to%20flucytosine.%20CONCLUSIONS%3A%20Mortality%20after%20CM%20diagnosis%20was%20high.%20A%20substantial%20portion%20of%20CM%20cases%20occurred%20after%20ART%20start%2C%20though%20incidence%20and%20mortality%20may%20be%20higher%20than%20reported%20due%20to%20ascertainment%20bias.%20Many%20sites%20lacked%20access%20to%20recommended%20CM%20treatment.%22%2C%22date%22%3A%22Jun%2016%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad076%22%2C%22ISSN%22%3A%221537-6591%20%28Electronic%29%201058-4838%20%28Print%29%201058-4838%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22D9WC3N3V%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22A3X487HE%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kubjane%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKubjane%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECornell%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOsman%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoulle%2C%20A.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJohnson%2C%20L.%20F.%3C%5C%2Fspan%3E%20%282023%29.%20Drivers%20of%20sex%20differences%20in%20the%20South%20African%20adult%20tuberculosis%20incidence%20and%20mortality%20trends%2C%201990-2019.%20%3Ci%3ESci%20Rep%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%20%281%29%2C%20S.%209487.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-36432-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-36432-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Drivers%20of%20sex%20differences%20in%20the%20South%20African%20adult%20tuberculosis%20incidence%20and%20mortality%20trends%2C%201990-2019%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kubjane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Osman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%5D%2C%22abstractNote%22%3A%22Males%20have%20higher%20tuberculosis%20incidence%20and%20mortality%20rates%20than%20females.%20This%20study%20aimed%20to%20assess%20how%20sex%20differences%20in%20tuberculosis%20incidence%20and%20mortality%20could%20be%20explained%20by%20sex%20differences%20in%20HIV%2C%20antiretroviral%20treatment%20%28ART%29%20uptake%2C%20smoking%2C%20alcohol%20abuse%2C%20undernutrition%2C%20diabetes%2C%20social%20contact%20rates%2C%20health-seeking%20patterns%2C%20and%20treatment%20discontinuation.%20We%20developed%20an%20age-sex-stratified%20dynamic%20tuberculosis%20transmission%20model%20and%20calibrated%20it%20to%20South%20African%20data.%20We%20estimated%20male-to-female%20%28M%3AF%29%20tuberculosis%20incidence%20and%20mortality%20ratios%2C%20the%20effect%20of%20the%20abovementioned%20factors%20on%20the%20M%3AF%20ratios%20and%20PAFs%20for%20the%20tuberculosis%20risk%20factors.%20Over%20the%20period%201990-2019%2C%20the%20M%3AF%20ratios%20for%20tuberculosis%20incidence%20and%20mortality%20rates%20persisted%20above%201.0%2C%20and%20the%20figures%20reached%201.70%20and%201.65%2C%20respectively%2C%20by%20the%20end%20of%202019.%20In%202019%2C%20HIV%20contributed%20greater%20increases%20in%20tuberculosis%20incidence%20among%20females%20than%20males%20%2854.5%25%20vs.%2045.6%25%29%3B%20however%2C%20females%20experienced%20more%20reductions%20due%20to%20ART%20than%20males%20%2838.3%25%20vs.%2017.5%25%29.%20PAFs%20for%20tuberculosis%20incidence%20due%20to%20alcohol%20abuse%2C%20smoking%2C%20and%20undernutrition%2C%20in%20men%20were%2051.4%25%2C%2029.5%25%2C%20and%2016.1%25%2C%20respectively%2C%20higher%20than%20females%20%2830.1%25%2C%2015.4%25%2C%20and%2010.7%25%2C%20respectively%29%3B%20the%20PAF%20due%20to%20diabetes%20was%20higher%20in%20females%20than%20males%20%2822.9%25%20vs.%2017.5%25%29.%20Lower%20health-seeking%20rates%20in%20males%20accounted%20for%20a%207%25%20higher%20mortality%20rate%20in%20men.%20The%20higher%20burden%20of%20tuberculosis%20in%20men%20highlights%20the%20need%20to%20improve%20men%27s%20access%20to%20routine%20screening%20and%20ensure%20earlier%20diagnosis.%20Sustained%20efforts%20in%20providing%20ART%20remain%20critical%20in%20reducing%20HIV-associated%20tuberculosis.%20Additional%20interventions%20to%20reduce%20alcohol%20abuse%20and%20tobacco%20smoking%20are%20also%20needed.%22%2C%22date%22%3A%22Jun%2010%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-023-36432-6%22%2C%22ISSN%22%3A%222045-2322%20%28Electronic%29%202045-2322%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A42%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22ZHPVL3IM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kassanjee%20et%20al.%22%2C%22parsedDate%22%3A%222023-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKassanjee%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavies%2C%20M.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENgwenya%2C%20O.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOsei-Yeboah%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJacobs%2C%20T.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20COVID-19%20among%20adults%20living%20with%20HIV%3A%20correlates%20of%20mortality%20among%20public%20sector%20healthcare%20users%20in%20Western%20Cape%2C%20South%20Africa.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E26%3C%5C%2Fi%3E%20%286%29%2C%20S.%20e26104.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26104%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26104%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22COVID-19%20among%20adults%20living%20with%20HIV%3A%20correlates%20of%20mortality%20among%20public%20sector%20healthcare%20users%20in%20Western%20Cape%2C%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Ngwenya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Osei-Yeboah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Jacobs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Morden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Timmerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Britz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mendelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Taljaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Riou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Tiffin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Zinyakatira%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20While%20a%20large%20proportion%20of%20people%20with%20HIV%20%28PWH%29%20have%20experienced%20SARS-CoV-2%20infections%2C%20there%20is%20uncertainty%20about%20the%20role%20of%20HIV%20disease%20severity%20on%20COVID-19%20outcomes%2C%20especially%20in%20lower-income%20settings.%20We%20studied%20the%20association%20of%20mortality%20with%20characteristics%20of%20HIV%20severity%20and%20management%2C%20and%20vaccination%2C%20among%20adult%20PWH.%20METHODS%3A%20We%20analysed%20observational%20cohort%20data%20on%20all%20PWH%20aged%20%3E%5C%2F%3D15%20years%20experiencing%20a%20diagnosed%20SARS-CoV-2%20infection%20%28until%20March%202022%29%2C%20who%20accessed%20public%20sector%20healthcare%20in%20the%20Western%20Cape%20province%20of%20South%20Africa.%20Logistic%20regression%20was%20used%20to%20study%20the%20association%20of%20mortality%20with%20evidence%20of%20antiretroviral%20therapy%20%28ART%29%20collection%2C%20time%20since%20first%20HIV%20evidence%2C%20CD4%20cell%20count%2C%20viral%20load%20%28among%20those%20with%20evidence%20of%20ART%20collection%29%20and%20COVID-19%20vaccination%2C%20adjusting%20for%20demographic%20characteristics%2C%20comorbidities%2C%20admission%20pressure%2C%20location%20and%20time%20period.%20RESULTS%3A%20Mortality%20occurred%20in%205.7%25%20%2895%25%20CI%3A%205.3%2C6.0%29%20of%2017%2C831%20first-diagnosed%20infections.%20Higher%20mortality%20was%20associated%20with%20lower%20recent%20CD4%2C%20no%20evidence%20of%20ART%20collection%2C%20high%20or%20unknown%20recent%20viral%20load%20and%20recent%20first%20HIV%20evidence%2C%20differentially%20by%20age.%20Vaccination%20was%20protective.%20The%20burden%20of%20comorbidities%20was%20high%2C%20and%20tuberculosis%20%28especially%20more%20recent%20episodes%20of%20tuberculosis%29%2C%20chronic%20kidney%20disease%2C%20diabetes%20and%20hypertension%20were%20associated%20with%20higher%20mortality%2C%20more%20strongly%20in%20younger%20adults.%20CONCLUSIONS%3A%20Mortality%20was%20strongly%20associated%20with%20suboptimal%20HIV%20control%2C%20and%20the%20prevalence%20of%20these%20risk%20factors%20increased%20in%20later%20COVID-19%20waves.%20It%20remains%20a%20public%20health%20priority%20to%20ensure%20PWH%20are%20on%20suppressive%20ART%20and%20vaccinated%2C%20and%20manage%20any%20disruptions%20in%20care%20that%20occurred%20during%20the%20pandemic.%20The%20diagnosis%20and%20management%20of%20comorbidities%2C%20including%20for%20tuberculosis%2C%20should%20be%20optimized.%22%2C%22date%22%3A%22Jun%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26104%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A36Z%22%7D%7D%2C%7B%22key%22%3A%227SE7PYQH%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lea%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-24%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELea%2C%20A.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELeyden%2C%20W.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESofrygin%2C%20O.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarafino%2C%20B.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESkarbinski%2C%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Human%20Immunodeficiency%20Virus%20Status%2C%20Tenofovir%20Exposure%2C%20and%20the%20Risk%20of%20Poor%20Coronavirus%20Disease%2019%20Outcomes%3A%20Real-World%20Analysis%20From%206%20United%20States%20Cohorts%20Before%20Vaccine%20Rollout.%20%3Ci%3EClin%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E76%3C%5C%2Fi%3E%20%2810%29%2C%20S.%201727%26%23x2013%3B1734.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad084%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad084%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Human%20Immunodeficiency%20Virus%20Status%2C%20Tenofovir%20Exposure%2C%20and%20the%20Risk%20of%20Poor%20Coronavirus%20Disease%2019%20Outcomes%3A%20Real-World%20Analysis%20From%206%20United%20States%20Cohorts%20Before%20Vaccine%20Rollout%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20N.%22%2C%22lastName%22%3A%22Lea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20A.%22%2C%22lastName%22%3A%22Leyden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Sofrygin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20J.%22%2C%22lastName%22%3A%22Marafino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Skarbinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Agil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Augenbraun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Benning%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Jefferson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Marconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20S.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20S.%22%2C%22lastName%22%3A%22Gordon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Bastarache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gangireddy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20B.%22%2C%22lastName%22%3A%22Coburn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20People%20with%20human%20immunodeficiency%20virus%20%28HIV%29%20%28PWH%29%20may%20be%20at%20increased%20risk%20for%20severe%20coronavirus%20disease%202019%20%28COVID-19%29%20outcomes.%20We%20examined%20HIV%20status%20and%20COVID-19%20severity%2C%20and%20whether%20tenofovir%2C%20used%20by%20PWH%20for%20HIV%20treatment%20and%20people%20without%20HIV%20%28PWoH%29%20for%20HIV%20prevention%2C%20was%20associated%20with%20protection.%20METHODS%3A%20Within%206%20cohorts%20of%20PWH%20and%20PWoH%20in%20the%20United%20States%2C%20we%20compared%20the%2090-day%20risk%20of%20any%20hospitalization%2C%20COVID-19%20hospitalization%2C%20and%20mechanical%20ventilation%20or%20death%20by%20HIV%20status%20and%20by%20prior%20exposure%20to%20tenofovir%2C%20among%20those%20with%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection%20between%201%20March%20and%2030%20November%202020.%20Adjusted%20risk%20ratios%20%28aRRs%29%20were%20estimated%20by%20targeted%20maximum%20likelihood%20estimation%2C%20with%20adjustment%20for%20demographics%2C%20cohort%2C%20smoking%2C%20body%20mass%20index%2C%20Charlson%20comorbidity%20index%2C%20calendar%20period%20of%20first%20infection%2C%20and%20CD4%20cell%20counts%20and%20HIV%20RNA%20levels%20%28in%20PWH%20only%29.%20RESULTS%3A%20Among%20PWH%20%28n%20%3D%201785%29%2C%2015%25%20were%20hospitalized%20for%20COVID-19%20and%205%25%20received%20mechanical%20ventilation%20or%20died%2C%20compared%20with%206%25%20and%202%25%2C%20respectively%2C%20for%20PWoH%20%28n%20%3D%20189%20351%29.%20Outcome%20prevalence%20was%20lower%20for%20PWH%20and%20PWoH%20with%20prior%20tenofovir%20use.%20In%20adjusted%20analyses%2C%20PWH%20were%20at%20increased%20risk%20compared%20with%20PWoH%20for%20any%20hospitalization%20%28aRR%2C%201.31%20%5B95%25%20confidence%20interval%2C%201.20-1.44%5D%29%2C%20COVID-19%20hospitalizations%20%281.29%20%5B1.15-1.45%5D%29%2C%20and%20mechanical%20ventilation%20or%20death%20%281.51%20%5B1.19-1.92%5D%29.%20Prior%20tenofovir%20use%20was%20associated%20with%20reduced%20hospitalizations%20among%20PWH%20%28aRR%2C%200.85%20%5B95%25%20confidence%20interval%2C%20.73-.99%5D%29%20and%20PWoH%20%280.71%20%5B.62-.81%5D%29.%20CONCLUSIONS%3A%20Before%20COVID-19%20vaccine%20availability%2C%20PWH%20were%20at%20greater%20risk%20for%20severe%20outcomes%20than%20PWoH.%20Tenofovir%20was%20associated%20with%20a%20significant%20reduction%20in%20clinical%20events%20for%20both%20PWH%20and%20PWoH.%22%2C%22date%22%3A%22May%2024%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad084%22%2C%22ISSN%22%3A%221537-6591%20%28Electronic%29%201058-4838%20%28Print%29%201058-4838%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A47%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22TTF9I5PE%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Banholzer%20et%20al.%22%2C%22parsedDate%22%3A%222023-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBanholzer%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZurcher%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJent%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBittel%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFurrer%2C%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20SARS-CoV-2%20transmission%20with%20and%20without%20mask%20wearing%20or%20air%20cleaners%20in%20schools%20in%20Switzerland%3A%20A%20modeling%20study%20of%20epidemiological%2C%20environmental%2C%20and%20molecular%20data.%20%3Ci%3EPLoS%20Med%3C%5C%2Fi%3E%2C%20%3Ci%3E20%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e1004226.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004226%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004226%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22SARS-CoV-2%20transmission%20with%20and%20without%20mask%20wearing%20or%20air%20cleaners%20in%20schools%20in%20Switzerland%3A%20A%20modeling%20study%20of%20epidemiological%2C%20environmental%2C%20and%20molecular%20data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Banholzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Zurcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Jent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Bittel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Furrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Hascher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Growing%20evidence%20suggests%20an%20important%20contribution%20of%20airborne%20transmission%20to%20the%20overall%20spread%20of%20Severe%20Acute%20Respiratory%20Syndrome%20Coronavirus%202%20%28SARS-CoV-2%29%2C%20in%20particular%20via%20smaller%20particles%20called%20aerosols.%20However%2C%20the%20contribution%20of%20school%20children%20to%20SARS-CoV-2%20transmission%20remains%20uncertain.%20The%20aim%20of%20this%20study%20was%20to%20assess%20transmission%20of%20airborne%20respiratory%20infections%20and%20the%20association%20with%20infection%20control%20measures%20in%20schools%20using%20a%20multiple-measurement%20approach.%20METHODS%20AND%20FINDINGS%3A%20We%20collected%20epidemiological%20%28cases%20of%20Coronavirus%20Disease%202019%20%28COVID-19%29%29%2C%20environmental%20%28CO2%2C%20aerosol%20and%20particle%20concentrations%29%2C%20and%20molecular%20data%20%28bioaerosol%20and%20saliva%20samples%29%20over%207%20weeks%20from%20January%20to%20March%202022%20%28Omicron%20wave%29%20in%202%20secondary%20schools%20%28n%20%3D%2090%2C%20average%2018%20students%5C%2Fclassroom%29%20in%20Switzerland.%20We%20analyzed%20changes%20in%20environmental%20and%20molecular%20characteristics%20between%20different%20study%20conditions%20%28no%20intervention%2C%20mask%20wearing%2C%20air%20cleaners%29.%20Analyses%20of%20environmental%20changes%20were%20adjusted%20for%20different%20ventilation%2C%20the%20number%20of%20students%20in%20class%2C%20school%20and%20weekday%20effects.%20We%20modeled%20disease%20transmission%20using%20a%20semi-mechanistic%20Bayesian%20hierarchical%20model%2C%20adjusting%20for%20absent%20students%20and%20community%20transmission.%20Molecular%20analysis%20of%20saliva%20%2821%5C%2F262%20positive%29%20and%20airborne%20samples%20%2810%5C%2F130%29%20detected%20SARS-CoV-2%20throughout%20the%20study%20%28weekly%20average%20viral%20concentration%200.6%20copies%5C%2FL%29%20and%20occasionally%20other%20respiratory%20viruses.%20Overall%20daily%20average%20CO2%20levels%20were%201%2C064%20%2B%5C%2F-%20232%20ppm%20%28%2B%5C%2F-%20standard%20deviation%29.%20Daily%20average%20aerosol%20number%20concentrations%20without%20interventions%20were%20177%20%2B%5C%2F-%20109%201%5C%2Fcm3%20and%20decreased%20by%2069%25%20%2895%25%20CrI%2042%25%20to%2086%25%29%20with%20mask%20mandates%20and%2039%25%20%2895%25%20CrI%204%25%20to%2069%25%29%20with%20air%20cleaners.%20Compared%20to%20no%20intervention%2C%20the%20transmission%20risk%20was%20lower%20with%20mask%20mandates%20%28adjusted%20odds%20ratio%200.19%2C%2095%25%20CrI%200.09%20to%200.38%29%20and%20comparable%20with%20air%20cleaners%20%281.00%2C%2095%25%20CrI%200.15%20to%206.51%29.%20Study%20limitations%20include%20possible%20confounding%20by%20period%20as%20the%20number%20of%20susceptible%20students%20declined%20over%20time.%20Furthermore%2C%20airborne%20detection%20of%20pathogens%20document%20exposure%20but%20not%20necessarily%20transmission.%20CONCLUSIONS%3A%20Molecular%20detection%20of%20airborne%20and%20human%20SARS-CoV-2%20indicated%20sustained%20transmission%20in%20schools.%20Mask%20mandates%20were%20associated%20with%20greater%20reductions%20in%20aerosol%20concentrations%20than%20air%20cleaners%20and%20with%20lower%20transmission.%20Our%20multiple-measurement%20approach%20could%20be%20used%20to%20continuously%20monitor%20transmission%20risk%20of%20respiratory%20infections%20and%20the%20effectiveness%20of%20infection%20control%20measures%20in%20schools%20and%20other%20congregate%20settings.%22%2C%22date%22%3A%22May%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pmed.1004226%22%2C%22ISSN%22%3A%221549-1676%20%28Electronic%29%201549-1277%20%28Print%29%201549-1277%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A35%3A48Z%22%7D%7D%2C%7B%22key%22%3A%224I6XHRSC%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nachega%20et%20al.%22%2C%22parsedDate%22%3A%222023-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENachega%2C%20J.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENsanzimana%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERawat%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWilson%2C%20L.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERosenthal%2C%20P.%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Advancing%20detection%20and%20response%20capacities%20for%20emerging%20and%20re-emerging%20pathogens%20in%20Africa.%20%3Ci%3ELancet%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E23%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e185%26%23x2013%3Be189.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2822%2900723-X%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2822%2900723-X%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Advancing%20detection%20and%20response%20capacities%20for%20emerging%20and%20re-emerging%20pathogens%20in%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20B.%22%2C%22lastName%22%3A%22Nachega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nsanzimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rawat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20J.%22%2C%22lastName%22%3A%22Rosenthal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Siedner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20K.%22%2C%22lastName%22%3A%22Varma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20H.%22%2C%22lastName%22%3A%22Kilmarx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mutesa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tanner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Binagwaho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Forrest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Mbala-Kingebeni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Muyembe-Tamfum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Ntoumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Zumla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22de%20Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20J.%22%2C%22lastName%22%3A%22Mills%22%7D%5D%2C%22abstractNote%22%3A%22Recurrent%20disease%20outbreaks%20caused%20by%20a%20range%20of%20emerging%20and%20resurging%20pathogens%20over%20the%20past%20decade%20reveal%20major%20gaps%20in%20public%20health%20preparedness%2C%20detection%2C%20and%20response%20systems%20in%20Africa.%20Underlying%20causes%20of%20recurrent%20disease%20outbreaks%20include%20inadequacies%20in%20the%20detection%20of%20new%20infectious%20disease%20outbreaks%20in%20the%20community%2C%20in%20rapid%20pathogen%20identification%2C%20and%20in%20proactive%20surveillance%20systems.%20In%20sub-Saharan%20Africa%2C%20where%2070%25%20of%20zoonotic%20outbreaks%20occur%2C%20there%20remains%20the%20perennial%20risk%20of%20outbreaks%20of%20new%20or%20re-emerging%20pathogens%20for%20which%20no%20vaccines%20or%20treatments%20are%20available.%20As%20the%20Ebola%20virus%20disease%2C%20COVID-19%2C%20and%20mpox%20%28formerly%20known%20as%20monkeypox%29%20outbreaks%20highlight%2C%20a%20major%20paradigm%20shift%20is%20required%20to%20establish%20an%20effective%20infrastructure%20and%20common%20frameworks%20for%20preparedness%20and%20to%20prompt%20national%20and%20regional%20public%20health%20responses%20to%20mitigate%20the%20effects%20of%20future%20pandemics%20in%20Africa.%22%2C%22date%22%3A%22May%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS1473-3099%2822%2900723-X%22%2C%22ISSN%22%3A%221474-4457%20%28Electronic%29%201473-3099%20%28Print%29%201473-3099%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A14%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22DBNA47PF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Murenzi%20et%20al.%22%2C%22parsedDate%22%3A%222023-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurenzi%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKim%2C%20H.%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShi%2C%20Q.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuhoza%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMunyaneza%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Association%20Between%20Time%20to%20Antiretroviral%20Therapy%20and%20Loss%20to%20Care%20Among%20Newly%20Diagnosed%20Rwandan%20People%20Living%20with%20Human%20Immunodeficiency%20Virus.%20%3Ci%3EAIDS%20Res%20Hum%20Retroviruses%3C%5C%2Fi%3E%2C%20%3Ci%3E39%3C%5C%2Fi%3E%20%285%29%2C%20S.%20253%26%23x2013%3B261.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2FAID.2022.0023%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2FAID.2022.0023%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20Between%20Time%20to%20Antiretroviral%20Therapy%20and%20Loss%20to%20Care%20Among%20Newly%20Diagnosed%20Rwandan%20People%20Living%20with%20Human%20Immunodeficiency%20Virus%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Y.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q.%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Muhoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Kubwimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Remera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nsanzimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20improved%20clinical%20outcomes%20of%20initiating%20antiretroviral%20therapy%20%28ART%29%20soon%20after%20diagnosis%2C%20conflicting%20evidence%20exists%20regarding%20the%20impact%20of%20same-day%20ART%20initiation%20on%20subsequent%20clinical%20outcomes.%20We%20aimed%20to%20characterize%20the%20associations%20of%20time%20to%20ART%20initiation%20with%20loss%20to%20care%20and%20viral%20suppression%20in%20a%20cohort%20of%20newly%20diagnosed%20people%20living%20with%20HIV%20%28PLHIV%29%20entering%20care%20after%20Rwanda%20implemented%20a%20national%20%5C%22Treat%20All%5C%22%20policy.%20We%20conducted%20a%20secondary%20analysis%20of%20routinely%20collected%20data%20of%20adult%20PLHIV%20enrolling%20in%20HIV%20care%20at%2010%20health%20facilities%20in%20Kigali%2C%20Rwanda.%20Time%20from%20enrollment%20to%20ART%20initiation%20was%20categorized%20as%20same%20day%2C%201-7%20days%2C%20or%20%3E7%20days.%20We%20examined%20associations%20between%20time%20to%20ART%20and%20loss%20to%20care%20%28%3E120%20days%20since%20last%20health%20facility%20visit%29%20using%20Cox%20proportional%20hazards%20models%2C%20and%20between%20time%20to%20ART%20and%20viral%20suppression%20using%20logistic%20regression.%20Of%202%2C524%20patients%20included%20in%20this%20analysis%2C%201%2C452%20%2857.5%25%29%20were%20women%20and%20the%20median%20age%20was%2032%20%28interquartile%20range%3A%2026-39%29.%20Loss%20to%20care%20was%20more%20frequent%20among%20patients%20who%20initiated%20ART%20on%20the%20same%20day%20%2815.9%25%29%2C%20compared%20with%20those%20initiating%20ART%201-7%20days%20%2812.3%25%29%20or%20%3E7%20days%20%2810.1%25%29%2C%20p%20%3C%20.001.%20In%20multivariable%20analyses%2C%20same-day%20ART%20initiation%20was%20associated%20with%20a%20greater%20hazard%20of%20loss%20to%20care%20compared%20with%20initiating%20%3E7%20days%20after%20enrollment%20%28adjusted%20hazard%20ratio%201.39%2C%2095%25%20confidence%20interval%3A%201.04-1.85%29.%20A%20total%20of%201%2C698%20%2867.3%25%29%20had%20available%20data%20on%20viral%20load%20measured%20within%20455%20days%20after%20enrollment.%20Of%20these%2C%201%2C476%20%2887%25%29%20were%20virally%20suppressed.%20A%20higher%20proportion%20of%20patients%20initiating%20ART%20on%20the%20same%20day%20were%20virally%20suppressed%20%2889%25%29%20compared%20with%20those%20initiating%201-7%20days%20%2884%25%29%20or%20%3E7%20days%20%2888%25%29%20after%20enrollment.%20This%20association%20was%20not%20statistically%20significant.%20Our%20findings%20suggest%20that%20ensuring%20adequate%2C%20early%20support%20for%20PLHIV%20initiating%20ART%20rapidly%20may%20be%20important%20to%20improve%20retention%20in%20care%20for%20newly%20diagnosed%20PLHIV%20in%20the%20era%20of%20Treat%20All.%22%2C%22date%22%3A%22May%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1089%5C%2FAID.2022.0023%22%2C%22ISSN%22%3A%221931-8405%20%28Electronic%29%200889-2229%20%28Print%29%200889-2229%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A16%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22UHLSUZVX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Admase%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-17%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAdmase%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJoshi%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBorse%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDeshpande%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKulkarni%2C%20V.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Challenges%20with%20the%20use%20of%20Xpert%20HPV%20as%20a%20screening%20tool%20for%20oral%20HPV%20among%20people%20living%20with%20HIV%20%28PLHIV%29%3A%20experiences%20from%20Pune%2C%20India.%20%3Ci%3EBMC%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E23%3C%5C%2Fi%3E%20%281%29%2C%20S.%20233.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-023-08210-2%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-023-08210-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Challenges%20with%20the%20use%20of%20Xpert%20HPV%20as%20a%20screening%20tool%20for%20oral%20HPV%20among%20people%20living%20with%20HIV%20%28PLHIV%29%3A%20experiences%20from%20Pune%2C%20India%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Admase%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Joshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Borse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Deshpande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Kulkarni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Thakur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Chavan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nimkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Mave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Marbaniang%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20People%20living%20with%20HIV%20%28PLHIV%29%20are%20at%20higher%20risk%20for%20human%20papillomavirus%20%28HPV%29-related%20oropharyngeal%20cancers%20compared%20to%20the%20general%20population.%20Xpert%20HPV%20test%20is%20a%20polymerase%20chain%20reaction%20%28PCR%29%20assay%20capable%20of%20rapid%20HPV%20detection.%20Performing%20the%20assay%20requires%20minimal%20intervention%20by%20laboratory%20personnel.%20Its%20use%20could%20improve%20oropharyngeal%20cancer%20screening%20among%20PLHIV%20living%20in%20low-and%20middle-income%20countries%20%28LMICs%29%20with%20limited%20diagnostic%20capacities.%20However%2C%20Xpert%20HPV%20performance%20for%20oral%20samples%20has%20not%20been%20evaluated.%20Here%2C%20we%20describe%20our%20experience%20with%20Xpert%20HPV%20and%20compare%20its%20results%20with%20traditional%20PCR%2C%20for%20oral%20samples.%20METHODS%3A%20Oral%20samples%20from%20429%20PLHIV%20receiving%20care%20at%20a%20tertiary%20care%20hospital%20affiliated%20antiretroviral%20therapy%20center%20in%20Pune%2C%20India%20were%20used.%20Samples%20were%20collected%20either%20after%20a%2030s%20oral%20rinse%20and%20gargle%20%28n%20%3D%20335%29%20or%20in%20combination%20with%20cytobrush%20scraping%20of%20the%20oral%20mucosa%20%28n%20%3D%2091%29.%20Unsuccessful%20tests%20were%20those%20that%20generated%20an%20invalid%20or%20error%20result%20on%20Xpert%20HPV.%20Successful%20tests%20were%20those%20that%20generated%20a%20positive%20or%20negative%20result.%20Kappa%20statistic%20was%20used%20to%20compare%20concordance%20between%20Xpert%20HPV%20and%20traditional%20real-time%20PCR%20results.%20RESULTS%3A%20There%20were%2029.8%25%20%28n%20%3D%20127%29%20unsuccessful%20tests%2C%20of%20which%2078.7%25%20%28n%20%3D%20100%29%20were%20invalid%20and%2021.3%25%20%28n%20%3D%2027%29%20were%20error%20results.%20Adding%20cytobrush%20scraping%20to%20oral%20rinse%20as%20a%20collection%20procedure%20did%20not%20significantly%20reduce%20the%20proportion%20of%20unsuccessful%20tests%20%28p%20%3D%200.9%29.%20For%20successful%20tests%2C%20HPV%20positivity%20on%20Xpert%20was%200.3%25%20%28n%20%3D%201%5C%2F299%29.%20Kappa%20statistic%20was%200.11%2C%20indicating%20poor%20agreement%20between%20Xpert%20HPV%20and%20traditional%20PCR%20results.%20CONCLUSIONS%3A%20Presently%2C%20Xpert%20HPV%20appears%20to%20have%20limited%20use%20for%20oral%20HPV%20detection%20among%20PLHIV%20using%20oral%20samples.%20More%20research%20to%20improve%20the%20diagnostic%20capabilities%20of%20Xpert%20HPV%20for%20oral%20samples%20among%20PLHIV%20is%20needed.%22%2C%22date%22%3A%22Apr%2017%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12879-023-08210-2%22%2C%22ISSN%22%3A%221471-2334%20%28Electronic%29%201471-2334%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A38%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22D5GI3MCT%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rajasuriar%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERajasuriar%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChong%2C%20M.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoss%2C%20J.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJiamsakul%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAvihingsanon%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Factors%20associated%20with%20reduced%20function%20and%20quality%20of%20life%20among%20adult%20people%20with%20HIV%20with%20depression%20and%20substance%20use%20in%20the%20Asia-Pacific%20region.%20%3Ci%3EAIDS%3C%5C%2Fi%3E%2C%20%3Ci%3E37%3C%5C%2Fi%3E%20%285%29%2C%20S.%20823%26%23x2013%3B835.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003474%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003474%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Factors%20associated%20with%20reduced%20function%20and%20quality%20of%20life%20among%20adult%20people%20with%20HIV%20with%20depression%20and%20substance%20use%20in%20the%20Asia-Pacific%20region%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Rajasuriar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Chong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ditangco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gatechompol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20I.%20E.%22%2C%22lastName%22%3A%22Melgar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20H.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stigma%20Depression%22%2C%22lastName%22%3A%22Substance%20use%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20Asia-Pacific%22%2C%22lastName%22%3A%22Disability%20study%20group%20of%20Ie%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Depression%20and%20substance%20use%20%28SU%29%20disorders%20are%20prevalent%20among%20people%20with%20HIV%20%28PWH%29%20and%20impact%20health%20outcomes%20despite%20successful%20antiretroviral%20therapy%20%28ART%29.%20We%20explored%20quality%20of%20life%2C%20functional%20ability%20and%20associated%20factors%20among%20PWH%20screened%20positive%20for%20depression%20and%5C%2For%20SU.%20METHODS%3A%20This%20cross-sectional%20study%20recruited%20adult%20PWH%20during%20routine%20follow-up%20at%20five%20HIV%20clinical%20sites%20in%20the%20Asia-Pacific%20region.%20Participants%20were%20screened%20for%20depression%20using%20Patient%20Health%20Questionnaire-9%20and%20SU%20using%20Alcohol%2C%20Smoking%2C%20and%20Substance%20Involvement%20Screening%20Test%20%28ASSIST%29.%20Quality%20of%20life%20%28QoL%29%20was%20assessed%20with%20WHOQOL-HIV%20BREF%20and%20functional%20ability%20with%20World%20Health%20Organization%20Disability%20Assessment%20Schedule%202.0%20%28WHODAS%202.0%29.%20Factors%20associated%20with%20mean%20QoL%20and%20disability%20scores%20were%20analysed%20using%20linear%20regression.%20RESULTS%3A%20Of%20864%20PWH%20enrolled%2C%20753%20screened%20positive%20for%20depression%20or%20SU.%20The%20median%20%28interquartile%20range%2C%20IQR%29%20age%20was%2038%20%2831-47%29%20years%20and%2097%25%20were%20on%20ART.%20Overall%20mean%20WHOQOL-HIV%20BREF%20and%20WHODAS%20scores%20indicated%20greater%20impairment%20with%20increasing%20depressive%20symptom%20severity%20and%20SU%20risk.%20In%20multivariate%20analysis%2C%20PWH%20reporting%20previous%20trauma%5C%2Fstress%20%28difference%20%3D%202.7%2C%2095%25%20confidence%20interval%20%5BCI%5D%201.5-3.9%2C%20P%20%3C%200.001%29%20and%20past%20mental%20health%20diagnosis%20%28difference%20%3D%205.0%2C%2095%25%20CI%202.9-7.1%2C%20P%20%3C%200.001%29%20were%20associated%20with%20greater%20disability%20and%20poorer%20QoL%20scores%20across%20multiple%20domains%20%28%20P%20%3C%200.01%20for%20all%29.%20Higher%20CD4%20T-cell%20counts%20was%20also%20associated%20with%20better%20QoL%20scores%20and%20functional%20ability.%20CONCLUSION%3A%20PWH%20with%20depression%5C%2FSU%20experienced%20poorer%20QoL%20and%20function%20despite%20routine%20engagement%20in%20HIV%20care.%20Efforts%20to%20integrate%20mental%20health%20services%20and%20interventions%20addressing%20disability%20into%20HIV%20management%20should%20be%20prioritized%20in%20the%20region.%22%2C%22date%22%3A%22Apr%201%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003474%22%2C%22ISSN%22%3A%221473-5571%20%28Electronic%29%200269-9370%20%28Print%29%200269-9370%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A45%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22MC2VDBK4%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Patten%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPatten%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESipambo%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETechnau%2C%20K.%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEuvrard%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFord%2C%20N.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Ongoing%20High%20Prevalence%20of%20Severe%20Immune%20Suppression%20Among%20Children%20in%20South%20Africa.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E92%3C%5C%2Fi%3E%20%284%29%2C%20S.%20273%26%23x2013%3B280.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003137%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003137%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ongoing%20High%20Prevalence%20of%20Severe%20Immune%20Suppression%20Among%20Children%20in%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Patten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Sipambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20G.%22%2C%22lastName%22%3A%22Technau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Among%20children%20in%20Southern%20Africa%20severe%20immune%20suppression%20%28SIS%29%20has%20declined%2C%20but%20most%20continue%20to%20initiate%20antiretroviral%20therapy%20%28ART%29%20with%20SIS.%20SETTING%3A%20Using%20data%20from%20South%20Africa%2C%20we%20describe%20SIS%20at%20ART%20start%20and%20on%20ART%20between%202007%20and%202020%2C%20among%20children%20%3C5%20years%20with%20a%20CD4%25%5C%2Fcell%20count%20at%20ART%20start%20and%20%3E%5C%2F%3D1%20subsequent%20measure.%20METHODS%3A%20Gap%20in%20care%20was%20defined%20as%20%3E9%20months%20without%20a%20recorded%20visit.%20We%20defined%20SIS%20according%20to%20age%20and%20CD4%25%5C%2Fcell%20count.%20A%20multistate%20model%20was%20used%20to%20estimate%20transition%20probabilities%20between%205%20states%3A%20SIS%20on%20ART%3B%20Stable%2C%20not%20SIS%3B%20Early%20Gap%2C%20commencing%20%3C9%20months%20from%20ART%20start%3B%20Late%20Gap%2C%20commencing%20%3E%5C%2F%3D9%20months%20on%20ART%3B%20and%20Death.%20RESULTS%3A%20Among%202536%20children%2C%2070%25%20had%20SIS%20at%20ART%20start%2C%20and%2036%25%20experienced%20SIS%20on%20ART.%20An%20increasing%20proportion%20were%20age%20%3C1%20year%20at%20ART%20initiation%20%282007-2009%3A%2043%25%20to%202013-2020%3A%2055%25%29.%20Increasingly%2C%20SIS%20on%20ART%20occurred%20after%20a%20gap%2C%20in%20those%20with%20SIS%20on%20ART%20for%20%3E1%20year%2C%20and%20after%20a%20period%20of%20unknown%20immune%20status.%20Later%20year%20of%20ART%20initiation%20was%20associated%20with%20reduced%20transition%20from%20SIS%20on%20ART%20to%20Stable.%20Infants%20and%20those%20initiating%20ART%20with%20SIS%20were%20more%20likely%20to%20transition%20from%20Stable%20to%20SIS.%20Viremia%20strongly%20predicted%20death%20from%20both%20the%20on%20ART%20states.%20CONCLUSIONS%3A%20Increasingly%20SIS%20occurred%20among%20ART-experienced%20children.%20Those%20starting%20ART%20with%20SIS%20and%20during%20infancy%20remained%20especially%20vulnerable%20to%20SIS%20once%20on%20treatment.%20Managing%20ART%20in%20these%20children%20may%20be%20more%20complex%20and%20further%20reducing%20AIDS-related%20mortality%20is%20likely%20to%20remain%20challenging.%22%2C%22date%22%3A%22Apr%201%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003137%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A35%3A24Z%22%7D%7D%2C%7B%22key%22%3A%2235XYKA8G%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zwyer%20et%20al.%22%2C%22parsedDate%22%3A%222023-04%22%2C%22numChildren%22%3A8%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZwyer%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERutaihwa%2C%20L.%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWindels%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHella%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMenardo%2C%20F.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Back-to-Africa%20introductions%20of%20Mycobacterium%20tuberculosis%20as%20the%20main%20cause%20of%20tuberculosis%20in%20Dar%20es%20Salaam%2C%20Tanzania.%20%3Ci%3EPLoS%20Pathog%3C%5C%2Fi%3E%2C%20%3Ci%3E19%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e1010893.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.ppat.1010893%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.ppat.1010893%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Back-to-Africa%20introductions%20of%20Mycobacterium%20tuberculosis%20as%20the%20main%20cause%20of%20tuberculosis%20in%20Dar%20es%20Salaam%2C%20Tanzania%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Zwyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20K.%22%2C%22lastName%22%3A%22Rutaihwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Windels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Hella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Menardo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Sasamalo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sommer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Schmulling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Borrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Reinhard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dotsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Hiza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Stritt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sikalengo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20C.%22%2C%22lastName%22%3A%22De%20Jong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kato-Maeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Jugheli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20D.%22%2C%22lastName%22%3A%22Ernst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Jeljeli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Rakotosamimanana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Yeboah-Manu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Asare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Malla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Y.%22%2C%22lastName%22%3A%22Dou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Zetola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20J.%22%2C%22lastName%22%3A%22Carter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Gnokoro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Abimiku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%20M.%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Fellay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Portevin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Reither%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Stadler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gagneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Brites%22%7D%5D%2C%22abstractNote%22%3A%22In%20settings%20with%20high%20tuberculosis%20%28TB%29%20endemicity%2C%20distinct%20genotypes%20of%20the%20Mycobacterium%20tuberculosis%20complex%20%28MTBC%29%20often%20differ%20in%20prevalence.%20However%2C%20the%20factors%20leading%20to%20these%20differences%20remain%20poorly%20understood.%20Here%20we%20studied%20the%20MTBC%20population%20in%20Dar%20es%20Salaam%2C%20Tanzania%20over%20a%20six-year%20period%2C%20using%201%2C082%20unique%20patient-derived%20MTBC%20whole-genome%20sequences%20%28WGS%29%20and%20associated%20clinical%20data.%20We%20show%20that%20the%20TB%20epidemic%20in%20Dar%20es%20Salaam%20is%20dominated%20by%20multiple%20MTBC%20genotypes%20introduced%20to%20Tanzania%20from%20different%20parts%20of%20the%20world%20during%20the%20last%20300%20years.%20The%20most%20common%20MTBC%20genotypes%20deriving%20from%20these%20introductions%20exhibited%20differences%20in%20transmission%20rates%20and%20in%20the%20duration%20of%20the%20infectious%20period%2C%20but%20little%20differences%20in%20overall%20fitness%2C%20as%20measured%20by%20the%20effective%20reproductive%20number.%20Moreover%2C%20measures%20of%20disease%20severity%20and%20bacterial%20load%20indicated%20no%20differences%20in%20virulence%20between%20these%20genotypes%20during%20active%20TB.%20Instead%2C%20the%20combination%20of%20an%20early%20introduction%20and%20a%20high%20transmission%20rate%20accounted%20for%20the%20high%20prevalence%20of%20L3.1.1%2C%20the%20most%20dominant%20MTBC%20genotype%20in%20this%20setting.%20Yet%2C%20a%20longer%20co-existence%20with%20the%20host%20population%20did%20not%20always%20result%20in%20a%20higher%20transmission%20rate%2C%20suggesting%20that%20distinct%20life-history%20traits%20have%20evolved%20in%20the%20different%20MTBC%20genotypes.%20Taken%20together%2C%20our%20results%20point%20to%20bacterial%20factors%20as%20important%20determinants%20of%20the%20TB%20epidemic%20in%20Dar%20es%20Salaam.%22%2C%22date%22%3A%22Apr%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.ppat.1010893%22%2C%22ISSN%22%3A%221553-7374%20%28Electronic%29%201553-7366%20%28Print%29%201553-7366%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A42%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22BP3RAY4M%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lu%20et%20al.%22%2C%22parsedDate%22%3A%222023-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELu%2C%20X.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWang%2C%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBandyopadhyay%2C%20D.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBakoyannis%2C%20G.%3C%5C%2Fspan%3E%20%282023%29.%20Sieve%20estimation%20of%20a%20class%20of%20partially%20linear%20transformation%20models%20with%20interval-censored%20competing%20risks%20data.%20%3Ci%3EStat%20Sin%3C%5C%2Fi%3E%2C%20%3Ci%3E33%3C%5C%2Fi%3E%20%282%29%2C%20S.%20685%26%23x2013%3B704.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5705%5C%2Fss.202021.0051%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5705%5C%2Fss.202021.0051%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sieve%20estimation%20of%20a%20class%20of%20partially%20linear%20transformation%20models%20with%20interval-censored%20competing%20risks%20data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X.%22%2C%22lastName%22%3A%22Lu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Bandyopadhyay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Bakoyannis%22%7D%5D%2C%22abstractNote%22%3A%22In%20this%20paper%2C%20we%20consider%20a%20class%20of%20partially%20linear%20transformation%20models%20with%20interval-censored%20competing%20risks%20data.%20Under%20a%20semiparametric%20generalized%20odds%20rate%20specification%20for%20the%20cause-specific%20cumulative%20incidence%20function%2C%20we%20obtain%20optimal%20estimators%20of%20the%20large%20number%20of%20parametric%20and%20nonparametric%20model%20components%20via%20maximizing%20the%20likelihood%20function%20over%20a%20joint%20B-spline%20and%20Bernstein%20polynomial%20spanned%20sieve%20space.%20Our%20specification%20considers%20a%20relatively%20simpler%20finite-dimensional%20parameter%20space%2C%20approximating%20the%20infinite-dimensional%20parameter%20space%20as%20n%20--%3E%20infinity%2C%20thereby%20allowing%20us%20to%20study%20the%20almost%20sure%20consistency%2C%20and%20rate%20of%20convergence%20for%20all%20parameters%2C%20and%20the%20asymptotic%20distributions%20and%20efficiency%20of%20the%20finite-dimensional%20components.%20We%20study%20the%20finite%20sample%20performance%20of%20our%20method%20through%20simulation%20studies%20under%20a%20variety%20of%20scenarios.%20Furthermore%2C%20we%20illustrate%20our%20methodology%20via%20application%20to%20a%20dataset%20on%20HIV-infected%20individuals%20from%20sub-Saharan%20Africa.%22%2C%22date%22%3A%22Apr%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.5705%5C%2Fss.202021.0051%22%2C%22ISSN%22%3A%221017-0405%20%28Print%29%201017-0405%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A28%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22TWFNFVP9%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Buzibye%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-31%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBuzibye%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWools-Kaloustian%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOlagunju%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETwinomuhwezi%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYiannoutsos%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Relating%20CYP2B6%20genotype%20and%20efavirenz%20resistance%20among%20post-partum%20women%20living%20with%20HIV%20with%20high%20viremia%20in%20Uganda%3A%20a%20nested%20cross-sectional%20study.%20%3Ci%3EAIDS%20Res%20Ther%3C%5C%2Fi%3E%2C%20%3Ci%3E20%3C%5C%2Fi%3E%20%281%29%2C%20S.%2020.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12981-023-00514-2%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12981-023-00514-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Relating%20CYP2B6%20genotype%20and%20efavirenz%20resistance%20among%20post-partum%20women%20living%20with%20HIV%20with%20high%20viremia%20in%20Uganda%3A%20a%20nested%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Buzibye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Olagunju%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Twinomuhwezi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Owen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Neary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Matovu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Banturaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Lamorde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khoo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Waitt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kiragga%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20We%20investigated%20the%20association%20between%20CYP2B6%20polymorphisms%20and%20efavirenz%20drug%20resistance%20among%20women%20living%20with%20HIV%20who%20started%20on%20antiretroviral%20therapy%20during%20pregnancy%20and%20with%20high%20viremia%20during%20post-partum.%20METHODS%3A%20This%20was%20a%20cross-sectional%20study%20of%20women%20with%20viral%20loads%20greater%20than%201000%20copies%5C%2Fml%20who%20were%20at%20least%206%20weeks%20postpartum.%20Sanger%20sequencing%20was%20used%20to%20detect%20resistant%20mutations%2C%20as%20well%20as%20host%20genotyping%2C%20and%20efavirenz%20resistance%20was%20compared%20among%20the%20metabolizer%20genotypes.%20RESULTS%3A%20Over%20the%20course%20of%20one%20year%20%28July%202017-July%202018%29%2C%20322%20women%20were%20screened%2C%20with%20110%20%2834.2%25%29%20having%20viral%20loads%20of%201000%20copies%5C%2Fml%20and%2062%20having%20whole%20blood%20available%20for%20genotyping.%20Fifty-nine%20of%20these%20women%20had%20both%20viral%20resistance%20and%20human%20host%20genotypic%20results.%20Efavirenz%20resistance%20according%20to%20metabolizer%20genotype%20was%3B%2047%25%20in%20slow%2C%2034%25%20in%20extensive%20and%2028%25%20in%20intermediate%20metabolizers%2C%20but%20the%20difference%20was%20not%20statistically%20significant%20due%20to%20the%20small%20sample%20size.%20CONCLUSIONS%3A%20There%20was%20no%20statistically%20significant%20difference%20in%20EFV%20resistance%20between%20EFV%20metabolizer%20genotypes%20in%20women%20who%20started%20antiretroviral%20therapy%20during%20pregnancy%20and%20had%20high%20viremia%20in%20the%20postpartum%20period.%20However%2C%20a%20numerical%20trend%20was%20discovered%2C%20which%20calls%20for%20confirmation%20in%20a%20large%2C%20well-designed%2C%20statistically%20powered%20study.%22%2C%22date%22%3A%22Mar%2031%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12981-023-00514-2%22%2C%22ISSN%22%3A%221742-6405%20%28Electronic%29%201742-6405%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A25%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22PA3KMANK%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Plaisy%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-27%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPlaisy%2C%20M.%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoni%2C%20S.%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoffie%2C%20P.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETanon%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EInnocent%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Barriers%20to%20early%20diagnosis%20of%20cervical%20cancer%3A%20a%20mixed-method%20study%20in%20Cote%20d%26%23x2019%3BIvoire%2C%20West%20Africa.%20%3Ci%3EBMC%20Womens%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E23%3C%5C%2Fi%3E%20%281%29%2C%20S.%20135.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12905-023-02264-9%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12905-023-02264-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Barriers%20to%20early%20diagnosis%20of%20cervical%20cancer%3A%20a%20mixed-method%20study%20in%20Cote%20d%27Ivoire%2C%20West%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20K.%22%2C%22lastName%22%3A%22Plaisy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20P.%22%2C%22lastName%22%3A%22Boni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20A.%22%2C%22lastName%22%3A%22Coffie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Tanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Innocent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Horo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Dabis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Bekelynck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20West%20Africa%20Collaboration%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Cervical%20cancer%2C%20a%20major%20public%20health%20problem%20in%20many%20developing%20countries%2C%20is%20usually%20associated%20with%20a%20poor%20survival%20related%20to%20an%20advanced%20disease%20at%20diagnosis.%20In%20Cote%20d%27Ivoire%20and%20other%20developing%20countries%20with%20high%20cervical%20cancer%20prevalence%2C%20little%20is%20known%20about%20factors%20associated%20with%20advanced%20cervical%20cancer%20stages%20in%20a%20context%20of%20limited%20access%20to%20screening%20services.%20METHODS%3A%20From%20May%20to%20July%202019%2C%20we%20conducted%20a%20cross-sectional%20study%20using%20a%20mixed%2C%20quantitative%20and%20qualitative%20method.%20Information%20on%20socio-demographic%20and%20history%20of%20the%20disease%20was%20extracted%20from%20a%20rapid%20case%20ascertainement%20study%20performed%20by%20the%20cancer%20registry%20of%20Cote%20d%27Ivoire%20that%20enrolled%20all%20women%20diagnosed%20with%20cervical%20cancer%20between%20July%202018%20and%20June%202019.%20In-depth%20semi-structured%20interviews%20were%20conducted%20among%20a%20subset%20of%20these%20women%20%2812%20women%29%20and%20six%20healthcare%20providers%20to%20further%20capture%20barriers%20to%20early%20cervical%20cancer%20diagnosis.%20Factors%20associated%20with%20an%20advanced%20stage%20III%2C%20IV%20%28according%20to%20FIGO%20classification%29%20were%20estimated%20by%20a%20logistic%20regression%20model.%20Qualitative%20data%20were%20analyzed%20using%20a%20thematic%20analysis%20technique%20guided%20by%20the%20treatment%20pathway%20model%20and%20triangulated%20with%20quantitative%20data.%20RESULTS%3A%20In%20total%2C%2095%20women%20with%20cervical%20cancer%20%5Bmedian%20age%20%3D%2051%20%28IQR%2042-59%29%5D%20years%2C%20were%20included.%20Among%20them%2C%2018.9%25%20were%20living%20with%20HIV%20and%20only%209.5%25%20were%20covered%20by%20a%20health%20insurance.%20The%20majority%20%2871.5%25%29%20were%20diagnosed%20with%20advanced%20cervical%20cancer.%20Being%20HIV-uninfected%20%28aOR%20%3D%205.4%3B%20%5B1.6-17.8%5D%2C%20p%20%3D%200.006%29%20and%20being%20uninsured%20%28aOR%20%3D%2013.1%3B%20%5B2.0-85.5%5D%2C%20p%20%3D%200.007%29%20were%20independently%20associated%20with%20advanced%20cervical%20cancer%20in%20multivariable%20analysis.%20Qualitative%20data%20raised%20additional%20factors%20potentially%20related%20to%20advanced%20cervical%20cancer%20stages%20at%20diagnosis%2C%20including%20the%20lack%20of%20patient%20information%20on%20cervical%20cancer%20by%20healthcare%20providers%20and%20inadequate%20national%20awareness%20and%20screening%20campaigns.%20CONCLUSION%3A%20In%20a%20context%20of%20challenges%20in%20access%20to%20systematic%20cervical%20cancer%20screening%20in%20Cote%20d%27Ivoire%2C%20access%20to%20health%20insurance%20or%20integrated%20healthcare%20program%20appear%20to%20be%20key%20determinants%20of%20early%20diagnosis%20of%20cervical%20cancer.%22%2C%22date%22%3A%22Mar%2027%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12905-023-02264-9%22%2C%22ISSN%22%3A%221472-6874%20%28Electronic%29%201472-6874%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A42%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22SF5ZU36U%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vreeman%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-13%22%2C%22numChildren%22%3A14%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVreeman%2C%20R.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYiannoutsos%2C%20C.%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYusoff%2C%20N.%20K.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWester%2C%20C.%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEdmonds%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Global%20HIV%20prevention%2C%20care%20and%20treatment%20services%20for%20children%3A%20a%20cross-sectional%20survey%20from%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e069399.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-069399%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-069399%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20HIV%20prevention%2C%20care%20and%20treatment%20services%20for%20children%3A%20a%20cross-sectional%20survey%20from%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20K.%20N.%22%2C%22lastName%22%3A%22Yusoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Ofner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lumbiganon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22de%20Menezes%20Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton-Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20E.%22%2C%22lastName%22%3A%22Takassi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Scanlon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22IeDea%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20assess%20access%20children%20with%20HIV%20have%20to%20comprehensive%20HIV%20care%20services%2C%20to%20longitudinally%20evaluate%20the%20implementation%20and%20scale-up%20of%20services%2C%20and%20to%20use%20site%20services%20and%20clinical%20cohort%20data%20to%20explore%20whether%20access%20to%20these%20services%20influences%20retention%20in%20care.%20METHODS%3A%20A%20cross-sectional%20standardised%20survey%20was%20completed%20in%202014-2015%20by%20sites%20providing%20paediatric%20HIV%20care%20across%20regions%20of%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20We%20developed%20a%20comprehensiveness%20score%20based%20on%20the%20WHO%27s%20nine%20categories%20of%20essential%20services%20to%20categorise%20sites%20as%20%27low%27%20%280-5%29%2C%20%27medium%27%2C%20%286-7%29%20or%20%27high%27%20%288-9%29.%20When%20available%2C%20comprehensiveness%20scores%20were%20compared%20with%20scores%20from%20a%202009%20survey.%20We%20used%20patient-level%20data%20with%20site%20services%20to%20investigate%20the%20relationship%20between%20the%20comprehensiveness%20of%20services%20and%20retention.%20RESULTS%3A%20Survey%20data%20from%20174%20IeDEA%20sites%20in%2032%20countries%20were%20analysed.%20Of%20the%20WHO%20essential%20services%2C%20sites%20were%20most%20likely%20to%20offer%20antiretroviral%20therapy%20%28ART%29%20provision%20and%20counselling%20%28n%3D173%3B%2099%25%29%2C%20co-trimoxazole%20prophylaxis%20%28168%3B%2097%25%29%2C%20prevention%20of%20perinatal%20transmission%20services%20%28167%3B%2096%25%29%2C%20outreach%20for%20patient%20engagement%20and%20follow-up%20%28166%3B%2095%25%29%2C%20CD4%20cell%20count%20testing%20%28126%3B%2088%25%29%2C%20tuberculosis%20screening%20%28151%3B%2087%25%29%20and%20select%20immunisation%20services%20%28126%3B%2072%25%29.%20Sites%20were%20less%20likely%20to%20offer%20nutrition%5C%2Ffood%20support%20%2897%3B%2056%25%29%2C%20viral%20load%20testing%20%2899%3B%2069%25%29%20and%20HIV%20counselling%20and%20testing%20%2869%3B%2040%25%29.%2010%25%20of%20sites%20rated%20%27low%27%2C%2059%25%20%27medium%27%20and%2031%25%20%27high%27%20in%20the%20comprehensiveness%20score.%20The%20mean%20comprehensiveness%20of%20services%20score%20increased%20significantly%20from%205.6%20in%202009%20to%207.3%20in%202014%20%28p%3C0.001%3B%20n%3D30%29.%20Patient-level%20analysis%20of%20lost%20to%20follow-up%20after%20ART%20initiation%20estimated%20the%20hazard%20was%20highest%20in%20sites%20rated%20%27low%27%20and%20lowest%20in%20sites%20rated%20%27high%27.%20CONCLUSION%3A%20This%20global%20assessment%20suggests%20the%20potential%20care%20impact%20of%20scaling-up%20and%20sustaining%20comprehensive%20paediatric%20HIV%20services.%20Meeting%20recommendations%20for%20comprehensive%20HIV%20services%20should%20remain%20a%20global%20priority.%22%2C%22date%22%3A%22Mar%2013%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2022-069399%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A19%3A46Z%22%7D%7D%2C%7B%22key%22%3A%2279FNT5LD%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Patten%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPatten%2C%20G.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEuvrard%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAnderegg%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoulle%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EArendse%2C%20K.%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Advanced%20HIV%20disease%20and%20engagement%20in%20care%20among%20patients%20on%20antiretroviral%20therapy%20in%20South%20Africa%3A%20results%20from%20a%20multi-state%20model.%20%3Ci%3EAIDS%3C%5C%2Fi%3E%2C%20%3Ci%3E37%3C%5C%2Fi%3E%20%283%29%2C%20S.%20513%26%23x2013%3B522.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003442%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003442%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Advanced%20HIV%20disease%20and%20engagement%20in%20care%20among%20patients%20on%20antiretroviral%20therapy%20in%20South%20Africa%3A%20results%20from%20a%20multi-state%20model%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20E.%22%2C%22lastName%22%3A%22Patten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Anderegg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20D.%22%2C%22lastName%22%3A%22Arendse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22von%20der%20Heyden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Despite%20improved%20access%20to%20antiretroviral%20therapy%20%28ART%29%20for%20people%20with%20HIV%20%28PWH%29%2C%20HIV%20continues%20to%20contribute%20considerably%20to%20morbidity%20and%20mortality.%20Increasingly%2C%20advanced%20HIV%20disease%20%28AHD%29%20is%20found%20among%20PWH%20who%20are%20ART-experienced.%20DESIGN%3A%20Using%20a%20multi-state%20model%20we%20examined%20associations%20between%20engagement%20with%20care%20and%20AHD%20on%20ART%20in%20South%20Africa.%20METHODS%3A%20Using%20data%20from%20IeDEA%20Southern%20Africa%2C%20we%20included%20PWH%20from%20South%20Africa%2C%20initiating%20ART%20from%202004%20to%202017%20aged%20more%20than%205%20years%20with%20a%20CD4%2B%20cell%20count%20at%20ART%20start%20and%20at%20least%20one%20subsequent%20measure.%20We%20defined%20a%20gap%20as%20no%20visit%20for%20at%20least%2018%20months.%20Five%20states%20were%20defined%3A%20%27AHD%20on%20ART%27%20%28CD4%2B%20cell%20count%20%3C200%20cells%5C%2Fmul%29%2C%20%27Clinically%20Stable%20on%20ART%27%20%28CD4%2B%20cell%20count%20%3E%5C%2F%3D200%20or%20if%20no%20CD4%2B%20cell%20count%2C%20viral%20load%20%3C1000%20copies%5C%2Fml%29%2C%20%27Early%20Gap%27%20%28commencing%20%3C%5C%2F%3D18%20months%20from%20ART%20start%29%2C%20%27Late%20Gap%27%20%28commencing%20%3E18%20months%20from%20ART%20start%29%20and%20%27Death%27.%20RESULTS%3A%20Among%2032%20452%20PWH%2C%20men%20and%20those%20aged%2015-25%20years%20were%20more%20likely%20to%20progress%20to%20unfavourable%20states.%20Later%20years%20of%20ART%20start%20were%20associated%20with%20a%20lower%20probability%20of%20transitioning%20from%20AHD%20to%20clinically%20stable%2C%20increasing%20the%20risk%20of%20death%20following%20AHD.%20In%20stratified%20analyses%2C%20those%20starting%20ART%20with%20AHD%20in%20later%20years%20were%20more%20likely%20to%20re-engage%20in%20care%20with%20AHD%20following%20a%20gap%20and%20to%20die%20following%20AHD%20on%20ART.%20CONCLUSION%3A%20In%20more%20recent%20years%2C%20those%20with%20AHD%20on%20ART%20were%20more%20likely%20to%20die%2C%20and%20AHD%20at%20re-engagement%20in%20care%20increased.%20To%20further%20reduce%20HIV-related%20mortality%2C%20efforts%20to%20address%20the%20challenges%20facing%20these%20more%20vulnerable%20patients%20are%20needed.%22%2C%22date%22%3A%22Mar%201%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003442%22%2C%22ISSN%22%3A%221473-5571%20%28Electronic%29%200269-9370%20%28Print%29%200269-9370%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A13%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22UCFEFJNP%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parcesepe%20et%20al.%22%2C%22parsedDate%22%3A%222023-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EParcesepe%2C%20A.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFiliatreau%2C%20L.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGomez%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEbasone%2C%20P.%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDzudie%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20HIV-Related%20Stigma%2C%20Social%20Support%2C%20and%20Symptoms%20of%20Mental%20Health%20Disorders%20Among%20People%20with%20HIV%20Initiating%20HIV%20Care%20in%20Cameroon.%20%3Ci%3EAIDS%20Patient%20Care%20STDS%3C%5C%2Fi%3E%2C%20%3Ci%3E37%3C%5C%2Fi%3E%20%283%29%2C%20S.%20146%26%23x2013%3B154.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fapc.2022.0187%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fapc.2022.0187%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV-Related%20Stigma%2C%20Social%20Support%2C%20and%20Symptoms%20of%20Mental%20Health%20Disorders%20Among%20People%20with%20HIV%20Initiating%20HIV%20Care%20in%20Cameroon%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20M.%22%2C%22lastName%22%3A%22Filiatreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20V.%22%2C%22lastName%22%3A%22Ebasone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dzudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20W.%22%2C%22lastName%22%3A%22Pence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Wainberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Pefura-Yone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nsame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%5D%2C%22abstractNote%22%3A%22HIV-related%20stigma%20has%20been%20associated%20with%20poor%20mental%20health%20among%20people%20with%20HIV%20%28PWH%29.%20Social%20support%20is%20a%20potentially%20modifiable%20factor%20that%20may%20buffer%20negative%20mental%20health%20sequelae%20of%20HIV-related%20stigma.%20Little%20is%20known%20about%20the%20extent%20to%20which%20the%20modifying%20effect%20of%20social%20support%20differs%20across%20mental%20health%20disorders.%20Interviews%20were%20conducted%20with%20426%20PWH%20in%20Cameroon.%20Log%20binomial%20regression%20analyses%20were%20used%20to%20estimate%20the%20association%20between%20high%20anticipated%20HIV-related%20stigma%20and%20low%20social%20support%20from%20family%20or%20friends%20and%20symptoms%20of%20depression%2C%20anxiety%2C%20post-traumatic%20stress%20disorder%20%28PTSD%29%2C%20and%20harmful%20alcohol%20use%2C%20separately.%20Anticipated%20HIV-related%20stigma%20was%20commonly%20endorsed%20with%20approximately%2080%25%20endorsing%20at%20least%201%20of%2012%20stigma-related%20concerns.%20In%20multivariable%20analyses%2C%20high%20anticipated%20HIV-related%20stigma%20was%20associated%20with%20greater%20prevalence%20of%20symptoms%20of%20depression%20adjusted%20prevalence%20ratio%20%28aPR%29%201.6%20%5B95%25%20confidence%20interval%20%28CI%29%201.1-2.2%5D%20and%20anxiety%20%5BaPR%202.0%20%2895%25%20CI%201.4-2.9%29%5D.%20Low%20social%20support%20was%20associated%20with%20greater%20prevalence%20of%20symptoms%20of%20depression%20%5BaPR%201.5%20%2895%25%20CI%201.1-2.2%29%5D%2C%20anxiety%20%5BaPR%201.7%20%2895%25%20CI%201.2-2.5%29%5D%2C%20and%20PTSD%20%5BaPR%201.6%20%2895%25%20CI%201.0-2.4%29%5D.%20However%2C%20social%20support%20did%20not%20meaningfully%20modify%20the%20relationship%20between%20HIV-related%20stigma%20and%20symptoms%20of%20any%20mental%20health%20disorders%20explored.%20Anticipated%20HIV-related%20stigma%20was%20commonly%20reported%20among%20this%20group%20of%20PWH%20initiating%20HIV%20care%20in%20Cameroon.%20Social%20concerns%20related%20to%20gossip%20or%20losing%20friends%20were%20of%20the%20greatest%20concern.%20Interventions%20focused%20on%20reducing%20stigma%20and%20strengthening%20support%20systems%20may%20be%20particularly%20beneficial%20and%20have%20the%20potential%20to%20improve%20the%20mental%20health%20of%20PWH%20in%20Cameroon.%22%2C%22date%22%3A%22Mar%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1089%5C%2Fapc.2022.0187%22%2C%22ISSN%22%3A%221557-7449%20%28Electronic%29%201087-2914%20%28Print%29%201087-2914%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A47%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22PCS9ZBZZ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lewis-Kulzer%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELewis-Kulzer%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMburu%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EObatsa%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECheruiyot%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKiprono%2C%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Patient%20perceptions%20of%20facilitators%20and%20barriers%20to%20reducing%20hazardous%20alcohol%20use%20among%20people%20living%20with%20HIV%20in%20East%20Africa.%20%3Ci%3ESubst%20Abuse%20Treat%20Prev%20Policy%3C%5C%2Fi%3E%2C%20%3Ci%3E18%3C%5C%2Fi%3E%20%281%29%2C%20S.%208.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13011-023-00520-7%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13011-023-00520-7%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Patient%20perceptions%20of%20facilitators%20and%20barriers%20to%20reducing%20hazardous%20alcohol%20use%20among%20people%20living%20with%20HIV%20in%20East%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Lewis-Kulzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mburu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Obatsa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Cheruiyot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Kiprono%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Apaka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Koros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20K.%22%2C%22lastName%22%3A%22Kwobah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Aluda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Goodrich%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Hazardous%20alcohol%20use%20among%20people%20living%20with%20HIV%20is%20associated%20with%20poor%20outcomes%20and%20increased%20morbidity%20and%20mortality.%20Understanding%20the%20hazardous%20drinking%20experiences%20of%20people%20living%20with%20HIV%20is%20needed%20to%20reduce%20their%20alcohol%20use.%20METHODS%3A%20We%20conducted%2060%20interviews%20among%20people%20living%20with%20HIV%20in%20East%20Africa%20with%20hazardous%20drinking%20histories.%20Interviews%20and%20Alcohol%20Use%20Disorder%20Identification%20Test%20%28AUDIT%29%20scores%20were%20conducted%2041%20-%2060%20months%20after%20their%20baseline%20assessment%20of%20alcohol%20use%20to%20identify%20facilitators%20and%20barriers%20to%20reduced%20alcohol%20use%20over%20time.%20RESULTS%3A%20People%20living%20with%20HIV%20who%20stopped%20or%20reduced%20hazardous%20drinking%20were%20primarily%20motivated%20by%20their%20HIV%20condition%20and%20desire%20for%20longevity.%20Facilitators%20of%20reduced%20drinking%20included%20health%20care%20workers%27%20recommendations%20to%20reduce%20drinking%20%28despite%20little%20counseling%20and%20no%20referrals%29%20and%20social%20support.%20In%20those%20continuing%20to%20drink%20at%20hazardous%20levels%2C%20barriers%20to%20reduced%20drinking%20were%20stress%2C%20social%20environment%2C%20alcohol%20accessibility%20and%20alcohol%20dependency.%20CONCLUSIONS%3A%20Interventions%20that%20capacity-build%20professional%20and%20lay%20health%20care%20workers%20with%20the%20skills%20and%20resources%20to%20decrease%20problematic%20alcohol%20use%2C%20along%20with%20alcohol%20cessation%20in%20peer%20support%20structures%2C%20should%20be%20explored.%22%2C%22date%22%3A%22Feb%203%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13011-023-00520-7%22%2C%22ISSN%22%3A%221747-597X%20%28Electronic%29%201747-597X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A25%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22K8BD5TSV%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lang%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELang%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHogan%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZhu%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcArthur%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELee%2C%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20The%20prevalence%20of%20mental%20health%20disorders%20in%20people%20with%20HIV%20and%20the%20effects%20on%20the%20HIV%20care%20continuum.%20%3Ci%3EAIDS%3C%5C%2Fi%3E%2C%20%3Ci%3E37%3C%5C%2Fi%3E%20%282%29%2C%20S.%20259%26%23x2013%3B269.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003420%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003420%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20prevalence%20of%20mental%20health%20disorders%20in%20people%20with%20HIV%20and%20the%20effects%20on%20the%20HIV%20care%20continuum%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Zhu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22McArthur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Zandi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Nestadt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Cook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Grelotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Closson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20D.%22%2C%22lastName%22%3A%22Lima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Goulet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20M.%22%2C%22lastName%22%3A%22Camoens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20E.%22%2C%22lastName%22%3A%22Nijhawan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22McGinnis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Eron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%20Cohort%20Collaboration%20on%20Research%22%2C%22lastName%22%3A%22North%20American%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22Design%20of%20the%20International%20Epidemiologic%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20describe%20the%20prevalence%20of%20diagnosed%20depression%2C%20anxiety%2C%20bipolar%20disorder%2C%20and%20schizophrenia%20in%20people%20with%20HIV%20%28PWH%29%20and%20the%20differences%20in%20HIV%20care%20continuum%20outcomes%20in%20those%20with%20and%20without%20mental%20health%20disorders%20%28MHDs%29.%20DESIGN%3A%20Observational%20study%20of%20participants%20in%20the%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design.%20METHODS%3A%20PWH%20%28%3E%5C%2F%3D18%20years%29%20contributed%20data%20on%20prevalent%20schizophrenia%2C%20anxiety%2C%20depressive%2C%20and%20bipolar%20disorders%20from%202008%20to%202018%20based%20on%20International%20Classification%20of%20Diseases%20code%20mapping.%20Mental%20health%20%28MH%29%20multimorbidity%20was%20defined%20as%20having%20two%20or%20more%20MHD.%20Log%20binomial%20models%20with%20generalized%20estimating%20equations%20estimated%20adjusted%20prevalence%20ratios%20%28aPR%29%20and%2095%25%20confidence%20intervals%20for%20retention%20in%20care%20%28%3E%5C%2F%3D1%20visit%5C%2Fyear%29%20and%20viral%20suppression%20%28HIV%20RNA%20%3C%5C%2F%3D200%20copies%5C%2Fml%29%20by%20presence%20vs.%20absence%20of%20each%20MHD%20between%202016%20and%202018.%20RESULTS%3A%20Among%20122%20896%20PWH%2C%2067%20643%20%2855.1%25%29%20were%20diagnosed%20with%20one%20or%20more%20MHD%3A%2039%25%20with%20depressive%20disorders%2C%2028%25%20with%20anxiety%20disorders%2C%2010%25%20with%20bipolar%20disorder%2C%20and%205%25%20with%20schizophrenia.%20The%20prevalence%20of%20depressive%20and%20anxiety%20disorders%20increased%20between%202008%20and%202018%2C%20whereas%20bipolar%20disorder%20and%20schizophrenia%20remained%20stable.%20MH%20multimorbidity%20affected%2024%25%20of%20PWH.%20From%202016%20to%202018%20%28N%20%3D%2064%20684%29%2C%20retention%20in%20care%20was%20marginally%20lower%20among%20PWH%20with%20depression%20or%20anxiety%2C%20however%20those%20with%20MH%20multimorbidity%20were%20more%20likely%20to%20be%20retained%20in%20care.%20PWH%20with%20bipolar%20disorder%20had%20marginally%20lower%20prevalence%20of%20viral%20suppression%20%28aPR%20%3D%200.98%20%5B0.98-0.99%5D%29%20as%20did%20PWH%20with%20MH%20multimorbidity%20%28aPR%20%3D%200.99%20%5B0.99-1.00%5D%29%20compared%20with%20PWH%20without%20MHD.%20CONCLUSION%3A%20The%20prevalence%20of%20MHD%20among%20PWH%20was%20high%2C%20including%20MH%20multimorbidity.%20Although%20retention%20and%20viral%20suppression%20were%20similar%20to%20people%20without%20MHD%2C%20viral%20suppression%20was%20lower%20in%20those%20with%20bipolar%20disorder%20and%20MH%20multimorbidity.%22%2C%22date%22%3A%22Feb%201%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003420%22%2C%22ISSN%22%3A%221473-5571%20%28Electronic%29%200269-9370%20%28Print%29%200269-9370%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A30%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22PYIMAJLN%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lang%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELang%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGill%2C%20M.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoburn%2C%20S.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGrossman%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGebo%2C%20K.%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20The%20changing%20prevalence%20of%20anemia%20and%20risk%20factors%20in%20people%20with%20HIV%20in%20North%20America%20who%20have%20initiated%20ART%2C%202007-2017.%20%3Ci%3EAIDS%3C%5C%2Fi%3E%2C%20%3Ci%3E37%3C%5C%2Fi%3E%20%282%29%2C%20S.%20287%26%23x2013%3B298.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003423%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003423%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20changing%20prevalence%20of%20anemia%20and%20risk%20factors%20in%20people%20with%20HIV%20in%20North%20America%20who%20have%20initiated%20ART%2C%202007-2017%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20B.%22%2C%22lastName%22%3A%22Coburn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Grossman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Willig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20B.%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22Bosch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20S.%22%2C%22lastName%22%3A%22Rabkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Design%20of%20the%20International%20Epidemiologic%20Databases%20to%20Evaluate%20Aids%22%2C%22lastName%22%3A%22North%20American%20Aids%20Cohort%20Collaboration%20on%20Research%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20characterize%20the%20prevalence%20of%20anemia%20and%20risk%20factors%20between%202007%20and%202017%20for%20moderate%5C%2Fsevere%20anemia%20among%20people%20with%20HIV%20%28PWH%29%20in%20North%20America%20who%20have%20initiated%20antiretroviral%20therapy%20%28ART%29.%20DESIGN%3A%20Observational%20study%20of%20participants%20in%20the%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20%28NA-ACCORD%29.%20METHODS%3A%20We%20estimated%20the%20annual%20prevalence%20between%201%20January%202007%20and%2031%20December%202017%20of%20mild%20%2811.0-12.9%20g%5C%2Fdl%20men%2C%2011.0-11.9%20g%5C%2Fdl%20women%29%2C%20moderate%20%288.0-10.9%20g%5C%2Fdl%20regardless%20of%20sex%29%20and%20severe%20%28%3C8.0%20g%5C%2Fdl%20regardless%20of%20sex%29%20anemia.%20Poisson%20regression%20models%20with%20robust%20variance%20and%20general%20estimating%20equations%20estimated%20crude%20and%20adjusted%20prevalence%20ratios%20%28aPR%29%20with%2095%25%20confidence%20intervals%20%28%5B-%5D%29%20comparing%20risk%20factors%20for%20moderate%5C%2Fsevere%20vs.%20no%5C%2Fmild%20anemia%20between%202007%20and%202017.%20RESULTS%3A%20Among%2073%20898%20PWH%20we%20observed%20366%20755%20hemoglobin%20measurements%20following%20ART%20initiation%2C%2037%20301%20%2850%25%29%20had%20one%20or%20more%20measures%20of%20anemia%20during%20follow-up%20%28mild%20%3D%2017%20743%20%5B24%25%5D%3B%20moderate%20%3D%2013%20383%5B18%25%5D%3B%20severe%20%3D%206175%20%5B8%25%5D%29.%20Moderate%5C%2Fsevere%20anemia%20was%20more%20prevalent%20among%20women%2C%20non-Hispanic%20Black%20and%20Hispanic%20PWH%20%28vs.%20non-Hispanic%20white%29%2C%20those%20with%20underweight%20body%20mass%20index%20%28%3C18.5%20kg%5C%2Fm2%29%20and%20with%20comorbidities%20and%20coinfections.%20Older%20age%20had%20increased%20prevalence%20of%20moderate%5C%2Fsevere%20anemia%20among%20males%20and%20decreased%20prevalence%20among%20females.%20Prevalence%20of%20moderate%5C%2Fsevere%20anemia%20was%20greater%20among%20those%20with%20lower%20CD4%2B%20cell%20count%20%28%3C%5C%2F%3D200%20cells%5C%2Fmul%29%20%5BaPR%20%3D%202.11%20%282.06-2.17%29%5D%20unsuppressed%20HIV%20viral%20load%20%28%3E200%20copies%5C%2Fml%29%20%5BaPR%20%3D%201.26%20%281.23-1.29%29%5D%20and%20within%20the%20first%206%20months%20of%20ART%20initiation%20%28vs.%20%3E1%20year%20of%20ART%29%20%5BaPR%20%3D%201.66%20%281.61-1.72%29%5D.%20CONCLUSION%3A%20The%20prevalence%20of%20anemia%20among%20PWH%20is%20reduced%20after%20ART%20initiation%20but%20remains%20high.%20Risk%20factors%20differ%20by%20sex%20and%20include%20comorbidities%20and%20HIV%20disease%20severity.%20The%20persistent%2C%20substantial%20prevalence%20of%20anemia%20among%20PWH%20merits%20further%20investigation%2C%20targeted%20screening%2C%20and%20clinical%20interventions.%22%2C%22date%22%3A%22Feb%201%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003423%22%2C%22ISSN%22%3A%221473-5571%20%28Electronic%29%200269-9370%20%28Print%29%200269-9370%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A29%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22ESC8Q9CS%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Aurpibul%20et%20al.%22%2C%22parsedDate%22%3A%222023-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAurpibul%2C%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKosalaraksa%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKawichai%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELumbiganon%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOunchanum%2C%20P.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Alcohol%20use%2C%20suicidality%20and%20virologic%20non-suppression%20among%20young%20adults%20with%20perinatally%20acquired%20HIV%20in%20Thailand%3A%20a%20cross-sectional%20study.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E26%3C%5C%2Fi%3E%20%282%29%2C%20S.%20e26064.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26064%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26064%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Alcohol%20use%2C%20suicidality%20and%20virologic%20non-suppression%20among%20young%20adults%20with%20perinatally%20acquired%20HIV%20in%20Thailand%3A%20a%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Aurpibul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Kosalaraksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kawichai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lumbiganon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Ounchanum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Natalie%20Songtaweesin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Sudjaritruk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Chokephaibulkit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Rungmaitree%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Suwanlerk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Puthanakit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Papaya%20study%20team%22%2C%22lastName%22%3A%22Thai%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Young%20adults%20with%20perinatally%20acquired%20HIV%20%28YA-PHIV%29%20are%20facing%20transitions%20to%20adult%20life.%20This%20study%20assessed%20health%20risk%20behaviours%20%28including%20substance%20use%29%2C%20mental%20health%2C%20quality%20of%20life%20%28QOL%29%20and%20HIV%20treatment%20outcomes%20of%20Thai%20YA-PHIV.%20METHODS%3A%20A%20cross-sectional%20study%20was%20conducted%20in%20Thai%20YA-PHIV%20aged%2018-25%20years%20who%20were%20enrolled%20in%20a%20prospective%20cohort%20study%20at%20five%20tertiary%20paediatric%20HIV%20care%20centres%20in%20Thailand.%20Study%20data%20were%20obtained%20through%20face-to-face%20interviews%20from%20November%202020%20to%20July%202021.%20Assessments%20were%20performed%20for%20alcohol%20use%20%28Alcohol%20Use%20Disorders%20Identification%20Test%3B%20AUDIT%29%2C%20smoking%20%28Fagerstrom%20Test%20for%20Nicotine%20Dependence%29%2C%20drug%5C%2Fsubstance%20use%20%28Drug%20Abuse%20Screening%20Test%3B%20DAST-10%29%2C%20depression%20%28Patient%20Health%20Questionnaire%20for%20Adolescents%3B%20PHQ-A%29%2C%20anxiety%20%28Generalized%20Anxiety%20Disorder%3B%20GAD-7%29%20and%20QOL%20%28World%20Health%20Organization%20QOL%20Brief-Thai%29.%20HIV%20treatment%20outcomes%20were%20extracted%20from%20the%20National%20AIDS%20Program%20database.%20RESULTS%3A%20Of%20355%20YA-PHIV%2C%20163%20%2846%25%29%20were%20males%3A%20their%20median%20age%20was%2021.7%20%28interquartile%20range%2C%20IQR%2020.2-23.5%29%20years.%20There%20were%20203%20YA-PHIV%20%2858%25%29%20who%20reported%20ever%20having%20sex%3B%20141%20%2840%25%29%20were%20sexually%20active%20in%20the%20past%206%20months%2C%20of%20whom%2086%20%2861%25%29%20reported%20100%25%20condom%20use.%20Overall%2C%2049%20%2814%25%29%20met%20the%20criteria%20for%20harmful%20alcohol%20use%3B%2028%20%287.9%25%29%20were%20alcohol%20dependent.%20Sixty%20%2817%25%29%20were%20current%20smokers%20and%2037%20%2811%25%29%20used%20drugs%5C%2Fsubstances.%20The%20frequency%20of%20moderate%20up%20to%20severe%20symptoms%20for%20depression%20was%2018%25%20and%20for%20anxiety%20was%209.7%25.%20Their%20overall%20QOL%20was%20good%20in%20180%20%2851%25%29%2C%20moderate%20in%20168%20%2847%25%29%20and%20poor%20in%20five%20%281.4%25%29.%20There%20were%2049%20YA-PHIV%20%2814%25%29%20with%20CD4%20%3C200%20cells%5C%2Fmm%283%29%20and%2085%20%2824%25%29%20with%20virologic%20non-suppression%20%28HIV-RNA%20%3E200%20copies%5C%2Fml%29.%20On%20multivariate%20analyses%2C%20the%20highest%20education%20at%20the%20primary%20to%20high%20school%20or%20vocational%20school%20levels%20%28adjusted%20odds%20ratio%20%5BaOR%5D%202.02%2C%2095%25%20CI%201.40-3.95%2C%20p%200.04%29%2C%20harmful%20alcohol%20use%20%28aOR%202.48%2C%2095%25%20CI%201.24-4.99%2C%20p%200.01%29%2C%20alcohol%20dependence%20%28aOR%203.54%2C%2095%25%20CI%201.51-8.31%2C%20p%20%3C0.01%29%20and%20lifetime%20suicidal%20attempt%20%28aOR%202.66%2C%2095%25%20CI%201.11-6.35%2C%20p%200.03%29%20were%20associated%20with%20non-suppression.%20CONCLUSIONS%3A%20Regular%20screening%20for%20alcohol%20use%20and%20mental%20health%2C%20including%20suicidality%2C%20would%20be%20useful%20to%20identify%20YA-PHIV%20who%20need%20more%20intensive%20psychosocial%20support%20or%20referral%20services%20to%20ensure%20they%20can%20achieve%20and%20maintain%20a%20high%20QOL%20into%20adult%20life.%22%2C%22date%22%3A%22Feb%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26064%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A14%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22DQZY2PUS%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ross%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-06%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoss%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFatti%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJaquet%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETanon%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Same-Day%20Antiretroviral%20Therapy%20Initiation%20as%20a%20Predictor%20of%20Loss%20to%20Follow-up%20and%20Viral%20Suppression%20Among%20People%20With%20Human%20Immunodeficiency%20Virus%20in%20Sub-Saharan%20Africa.%20%3Ci%3EClin%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E76%3C%5C%2Fi%3E%20%281%29%2C%20S.%2039%26%23x2013%3B47.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac759%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac759%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Same-Day%20Antiretroviral%20Therapy%20Initiation%20as%20a%20Predictor%20of%20Loss%20to%20Follow-up%20and%20Viral%20Suppression%20Among%20People%20With%20Human%20Immunodeficiency%20Virus%20in%20Sub-Saharan%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Tanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Treat-All%20guidelines%20recommend%20initiation%20of%20antiretroviral%20therapy%20%28ART%29%20for%20all%20people%20with%20HIV%20%28PWH%29%20on%20the%20day%20of%20diagnosis%20when%20possible%2C%20yet%20uncertainty%20exists%20about%20the%20impact%20of%20same-day%20ART%20initiation%20on%20subsequent%20care%20engagement.%20We%20examined%20the%20association%20of%20same-day%20ART%20initiation%20with%20loss%20to%20follow-up%20and%20viral%20suppression%20among%20patients%20in%2011%20sub-Saharan%20African%20countries.%20METHODS%3A%20We%20included%20ART-naive%20adult%20PWH%20from%20sites%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20who%20enrolled%20in%20care%20after%20Treat-All%20implementation%20and%20prior%20to%20January%202019.%20We%20used%20multivariable%20Cox%20regression%20to%20estimate%20the%20association%20between%20same-day%20ART%20initiation%20and%20loss%20to%20follow-up%20and%20Poisson%20regression%20to%20estimate%20the%20association%20between%20same-day%20ART%20initiation%20and%206-month%20viral%20suppression.%20RESULTS%3A%20Among%2029%20017%20patients%20from%2063%20sites%2C%2018%20584%20%2864.0%25%29%20initiated%20ART%20on%20the%20day%20of%20enrollment.%20Same-day%20ART%20initiation%20was%20less%20likely%20among%20those%20with%20advanced%20HIV%20disease%20versus%20early-stage%20disease.%20Loss%20to%20follow-up%20was%20significantly%20lower%20among%20those%20initiating%20ART%20%3E%5C%2F%3D1%20day%20of%20enrollment%2C%20compared%20with%20same-day%20ART%20initiators%20%2820.6%25%20vs%2027.7%25%3B%20adjusted%20hazard%20ratio%3A%20.66%3B%2095%25%20CI%20.57-.76%29.%20No%20difference%20in%20viral%20suppression%20was%20observed%20by%20time%20to%20ART%20initiation%20%28adjusted%20rate%20ratio%3A%201.00%3B%2095%25%20CI%3A%20.98-1.02%29.%20CONCLUSIONS%3A%20Patients%20initiating%20ART%20on%20the%20day%20of%20enrollment%20were%20more%20frequently%20lost%20to%20follow-up%20than%20those%20initiating%20later%20but%20were%20equally%20likely%20to%20be%20virally%20suppressed.%20Our%20findings%20support%20recent%20World%20Health%20Organization%20recommendations%20for%20providing%20tailored%20counseling%20and%20support%20to%20patients%20who%20accept%20an%20offer%20of%20same-day%20ART.%22%2C%22date%22%3A%22Jan%206%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac759%22%2C%22ISSN%22%3A%221537-6591%20%28Electronic%29%201058-4838%20%28Print%29%201058-4838%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A27%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22UNWNFBZN%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ross%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoss%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERupasinghe%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAvihingsanon%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELee%2C%20M.%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPujari%2C%20S.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Trends%20in%20hepatitis%20C%20virus%20coinfection%20and%20its%20cascade%20of%20care%20among%20adults%20living%20with%20HIV%20in%20Asia%20between%202010%20and%202020.%20%3Ci%3EPLoS%20One%3C%5C%2Fi%3E%2C%20%3Ci%3E18%3C%5C%2Fi%3E%20%286%29%2C%20S.%20e0287909.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0287909%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0287909%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Trends%20in%20hepatitis%20C%20virus%20coinfection%20and%20its%20cascade%20of%20care%20among%20adults%20living%20with%20HIV%20in%20Asia%20between%202010%20and%202020%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Pujari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sharp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Khol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20K.%22%2C%22lastName%22%3A%22Agus%20Somia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20N.%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Duy%20Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22Tahod-Lite%20study%20group%20of%20IeDEA%20Asia-Pacific%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Chronic%20hepatitis%20C%20virus%20%28HCV%29%20infection%20contributes%20to%20substantial%20morbidity%20and%20mortality%20among%20adults%20living%20with%20HIV.%20Cascades%20of%20HCV%20care%20support%20monitoring%20of%20program%20performance%2C%20but%20data%20from%20Asia%20are%20limited.%20We%20assessed%20regional%20HCV%20coinfection%20and%20cascade%20outcomes%20among%20adults%20living%20with%20HIV%20in%20care%20from%202010-2020.%20METHODS%3A%20Patients%20%3E%5C%2F%3D18%20years%20old%20with%20confirmed%20HIV%20infection%20on%20antiretroviral%20therapy%20%28ART%29%20at%2011%20clinical%20sites%20in%20Cambodia%2C%20China%2C%20India%2C%20Indonesia%2C%20South%20Korea%2C%20Thailand%20and%20Vietnam%20were%20included.%20HCV-%20and%20HIV-related%20treatment%20and%20laboratory%20data%20were%20collected%20from%20those%20with%20a%20positive%20HCV%20antibody%20%28anti-HCV%29%20test%20after%20January%202010.%20An%20HCV%20cascade%20was%20evaluated%2C%20including%20proportions%20positive%20for%20anti-HCV%2C%20tested%20for%20HCV%20RNA%20or%20HCV%20core%20antigen%20%28HCVcAg%29%2C%20initiated%20on%20HCV%20treatment%2C%20and%20achieved%20sustained%20virologic%20response%20%28SVR%29.%20Factors%20associated%20with%20screening%20uptake%2C%20treatment%20initiation%2C%20and%20treatment%20response%20were%20analyzed%20using%20Fine%20and%20Gray%27s%20competing%20risk%20regression%20model.%20RESULTS%3A%20Of%2024%2C421%20patients%2C%209169%20%2838%25%29%20had%20an%20anti-HCV%20test%2C%20and%20971%20%2811%25%29%20had%20a%20positive%20result.%20The%20proportion%20with%20positive%20anti-HCV%20was%2012.1%25%20in%202010-2014%2C%203.9%25%20in%202015-2017%2C%20and%203.8%25%20in%202018-2020.%20From%202010%20to%202014%2C%2034%25%20with%20positive%20anti-HCV%20had%20subsequent%20HCV%20RNA%20or%20HCVcAg%20testing%2C%2066%25%20initiated%20HCV%20treatment%2C%20and%2083%25%20achieved%20SVR.%20From%202015%20to%202017%2C%2069%25%20with%20positive%20anti-HCV%20had%20subsequent%20HCV%20RNA%20or%20HCVcAg%20testing%2C%2059%25%20initiated%20HCV%20treatment%2C%20and%2088%25%20achieved%20SVR.%20From%202018%20to%202020%2C%2080%25%20had%20subsequent%20HCV%20RNA%20or%20HCVcAg%20testing%2C%2061%25%20initiated%20HCV%20treatment%2C%20and%2096%25%20achieved%20SVR.%20Having%20chronic%20HCV%20in%20later%20calendar%20years%20and%20in%20high-income%20countries%20were%20associated%20with%20increased%20screening%2C%20treatment%20initiation%20or%20achieving%20SVR.%20Older%20age%2C%20injecting%20drug%20use%20HIV%20exposure%2C%20lower%20CD4%20and%20higher%20HIV%20RNA%20were%20associated%20with%20reduced%20HCV%20screening%20or%20treatment%20initiation.%20CONCLUSIONS%3A%20Our%20analysis%20identified%20persistent%20gaps%20in%20the%20HCV%20cascade%20of%20care%2C%20highlighting%20the%20need%20for%20focused%20efforts%20to%20strengthen%20chronic%20HCV%20screening%2C%20treatment%20initiation%2C%20and%20monitoring%20among%20adult%20PLHIV%20in%20the%20Asia%20region.%22%2C%22date%22%3A%222023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0287909%22%2C%22ISSN%22%3A%221932-6203%20%28Electronic%29%201932-6203%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A50%3A34Z%22%7D%7D%2C%7B%22key%22%3A%222HC7HZUH%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marincowitz%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarincowitz%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHodkinson%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcAlpine%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFuller%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGoodacre%2C%20S.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20LMIC-PRIEST%3A%20Derivation%20and%20validation%20of%20a%20clinical%20severity%20score%20for%20acutely%20ill%20adults%20with%20suspected%20COVID-19%20in%20a%20middle-income%20setting.%20%3Ci%3EPLoS%20One%3C%5C%2Fi%3E%2C%20%3Ci%3E18%3C%5C%2Fi%3E%20%286%29%2C%20S.%20e0287091.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0287091%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0287091%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22LMIC-PRIEST%3A%20Derivation%20and%20validation%20of%20a%20clinical%20severity%20score%20for%20acutely%20ill%20adults%20with%20suspected%20COVID-19%20in%20a%20middle-income%20setting%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Marincowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Hodkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22McAlpine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Fuller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Goodacre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20A.%22%2C%22lastName%22%3A%22Bath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Sbaffi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Hasan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Omer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Wallis%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Uneven%20vaccination%20and%20less%20resilient%20health%20care%20systems%20mean%20hospitals%20in%20LMICs%20are%20at%20risk%20of%20being%20overwhelmed%20during%20periods%20of%20increased%20COVID-19%20infection.%20Risk-scores%20proposed%20for%20rapid%20triage%20of%20need%20for%20admission%20from%20the%20emergency%20department%20%28ED%29%20have%20been%20developed%20in%20higher-income%20settings%20during%20initial%20waves%20of%20the%20pandemic.%20METHODS%3A%20Routinely%20collected%20data%20for%20public%20hospitals%20in%20the%20Western%20Cape%2C%20South%20Africa%20from%20the%2027th%20August%202020%20to%2011th%20March%202022%20were%20used%20to%20derive%20a%20cohort%20of%20446%2C084%20ED%20patients%20with%20suspected%20COVID-19.%20The%20primary%20outcome%20was%20death%20or%20ICU%20admission%20at%2030%20days.%20The%20cohort%20was%20divided%20into%20derivation%20and%20Omicron%20variant%20validation%20sets.%20We%20developed%20the%20LMIC-PRIEST%20score%20based%20on%20the%20coefficients%20from%20multivariable%20analysis%20in%20the%20derivation%20cohort%20and%20existing%20triage%20practices.%20We%20externally%20validated%20accuracy%20in%20the%20Omicron%20period%20and%20a%20UK%20cohort.%20RESULTS%3A%20We%20analysed%20305%2C564%20derivation%2C%20140%2C520%20Omicron%20and%2012%2C610%20UK%20validation%20cases.%20Over%20100%20events%20per%20predictor%20parameter%20were%20modelled.%20Multivariable%20analyses%20identified%20eight%20predictor%20variables%20retained%20across%20models.%20We%20used%20these%20findings%20and%20clinical%20judgement%20to%20develop%20a%20score%20based%20on%20South%20African%20Triage%20Early%20Warning%20Scores%20and%20also%20included%20age%2C%20sex%2C%20oxygen%20saturation%2C%20inspired%20oxygen%2C%20diabetes%20and%20heart%20disease.%20The%20LMIC-PRIEST%20score%20achieved%20C-statistics%3A%200.82%20%2895%25%20CI%3A%200.82%20to%200.83%29%20development%20cohort%3B%200.79%20%2895%25%20CI%3A%200.78%20to%200.80%29%20Omicron%20cohort%3B%20and%200.79%20%2895%25%20CI%3A%200.79%20to%200.80%29%20UK%20cohort.%20Differences%20in%20prevalence%20of%20outcomes%20led%20to%20imperfect%20calibration%20in%20external%20validation.%20However%2C%20use%20of%20the%20score%20at%20thresholds%20of%20three%20or%20less%20would%20allow%20identification%20of%20very%20low-risk%20patients%20%28NPV%20%3E%5C%2F%3D0.99%29%20who%20could%20be%20rapidly%20discharged%20using%20information%20collected%20at%20initial%20assessment.%20CONCLUSION%3A%20The%20LMIC-PRIEST%20score%20shows%20good%20discrimination%20and%20high%20sensitivity%20at%20lower%20thresholds%20and%20can%20be%20used%20to%20rapidly%20identify%20low-risk%20patients%20in%20LMIC%20ED%20settings.%22%2C%22date%22%3A%222023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0287091%22%2C%22ISSN%22%3A%221932-6203%20%28Electronic%29%201932-6203%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A36%3A35Z%22%7D%7D%2C%7B%22key%22%3A%226YLLHW7Q%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMaruri%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWester%2C%20C.%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMusick%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFreeman%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Design%20and%20implementation%20of%20a%20global%20site%20assessment%20survey%20among%20HIV%20clinics%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20research%20consortium.%20%3Ci%3EPLoS%20One%3C%5C%2Fi%3E%2C%20%3Ci%3E18%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e0268167.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0268167%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0268167%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Design%20and%20implementation%20of%20a%20global%20site%20assessment%20survey%20among%20HIV%20clinics%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20research%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Hossmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Christ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kimmel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20E.%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Golub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%20consortium%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Timely%20descriptions%20of%20HIV%20service%20characteristics%20and%20their%20evolution%20over%20time%20across%20diverse%20settings%20are%20important%20for%20monitoring%20the%20scale-up%20of%20evidence-based%20program%20strategies%2C%20understanding%20the%20implementation%20landscape%2C%20and%20examining%20service%20delivery%20factors%20that%20influence%20HIV%20care%20outcomes.%20METHODS%3A%20The%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20undertakes%20periodic%20cross-sectional%20surveys%20on%20service%20availability%20and%20care%20at%20participating%20HIV%20treatment%20sites%20to%20characterize%20trends%20and%20inform%20the%20scientific%20agenda%20for%20HIV%20care%20and%20implementation%20science%20communities.%20IeDEA%27s%202020%20general%20site%20assessment%20survey%20was%20developed%20through%20a%20consultative%2C%2018-month%20process%20that%20engaged%20diverse%20researchers%20in%20identifying%20content%20from%20previous%20surveys%20that%20should%20be%20retained%20for%20longitudinal%20analyses%20and%20in%20developing%20expanded%20and%20new%20content%20to%20address%20gaps%20in%20the%20literature.%20An%20iterative%20review%20process%20was%20undertaken%20to%20standardize%20the%20format%20of%20new%20survey%20questions%20and%20align%20them%20with%20best%20practices%20in%20survey%20design%20and%20measurement%20and%20lessons%20learned%20through%20prior%20IeDEA%20site%20assessment%20surveys.%20RESULTS%3A%20The%20survey%20questionnaire%20developed%20through%20this%20process%20included%20eight%20content%20domains%20covered%20in%20prior%20surveys%20%28patient%20population%2C%20staffing%20and%20community%20linkages%2C%20HIV%20testing%20and%20diagnosis%2C%20new%20patient%20care%2C%20treatment%20monitoring%20and%20retention%2C%20routine%20HIV%20care%20and%20screening%2C%20pharmacy%2C%20record-keeping%20and%20patient%20tracing%29%2C%20along%20with%20expanded%20content%20related%20to%20antiretroviral%20therapy%20%28differentiated%20service%20delivery%20and%20roll-out%20of%20dolutegravir-based%20regimens%29%3B%20mental%20health%20and%20substance%20use%20disorders%3B%20care%20for%20pregnant%5C%2Fpostpartum%20women%20and%20HIV-exposed%20infants%3B%20tuberculosis%20preventive%20therapy%3B%20and%20pediatric%5C%2Fadolescent%20tuberculosis%20care%3B%20and%20new%20content%20related%20to%20Kaposi%27s%20sarcoma%20diagnostics%2C%20the%20impact%20of%20COVID-19%20on%20service%20delivery%2C%20and%20structural%20barriers%20to%20HIV%20care.%20The%20survey%20was%20distributed%20to%20238%20HIV%20treatment%20sites%20in%20late%202020%2C%20with%20a%2095%25%20response%20rate.%20CONCLUSION%3A%20IeDEA%27s%20approach%20for%20site%20survey%20development%20has%20broad%20relevance%20for%20HIV%20research%20networks%20and%20other%20priority%20health%20conditions.%22%2C%22date%22%3A%222023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0268167%22%2C%22ISSN%22%3A%221932-6203%20%28Electronic%29%201932-6203%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A18%3A14Z%22%7D%7D%5D%7D
Dantuluri, M. L. ;
Rubin, L. H. ;
Manabe, Y. C. ;
Moore, R. D. &
Althoff, K. N. (2023). Selection of cognitive impairment screening tools for longitudinal implementation in an HIV clinical care setting.
AIDS Care ,
35 (10), S. 1619–1627.
http://doi.org/10.1080/09540121.2023.2165614 .
Bocage, A. E. ; Coelho, L. E. ; Lake, J. E. ; Clark, J. L. ; Torres, T. S. et al. (2023). The Impact of COVID-19 on HIV Care in Rio de Janeiro, Brazil 2019-2021: Disparities by Age and Gender.
AIDS Behav ,
27 (8), S. 2629–2641.
http://doi.org/10.1007/s10461-023-03988-3 .
Zhou, W. ;
Bakoyannis, G. ;
Zhang, Y. &
Yiannoutsos, C. T. (2023). Semiparametric marginal regression for clustered competing risks data with missing cause of failure.
Biostatistics ,
24 (3), S. 795–810.
http://doi.org/10.1093/biostatistics/kxac012 .
Siedentop, B. ; Kachalov, V. N. ; Witzany, C. ; Egger, M. ; Kouyos, R. D. et al. (2023). The effect of combining antibiotics on resistance: A systematic review and meta-analysis.
MedRxiv , S. 2023.07.10.23292374.
http://doi.org/10.1101/2023.07.10.23292374 .
Thomadakis, C. ; Yiannoutsos, C. T. ; Pantazis, N. ; Diero, L. ; Mwangi, A. et al. (2023). The Effect of HIV Treatment Interruption on Subsequent Immunological Response.
Am J Epidemiol ,
192 (7), S. 1181–1191.
http://doi.org/10.1093/aje/kwad076 .
Ingle, S. M. ; Miro, J. M. ; May, M. T. ; Cain, L. E. ; Schwimmer, C. et al. (2023). Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study.
Clin Infect Dis ,
77 (1), S. 64–73.
http://doi.org/10.1093/cid/ciad122 .
Marincowitz, C. ; Sbaffi, L. ; Hasan, M. ; Hodkinson, P. ; McAlpine, D. et al. (2023). External validation of triage tools for adults with suspected COVID-19 in a middle-income setting: an observational cohort study.
Emerg Med J ,
40 (7), S. 509–517.
http://doi.org/10.1136/emermed-2022-212827 .
Person, A. K. ; Crabtree-Ramirez, B. ; Kim, A. ; Veloso, V. ; Maruri, F. et al. (2023). Cryptococcal Meningitis and Clinical Outcomes in Persons With Human Immunodeficiency Virus: A Global View.
Clin Infect Dis ,
76 (12), S. 2116–2125.
http://doi.org/10.1093/cid/ciad076 .
Kubjane, M. ;
Cornell, M. ;
Osman, M. ;
Boulle, A. &
Johnson, L. F. (2023). Drivers of sex differences in the South African adult tuberculosis incidence and mortality trends, 1990-2019.
Sci Rep ,
13 (1), S. 9487.
http://doi.org/10.1038/s41598-023-36432-6 .
Kassanjee, R. ; Davies, M. A. ; Ngwenya, O. ; Osei-Yeboah, R. ; Jacobs, T. et al. (2023). COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa.
J Int AIDS Soc ,
26 (6), S. e26104.
http://doi.org/10.1002/jia2.26104 .
Lea, A. N. ; Leyden, W. A. ; Sofrygin, O. ; Marafino, B. J. ; Skarbinski, J. et al. (2023). Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout.
Clin Infect Dis ,
76 (10), S. 1727–1734.
http://doi.org/10.1093/cid/ciad084 .
Banholzer, N. ; Zurcher, K. ; Jent, P. ; Bittel, P. ; Furrer, L. et al. (2023). SARS-CoV-2 transmission with and without mask wearing or air cleaners in schools in Switzerland: A modeling study of epidemiological, environmental, and molecular data.
PLoS Med ,
20 (5), S. e1004226.
http://doi.org/10.1371/journal.pmed.1004226 .
Nachega, J. B. ; Nsanzimana, S. ; Rawat, A. ; Wilson, L. A. ; Rosenthal, P. J. et al. (2023). Advancing detection and response capacities for emerging and re-emerging pathogens in Africa.
Lancet Infect Dis ,
23 (5), S. e185–e189.
http://doi.org/10.1016/S1473-3099(22)00723-X .
Murenzi, G. ; Kim, H. Y. ; Shi, Q. ; Muhoza, B. ; Munyaneza, A. et al. (2023). Association Between Time to Antiretroviral Therapy and Loss to Care Among Newly Diagnosed Rwandan People Living with Human Immunodeficiency Virus.
AIDS Res Hum Retroviruses ,
39 (5), S. 253–261.
http://doi.org/10.1089/AID.2022.0023 .
Admase, A. ; Joshi, S. ; Borse, R. ; Deshpande, P. ; Kulkarni, V. et al. (2023). Challenges with the use of Xpert HPV as a screening tool for oral HPV among people living with HIV (PLHIV): experiences from Pune, India.
BMC Infect Dis ,
23 (1), S. 233.
http://doi.org/10.1186/s12879-023-08210-2 .
Rajasuriar, R. ; Chong, M. L. ; Ross, J. L. ; Jiamsakul, A. ; Avihingsanon, A. et al. (2023). Factors associated with reduced function and quality of life among adult people with HIV with depression and substance use in the Asia-Pacific region.
AIDS ,
37 (5), S. 823–835.
http://doi.org/10.1097/QAD.0000000000003474 .
Patten, G. ; Sipambo, N. ; Technau, K. G. ; Euvrard, J. ; Ford, N. et al. (2023). Ongoing High Prevalence of Severe Immune Suppression Among Children in South Africa.
J Acquir Immune Defic Syndr ,
92 (4), S. 273–280.
http://doi.org/10.1097/QAI.0000000000003137 .
Zwyer, M. ; Rutaihwa, L. K. ; Windels, E. ; Hella, J. ; Menardo, F. et al. (2023). Back-to-Africa introductions of Mycobacterium tuberculosis as the main cause of tuberculosis in Dar es Salaam, Tanzania.
PLoS Pathog ,
19 (4), S. e1010893.
http://doi.org/10.1371/journal.ppat.1010893 .
Lu, X. ;
Wang, Y. ;
Bandyopadhyay, D. &
Bakoyannis, G. (2023). Sieve estimation of a class of partially linear transformation models with interval-censored competing risks data.
Stat Sin ,
33 (2), S. 685–704.
http://doi.org/10.5705/ss.202021.0051 .
Buzibye, A. ; Wools-Kaloustian, K. ; Olagunju, A. ; Twinomuhwezi, E. ; Yiannoutsos, C. et al. (2023). Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study.
AIDS Res Ther ,
20 (1), S. 20.
http://doi.org/10.1186/s12981-023-00514-2 .
Plaisy, M. K. ; Boni, S. P. ; Coffie, P. A. ; Tanon, A. ; Innocent, A. et al. (2023). Barriers to early diagnosis of cervical cancer: a mixed-method study in Cote d’Ivoire, West Africa.
BMC Womens Health ,
23 (1), S. 135.
http://doi.org/10.1186/s12905-023-02264-9 .
Vreeman, R. C. ; Yiannoutsos, C. T. ; Yusoff, N. K. N. ; Wester, C. W. ; Edmonds, A. et al. (2023). Global HIV prevention, care and treatment services for children: a cross-sectional survey from the International Epidemiology Databases to Evaluate AIDS (IeDEA) consortium.
BMJ Open ,
13 (3), S. e069399.
http://doi.org/10.1136/bmjopen-2022-069399 .
Patten, G. E. ; Euvrard, J. ; Anderegg, N. ; Boulle, A. ; Arendse, K. D. et al. (2023). Advanced HIV disease and engagement in care among patients on antiretroviral therapy in South Africa: results from a multi-state model.
AIDS ,
37 (3), S. 513–522.
http://doi.org/10.1097/QAD.0000000000003442 .
Parcesepe, A. M. ; Filiatreau, L. M. ; Gomez, A. ; Ebasone, P. V. ; Dzudie, A. et al. (2023). HIV-Related Stigma, Social Support, and Symptoms of Mental Health Disorders Among People with HIV Initiating HIV Care in Cameroon.
AIDS Patient Care STDS ,
37 (3), S. 146–154.
http://doi.org/10.1089/apc.2022.0187 .
Lewis-Kulzer, J. ; Mburu, M. ; Obatsa, S. ; Cheruiyot, J. ; Kiprono, L. et al. (2023). Patient perceptions of facilitators and barriers to reducing hazardous alcohol use among people living with HIV in East Africa.
Subst Abuse Treat Prev Policy ,
18 (1), S. 8.
http://doi.org/10.1186/s13011-023-00520-7 .
Lang, R. ; Hogan, B. ; Zhu, J. ; McArthur, K. ; Lee, J. et al. (2023). The prevalence of mental health disorders in people with HIV and the effects on the HIV care continuum.
AIDS ,
37 (2), S. 259–269.
http://doi.org/10.1097/QAD.0000000000003420 .
Lang, R. ; Gill, M. J. ; Coburn, S. B. ; Grossman, J. ; Gebo, K. A. et al. (2023). The changing prevalence of anemia and risk factors in people with HIV in North America who have initiated ART, 2007-2017.
AIDS ,
37 (2), S. 287–298.
http://doi.org/10.1097/QAD.0000000000003423 .
Aurpibul, L. ; Kosalaraksa, P. ; Kawichai, S. ; Lumbiganon, P. ; Ounchanum, P. et al. (2023). Alcohol use, suicidality and virologic non-suppression among young adults with perinatally acquired HIV in Thailand: a cross-sectional study.
J Int AIDS Soc ,
26 (2), S. e26064.
http://doi.org/10.1002/jia2.26064 .
Ross, J. ; Brazier, E. ; Fatti, G. ; Jaquet, A. ; Tanon, A. et al. (2023). Same-Day Antiretroviral Therapy Initiation as a Predictor of Loss to Follow-up and Viral Suppression Among People With Human Immunodeficiency Virus in Sub-Saharan Africa.
Clin Infect Dis ,
76 (1), S. 39–47.
http://doi.org/10.1093/cid/ciac759 .
Ross, J. ; Rupasinghe, D. ; Avihingsanon, A. ; Lee, M. P. ; Pujari, S. et al. (2023). Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020.
PLoS One ,
18 (6), S. e0287909.
http://doi.org/10.1371/journal.pone.0287909 .
Marincowitz, C. ; Hodkinson, P. ; McAlpine, D. ; Fuller, G. ; Goodacre, S. et al. (2023). LMIC-PRIEST: Derivation and validation of a clinical severity score for acutely ill adults with suspected COVID-19 in a middle-income setting.
PLoS One ,
18 (6), S. e0287091.
http://doi.org/10.1371/journal.pone.0287091 .
Brazier, E. ; Maruri, F. ; Wester, C. W. ; Musick, B. ; Freeman, A. et al. (2023). Design and implementation of a global site assessment survey among HIV clinics participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) research consortium.
PLoS One ,
18 (3), S. e0268167.
http://doi.org/10.1371/journal.pone.0268167 .
2022
2775998
GXCKG69T
2022
items
1
0
date
desc
https://www.iedea.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22instance%22%3A%22zotpress-5a5b0ae5f799513f6d2e208cdff932c5%22%2C%22meta%22%3A%7B%22request_last%22%3A50%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%2298CREFCG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Salvi%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-17%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESalvi%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERaichur%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKadam%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESangle%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGupte%2C%20N.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Virological%20failure%20among%20people%20living%20with%20HIV%20receiving%20second-line%20antiretroviral%20therapy%20in%20Pune%2C%20India.%20%3Ci%3EBMC%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E22%3C%5C%2Fi%3E%20%281%29%2C%20S.%20951.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-022-07894-2%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-022-07894-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Virological%20failure%20among%20people%20living%20with%20HIV%20receiving%20second-line%20antiretroviral%20therapy%20in%20Pune%2C%20India%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Salvi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Raichur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Kadam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Sangle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Gupte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Nevrekar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Patil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Chavan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nimkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Marbaniang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Mave%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20number%20of%20people%20receiving%20second-line%20antiretroviral%20therapy%20%28ART%29%20has%20increased%20as%20global%20access%20to%20ART%20has%20expanded.%20Data%20on%20the%20burden%20and%20factors%20associated%20with%20second-line%20ART%20virologic%20failure%20%28VF%29%20from%20India%20remain%20limited.%20METHODS%3A%20We%20conducted%20cross-sectional%20viral%20load%20%28VL%29%20testing%20among%20adults%20%28%3E%5C%2F%3D%2018%20years%29%20who%20were%20registered%20at%20a%20publicly%20funded%20ART%20center%20in%20western%20India%20between%202014%20and%202015%20and%20had%20received%20second-line%20ART%20for%20at%20least%206%20months.%20Sociodemographic%20and%20clinical%20characteristics%20were%20abstracted%20from%20routinely%20collected%20programmatic%20data.%20Logistic%20regression%20evaluated%20factors%20associated%20with%20VF%20%28defined%20as%20VL%20%3E%201000%20copies%5C%2FmL%29.%20RESULTS%3A%20Among%20400%20participants%2C%20median%20age%20was%2040%20years%20%28IQR%2034-44%29%2C%2071%25%20%28285%5C%2F400%29%20were%20male%2C%20and%2015%25%20%2859%5C%2F400%29%20had%20VF.%20Relative%20to%20participants%20without%20VF%2C%20those%20with%20VF%20had%20lower%20median%20CD4%20counts%20%28230%20vs%20406%20cells%5C%2Fmm%283%29%2C%20p%20%3C%200.0001%29%2C%20lower%20weight%20at%20first-line%20failure%20%2849%20vs%2052%20kg%2C%20p%20%3D%200.003%29%2C%20were%20more%20likely%20to%20have%20an%20opportunistic%20infection%20%2817%25%20vs%203%25%2C%20p%20%3C%200.0001%29%20and%20less%20likely%20to%20have%20optimal%20ART%20adherence%20%2871%25%20vs%2087%25%2C%20p%20%3D%200.005%29.%20In%20multivariable%20analysis%2C%20VF%20was%20associated%20with%20opportunistic%20infection%20%28aOR%2C%204.84%3B%2095%25%20CI%2C%201.77-13.24%29%2C%20lower%20CD4%20count%20%28aOR%204.15%3B%2095%25%20CI%2C%201.98-8.71%29%20and%20lower%20weight%20at%20first-line%20failure%20%28aOR%2C%202.67%3B%2095%25%20CI%2C%201.33-5.34%29.%20CONCLUSIONS%3A%20We%20found%20second-line%20VF%20in%20about%20a%20sixth%20of%20participants%20in%20our%20setting%2C%20which%20was%20associated%20with%20nearly%20fivefold%20increased%20odds%20in%20the%20context%20of%20opportunistic%20infection.%20Weight%20could%20be%20a%20useful%20clinical%20indicator%20for%20second-line%20VF.%22%2C%22date%22%3A%22Dec%2017%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12879-022-07894-2%22%2C%22ISSN%22%3A%221471-2334%20%28Electronic%29%201471-2334%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A33%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22ER3TKIH8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bourgi%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-15%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBourgi%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOfner%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMusick%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGriffith%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDiero%2C%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Weight%20Gain%20Among%20Treatment-Naive%20Persons%20With%20HIV%20Receiving%20Dolutegravir%20in%20Kenya.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E91%3C%5C%2Fi%3E%20%285%29%2C%20S.%20490%26%23x2013%3B496.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003087%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003087%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Weight%20Gain%20Among%20Treatment-Naive%20Persons%20With%20HIV%20Receiving%20Dolutegravir%20in%20Kenya%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Bourgi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Ofner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Griffith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20K.%22%2C%22lastName%22%3A%22Gupta%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Several%20recent%20studies%20have%20linked%20integrase%20strand%20transfer%20inhibitors%20%28INSTI%29%20with%20increased%20weight%20gain.%20SETTING%3A%20The%20effects%20of%20sex%20on%20weight%20gain%20with%20dolutegravir%20%28DTG%29-based%20antiretroviral%20therapy%20%28ART%29%20among%20treatment-naive%20participants%20in%20a%20lower-income%2C%20sub-Saharan%20population%20with%20high%20rates%20of%20pre-ART%20underweight%20and%20tuberculosis%20%28TB%29%20coinfection%20are%20unknown.%20METHODS%3A%20Our%20analysis%20included%20treatment-naive%20participants%20in%20Kenya%20and%20starting%20their%20first%20treatment%20regimen%20between%20January%201%2C%202015%2C%20and%20September%2030%2C%202018.%20Participants%20were%20grouped%20into%202%20cohorts%20based%20on%20the%20initial%20treatment%20regimen%20%5BDTG%20vs.%20nonnucleoside%20reverse%20transcriptase%20inhibitors%20%28NNRTI%29%5D.%20We%20modelled%20weight%20changes%20over%20time%20using%20a%20multivariable%20nonlinear%20mixed-effect%20model%2C%20with%20participant%20as%20a%20random%20effect.%20Logistic%20regression%20models%20were%20constructed%20to%20evaluate%20the%20association%20between%20different%20variables%20with%20extreme%20increase%20in%20body%20mass%20index%20%28%3E%5C%2F%3D10%25%20increase%29.%20RESULTS%3A%20Seventeen%20thousand%20forty-four%20participants%20met%20our%20inclusion%20criteria.%20Sixty-two%20percent%20of%20participants%20were%20women%2C%206%25%20were%20receiving%20active%20TB%20therapy%2C%20and%2097%25%20were%20on%20NNRTI-based%20regimens.%20Participants%20starting%20DTG-based%20regimens%20were%20more%20likely%20to%20gain%20weight%20when%20compared%20with%20participants%20starting%20NNRTI-based%20regimens.%20Female%20participants%20starting%20DTG-based%20regimens%20experienced%20the%20highest%20weight%20gain%20compared%20with%20other%20participants%20%28mean%20gain%20of%206.1%20kgs%20at%2018%20months%29.%20Female%20participants%20receiving%20DTG-based%20regimens%2C%20along%20with%20participants%20with%20lower%20CD4%20cell%20counts%2C%20underweight%20at%20baseline%2C%20and%20those%20receiving%20active%20TB%20therapy%20were%20also%20at%20higher%20risk%20for%20extreme%20body%20mass%20index%20increase.%20CONCLUSIONS%3A%20Our%20study%20in%20a%20lower-income%20sub-Saharan%20African%20population%20confirms%20higher%20weight%20gain%20with%20DTG-based%20regimens%20compared%20with%20traditional%20ART%20for%20treatment-naive%20patients.%22%2C%22date%22%3A%22Dec%2015%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003087%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A34%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22TE2K37AV%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lesko%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELesko%2C%20C.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKeruly%2C%20J.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMoore%2C%20R.%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShen%2C%20N.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPytell%2C%20J.%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20COVID-19%20and%20the%20HIV%20continuum%20in%20people%20living%20with%20HIV%20enrolled%20in%20Collaborating%20Consortium%20of%20Cohorts%20Producing%20NIDA%20Opportunities%20%28C3PNO%29%20cohorts.%20%3Ci%3EDrug%20Alcohol%20Depend%3C%5C%2Fi%3E%2C%20%3Ci%3E241%3C%5C%2Fi%3E%2C%20S.%20109355.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.drugalcdep.2022.109355%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.drugalcdep.2022.109355%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22COVID-19%20and%20the%20HIV%20continuum%20in%20people%20living%20with%20HIV%20enrolled%20in%20Collaborating%20Consortium%20of%20Cohorts%20Producing%20NIDA%20Opportunities%20%28C3PNO%29%20cohorts%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20R.%22%2C%22lastName%22%3A%22Lesko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20C.%22%2C%22lastName%22%3A%22Keruly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20M.%22%2C%22lastName%22%3A%22Shen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20D.%22%2C%22lastName%22%3A%22Pytell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Lau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20T.%22%2C%22lastName%22%3A%22Fojo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20H.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kipke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20K.%22%2C%22lastName%22%3A%22Baum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Shoptaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Gorbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Mustanski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Javanbakht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Siminski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Chander%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20COVID-19%20pandemic%20disrupted%20the%20normal%20delivery%20of%20HIV%20care%2C%20altered%20social%20support%20networks%2C%20and%20caused%20economic%20insecurity.%20People%20with%20HIV%20%28PWH%29%20are%20vulnerable%20to%20such%20disruptions%2C%20particularly%20if%20they%20have%20a%20history%20of%20substance%20use.%20We%20describe%20engagement%20in%20care%20and%20adherence%20to%20antiretroviral%20therapy%20%28ART%29%20for%20PWH%20during%20the%20pandemic.%20METHODS%3A%20From%20May%202020%20to%20February%202021%2C%20773%20PWH%20enrolled%20in%206%20existing%20cohorts%20completed%201495%20surveys%20about%20substance%20use%20and%20engagement%20in%20HIV%20care%20during%20the%20COVID-19%20pandemic.%20We%20described%20the%20prevalence%20and%20correlates%20of%20having%20missed%20a%20visit%20with%20an%20HIV%20provider%20in%20the%20past%20month%20and%20having%20missed%20a%20dose%20of%20ART%20in%20the%20past%20week.%20RESULTS%3A%20Thirteen%20percent%20of%20people%20missed%20an%20HIV%20visit%20in%20the%20past%20month.%20Missing%20a%20visit%20was%20associated%20with%20unstable%20housing%2C%20food%20insecurity%2C%20anxiety%2C%20low%20resiliency%2C%20disruptions%20to%20mental%20health%20care%2C%20and%20substance%20use%20including%20cigarette%20smoking%2C%20hazardous%20alcohol%20use%2C%20cocaine%2C%20and%20cannabis%20use.%20Nineteen%20percent%20of%20people%20reported%20missing%20at%20least%20one%20dose%20of%20ART%20in%20the%20week%20prior%20to%20their%20survey.%20Missing%20a%20dose%20of%20ART%20was%20associated%20with%20being%20a%20man%2C%20low%20resiliency%2C%20disruptions%20to%20mental%20health%20care%2C%20cigarette%20smoking%2C%20hazardous%20alcohol%20use%2C%20cocaine%2C%20and%20cannabis%20use%2C%20and%20experiencing%20disruptions%20to%20substance%20use%20treatment.%20CONCLUSIONS%3A%20Social%20determinants%20of%20health%2C%20substance%20use%2C%20and%20disruptions%20to%20mental%20health%20and%20substance%20use%20treatment%20were%20associated%20with%20poorer%20engagement%20in%20HIV%20care.%20Close%20attention%20to%20continuity%20of%20care%20during%20times%20of%20social%20disruption%20is%20especially%20critical%20for%20PWH.%22%2C%22date%22%3A%22Dec%201%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.drugalcdep.2022.109355%22%2C%22ISSN%22%3A%221879-0046%20%28Electronic%29%200376-8716%20%28Print%29%200376-8716%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22LHALPPPF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22McCann%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcCann%2C%20N.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStanic%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPenazzato%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFlanagan%2C%20C.%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAbrams%2C%20E.%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Prevalence%20of%20undiagnosed%20HIV%20among%20children%20in%20South%20Africa%2C%20Cote%20d%26%23x2019%3BIvoire%20and%20Zimbabwe%3A%20a%20model-based%20analysis%20to%20inform%20paediatric%20HIV%20screening%20programmes.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%2812%29%2C%20S.%20e26045.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26045%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26045%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20of%20undiagnosed%20HIV%20among%20children%20in%20South%20Africa%2C%20Cote%20d%27Ivoire%20and%20Zimbabwe%3A%20a%20model-based%20analysis%20to%20inform%20paediatric%20HIV%20screening%20programmes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20C.%22%2C%22lastName%22%3A%22McCann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Stanic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Penazzato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20F.%22%2C%22lastName%22%3A%22Flanagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20J.%22%2C%22lastName%22%3A%22Abrams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Dugdale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Neilan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Freedberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Fassinou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Doherty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Essajee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mushavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20I.%22%2C%22lastName%22%3A%22Soeteman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Ciaranello%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20To%20improve%20the%20diagnosis%20and%20survival%20of%20children%20living%20with%20HIV%20%28CLWH%29%2C%20the%20World%20Health%20Organization%20recommends%20testing%20approaches%20beyond%20traditional%20infant%20HIV%20testing%20programmes.%20Information%20about%20undiagnosed%20HIV%20prevalence%20among%20children%20of%20varying%20ages%20in%20the%20general%20population%20is%20needed%20to%20guide%20innovative%20national%5C%2Fsubnational%20case-finding%20and%20testing%20approaches.%20METHODS%3A%20We%20used%20the%20Cost-Effectiveness%20of%20Preventing%20AIDS%20Complications%20%28CEPAC%29-Pediatric%20model%20to%20estimate%20the%20prevalence%20of%20undiagnosed%20HIV%20in%202-%2C%205-%20and%2010-year-old%20children%20in%20South%20Africa%2C%20Cote%20d%27Ivoire%20and%20Zimbabwe%20in%202018.%20We%20simulated%20cohorts%20of%20children%20born%20in%202008%20%2810-year-olds%29%2C%202013%20%285-year-olds%29%20and%202016%20%282-year-olds%29.%20Country-%5C%2Fyear-specific%20inputs%20for%20pregnant%5C%2Fbreastfeeding%20women%20included%3A%20HIV%20prevalence%20%284.2-32.3%25%29%2C%20HIV%20incidence%20%280.03-0.24%25%5C%2Fmonth%29%2C%20knowledge%20of%20HIV%20status%20%2827-89%25%29%20and%20antiretroviral%20drug%20coverage%20%2836-95%25%29.%20Paediatric%20inputs%20included%20early%20infant%20testing%20coverage%20%286-95%25%29%20and%20breastfeeding%20duration%20%280-20%20months%29.%20We%20projected%20the%20proportion%20of%20surviving%20CLWH%20in%20whom%20HIV%20remained%20undiagnosed%20and%20the%20undiagnosed%20HIV%20prevalence%20among%20surviving%20children%20of%20each%20age%20in%20the%20general%20population.%20For%20children%20born%20in%202016%2C%20we%20projected%20survival%20and%20diagnosis%20of%20all%20CLWH%20through%202026.%20We%20conducted%20sensitivity%20analyses%20on%20model%20parameters.%20RESULTS%3A%20In%202018%2C%20the%20projected%20proportion%20of%20surviving%20CLWH%20whose%20HIV%20remained%20undiagnosed%20in%20South%20Africa%5C%2FCote%20d%27Ivoire%5C%2FZimbabwe%20was%2044.2%25%5C%2F55.8%25%5C%2F52.9%25%20among%202-year-old%20CLWH%3B%2029.0%25%5C%2F37.8%25%5C%2F33.2%25%20among%205-year-old%20CLWH%3B%20and%2018.3%25%5C%2F25.4%25%5C%2F23.1%25%20among%2010-year-old%20CLWH.%20Projected%20general%20population%20undiagnosed%20HIV%20prevalence%20in%20South%20Africa%5C%2FCote%20d%27Ivoire%5C%2FZimbabwe%20was%200.44%25%5C%2F0.32%25%5C%2F0.68%25%20among%202-year-olds%3B%200.25%25%5C%2F0.17%25%5C%2F0.41%25%20among%205-year-olds%3B%20and%200.24%25%5C%2F0.14%25%5C%2F0.38%25%20among%2010-year-olds.%20Among%20all%20CLWH%20born%20in%202016%2C%2050-54%25%20were%20projected%20to%20die%20without%20HIV%20diagnosis%20%28and%20subsequently%20without%20treatment%29%20within%2010%20years%20after%20birth%3B%2080-85%25%20of%20these%20deaths%20occurred%20in%20the%20first%202%20years.%20CONCLUSIONS%3A%20Projected%20population-level%20undiagnosed%20HIV%20prevalence%20is%20low%20and%20sharply%20decreases%20after%20age%202%2C%20with%20more%20CLWH%20dying%20than%20being%20diagnosed.%20Despite%20low%20undiagnosed%20prevalence%20in%20the%20general%20population%20of%20older%20children%2C%20we%20project%20that%20a%20large%20proportion%20of%20CLWH%20remain%20undiagnosed%2C%20suggesting%20that%20innovative%20strategies%20targeting%20untested%20children%20of%20all%20ages%20outside%20of%20health%20facility%20settings%20should%20be%20prioritized.%20Programmes%20could%20consider%20routine%20testing%20of%20the%20general%20population%20of%20children%20below%202%20in%20all%20settings%20and%20children%20of%20all%20ages%20in%20high-prevalence%20settings.%22%2C%22date%22%3A%22Dec%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26045%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A24%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22P6SLCVLG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chihota%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChihota%2C%20B.%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMandiriri%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShamu%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuula%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyamutowa%2C%20H.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Metabolic%20syndrome%20among%20treatment-naive%20people%20living%20with%20and%20without%20HIV%20in%20Zambia%20and%20Zimbabwe%3A%20a%20cross-sectional%20analysis.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%2812%29%2C%20S.%20e26047.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26047%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26047%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Metabolic%20syndrome%20among%20treatment-naive%20people%20living%20with%20and%20without%20HIV%20in%20Zambia%20and%20Zimbabwe%3A%20a%20cross-sectional%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20V.%22%2C%22lastName%22%3A%22Chihota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mandiriri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Nyamutowa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Taderera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Mwamba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chilengi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton-Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bosomprah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20Southern%20Africa%22%2C%22lastName%22%3A%22for%20Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Chronic%20viral%20replication%20has%20been%20linked%20to%20an%20increased%20risk%20of%20cardiovascular%20and%20metabolic%20diseases%20in%20people%20living%20with%20HIV%20%28PLWH%29%2C%20but%20few%20studies%20have%20evaluated%20this%20association%20in%20Southern%20Africa.%20We%20explored%20the%20determinants%20of%20metabolic%20syndrome%20%28MetS%29%20among%20treatment-naive%20adults%20living%20with%20and%20without%20HIV%20in%20Southern%20Africa.%20METHODS%3A%20Treatment-naive%20PLWH%20and%20people%20living%20without%20HIV%20%28PLWOH%29%20%3E%5C%2F%3D30%20years%20were%20consecutively%20enrolled%20from%20primary%20care%20clinics%20in%20Zambia%20and%20Zimbabwe.%20PLWOH%20were%20seronegative%20partners%20or%20persons%20presenting%20for%20HIV%20testing.%20We%20defined%20MetS%20as%20the%20presence%20of%20central%20obesity%20plus%20any%20two%20of%20the%20following%3A%20raised%20blood%20pressure%2C%20impaired%20fasting%20glucose%2C%20reduced%20high-density%20lipoprotein%20cholesterol%20and%20raised%20triglycerides%2C%20as%20defined%20by%20the%20International%20Diabetes%20Federation.%20We%20used%20logistic%20regression%20to%20determine%20factors%20associated%20with%20MetS.%20RESULTS%3A%20Between%20August%202019%20and%20March%202022%2C%20we%20screened%201285%20adults%20and%20enrolled%20420%20%2847%25%29%20PLWH%20and%20481%20%2853%25%29%20PLWOH.%20The%20median%20age%20was%20similar%20between%20PLWH%20and%20PLWOH%20%2840%20vs.%2038%20years%2C%20p%20%3C%200.24%29.%20In%20PLWH%2C%20the%20median%20CD4%28%2B%29%20count%20was%20228%20cells%5C%2Fmm%283%29%20%28IQR%20108-412%29%20and%20the%20viral%20load%20was%2024%2C114%20copies%5C%2Fml%20%28IQR%20277-214%2C271%29.%20Central%20obesity%20was%20present%20in%20365%5C%2F523%20%2870%25%29%20females%20and%2057%5C%2F378%20males%20%2815%25%29.%20MetS%20was%20diagnosed%20in%20172%5C%2F901%20%2819%25%2C%2095%25%20confidence%20interval%20%5BCI%5D%2017-22%25%29%2C%20and%20prevalence%20was%20higher%20among%20females%20than%20males%20%2827%25%20vs.%209%25%29.%20In%20multivariable%20analyses%2C%20HIV%20status%20was%20not%20associated%20with%20MetS%20%28adjusted%20odds%20ratio%20%5BaOR%5D%201.05%2C%2095%25%20CI%200.74-1.51%29.%20Risk%20factors%20for%20MetS%20included%20age%20older%20than%2050%20years%20%28aOR%202.31%2C%2095%25%20CI%201.49-3.59%29%2C%20female%20sex%20%28aOR%203.47%2C%2095%25%20CI%202.15-5.60%29%2C%20highest%20income%20%28aOR%202.19%2C%2095%25%20CI%201.39-3.44%29%20and%20less%20than%20World%20Health%20Organization%20recommended%20weekly%20physical%20activity%20%28aOR%203.35%2C%2095%25%20CI%201.41-7.96%29.%20CONCLUSIONS%3A%20We%20report%20a%20high%20prevalence%20of%20MetS%20and%20central%20obesity%20among%20females%20in%20urban%20Zambia%20and%20Zimbabwe.%20Lifestyle%20factors%20and%20older%20age%20appear%20to%20be%20the%20strongest%20predictors%20of%20MetS%20in%20our%20population%2C%20with%20no%20evident%20difference%20in%20MetS%20prevalence%20between%20treatment-naive%20PLWH%20and%20PLWOH.%22%2C%22date%22%3A%22Dec%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26047%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A34%3A26Z%22%7D%7D%2C%7B%22key%22%3A%224QMJKWAF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAjeh%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMaruri%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMusick%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFreeman%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Service%20delivery%20challenges%20in%20HIV%20care%20during%20the%20first%20year%20of%20the%20COVID-19%20pandemic%3A%20results%20from%20a%20site%20assessment%20survey%20across%20the%20global%20IeDEA%20consortium.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%2812%29%2C%20S.%20e26036.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26036%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26036%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Service%20delivery%20challenges%20in%20HIV%20care%20during%20the%20first%20year%20of%20the%20COVID-19%20pandemic%3A%20results%20from%20a%20site%20assessment%20survey%20across%20the%20global%20IeDEA%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree%20Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22d%27Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Tanser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Interruptions%20in%20treatment%20pose%20risks%20for%20people%20with%20HIV%20%28PWH%29%20and%20threaten%20progress%20in%20ending%20the%20HIV%20epidemic%3B%20however%2C%20the%20COVID-19%20pandemic%27s%20impact%20on%20HIV%20service%20delivery%20across%20diverse%20settings%20is%20not%20broadly%20documented.%20METHODS%3A%20From%20September%202020%20to%20March%202021%2C%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20research%20consortium%20surveyed%20238%20HIV%20care%20sites%20across%20seven%20geographic%20regions%20to%20document%20constraints%20in%20HIV%20service%20delivery%20during%20the%20first%20year%20of%20the%20pandemic%20and%20strategies%20for%20ensuring%20care%20continuity%20for%20PWH.%20Descriptive%20statistics%20were%20stratified%20by%20national%20HIV%20prevalence%20%28%3C1%25%2C%201-4.9%25%20and%20%3E%5C%2F%3D5%25%29%20and%20country%20income%20levels.%20RESULTS%3A%20Questions%20about%20pandemic-related%20consequences%20for%20HIV%20care%20were%20completed%20by%20225%20%2895%25%29%20sites%20in%2042%20countries%20with%20low%20%28n%20%3D%2082%29%2C%20medium%20%28n%20%3D%2086%29%20and%20high%20%28n%20%3D%2057%29%20HIV%20prevalence%2C%20including%20low-%20%28n%20%3D%2057%29%2C%20lower-middle%20%28n%20%3D%2079%29%2C%20upper-middle%20%28n%20%3D%2039%29%20and%20high-%20%28n%20%3D%2050%29%20income%20countries.%20Most%20sites%20reported%20being%20subject%20to%20pandemic-related%20restrictions%20on%20travel%2C%20service%20provision%20or%20other%20operations%20%2875%25%29%2C%20and%20experiencing%20negative%20impacts%20%2876%25%29%20on%20clinic%20operations%2C%20including%20decreased%20hours%5C%2Fdays%2C%20reduced%20provider%20availability%2C%20clinic%20reconfiguration%20for%20COVID-19%20services%2C%20record-keeping%20interruptions%20and%20suspension%20of%20partner%20support.%20Almost%20all%20sites%20in%20low-prevalence%20and%20high-income%20countries%20reported%20increased%20use%20of%20telemedicine%20%2885%25%20and%20100%25%2C%20respectively%29%2C%20compared%20with%20less%20than%20half%20of%20sites%20in%20high-prevalence%20and%20lower-income%20settings.%20Few%20sites%20in%20high-prevalence%20settings%20%282%25%29%20reported%20suspending%20antiretroviral%20therapy%20%28ART%29%20clinic%20services%2C%20and%20many%20reported%20adopting%20mitigation%20strategies%20to%20support%20adherence%2C%20including%20multi-month%20dispensing%20of%20ART%20%2895%25%29%20and%20designating%20community%20ART%20pick-up%20points%20%2844%25%29.%20While%20few%20sites%20%285%25%29%20reported%20stockouts%20of%20first-line%20ART%20regimens%2C%2010-11%25%20reported%20stockouts%20of%20second-%20and%20third-line%20regimens%2C%20respectively%2C%20primarily%20in%20high-prevalence%20and%20lower-income%20settings.%20Interruptions%20in%20HIV%20viral%20load%20%28VL%29%20testing%20included%20suspension%20of%20testing%20%2822%25%29%2C%20longer%20turnaround%20times%20%2841%25%29%20and%20supply%5C%2Freagent%20stockouts%20%2822%25%29%2C%20but%20did%20not%20differ%20across%20settings.%20CONCLUSIONS%3A%20While%20many%20sites%20in%20high%20HIV%20prevalence%20settings%20and%20lower-income%20countries%20reported%20introducing%20or%20expanding%20measures%20to%20support%20treatment%20adherence%20and%20continuity%20of%20care%2C%20the%20COVID-19%20pandemic%20resulted%20in%20disruptions%20to%20VL%20testing%20and%20ART%20supply%20chains%20that%20may%20negatively%20affect%20the%20quality%20of%20HIV%20care%20in%20these%20settings.%22%2C%22date%22%3A%22Dec%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26036%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A27%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22UUQZLRB7%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jiamsakul%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJiamsakul%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGani%2C%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAvihingsanon%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAzwa%2C%20I.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChaiwarith%2C%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Brief%20Report%3A%20Mortality%20After%20Loss%20to%20Follow-Up-A%20Linkage%20Study%20of%20People%20Living%20With%20HIV%20in%20Thailand%20and%20Malaysia.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E91%3C%5C%2Fi%3E%20%283%29%2C%20S.%20290%26%23x2013%3B295.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003067%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003067%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Brief%20Report%3A%20Mortality%20After%20Loss%20to%20Follow-Up-A%20Linkage%20Study%20of%20People%20Living%20With%20HIV%20in%20Thailand%20and%20Malaysia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Gani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Azwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chaiwarith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20Asia-Pacific%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Linkage%20studies%20have%20reported%20high%20rates%20of%20previously%20unascertained%20mortality%20among%20people%20living%20with%20HIV%20%28PLHIV%29%20who%20have%20been%20lost%20to%20follow-up%20%28LTFU%29.%20We%20assessed%20survival%20outcomes%20among%20PLHIV%20who%20were%20LTFU%20in%20Thailand%20and%20Malaysia%2C%20through%20linkages%20to%20a%20national%20death%20registry%20or%20HIV%20database.%20METHODS%3A%20Data%20linkages%20with%20the%20national%20death%20registry%20or%20national%20HIV%20database%20were%20conducted%20in%202020%20on%20all%20PLHIV%20who%20met%20LTFU%20criteria%20while%20enrolled%20in%20care%20at%20participating%20HIV%20clinical%20sites.%20LTFU%20was%20defined%20as%20having%20no%20documented%20clinical%20contact%20in%20the%20previous%20year%2C%20excluding%20transfers%20and%20deaths.%20Survival%20time%20was%20analyzed%20using%20the%20Cox%20regression%2C%20stratified%20by%20site.%20RESULTS%3A%20Data%20linkages%20were%20performed%20for%20489%20PLHIV%20who%20had%20been%20LTFU%20at%20sites%20in%20Malaysia%20%28n%20%3D%202%29%20and%20Thailand%20%28n%20%3D%204%29.%20There%20were%20151%20%2831%25%29%20deaths%20after%20being%20LTFU%3B%20the%20mortality%20rate%20was%204.89%20per%20100%20person-years.%20Risk%20factors%20for%20mortality%20after%20being%20LTFU%20were%20older%20age%20%5B41-50%20years%3A%20hazard%20ratio%20%28HR%29%20%3D%201.99%2C%2095%25%20confidence%20interval%20%28CI%29%3A%201.08%20to%203.68%3B%20and%20older%20than%2050%20years%3A%20HR%20%3D%204.93%2C%2095%25%20CI%3A%202.63%20to%209.22%3B%20vs.%20age%2030%20years%20or%20younger%5D%3B%20receiving%20NRTI%20%2B%20PI%20%28HR%20%3D%201.87%2C%2095%25%20CI%3A%201.22%20to%202.85%20vs.%20NRTI%20%2B%20NNRTI%29%3B%20positive%20hepatitis%20C%20antibody%20%28HR%20%3D%202.25%2C%2095%25%20CI%3A%201.40%20to%203.62%29%3B%20and%20having%20previous%20AIDS%20illness%20%28HR%20%3D%201.45%2C%2095%25%20CI%3A%201.03%20to%202.05%29.%20An%20improved%20survival%20was%20seen%20with%20a%20higher%20CD4%20count%20%28CD4%20351-500%20cells%5C%2FmicroL%3A%20HR%20%3D%200.40%2C%2095%25CI%3A%200.21-0.76%3B%20and%20CD4%20%26gt%3B500%20cells%5C%2FmicroL%3A%20HR%20%3D%200.43%2C%2095%25CI%3A%200.25-0.75%3B%20vs.%20CD4%20%3C%5C%2F%3D200%20cells%5C%2FmicroL%29.%20CONCLUSIONS%3A%20Almost%20one-third%20of%20PLHIV%20who%20were%20LTFU%20in%20this%20cohort%20had%20died%20while%20out%20of%20care%2C%20emphasizing%20the%20importance%20of%20efforts%20to%20reengage%20PLHIV%20after%20they%20have%20been%20LTFU%20and%20ensure%20they%20have%20access%20to%20ongoing%20ART.%22%2C%22date%22%3A%22Nov%201%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003067%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A37%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22HRKURFRR%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rupasinghe%20et%20al.%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERupasinghe%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChoi%2C%20J.%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYunihastuti%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKiertiburanakul%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoss%2C%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Factors%20associated%20with%20high%20alanine%20aminotransferase%20%28ALT%29%20and%20cirrhosis%20in%20people%20living%20with%20HIV%20on%20combination%20antiretroviral%20treatment%20%28cART%29%20in%20the%20Asia-Pacific.%20%3Ci%3EJ%20Med%20Virol%3C%5C%2Fi%3E%2C%20%3Ci%3E94%3C%5C%2Fi%3E%20%2811%29%2C%20S.%205451%26%23x2013%3B5464.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjmv.28019%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjmv.28019%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Factors%20associated%20with%20high%20alanine%20aminotransferase%20%28ALT%29%20and%20cirrhosis%20in%20people%20living%20with%20HIV%20on%20combination%20antiretroviral%20treatment%20%28cART%29%20in%20the%20Asia-Pacific%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Yunihastuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20S.%22%2C%22lastName%22%3A%22Ly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chaiwarith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kamarulzaman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Van%20Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20P.%22%2C%22lastName%22%3A%22Merati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Sangle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Oon%20Tek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Tanuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ditangco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20L.%20H.%22%2C%22lastName%22%3A%22Sim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Pujari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22Treat%20Asia%20HIV%20Observational%20Database%20of%20IeDEA%20Asia-Pacific%22%7D%5D%2C%22abstractNote%22%3A%22Liver%20disease%20is%20a%20growing%20burden%20among%20people%20living%20with%20HIV%20%28PLHIV%29%20in%20resource-limited%20settings.%20As%20an%20indicator%20of%20liver%20disease%2C%20risk%20factors%20of%20high%20alanine%20aminotransferase%20%28ALT%29%20and%20cirrhosis%20were%20assessed%20among%20PLHIV%20in%20the%20TREAT%20Asia%20HIV%20Observational%20Database%20%28TAHOD%29.%20Patients%20on%20combination%20antiretroviral%20therapy%20%28cART%29%20with%20a%20pre-cART%20ALT%20measurement%20and%20at%20least%20one%20follow-up%20ALT%20measurement%20were%20included.%20Factors%20associated%20with%20high%20ALT%20%28ALT%20levels%20%3E%205%20times%20its%20upper%20limit%20of%20normal%29%20were%20analyzed%20using%20repeated%20measure%20logistic%20regression%20over%20a%2010-year%20follow-up%20period.%20Liver%20cirrhosis%20was%20defined%20as%20having%20an%20AST%20to%20Platelet%20Ratio%20Index%20score%20%3E%201.5%2C%20fibrosis-4%20score%20%3E%203.25%2C%20or%20a%20clinical%20diagnosis%20of%20cirrhosis.%20Cox%20regression%20analysis%20stratified%20by%20site%20was%20used%20to%20analyze%20factors%20associated%20with%20cirrhosis%20among%20those%20in%20follow-up%20after%202015.%20Of%205182%20patients%2C%20101%20patients%20%281.9%25%29%20had%20high%20ALT%20levels%20with%20hepatitis%20C%20virus%20%28HCV%29%20antibody%20positive%20%28odds%20ratio%20%5BOR%5D%3A%204.98%2C%2095%25%20confidence%20interval%20%5BCI%5D%3A%202.82-8.77%2C%20p%20%3C%200.001%29%20and%20ever%20high%20alcohol%20consumption%20%28OR%3A%202.33%2C%2095%25%20CI%3A%201.00-5.46%2C%20p%20%3D%200.050%29%20as%20likely%20factors.%20Among%206318%20PLHIV%20in%20the%20liver%20cirrhosis%20analysis%2C%20151%20%282%25%29%20developed%20cirrhosis%20%28incidence%20rate%20%3D%200.82%20per%20100%20person-years%29.%20Those%20HCV-antibody%20positive%20%28hazard%20ratio%20%5BHR%5D%3A%205.54%2C%2095%25%20CI%3A%203.75-8.18%2C%20p%20%3C%200.001%29%20and%20had%20high%20alcohol%20consumption%20%28HR%3A%202.06%2C%2095%25%20CI%3A%201.23-3.45%2C%20p%20%3D%200.006%29%20were%20associated%20with%20liver%20cirrhosis.%20HCV-antibody%20positive%20and%20high%20alcohol%20consumption%20are%20factors%20associated%20with%20high%20ALT.%20With%20raised%20ALT%20levels%20as%20a%20known%20factor%20associated%20with%20liver%20cirrhosis%2C%20greater%20efforts%20are%20required%20in%20managing%20ALT%20levels%20and%20reducing%20the%20risk%20of%20developing%20liver%20cirrhosis%20among%20those%20positive%20for%20HCV-antibody%20and%20those%20who%20consume%20alcohol.%22%2C%22date%22%3A%22Nov%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjmv.28019%22%2C%22ISSN%22%3A%221096-9071%20%28Electronic%29%200146-6615%20%28Print%29%200146-6615%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A45%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22TLX7GHP2%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sobral%20et%20al.%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESobral%2C%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EArriaga%2C%20M.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESouza%2C%20A.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAraujo-Pereira%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBarreto-Duarte%2C%20B.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Determinants%20of%20losses%20in%20the%20tuberculosis%20infection%20cascade%20of%20care%20among%20children%20and%20adolescent%20contacts%20of%20pulmonary%20tuberculosis%20cases%3A%20A%20Brazilian%20multi-centre%20longitudinal%20study.%20%3Ci%3ELancet%20Reg%20Health%20Am%3C%5C%2Fi%3E%2C%20%3Ci%3E15%3C%5C%2Fi%3E%2C%20S.%20100358.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2022.100358%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2022.100358%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determinants%20of%20losses%20in%20the%20tuberculosis%20infection%20cascade%20of%20care%20among%20children%20and%20adolescent%20contacts%20of%20pulmonary%20tuberculosis%20cases%3A%20A%20Brazilian%20multi-centre%20longitudinal%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Sobral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Araujo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Sales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22de%20Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Silva%20J.%20R.%22%2C%22lastName%22%3A%22Lapa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Approximately%2010%25%20of%20the%20global%20tuberculosis%20%28TB%29%20burden%20is%20in%20children.%20Identification%2C%20diagnosis%2C%20and%20early%20treatment%20of%20Mycobacterium%20tuberculosis%20infection%20%28TBI%29%20is%20critical%20to%20prevent%20progression%20to%20TB%20in%20children.%20The%20risk%20of%20TB%2C%20including%20severe%20disease%2C%20is%20highest%20in%20children%20%3C5%20years%20old.%20We%20evaluated%20the%20cascade%20of%20TBI%20care%20among%20child%20and%20adolescent%20TB%20contacts%20to%20identify%20factors%20associated%20with%20losses%20in%20the%20cascade.%20METHODS%3A%20Close%20contacts%20%3C%5C%2F%3D%2018%20years%20old%20of%20pulmonary%20TB%20patients%20enrolled%20between%202015%20and%202019%20in%20a%20multi-centre%20Brazilian%20cohort%20were%20followed%20for%20up%20to%2024%20months%20and%20classified%20according%20to%20age%20groups%3A%20%3C5%20years%2C%205-9%20years%2C%2010-14%20years%20and%2015-18%20years.%20Data%20on%20clinical%20investigation%2C%20radiographic%20examination%2C%20IGRA%20testing%20at%20baseline%20and%206%20months%2C%20initiation%20and%20completion%20of%20TB%20preventive%20treatment%20%28TPT%29%20were%20collected.%20Multivariable%20regression%20analyses%20identified%20factors%20associated%20with%20TBI%20and%20losses%20in%20the%20cascade%20of%20care%20in%20children%20and%20adolescents.%20FINDINGS%3A%20Among%201795%20TB%20contacts%20initially%20identified%2C%20530%20%2829.5%25%29%20were%20%3C%5C%2F%3D18%20years%20old.%20Losses%20for%20all%20steps%20in%20the%20cascade%20were%20especially%20high%20in%20children%20%3C5%20years%20old%20%2888%25%29%20because%20at%20this%20age%20all%20contacts%20are%20recommended%20to%20initiate%20TPT.%20As%20a%20proportion%20of%20all%20children%2C%20completion%20of%20TPT%20was%20low%20%28between%2010%25%20and%2013%25%29%20in%20all%20age-groups.%20Furthermore%2C%20multivariable%20regression%20revealed%20that%20younger%20age%20of%20contacts%20and%20TB%20index%20cases%20who%20were%20female%2C%20had%20pulmonary%20cavities%2C%20and%20persistent%20cough%20were%20independently%20associated%20with%20losses%20in%20the%20cascade%20of%20care%20among%20persons%20%3C%5C%2F%3D18%20years%20old.%20INTERPRETATION%3A%20Losses%20in%20the%20TBI%20cascade%20were%20the%20highest%20among%20children%20%3C5%20years%2C%20which%20was%20the%20group%20at%20highest%20risk%20for%20TB%20among%20the%20four%20age%20groups.%20The%20findings%20highlight%20the%20need%20to%20improve%20screening%2C%20initiation%2C%20and%20completion%20of%20TPT%20of%20young%20children%20who%20are%20close%20contacts%20of%20people%20with%20TB%20in%20Brazil.%20FUNDING%3A%20National%20Institutes%20of%20Allergy%20and%20Infectious%20Diseases.%22%2C%22date%22%3A%22Nov%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2022.100358%22%2C%22ISSN%22%3A%222667-193X%20%28Electronic%29%202667-193X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A41%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22LC8RM56M%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bartelt%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-26%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBartelt%2C%20L.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarkmann%2C%20A.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENelson%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKeys%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoot%2C%20H.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Outcomes%20of%20Convalescent%20Plasma%20with%20Defined%20High%20versus%20Lower%20Neutralizing%20Antibody%20Titers%20against%20SARS-CoV-2%20among%20Hospitalized%20Patients%3A%20CoronaVirus%20Inactivating%20Plasma%20%28CoVIP%29%20Study.%20%3Ci%3EMBio%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e0175122.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2Fmbio.01751-22%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2Fmbio.01751-22%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20of%20Convalescent%20Plasma%20with%20Defined%20High%20versus%20Lower%20Neutralizing%20Antibody%20Titers%20against%20SARS-CoV-2%20among%20Hospitalized%20Patients%3A%20CoronaVirus%20Inactivating%20Plasma%20%28CoVIP%29%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Bartelt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20J.%22%2C%22lastName%22%3A%22Markmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Nelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Keys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Root%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20I.%22%2C%22lastName%22%3A%22Henderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Kuruc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Baker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Bhowmik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Hou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Premkumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cornaby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Schmitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Weiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Baric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22de%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lachiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22van%20Duin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Margolis%22%7D%5D%2C%22abstractNote%22%3A%22COVID-19%20convalescent%20plasma%20%28CCP%29%20was%20an%20early%20and%20widely%20adopted%20putative%20therapy%20for%20severe%20COVID-19.%20Results%20from%20randomized%20control%20trials%20and%20observational%20studies%20have%20failed%20to%20demonstrate%20a%20clear%20therapeutic%20role%20for%20CCP%20for%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20%28SARS-CoV-2%29%20infection.%20Underlying%20these%20inconclusive%20findings%20is%20a%20broad%20heterogeneity%20in%20the%20concentrations%20of%20neutralizing%20antibodies%20%28nAbs%29%20between%20different%20CCP%20donors.%20We%20conducted%20this%20study%20to%20evaluate%20the%20effectiveness%20and%20safety%20of%20nAb%20titer-defined%20CCP%20in%20adults%20admitted%20to%20an%20academic%20referral%20hospital.%20Patients%20positive%20by%20a%20SARS-CoV-2%20nucleic%20acid%20amplification%20test%20and%20with%20symptoms%20for%20%3C10%20days%20were%20eligible.%20Participants%20received%20either%20CCP%20with%20nAb%20titers%20of%20%3E1%3A640%20%28high-titer%20group%29%20or%20%3E%5C%2F%3D1%3A160%20to%201%3A640%20%28standard-titer%20group%29%20in%20addition%20to%20standard%20of%20care%20treatments.%20The%20primary%20clinical%20outcome%20was%20time%20to%20hospital%20discharge%2C%20with%20mortality%20and%20respiratory%20support%20evaluated%20as%20secondary%20outcomes.%20Adverse%20events%20were%20contrasted%20by%20CCP%20titer.%20Between%2028%20August%20and%204%20December%202020%2C%20316%20participants%20were%20screened%2C%20and%2055%20received%20CCP%2C%20with%2014%20and%2041%20receiving%20high-%20versus%20standard-titer%20CCP%2C%20respectively.%20Time%20to%20hospital%20discharge%20was%20shorter%20among%20participants%20receiving%20high-%20versus%20standard-titer%20CCP%2C%20accounting%20for%20death%20as%20a%20competing%20event%20%28hazard%20ratio%2C%201.94%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%201.05%20to%203.58%3B%20Gray%27s%20P%20%3D%200.02%29.%20Severe%20adverse%20events%20%28SAEs%29%20%28%3E%5C%2F%3Dgrade%203%29%20occurred%20in%204%20%2829%25%29%20and%2023%20%2856%25%29%20of%20participants%20receiving%20the%20high%20versus%20standard%20titer%2C%20respectively%2C%20by%20day%2028%20%28risk%20ratio%2C%200.51%3B%2095%25%20CI%2C%200.21%20to%201.22%3B%20Fisher%27s%20P%20%3D%200.12%29.%20There%20were%20no%20observed%20treatment-related%20AEs.%20%28This%20study%20has%20been%20registered%20at%20ClinicalTrials.gov%20under%20registration%20no.%20NCT04524507%29.%20IMPORTANCE%20In%20this%20study%2C%20in%20a%20high-risk%20population%20of%20patients%20admitted%20for%20COVID-19%2C%20we%20found%20an%20earlier%20time%20to%20hospital%20discharge%20among%20participants%20receiving%20CCP%20with%20nAb%20titers%20of%20%3E1%3A640%20compared%20with%20participants%20receiving%20CCP%20with%20a%20lower%20nAb%20titer%20and%20no%20CCP-related%20AEs.%20The%20significance%20of%20our%20research%20is%20in%20identifying%20a%20dose%20response%20of%20CCP%20and%20clinical%20outcomes%20based%20on%20nAb%20titer.%20Although%20limited%20by%20a%20small%20study%20size%2C%20these%20findings%20support%20further%20study%20of%20high-nAb-titer%20CCP%20defined%20as%20%3E1%3A640%20in%20the%20treatment%20of%20COVID-19.%22%2C%22date%22%3A%22Oct%2026%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1128%5C%2Fmbio.01751-22%22%2C%22ISSN%22%3A%222150-7511%20%28Electronic%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A26%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22VIS9ZD6Y%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Horberg%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHorberg%2C%20M.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWatson%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBhatia%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJefferson%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECerta%2C%20J.%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Post-acute%20sequelae%20of%20SARS-CoV-2%20with%20clinical%20condition%20definitions%20and%20comparison%20in%20a%20matched%20cohort.%20%3Ci%3ENat%20Commun%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%20%281%29%2C%20S.%205822.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41467-022-33573-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41467-022-33573-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Post-acute%20sequelae%20of%20SARS-CoV-2%20with%20clinical%20condition%20definitions%20and%20comparison%20in%20a%20matched%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bhatia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Jefferson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Certa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fathi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Moore%22%7D%5D%2C%22abstractNote%22%3A%22Disease%20characterization%20of%20Post-Acute%20Sequelae%20of%20SARS-CoV-2%20%28PASC%29%20does%20not%20account%20for%20pre-existing%20conditions%20and%20time%20course%20of%20incidence.%20We%20utilized%20longitudinal%20data%20and%20matching%20to%20a%20COVID%20PCR-negative%20population%20to%20discriminate%20PASC%20conditions%20over%20time%20within%20our%20patient%20population%20during%202020.%20Clinical%20Classification%20Software%20was%20used%20to%20identify%20PASC%20condition%20groupings.%20Conditions%20were%20specified%20acute%20and%20persistent%20%28occurring%200-30%20days%20post%20COVID%20PCR%20and%20persisted%2030-120%20days%20post-test%29%20or%20late%20%28occurring%20initially%2030-120%20days%20post-test%29.%20We%20matched%203%3A1%20COVID%20PCR-negative%20COVIDPCR-positive%20by%20age%2C%20sex%2C%20testing%20month%20and%20service%20area%2C%20controlling%20for%20pre-existing%20conditions%20up%20to%20four%20years%20prior%3B%2028%2C118%20PCR-positive%20to%2070%2C293%20PCR-negative%20patients%20resulted.%20We%20estimated%20PASC%20risk%20from%20the%20matched%20cohort.%20Risk%20of%20any%20PASC%20condition%20was%2012%25%20greater%20for%20PCR-positive%20patients%20in%20the%20late%20period%20with%20a%20significantly%20higher%20risk%20of%20anosmia%2C%20cardiac%20dysrhythmia%2C%20diabetes%2C%20genitourinary%20disorders%2C%20malaise%2C%20and%20nonspecific%20chest%20pain.%20Our%20findings%20contribute%20to%20a%20more%20refined%20PASC%20definition%20which%20can%20enhance%20clinical%20care.%22%2C%22date%22%3A%22Oct%2012%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41467-022-33573-6%22%2C%22ISSN%22%3A%222041-1723%20%28Electronic%29%202041-1723%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A23%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22HLEGYTCW%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kalua%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalua%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEgger%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJahn%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChimpandule%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKolola%2C%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20HIV%20suppression%20was%20maintained%20during%20the%20COVID-19%20pandemic%20in%20Malawi%3A%20a%20program-level%20cohort%20study.%20%3Ci%3EJ%20Clin%20Epidemiol%3C%5C%2Fi%3E%2C%20%3Ci%3E150%3C%5C%2Fi%3E%2C%20S.%20116%26%23x2013%3B125.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jclinepi.2022.06.019%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jclinepi.2022.06.019%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20suppression%20was%20maintained%20during%20the%20COVID-19%20pandemic%20in%20Malawi%3A%20a%20program-level%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Kalua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Chimpandule%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kolola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Anderegg%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Measures%20introduced%20to%20reduce%20the%20spread%20of%20SARS-CoV-2%20by%20the%20Malawi%20government%20and%20the%20national%20HIV%20care%20program%20might%20have%20compromised%20treatment%20outcomes%20of%20patients%20living%20with%20HIV%20on%20antiretroviral%20therapy%20%28ART%29.%20We%20studied%20viral%20load%20%28VL%29%20outcomes%20before%20and%20during%20the%20COVID-19%20epidemic%20in%20Malawi.%20METHODS%3A%20In%20this%20population-based%20cohort%20study%2C%20we%20included%20all%20routine%20VL%20measurements%20collected%20from%20July%202019%20to%20December%202020%20in%20about%20650%20ART%20clinics%20in%20Malawi.%20We%20examined%20differences%20between%20pandemic%20periods%20%28before%5C%2Fduring%20COVID-19%29%20for%20i%29%20VL%20monitoring%2C%20and%20ii%29%20VL%20suppression%20%28VLS%3A%20%3C1%2C000%20copies%5C%2Fml%29.%20For%20i%29%20we%20studied%20the%20number%20of%20VL%20measurements%20over%20time%20and%20assessed%20predictors%20of%20missed%20measurements%20before%20and%20during%20COVID-19%20in%20logistic%20regression%20models.%20For%20ii%29%20we%20estimated%20the%20odds%20of%20VLS%20before%20and%20during%20the%20COVID-19%20epidemic%20stratified%20by%20treatment%20regimen%20using%20generalized%20estimation%20equations%20adjusted%20for%20age%2C%20sex%2C%20time%20on%20ART%2C%20and%20type%20of%20biological%20sample.%20We%20imputed%20missing%20treatment%20regimens%20by%20population-calibrated%20multiple%20imputation.%20RESULTS%3A%20We%20included%20607%2C894%20routine%20VL%20samples%20from%20556%2C281%20patients.%20VL%20testing%20declined%20during%20COVID-19%20%28243%2C729%3B%2040%25%29%20compared%20to%20before%20COVID-19%20%28365%2C265%3B%2060%25%29%2C%20but%20predictors%20of%20missing%20tests%20were%20similar%20in%20the%20two%20periods.%20VLS%20rates%20increased%20slightly%20from%2093%25%20before%20to%2094%25%20during%20COVID-19.%20Compared%20to%20before%20COVID-19%2C%20the%20odds%20of%20VLS%20increased%20during%20COVID-19%20for%20patients%20on%20protease%20inhibitor-based%20%28PI%29%20regimens%20%28adjusted%20odds%20ratio%20%5BaOR%5D%201.22%2C%2095%25%20CI%3A%200.99-1.49%29%20and%20for%20patients%20on%20integrase%20strand%20transfer%20inhibitor-based%20%28INSTI%29%20regimens%20%28aOR%201.10%2C%2095%25%20CI%3A%201.03-1.17%29.%20There%20was%20no%20difference%20in%20VLS%20between%20the%20two%20periods%20among%20patients%20on%20nonnucleoside%20reverse%20transcriptase%20inhibitor-based%20%28NNRTI%29%20regimens.%20VLS%20varied%20by%20age%2C%20sex%2C%20regimen%2C%20and%20duration%20on%20ART%2C%20ranging%20from%2045.1%25%20%2895%25%20CI%2040.3-50.0%25%29%20to%2097.2%25%20%2895%25%20CI%2096.9-97.4%25%29.%20CONCLUSION%3A%20There%20was%20a%20significant%20decline%20in%20VL%20monitoring%20during%20COVID-19%2C%20but%20we%20did%20not%20find%20clear%20evidence%20that%20the%20pandemic%20reduced%20VL%20suppression%20rates.%20Routine%20scheduled%20VL%20monitoring%2C%20targeted%20adherence%20support%2C%20and%20timely%20regimen%20switches%20for%20patients%20with%20treatment%20failure%20remain%20critical%20to%20improving%20VLS.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jclinepi.2022.06.019%22%2C%22ISSN%22%3A%221878-5921%20%28Electronic%29%200895-4356%20%28Print%29%200895-4356%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A20%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22AWBVNXEF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marti%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A8%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarti%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZurcher%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEnane%2C%20L.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDiero%2C%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarcy%2C%20O.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Impact%20of%20the%20COVID-19%20pandemic%20on%20TB%20services%20at%20ART%20programmes%20in%20low-%20and%20middle-income%20countries%3A%20a%20multi-cohort%20survey.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%2810%29%2C%20S.%20e26018.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26018%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26018%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20the%20COVID-19%20pandemic%20on%20TB%20services%20at%20ART%20programmes%20in%20low-%20and%20middle-income%20countries%3A%20a%20multi-cohort%20survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Marti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Zurcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Yunihastuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Reubenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20S.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20global%20consortium%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20COVID-19%20stretched%20healthcare%20systems%20to%20their%20limits%2C%20particularly%20in%20settings%20with%20a%20pre-existing%20high%20burden%20of%20infectious%20diseases%2C%20including%20HIV%20and%20tuberculosis%20%28TB%29.%20We%20studied%20the%20impact%20of%20COVID-19%20on%20TB%20services%20at%20antiretroviral%20therapy%20%28ART%29%20clinics%20in%20low-%20and%20middle-income%20countries.%20METHODS%3A%20We%20surveyed%20ART%20clinics%20providing%20TB%20services%20in%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20in%20Africa%20and%20the%20Asia-Pacific%20until%20July%202021%20%28TB%20diagnoses%20until%20the%20end%20of%202021%29.%20We%20collected%20site-level%20data%20using%20standardized%20questionnaires.%20RESULTS%3A%20Of%2046%20participating%20ART%20clinics%2C%2032%20%2870%25%29%20were%20in%20Africa%20and%2014%20%2830%25%29%20in%20the%20Asia-Pacific%3B%2052%25%20provided%20tertiary%20care.%20Most%20clinics%20%2885%25%29%20reported%20disrupted%20routine%20HIV%20care%20services%20during%20the%20pandemic%2C%20both%20in%20Africa%20%2884%25%29%20and%20the%20Asia-Pacific%20%2886%25%29.%20The%20most%20frequently%20reported%20impacts%20were%20on%20staff%20%2852%25%29%20and%20resource%20shortages%20%2837%25%3B%20protective%20clothing%2C%20face%20masks%20and%20disinfectants%29.%20Restrictions%20in%20TB%20health%20services%20were%20observed%20in%2012%20clinics%20%2826%25%29%2C%20mainly%20reduced%20access%20to%20TB%20diagnosis%20and%20postponed%20follow-up%20visits%20%286%5C%2F12%2C%2050%25%20each%29%2C%20and%20restrictions%20in%20TB%20laboratory%20services%20%2822%25%29.%20Restrictions%20of%20TB%20services%20were%20addressed%20by%20dispensing%20TB%20drugs%20for%20longer%20periods%20than%20usual%20%287%5C%2F12%2C%2058%25%29%2C%20providing%20telehealth%20services%20%283%5C%2F12%2C%2025%25%29%20and%20with%20changes%20in%20directly%20observed%20therapy%20%28DOT%29%20%28e.g.%20virtual%20DOT%2C%203%5C%2F12%29.%20The%20number%20of%20TB%20diagnoses%20at%20participating%20clinics%20decreased%20by%2021%25%20in%202020%20compared%20to%202019%3B%20the%20decline%20was%20more%20pronounced%20in%20tertiary%20than%20primary%5C%2Fsecondary%20clinics%20%2824%25%20vs.%2012%25%29%20and%20in%20sites%20from%20the%20Asia-Pacific%20compared%20to%20Africa%20%2846%25%20vs.%2014%25%29.%20In%202021%2C%20TB%20diagnoses%20continued%20to%20decline%20in%20Africa%20%28-8%25%29%20but%20not%20in%20the%20Asia-Pacific%20%28%2B62%25%29%20compared%20to%202020.%20During%20the%20pandemic%2C%20new%20infection%20control%20measures%20were%20introduced%20or%20intensified%20at%20the%20clinics%2C%20including%20wearing%20face%20masks%2C%20hand%20sanitation%20and%20patient%20triage.%20CONCLUSIONS%3A%20The%20COVID-19%20pandemic%20led%20to%20staff%20shortages%2C%20reduced%20access%20to%20TB%20care%20and%20delays%20in%20follow-up%20visits%20for%20people%20with%20TB%20across%20IeDEA%20sites%20in%20Africa%20and%20the%20Asia-Pacific.%20Increased%20efforts%20are%20needed%20to%20restore%20and%20secure%20ongoing%20access%20to%20essential%20TB%20services%20in%20these%20contexts.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26018%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A21%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22R8NTX9IG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stalter%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStalter%2C%20R.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAmorim%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMocello%2C%20A.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJakait%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShepherd%2C%20B.%20E.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Contraceptive%20implant%20use%20duration%20is%20not%20associated%20with%20breakthrough%20pregnancy%20among%20women%20living%20with%20HIV%20and%20using%20efavirenz%3A%20a%20retrospective%2C%20longitudinal%20analysis.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%289%29%2C%20S.%20e26001.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26001%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26001%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Contraceptive%20implant%20use%20duration%20is%20not%20associated%20with%20breakthrough%20pregnancy%20among%20women%20living%20with%20HIV%20and%20using%20efavirenz%3A%20a%20retrospective%2C%20longitudinal%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20M.%22%2C%22lastName%22%3A%22Stalter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20R.%22%2C%22lastName%22%3A%22Mocello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Jakait%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20A.%22%2C%22lastName%22%3A%22Bukusi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20R.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Group%22%2C%22lastName%22%3A%22Implant%5C%2FEfavirenz%20Study%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20regional%20consortium%22%2C%22lastName%22%3A%22the%20East%20Africa%20Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Contraceptive%20implants%20containing%20etonogestrel%20and%20levonorgestrel%20have%20emerged%20as%20popular%20contraceptive%20options%20among%20women%20in%20areas%20of%20high%20HIV%20burden%20in%20sub-Saharan%20Africa.%20However%2C%20recent%20pharmacokinetic%20data%20have%20shown%20drug-drug%20interactions%20between%20implants%20and%20efavirenz-containing%20antiretroviral%20therapy%20%28ART%29%2C%20reducing%20the%20effectiveness%20of%20the%20implants.%20Here%2C%20we%20evaluated%20pregnancy%20incidence%20in%206-month%20intervals%20following%20implant%20initiation%20among%20women%20using%20efavirenz%20and%20contraceptive%20implants%20to%20assess%20whether%20the%20risk%20of%20breakthrough%20pregnancy%20is%20higher%20after%20specific%20periods%20of%20implant%20use.%20METHODS%3A%20We%20used%20data%20from%20a%20retrospective%20longitudinal%20analysis%20of%20women%20living%20with%20HIV%20ages%2018-45%20years%20in%20western%20Kenya%20who%20attended%20HIV-care%20facilities%20between%202011%20and%202015.%20We%20used%20Cox%20proportional%20hazard%20models%20to%20compute%20hazard%20ratios%20%28HRs%29%20for%20breakthrough%20pregnancy%20by%20implant%20type%20and%20ART%20regimen.%20Depending%20on%20the%20model%2C%20we%20adjusted%20for%20socio-demographic%20and%20clinical%20factors%2C%20programme%2C%20site%20and%20interaction%20between%20calendar%20time%20and%20ART%20regimen.%20We%20utilized%20inverse%20probability%20weights%20%28IPWs%29%20to%20account%20for%20three%20sampling%20phases%20%28electronic%20medical%20record%20%5BEMR%5D%2C%20chart%20review%20and%20phone%20interview%29%20and%20calculated%20overall%20parameter%20estimates.%20RESULTS%3A%20Women%20contributed%2014%2C768%20woman-years%20from%20the%20largest%20sampling%20phase%20%28EMR%29.%20The%20median%20age%20was%2031%20years.%20Women%20used%20etonogestrel%20implants%20for%2026-69%25%20of%20the%20time%20and%20levonorgestrel%20implants%20for%207-31%25%20of%20the%20time%2C%20depending%20on%20the%20sampling%20phase.%20Women%20used%20efavirenz%2C%20nevirapine%20or%20no%20ART%20for%2027-33%25%2C%2040-46%25%20and%2015-26%25%20of%20follow-ups%2C%20respectively.%20When%20combining%20sampling%20phases%2C%20there%20was%20little%20evidence%20to%20suggest%20that%20the%20relative%20hazard%20of%20pregnancy%20among%20efavirenz-containing%20ART%20users%20relative%20to%20nevirapine-containing%20ART%20changed%20with%20length%20of%20time%20on%20implants%3A%20IPW-adjusted%20HR%20of%203.1%20%28CI%3A%20%5B1.5%3B%206.4%5D%29%20at%2012%20months%2C%203.4%20%28CI%3A%20%5B1.8%3B%206.3%5D%29%20at%2024%20months%2C%203.8%20%28CI%3A%20%5B1.9%3B%207.7%5D%29%20at%2036%20months%20and%204.2%20%28CI%3A%20%5B1.6%3B%2011.1%5D%29%20at%2048%20months%20%28interaction%20p-value%20%3D%200.88%29.%20Similarly%2C%20no%20significant%20change%20in%20HRs%20over%20time%20was%20found%20when%20comparing%20women%20not%20using%20ART%20to%20nevirapine-containing%20ART%20users%20%28interaction%20p-value%20%3D%200.49%29.%20CONCLUSIONS%3A%20We%20did%20not%20find%20evidence%20to%20suggest%20implants%20being%20more%20fallible%20from%20drug-drug%20interactions%20with%20efavirenz%20at%20later%20time%20intervals%20of%20implant%20use.%20Thus%2C%20we%20would%20not%20recommend%20shortening%20the%20duration%20of%20implant%20use%20or%20replacing%20implants%20sooner%20when%20concomitantly%20used%20with%20efavirenz.%22%2C%22date%22%3A%22Sep%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26001%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22YNT7B8LY%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wada%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A12%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWada%2C%20P.%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKim%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJayathilake%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDuda%2C%20S.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAbo%2C%20Y.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Site-Level%20Comprehensiveness%20of%20Care%20Is%20Associated%20with%20Individual%20Clinical%20Retention%20Among%20Adults%20Living%20with%20HIV%20in%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%2C%20a%20Global%20HIV%20Cohort%20Collaboration%2C%202000-2016.%20%3Ci%3EAIDS%20Patient%20Care%20STDS%3C%5C%2Fi%3E%2C%20%3Ci%3E36%3C%5C%2Fi%3E%20%289%29%2C%20S.%20343%26%23x2013%3B355.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fapc.2022.0042%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fapc.2022.0042%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Site-Level%20Comprehensiveness%20of%20Care%20Is%20Associated%20with%20Individual%20Clinical%20Retention%20Among%20Adults%20Living%20with%20HIV%20in%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%2C%20a%20Global%20HIV%20Cohort%20Collaboration%2C%202000-2016%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Y.%22%2C%22lastName%22%3A%22Wada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Abo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22Retention%20in%20care%20%28RIC%29%20reduces%20HIV%20transmission%20and%20associated%20morbidity%20and%20mortality.%20We%20examined%20whether%20delivery%20of%20comprehensive%20services%20influenced%20individual%20RIC%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20network.%20We%20collected%20site%20data%20through%20IeDEA%20assessments%201.0%20%282000-2009%29%20and%202.0%20%282010-2016%29.%20Each%20site%20received%20a%20comprehensiveness%20score%20for%20service%20availability%20%281%20%3D%20present%2C%200%20%3D%20absent%29%2C%20with%20tallies%20ranging%20from%200%20to%207.%20We%20obtained%20individual-level%20cohort%20data%20for%20adults%20with%20at%20least%20one%20visit%20from%202000%20to%202016%20at%20sites%20responding%20to%20either%20assessment.%20Person-time%20was%20recorded%20annually%2C%20with%20RIC%20defined%20as%20completing%20two%20visits%20at%20least%2090%20days%20apart%20in%20each%20calendar%20year.%20Multivariable%20modified%20Poisson%20regression%20clustered%20by%20site%20yielded%20risk%20ratios%20and%20predicted%20probabilities%20for%20individual%20RIC%20by%20comprehensiveness.%20Among%20347%2C060%20individuals%20in%20care%20at%20122%20sites%20with%201%2C619%2C558%20person-years%20of%20follow-up%2C%2069.8%25%20of%20person-time%20was%20retained%20in%20care%2C%20varying%20by%20region%20from%2053.8%25%20%28Asia-Pacific%29%20to%2082.7%25%20%28East%20Africa%29%3B%20RIC%20improved%20by%20about%202%25%20per%20year%20from%202000%20to%202016%20%28p%20%3D%200.012%29.%20Every%20site%20provided%20CD4%28%2B%29%20count%20testing%2C%20and%20%3E90%25%20of%20individuals%20received%20care%20at%20sites%20that%20provided%20combination%20antiretroviral%20therapy%20adherence%20measures%2C%20prevention%20of%20mother-to-child%20transmission%2C%20tuberculosis%20screening%2C%20HIV-related%20prevention%2C%20and%20community%20tracing%20services.%20In%20adjusted%20models%2C%20individuals%20at%20sites%20with%20more%20comprehensive%20services%20had%20higher%20probabilities%20of%20RIC%20%280.71%2C%200.74%2C%20and%200.83%20for%20scores%205%2C%206%2C%20and%207%2C%20respectively%3B%20p%20%3D%200.019%29.%20Within%20IeDEA%2C%20greater%20site-level%20comprehensiveness%20of%20services%20was%20associated%20with%20improved%20individual%20RIC.%20Much%20work%20remains%20in%20exploring%20this%20relationship%2C%20which%20may%20inform%20HIV%20clinical%20practice%20and%20health%20systems%20planning.%22%2C%22date%22%3A%22Sep%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1089%5C%2Fapc.2022.0042%22%2C%22ISSN%22%3A%221557-7449%20%28Electronic%29%201087-2914%20%28Print%29%201087-2914%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A28%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22EQJ3YSKM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Murenzi%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurenzi%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShumbusho%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHansen%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMunyaneza%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGage%2C%20J.%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Long-term%20human%20papillomavirus%20vaccination%20effectiveness%20and%20immunity%20in%20Rwandan%20women%20living%20with%20and%20without%20HIV%3A%20a%20study%20protocol.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e061650.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-061650%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-061650%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20human%20papillomavirus%20vaccination%20effectiveness%20and%20immunity%20in%20Rwandan%20women%20living%20with%20and%20without%20HIV%3A%20a%20study%20protocol%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Shumbusho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20C.%22%2C%22lastName%22%3A%22Gage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Muhoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Kanyabwisha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Pierz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Tuyisenge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20E.%22%2C%22lastName%22%3A%22Castle%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Prophylactic%20human%20papillomavirus%20%28HPV%29%20vaccines%20have%20been%20shown%20to%20be%20highly%20effective%20in%20protecting%20women%20against%20cervical%20infections%2C%20high-grade%20abnormalities%20and%20cancer%20caused%20by%20the%20targeted%20HPV%20types.%20However%2C%20the%20evidence%20for%20their%20effectiveness%20in%20women%20living%20with%20HIV%20%28WLWH%29%20is%20less%20clear.%20METHODS%3A%20WLWH%20and%20HIV-negative%20women%20who%20likely%20did%20%28birth%20cohorts%201996%20and%20later%29%20and%20WLWH%20and%20HIV%28-%29%20negative%20who%20likely%20did%20not%20%28birth%20cohorts%20before%201996%29%20receive%20HPV%20vaccination%20%28n%3D3028%3B%20757%20participants%20for%20each%20of%20the%20four%20groups%29.%20Between%20groups%2C%20we%20will%20compare%20cervicovaginal%2C%20anal%20and%20oral%20prevalent%20and%206-12%20month%20persistent%20HPV6%5C%2F11%5C%2F16%5C%2F18%20infections%20as%20measured%20using%20a%20modified%20AmpFire%20HPV%20genotyping%20assay%20that%20tests%20for%2015%20high-risk%20or%20intermediate-risk%20HPV%20genotypes%2C%20HPV6%20and%20HPV11.%20We%20will%20also%20compare%20the%20HPV%20immune%20response%20in%20HPV-vaccinated%20WLWH%20to%20HPV-vaccinated%20HIV-negative%20women%20using%20an%20anti-HPV16%20and%20anti-HPV18%20ELISA.%20Vaccination%20status%20will%20be%20confirmed%20through%20national%20vaccination%20records.%20ANALYSIS%3A%20We%20will%20calculate%20point%20prevalence%20and%20prevalence%20of%206-12%20month%20persisting%20infections%20by%20individual%20HPV-type%20specific%20infections%20and%20groups%20of%20infections%20for%20each%20anatomic%20site%20and%20for%20each%20group%20of%20women.%20Results%20will%20be%20stratified%20by%20age%20at%20vaccination%2C%20age%20at%20enrolment%20and%20the%20number%20of%20doses%20%283%20vs%202%29%20as%20well%20as%20other%20factors%20possibly%20associated%20with%20HPV%20prevalence.%20Differences%20in%20endpoints%20between%20groups%2C%20overall%20and%20between%20subgroups%2C%20will%20be%20tested%20for%20statistical%20significance%20%28p%3C0.05%29%20using%20Fisher%27s%20exact%20or%20Pearson%20chi%282%29%20test.%20Differences%20in%20geometric%20mean%20titres%20and%20seropositivity%20will%20be%20tested%20for%20statistical%20significance%20using%20the%20Mann-Whitney%20and%20Fisher%27s%20exact%20tests%2C%20respectively.%20ETHICS%20AND%20DISSEMINATION%3A%20The%20study%20was%20approved%20by%20the%20Albert%20Einstein%20College%20of%20Medicine%20Institutional%20Review%20Board%20and%20the%20Rwanda%20National%20Ethics%20Committee.%20Results%20will%20be%20disseminated%20through%20publication%20in%20peer-reviewed%20journals.%22%2C%22date%22%3A%22Aug%2025%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2022-061650%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A37%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22T3VRSJI7%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Asangbeh-Kerman%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAsangbeh-Kerman%2C%20S.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavidovic%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETaghavi%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKachingwe%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERammipi%2C%20K.%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Cervical%20cancer%20prevention%20in%20countries%20with%20the%20highest%20HIV%20prevalence%3A%20a%20review%20of%20policies.%20%3Ci%3EBMC%20Public%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E22%3C%5C%2Fi%3E%20%281%29%2C%20S.%201530.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-022-13827-0%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-022-13827-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cervical%20cancer%20prevention%20in%20countries%20with%20the%20highest%20HIV%20prevalence%3A%20a%20review%20of%20policies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20L.%22%2C%22lastName%22%3A%22Asangbeh-Kerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Davidovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Taghavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Kachingwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Rammipi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Muzingwani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Pascoe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Jousse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mulongo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mwanahamuntu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Tapela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Akintade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Basu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X.%22%2C%22lastName%22%3A%22Dlamini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Bohlius%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Cervical%20cancer%20%28CC%29%20is%20the%20leading%20cause%20of%20cancer-related%20death%20among%20women%20in%20sub-Saharan%20Africa.%20It%20occurs%20most%20frequently%20in%20women%20living%20with%20HIV%20%28WLHIV%29%20and%20is%20classified%20as%20an%20AIDS-defining%20illness.%20Recent%20World%20Health%20Organisation%20%28WHO%29%20recommendations%20provide%20guidance%20for%20CC%20prevention%20policies%2C%20with%20specifications%20for%20WLHIV.%20We%20systematically%20reviewed%20policies%20for%20CC%20prevention%20and%20control%20in%20sub-Saharan%20countries%20with%20the%20highest%20HIV%20prevalence.%20METHODS%3A%20We%20included%20countries%20with%20an%20HIV%20prevalence%20%3E%5C%2F%3D%2010%25%20in%202018%20and%20policies%20published%20between%20January%201%28st%29%202010%20and%20March%2031%28st%29%202022.%20We%20searched%20Medline%20via%20PubMed%2C%20the%20international%20cancer%20control%20partnership%20website%20and%20national%20governmental%20websites%20of%20included%20countries%20for%20relevant%20policy%20documents.%20The%20online%20document%20search%20was%20supplemented%20with%20expert%20consultation%20for%20each%20included%20country.%20We%20synthesised%20aspects%20defined%20in%20policies%20for%20HPV%20vaccination%2C%20sex%20education%2C%20condom%20use%2C%20tobacco%20control%2C%20male%20circumcision%2Ccervical%20screening%2C%20diagnosis%20and%20treatment%20of%20cervical%20pre-cancerous%20lesions%20and%20cancer%2C%20monitoring%20mechanisms%20and%20cost%20of%20services%20to%20women%20while%20highlighting%20specificities%20for%20WLHIV.%20RESULTS%3A%20We%20reviewed%2033%20policy%20documents%20from%20nine%20countries.%20All%20included%20countries%20had%20policies%20on%20CC%20prevention%20and%20control%20either%20as%20a%20standalone%20policy%20%2877.8%25%29%2C%20or%20as%20part%20of%20a%20cancer%20or%20non-communicable%20diseases%20policy%20%2822.2%25%29%20or%20both%20%2866.7%25%29.%20Aspects%20of%20HPV%20vaccination%20were%20reported%20in%207%20%2877.8%25%29%20of%20the%209%20countries.%20All%20countries%20%28100%25%29%20planned%20to%20develop%20or%20review%20Information%2C%20Education%20and%20Communication%20%28IEC%29%20materials%20for%20CC%20prevention%20including%20condom%20use%20and%20tobacco%20control.%20Age%20at%20screening%20commencement%20and%20screening%20intervals%20for%20WLHIV%20varied%20across%20countries.%20The%20most%20common%20recommended%20screening%20and%20treatment%20methods%20were%20visual%20inspection%20with%20acetic%20acid%20%28VIA%29%20%2888.9%25%29%2C%20Pap%20smear%20%2877.8%25%29%3B%20cryotherapy%20%28100%25%29%20and%20loop%20electrosurgical%20procedure%20%28LEEP%29%20%2888.9%25%29%20respectively.%20Global%20indicators%20disaggregated%20by%20HIV%20status%20for%20monitoring%20CC%20programs%20were%20rarely%20reported.%20CC%20prevention%20and%20care%20policies%20included%20service%20costs%20at%20various%20stages%20in%20three%20countries%20%2833.3%25%29.%20CONCLUSION%3A%20Considerable%20progress%20has%20been%20made%20in%20policy%20development%20for%20CC%20prevention%20and%20control%20in%20sub%20Saharan%20Africa.%20However%2C%20in%20countries%20with%20a%20high%20HIV%20burden%2C%20there%20is%20need%20to%20tailor%20these%20policies%20to%20respond%20to%20the%20specific%20needs%20of%20WLHIV.%20Countries%20may%20consider%20updating%20policies%20using%20the%20recent%20WHO%20guidelines%20for%20CC%20prevention%2C%20while%20adapting%20them%20to%20context%20realities.%22%2C%22date%22%3A%22Aug%2010%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-022-13827-0%22%2C%22ISSN%22%3A%221471-2458%20%28Electronic%29%201471-2458%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A38%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22VZAULTB8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Christ%20et%20al.%22%2C%22parsedDate%22%3A%222022-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChrist%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Evan%20Dijk%2C%20J.%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyandoro%2C%20T.%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EReichmuth%2C%20M.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKunzekwenyika%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Availability%20and%20experiences%20of%20differentiated%20antiretroviral%20therapy%20delivery%20at%20HIV%20care%20facilities%20in%20rural%20Zimbabwe%3A%20a%20mixed-method%20study.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e25944.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25944%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25944%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Availability%20and%20experiences%20of%20differentiated%20antiretroviral%20therapy%20delivery%20at%20HIV%20care%20facilities%20in%20rural%20Zimbabwe%3A%20a%20mixed-method%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Christ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20H.%22%2C%22lastName%22%3A%22van%20Dijk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20Y.%22%2C%22lastName%22%3A%22Nyandoro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Reichmuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chammartin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Wringe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%20in%20Southern%20Africa%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Zimbabwe%20adopted%20differentiated%20HIV%20care%20policies%20in%202015%20to%20promote%20client-centred%20care%20and%20relieve%20strain%20on%20health%20facilities.%20We%20examined%20the%20availability%2C%20experiences%20and%20perceptions%20of%20differentiated%20antiretroviral%20therapy%20%28ART%29%20delivery%20in%20rural%20Zimbabwe%20following%20the%20policy%20adoption.%20METHODS%3A%20We%20undertook%20a%20cross-sectional%20mixed%20methods%20study%20in%20all%20the%2026%20facilities%20providing%20HIV%20care%20in%20a%20rural%20district%20in%20Zimbabwe.%20We%20collected%20quantitative%20data%20about%20ART%20delivery%20and%20visit%20durations%20from%2031%20healthcare%20providers%20and%20a%20purposive%20stratified%20sample%20of%20378%20clients%20obtaining%20ART%20either%20through%20routine%20care%20or%20differentiated%20ART%20delivery%20models.%20We%20performed%2026%20semi-structured%20interviews%20among%20healthcare%20providers%20and%20seven%20focus%20group%20discussions%20%28FGDs%29%20among%20clients%20to%20elicit%20their%20perceptions%20and%20experiences%20of%20ART%20delivery.%20Data%20were%20collected%20in%202019%2C%20with%20one%20follow-up%20FGD%20in%202021.%20We%20analysed%20the%20transcripts%20thematically%2C%20with%20inductive%20coding%2C%20to%20identify%20emerging%20themes.%20RESULTS%3A%20Twenty%20facilities%20%2877%25%29%20offered%20at%20least%20one%20differentiated%20ART%20delivery%20models%2C%20including%20community%20ART%20refill%20groups%20%28CARGs%3B%2013%20facilities%2C%2050%25%29%2C%20fast-track%20refill%20%288%2C%2031%25%29%2C%20family%20refill%20%286%2C%2023%25%29%20or%20club%20refill%20%281%2C%204%25%29.%20Thirteen%20facilities%20%2850%25%29%20offered%20only%20one%20model.%20The%20median%20visit%20duration%20was%2028%20minutes%20%28interquartile%20range%20%5BIQR%5D%3A%2016-62%29.%20Participants%20in%20fast-track%20had%20the%20shortest%20visit%20durations%20%2818%20minutes%2C%20IQR%3A%2011-24%29.%20Confidentiality%20and%20disclosure%20of%20HIV%20status%2C%20travelling%20long%20distances%2C%20travel%20costs%20and%20waiting%20times%20were%20the%20main%20issues%20influencing%20clients%27%20views%20on%20differentiated%20ART%20delivery.%20Fast-track%20refill%20was%20perceived%20as%20the%20preferred%20model%20of%20clients%20for%20its%20limited%20involuntary%20disclosure%20and%20efficiency.%20In%20contrast%2C%20group-%20and%20community-based%20refill%20models%20reduced%20travel%20costs%20but%20were%20felt%20to%20be%20associated%20with%20involuntary%20disclosure%20of%20HIV%20status%2C%20which%20could%20discourage%20clients.%20Healthcare%20providers%20also%20experienced%20an%20additional%20workload%20when%20offering%20facility-based%20group%20models%2C%20such%20as%20CARGs.%20CONCLUSIONS%3A%20Differentiated%20ART%20delivery%20models%20were%20widely%20available%20in%20this%20rural%20setting%2C%20but%20most%20facilities%20did%20not%20offer%20a%20choice%20of%20models%20to%20address%20clients%27%20diverse%20preferences.%20A%20minority%20offered%20fast-track%20refills%2C%20although%20this%20model%20was%20often%20mentioned%20as%20desirable.%20Confidentiality%2C%20travel%20expenses%20and%20client%20waiting%20times%20are%20key%20elements%20to%20consider%20when%20planning%20and%20rolling%20out%20differentiated%20HIV%20care.%22%2C%22date%22%3A%22Aug%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25944%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22998APCFS%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Freeman%20et%20al.%22%2C%22parsedDate%22%3A%222022-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFreeman%2C%20E.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcCann%2C%20N.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESemeere%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EReddy%2C%20K.%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELaker-Oketta%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Evaluation%20of%20four%20chemotherapy%20regimens%20for%20treatment%20of%20advanced%20AIDS-associated%20Kaposi%20sarcoma%20in%20Kenya%3A%20a%20cost-effectiveness%20analysis.%20%3Ci%3ELancet%20Glob%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E10%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e1179%26%23x2013%3Be1188.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2214-109X%2822%2900242-X%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2214-109X%2822%2900242-X%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20four%20chemotherapy%20regimens%20for%20treatment%20of%20advanced%20AIDS-associated%20Kaposi%20sarcoma%20in%20Kenya%3A%20a%20cost-effectiveness%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20E.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20C.%22%2C%22lastName%22%3A%22McCann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20P.%22%2C%22lastName%22%3A%22Reddy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Laker-Oketta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20P.%22%2C%22lastName%22%3A%22Pei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20E.%22%2C%22lastName%22%3A%22Hajny%20Fernandez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kiprono%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Busakhala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20N.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20V.%22%2C%22lastName%22%3A%22Bassett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Freedberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20P.%22%2C%22lastName%22%3A%22Hyle%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20most%20effective%20treatment%20for%20advanced%20AIDS-associated%20Kaposi%20sarcoma%20is%20paclitaxel%20or%20pegylated%20liposomal%20doxorubicin%20%28PLD%29%3B%20neither%20is%20routinely%20used%20in%20sub-Saharan%20Africa%20due%20to%20limited%20availability%20and%20high%20cost.%20We%20examined%20the%20clinical%20impact%2C%20costs%2C%20and%20cost-effectiveness%20of%20paclitaxel%20or%20PLD%20in%20Kenya%2C%20compared%20with%20etoposide%20or%20bleomycin-vincristine.%20METHODS%3A%20In%20this%20study%2C%20we%20use%20the%20Cost-Effectiveness%20of%20Preventing%20AIDS%20Complications%20%28CEPAC%29-International%20Model%20to%20project%20clinical%20outcomes%20and%20costs%20among%20people%20living%20with%20HIV%20and%20advanced%20Kaposi%20sarcoma%20on%20antiretroviral%20therapy.%20We%20compared%20four%20different%20treatment%20strategies%3A%20etoposide%2C%20bleomycin-vincristine%2C%20paclitaxel%2C%20or%20PLD.%20We%20derived%20cohort%20characteristics%20and%20costs%20from%20the%20Kenyan%20Academic%20Model%20for%20Providing%20Access%20to%20Healthcare%20network%2C%20and%20adverse%20events%2C%20efficacy%2C%20and%20mortality%20from%20clinical%20trials.%20We%20projected%20model%20outcomes%20over%20a%20lifetime%20and%20included%20life%20expectancy%2C%20per-person%20lifetime%20costs%2C%20and%20incremental%20cost-effectiveness%20ratios%20%28ICERs%29.%20We%20conducted%20budget%20impact%20analysis%20for%205-year%20total%20costs%20and%20did%20deterministic%20and%20probabilistic%20sensitivity%20analyses%20to%20evaluate%20the%20effect%20of%20uncertainty%20in%20input%20parameters.%20FINDINGS%3A%20We%20found%20that%20paclitaxel%20would%20be%20more%20effective%20than%20bleomycin-vincristine%20and%20would%20increase%20life%20expectancy%20by%204.2%20years%20per%20person.%20PLD%20would%20further%20increase%20life%20expectancy%20by%200.6%20years%20per%20person.%20Paclitaxel%20would%20be%20the%20most%20cost-effective%20strategy%20%28ICER%20US%24380%20per%20year-of-life-saved%20compared%20with%20bleomycin-vincristine%29%20and%20would%20remain%20cost-effective%20across%20a%20range%20of%20scenarios.%20PLD%20would%20be%20cost-effective%20compared%20with%20paclitaxel%20if%20its%20price%20were%20reduced%20to%20%24100%20per%20cycle%20%28base%20case%20%24180%20per%20cycle%29.%20Implementing%20paclitaxel%20instead%20of%20bleomycin-vincristine%20would%20save%20approximately%206400%20life-years%20and%20would%20increase%20the%20overall%205-year%20Kenyan%20health-care%20costs%20by%20%243.7%20million%3B%20increased%20costs%20would%20be%20primarily%20related%20to%20ongoing%20HIV%20care%20given%20improved%20survival.%20INTERPRETATION%3A%20Paclitaxel%20would%20substantially%20increase%20life%20expectancy%20and%20be%20cost-effective%20compared%20with%20bleomycin-vincristine%20for%20advanced%20AIDS-associated%20Kaposi%20sarcoma%20in%20Kenya%20and%20should%20be%20the%20standard%20of%20care.%20PLD%20would%20further%20improve%20survival%20and%20be%20cost-effective%20with%20a%2044%25%20price%20reduction.%20FUNDING%3A%20US%20National%20Institutes%20of%20Health%20and%20Massachusetts%20General%20Hospital.%20TRANSLATION%3A%20For%20the%20Swahili%20translation%20of%20the%20abstract%20see%20Supplementary%20Materials%20section.%22%2C%22date%22%3A%22Aug%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2214-109X%2822%2900242-X%22%2C%22ISSN%22%3A%222214-109X%20%28Electronic%29%202214-109X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A44%3A58Z%22%7D%7D%2C%7B%22key%22%3A%22M7JZWQTU%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Teeraananchai%20et%20al.%22%2C%22parsedDate%22%3A%222022-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETeeraananchai%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELaw%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoettiger%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMata%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGupte%2C%20N.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Virological%20failure%20and%20treatment%20switch%20after%20ART%20initiation%20among%20people%20living%20with%20HIV%20with%20and%20without%20routine%20viral%20load%20monitoring%20in%20Asia.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e25989.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25989%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25989%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Virological%20failure%20and%20treatment%20switch%20after%20ART%20initiation%20among%20people%20living%20with%20HIV%20with%20and%20without%20routine%20viral%20load%20monitoring%20in%20Asia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Teeraananchai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Boettiger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Mata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Gupte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20L.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20N.%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chaiwarith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20S.%22%2C%22lastName%22%3A%22Ly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Yunihastuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Pujari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Azwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20K.%20A.%22%2C%22lastName%22%3A%22Somia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Tanuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ditangco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20T.%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Gani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22Treat%20Asia%20HIV%20Observational%20Database%20of%20IeDEA%20Asia-Pacific%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Viral%20load%20%28VL%29%20testing%20is%20still%20challenging%20to%20monitor%20treatment%20responses%20of%20antiretroviral%20therapy%20%28ART%29%20for%20HIV%20treatment%20programme%20in%20Asia.%20We%20assessed%20the%20association%20between%20routine%20VL%20testing%20and%20virological%20failure%20%28VF%29%20and%20determine%20factors%20associated%20with%20switching%20to%20second-line%20regimen.%20METHODS%3A%20Among%2021%20sites%20from%20the%20TREAT%20Asia%20HIV%20Observational%20Database%20%28TAHOD%29%2C%20people%20living%20with%20HIV%20%28PLHIV%29%20aged%20%3E%5C%2F%3D18%20years%20initiating%20ART%20from%202003%20to%202021%20were%20included.%20We%20calculated%20the%20average%20number%20of%20VL%20tests%20per%20patient%20per%20year%20between%20the%20date%20of%20ART%20initiation%20and%20the%20most%20recent%20visit.%20If%20the%20median%20average%20number%20of%20VL%20tests%20was%20%3E%5C%2F%3D%200.80%20per%20patient%20per%20year%2C%20the%20site%20was%20classified%20as%20a%20routine%20VL%20site.%20A%20site%20with%20a%20median%20%3C%200.80%20was%20classified%20into%20the%20non-routine%20VL%20sites.%20VF%20was%20defined%20as%20VL%20%3E%5C%2F%3D1000%20copies%5C%2Fml%20during%20first-line%20therapy.%20Factors%20associated%20with%20VF%20were%20analysed%20using%20generalized%20estimating%20equations%20with%20Poisson%20distribution.%20RESULTS%3A%20Of%206277%20PLHIV%20starting%20ART%20after%202003%2C%203030%20%2848%25%29%20were%20from%2011%20routine%20VL%20testing%20sites%20and%203247%20%2852%25%29%20were%20from%2010%20non-routine%20VL%20testing%20sites.%20The%20median%20follow-up%20was%209%20years%20%28IQR%205-13%29.%20The%20median%20age%20was%2035%20%2830-42%29%20years%3B%2068%25%20were%20male%20and%205729%20%2891%25%29%20started%20non-nucleoside%20reverse-transcriptase%20inhibitor-based%20regimen.%20The%20median%20pre-ART%20CD4%20count%20in%20PLHIV%20from%20routine%20VL%20sites%20was%20lower%20compared%20to%20non-routine%20VL%20sites%20%28144%20vs.%20156%20cells%5C%2Fmm%283%29%20%2C%20p%20%3C0.001%29.%20Overall%2C%201021%20subsequent%20VF%20at%20a%20rate%20of%202.15%20%2895%25%20CI%202.02-2.29%29%20per%20100%20person-years%20%28PY%29.%20VF%20was%20more%20frequent%20at%20non-routine%20VL%20sites%20%28adjusted%20incidence%20rate%20ratio%202.85%20%5B95%25%20CI%202.27-3.59%5D%29%20compared%20to%20routine%20VL%20sites.%20Other%20factors%20associated%20with%20an%20increased%20rate%20of%20VF%20were%20age%20%3C50%20years%20and%20CD4%20count%20%3C350%20cells%5C%2Fmm%283%29%20.%20A%20total%20of%20817%20%2813%25%29%20patients%20switched%20to%20second-line%20regimen%20at%20a%20rate%20of%201.44%20%2895%25%20CI%201.35-1.54%29%20per%20100%20PY.%20PLHIV%20at%20routine%20VL%20monitoring%20sites%20were%20at%20higher%20risk%20of%20switching%20than%20those%20at%20non-routine%20VL%20sites%20%28adjusted%20sub-hazard%20ratio%201.78%2095%25%20CI%20%5B1.17-2.71%5D%29.%20CONCLUSIONS%3A%20PLHIV%20from%20non-routine%20VL%20sites%20had%20a%20higher%20incidence%20of%20persistent%20VF%20and%20a%20low%20switching%20regimen%20rate%2C%20reflecting%20possible%20under-utilized%20VL%20testing.%22%2C%22date%22%3A%22Aug%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25989%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A33%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22U2PE9QVY%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chihota%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChihota%2C%20B.%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERiebensahm%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuula%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESinkala%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChilengi%2C%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Liver%20steatosis%20and%20metabolic%20dysfunction-associated%20fatty%20liver%20disease%20among%20HIV-positive%20and%20negative%20adults%20in%20urban%20Zambia.%20%3Ci%3EBMJ%20Open%20Gastroenterol%3C%5C%2Fi%3E%2C%20%3Ci%3E9%3C%5C%2Fi%3E%20%281%29%2C%20S.%20e000945.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgast-2022-000945%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgast-2022-000945%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Liver%20steatosis%20and%20metabolic%20dysfunction-associated%20fatty%20liver%20disease%20among%20HIV-positive%20and%20negative%20adults%20in%20urban%20Zambia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20V.%22%2C%22lastName%22%3A%22Chihota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Riebensahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Sinkala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chilengi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mulenga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bosomprah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton-Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rauch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Berzigotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20southern%20Africa%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20The%20growing%20importance%20of%20non-communicable%20diseases%20%28NCDs%29%20and%20high%20HIV%20prevalence%20in%20urban%20African%20settings%20may%20increase%20the%20burden%20of%20metabolic%20dysfunction-associated%20fatty%20liver%20disease%20%28MAFLD%29.%20We%20assessed%20liver%20steatosis%20among%20HIV-positive%20and%20negative%20adults%20in%20urban%20Zambia.%20METHODS%3A%20Adults%2030%20years%20and%20older%20who%20were%20newly%20diagnosed%20with%20HIV%2C%20or%20tested%20HIV-negative%20at%20two%20primary%20care%20clinics%20in%20Lusaka%2C%20Zambia%2C%20were%20assessed%20for%20liver%20steatosis.%20Cardiometabolic%20data%20were%20collected%20through%20comprehensive%20clinical%20and%20laboratory%20assessments.%20Transient%20elastography%20was%20performed%20to%20measure%20controlled-attenuation%20parameter%20%28%3E%5C%2F%3D248%20dB%5C%2Fm%29.%20We%20used%20multivariable%20logistic%20regression%20models%20to%20determine%20the%20factors%20associated%20with%20the%20presence%20of%20steatosis.%20RESULTS%3A%20We%20enrolled%20381%20patients%2C%20including%20154%20%2840%25%29%20antiretroviral%20therapy-naive%20people%20living%20with%20HIV%20%28PLWH%29%20with%20a%20median%20CD4%2B%20count%20of%20247%20cells%5C%2Fmm%283%29%20and%20a%20mean%20body%20mass%20index%20%28BMI%29%20of%2023.8%20kg%5C%2Fm%282%29.%20Liver%20steatosis%20was%20observed%20in%2010%25%20of%20participants%20overall%20and%20was%20more%20common%20among%20HIV-negative%20adults%20than%20in%20PLWH%20%2815%25%20vs%203%25%29.%20The%20proportion%20of%20patients%20with%20steatosis%20was%2025%25%20among%20obese%20%28BMI%20%3E%5C%2F%3D30%20kg%5C%2Fm%282%29%29%20participants%2C%2012%25%20among%20those%20overweight%20%28BMI%2025-29.9%20kg%5C%2Fm%282%29%29%2C%20and%207%25%20among%20those%20with%20a%20BMI%20%3C25%20kg%5C%2Fm%282%29.%20Among%20patients%20with%20a%20fasting%20glucose%20%3E%5C%2F%3D7%20mmol%5C%2FL%20or%20confirmed%20diabetes%2C%2057%25%20had%20liver%20steatosis.%20In%20multivariable%20analyses%2C%20HIV%20status%20%28adjusted%20odds%20ratio%20%28aOR%29%200.18%2C%2095%25%20CI%200.06%20to%200.53%29%2C%20confirmed%20diabetes%20or%20elevated%20fasting%20glucose%20%28aOR%203.92%2C%2095%25%20CI%201.57%20to%209.78%29%20and%20elevated%20blood%20pressure%20%28aOR%202.95%2C%2095%25%20CI%201.34%20to%206.48%29%20were%20associated%20with%20steatosis.%20The%20association%20between%20BMI%3E25%20kg%5C%2Fm%282%29%20and%20liver%20steatosis%20was%20attenuated%20after%20adjustment%20for%20potential%20confounders%20%28aOR%201.96%2C%2095%25%20CI%200.88-4.40%29.%20Overall%2C%2021%20%289%25%29%20participants%20without%20HIV%20and%204%20%283%25%29%20with%20HIV%20met%20the%20criteria%20for%20MAFLD.%20Among%20individuals%20with%20liver%20steatosis%2C%2065%25%20%2895%25%20CI%2049%25%20to%2080%25%29%20fulfilled%20criteria%20of%20MAFLD%2C%20whereas%2015%20%2839%25%29%20of%20them%20had%20elevated%20transaminases%20and%203%20%288%25%29%20F2-F4%20fibrosis.%20CONCLUSIONS%3A%20The%20prevalence%20of%20liver%20steatosis%20in%20this%20urban%20cohort%20of%20HIV-positive%20and%20negative%20adults%20in%20Zambia%20was%20low%2C%20despite%20a%20large%20proportion%20of%20patients%20with%20high%20BMI%20and%20central%20obesity.%20Our%20study%20is%20among%20the%20first%20to%20report%20data%20on%20MAFLD%20among%20adults%20in%20Africa%2C%20demonstrating%20that%20metabolic%20risk%20factors%20are%20key%20drivers%20of%20liver%20steatosis%20and%20supporting%20the%20adoption%20of%20the%20criteria%20for%20MAFLD%20in%20African%20populations.%22%2C%22date%22%3A%22Jul%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjgast-2022-000945%22%2C%22ISSN%22%3A%222054-4774%20%28Print%29%202054-4774%20%28Electronic%29%202054-4774%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A36%3A29Z%22%7D%7D%2C%7B%22key%22%3A%228N68RLVP%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Romo%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A10%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERomo%2C%20M.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMahambou-Nsonde%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDe%20Waal%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESekaggya-Wiltshire%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Real-world%20use%20and%20outcomes%20of%20dolutegravir-containing%20antiretroviral%20therapy%20in%20HIV%20and%20tuberculosis%20co-infection%3A%20a%20site%20survey%20and%20cohort%20study%20in%20sub-Saharan%20Africa.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%287%29%2C%20S.%20e25961.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25961%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25961%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Real-world%20use%20and%20outcomes%20of%20dolutegravir-containing%20antiretroviral%20therapy%20in%20HIV%20and%20tuberculosis%20co-infection%3A%20a%20site%20survey%20and%20cohort%20study%20in%20sub-Saharan%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Romo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Mahambou-Nsonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22De%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Sekaggya-Wiltshire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20R.%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Muhairwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dzudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Rafael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20C.%22%2C%22lastName%22%3A%22Ezechi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20S.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Dolutegravir%20is%20being%20scaled%20up%20globally%20as%20part%20of%20antiretroviral%20therapy%20%28ART%29%2C%20but%20for%20people%20with%20HIV%20and%20tuberculosis%20co-infection%2C%20its%20use%20is%20complicated%20by%20a%20drug-drug%20interaction%20with%20rifampicin%20requiring%20an%20additional%20daily%20dose%20of%20dolutegravir.%20This%20represents%20a%20disadvantage%20over%20efavirenz%2C%20which%20does%20not%20have%20a%20major%20drug-drug%20interaction%20with%20rifampicin.%20We%20sought%20to%20describe%20HIV%20clinic%20practices%20for%20prescribing%20concomitant%20dolutegravir%20and%20rifampicin%2C%20and%20characterize%20virologic%20outcomes%20among%20patients%20with%20tuberculosis%20co-infection%20receiving%20dolutegravir%20or%20efavirenz.%20METHODS%3A%20Within%20the%20four%20sub-Saharan%20Africa%20regions%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20consortium%2C%20we%20conducted%20a%20site%20survey%20%282021%29%20and%20a%20cohort%20study%20%282015-2021%29.%20The%20cohort%20study%20used%20routine%20clinical%20data%20and%20included%20patients%20newly%20initiating%20or%20already%20receiving%20dolutegravir%20or%20efavirenz%20at%20the%20time%20of%20tuberculosis%20diagnosis.%20Patients%20were%20followed%20from%20tuberculosis%20diagnosis%20until%20viral%20suppression%20%28%3C1000%20copies%5C%2Fml%29%2C%20a%20competing%20event%20%28switching%20ART%20regimen%3B%20loss%20to%20program%5C%2Fdeath%29%20or%20administrative%20censoring%20at%2012%20months.%20RESULTS%3A%20In%20the%20survey%2C%2086%20of%2090%20%2896%25%29%20HIV%20clinics%20in%2018%20countries%20reported%20prescribing%20dolutegravir%20to%20patients%20who%20were%20receiving%20rifampicin%20as%20part%20of%20tuberculosis%20treatment%2C%20with%2077%20%2890%25%29%20reporting%20that%20they%20use%20twice-daily%20dosing%20of%20dolutegravir%2C%20of%20which%2074%20%2896%25%29%20reported%20having%2050%20mg%20tablets%20available%20to%20accommodate%20twice-daily%20dosing.%20The%20cohort%20study%20included%203563%20patients%20in%2011%20countries%2C%20with%2067%25%20newly%20or%20recently%20initiating%20ART.%20Among%20patients%20receiving%20dolutegravir%20%28n%20%3D%20465%29%2C%20the%20cumulative%20incidence%20of%20viral%20suppression%20was%2058.9%25%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%2054.3-63.3%25%29%2C%20switching%20ART%20regimen%20was%204.1%25%20%2895%25%20CI%3A%202.6-6.2%25%29%20and%20loss%20to%20program%5C%2Fdeath%20was%2023.4%25%20%2895%25%20CI%3A%2019.7-27.4%25%29.%20Patients%20receiving%20dolutegravir%20had%20improved%20viral%20suppression%20compared%20with%20patients%20receiving%20efavirenz%20who%20had%20a%20tuberculosis%20diagnosis%20before%20site%20dolutegravir%20availability%20%28adjusted%20subdistribution%20hazard%20ratio%20%5BaSHR%5D%3A%201.47%2C%2095%25%20CI%3A%201.28-1.68%29%20and%20after%20site%20dolutegravir%20availability%20%28aSHR%201.28%2C%2095%25%20CI%3A%201.08-1.51%29.%20CONCLUSIONS%3A%20At%20a%20programmatic%20level%2C%20dolutegravir%20was%20being%20widely%20prescribed%20in%20sub-Saharan%20Africa%20for%20people%20with%20HIV%20and%20tuberculosis%20co-infection%20with%20a%20dose%20adjustment%20for%20the%20drug-drug%20interaction%20with%20rifampicin.%20Despite%20this%20more%20complex%20regimen%2C%20our%20cohort%20study%20revealed%20that%20dolutegravir%20did%20not%20negatively%20impact%20viral%20suppression.%22%2C%22date%22%3A%22Jul%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25961%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A25%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22K25THJJP%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baidya%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBaidya%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESangle%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarbaniang%2C%20I.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKulkarni%2C%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDeshpande%2C%20P.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Clinical%20and%20Immunological%20Markers%20of%20Pulmonary%20Impairment%20Among%20People%20With%20HIV%20in%20India.%20%3Ci%3EOpen%20Forum%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E9%3C%5C%2Fi%3E%20%287%29%2C%20S.%20ofac233.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac233%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac233%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20and%20Immunological%20Markers%20of%20Pulmonary%20Impairment%20Among%20People%20With%20HIV%20in%20India%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Baidya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Sangle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Marbaniang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Kulkarni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Deshpande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nimkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Chavan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Salvi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lokhande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Kadam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Mave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20N.%22%2C%22lastName%22%3A%22Gupte%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Despite%20antiretroviral%20therapy%2C%20chronic%20lung%20diseases%20remain%20an%20important%20source%20of%20morbidity%20and%20mortality%20in%20people%20with%20HIV%20%28PWH%29.%20We%20sought%20to%20identify%20clinical%20and%20immunological%20markers%20of%20pulmonary%20impairment%20among%20PWH%20in%20India.%20METHODS%3A%20Two%20hundred%20ten%20adult%20PWH%20receiving%20antiretroviral%20therapy%20%28ART%29%20were%20prospectively%20evaluated%20for%203%20years.%20Plasma%20concentrations%20of%20interleukin%20%28IL%29-6%2C%20IL-10%2C%20tumor%20necrosis%20factor%20alpha%2C%20D-dimer%2C%20C-reactive%20protein%2C%20soluble%20%28s%29CD14%2C%20and%20sCD163%20were%20measured%20at%20enrollment.%20We%20used%20multivariable%20linear%20and%20logistic%20regression%20to%20measure%20the%20association%20of%20baseline%20and%20time-varying%20clinical%20and%20immunological%20variables%20with%20spirometry-defined%20chronic%20obstructive%20pulmonary%20disease%20%28COPD%29%2C%20restrictive%20spirometry%20pattern%20%28RSP%29%2C%20preserved%20ratio%20impaired%20spirometry%20%28PRISm%29%2C%20forced%20expiratory%20volume%20in%201%20second%20%28FEV1%29%2C%20and%20forced%20vital%20capacity%20%28FVC%29%20during%20the%20third%20year%20of%20follow-up.%20RESULTS%3A%20After%20adjusting%20confounders%2C%20females%20were%207%20times%20more%20likely%20to%20have%20RSP%20%2895%25%20CI%2C%202.81%20to%2017.62%3B%20P%20%3C%20.001%29%20and%2022%20times%20more%20likely%20to%20have%20PRISm%20%2895%25%20CI%2C%207.42%20to%2069.92%3B%20P%20%3C%20.001%29%20compared%20with%20men.%20Higher%20IL-6%20concentrations%20were%20associated%20with%20lower%20FEV1%20z-scores%20%28beta%2C%20-0.14%20per%20log-higher%3B%2095%25%20CI%2C%20-0.29%20to%200.008%3B%20P%20%3D%20.06%29%20and%20higher%20odds%20of%20COPD%20%28adjusted%20odds%20ratio%20%5BaOR%5D%2C%202.66%20per%20log-higher%3B%2095%25%20CI%2C%201.16%20to%206.09%3B%20P%20%3D%20.02%29.%20Higher%20D-dimer%20concentrations%20were%20associated%20with%20lower%20FVC%20z-scores%20%28beta%2C%20-0.40%20per%20log-higher%3B%2095%25%20CI%2C%20-0.78%20to%20-0.01%3B%20P%20%3D%20.04%29.%20Conversely%2C%20higher%20IL-10%20concentrations%20were%20associated%20with%20lower%20odds%20of%20PRISm%20%28aOR%2C%200.76%20per%20log-higher%3B%2095%25%20CI%2C%200.59%20to%200.99%3B%20P%20%3D%20.04%29.%20CONCLUSIONS%3A%20Female%20sex%2C%20higher%20concentrations%20of%20IL-6%20and%20D-dimer%2C%20and%20lower%20concentrations%20of%20IL-10%20were%20associated%20with%20pulmonary%20impairment%20in%20adult%20PWH%20receiving%20ART%20in%20India.%22%2C%22date%22%3A%22Jul%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofac233%22%2C%22ISSN%22%3A%222328-8957%20%28Print%29%202328-8957%20%28Electronic%29%202328-8957%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A39%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22JKGXEYY8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kalk%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-29%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalk%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHeekes%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESlogrove%2C%20A.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPhelanyane%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavies%2C%20M.%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Cohort%20profile%3A%20the%20Western%20Cape%20Pregnancy%20Exposure%20Registry%20%28WCPER%29.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%20%286%29%2C%20S.%20e060205.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-060205%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-060205%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cohort%20profile%3A%20the%20Western%20Cape%20Pregnancy%20Exposure%20Registry%20%28WCPER%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Phelanyane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kroon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Petro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Fieggen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Rhoda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gebhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Osman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Mehta%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20The%20Western%20Cape%20Pregnancy%20Exposure%20Registry%20%28PER%29%20was%20established%20at%20two%20public%20sector%20healthcare%20sentinel%20sites%20in%20the%20Western%20Cape%20province%2C%20South%20Africa%2C%20to%20provide%20ongoing%20surveillance%20of%20drug%20exposures%20in%20pregnancy%20and%20associations%20with%20pregnancy%20outcomes.%20PARTICIPANTS%3A%20Established%20in%202016%2C%20all%20women%20attending%20their%20first%20antenatal%20visit%20at%20primary%20care%20obstetric%20facilities%20were%20enrolled%20and%20followed%20to%20pregnancy%20outcome%20regardless%20of%20the%20site%20%28ie%2C%20primary%2C%20secondary%2C%20tertiary%20facility%29.%20Routine%20operational%20obstetric%20and%20medical%20data%20are%20digitised%20from%20the%20clinical%20stationery%20at%20the%20healthcare%20facilities.%20Data%20collection%20has%20been%20integrated%20into%20existing%20services%20and%20information%20platforms%20and%20supports%20routine%20operations.%20The%20PER%20is%20situated%20within%20the%20Provincial%20Health%20Data%20Centre%2C%20an%20information%20exchange%20that%20harmonises%20and%20consolidates%20all%20health-related%20electronic%20data%20in%20the%20province.%20Data%20are%20contributed%20via%20linkage%20across%20a%20unique%20identifier.%20This%20relationship%20limits%20the%20missing%20data%20in%20the%20PER%2C%20allows%20validation%20and%20avoids%20misclassification%20in%20the%20population-level%20data%20set.%20FINDINGS%20TO%20DATE%3A%20Approximately%205000%20and%203500%20pregnant%20women%20enter%20the%20data%20set%20annually%20at%20the%20urban%20and%20rural%20sites%2C%20respectively.%20As%20of%20August%202021%2C%20%3E30%20000%20pregnancies%20have%20been%20recorded%20and%20outcomes%20have%20been%20determined%20for%2093%25.%20Analysis%20of%20key%20obstetric%20and%20neonatal%20health%20indicators%20derived%20from%20the%20PER%20are%20consistent%20with%20the%20aggregate%20data%20in%20the%20District%20Health%20Information%20System.%20FUTURE%20PLANS%3A%20This%20represents%20significant%20infrastructure%2C%20able%20to%20address%20clinical%20and%20epidemiological%20concerns%20in%20a%20low%5C%2Fmiddle-income%20setting.%22%2C%22date%22%3A%22Jun%2029%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2021-060205%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A39%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22IBITJURF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lewis%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-06%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELewis%2C%20J.%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBrazier%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKatz%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENash%2C%20D.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDuda%2C%20S.%20N.%3C%5C%2Fspan%3E%20%282022%29.%20A%20Method%20for%20Generating%20Dashboard%20Aggregations%20in%20an%20International%20HIV%20Consortium.%20%3Ci%3EStud%20Health%20Technol%20Inform%3C%5C%2Fi%3E%2C%20%3Ci%3E290%3C%5C%2Fi%3E%2C%20S.%201048%26%23x2013%3B1049.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FSHTI220261%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FSHTI220261%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Method%20for%20Generating%20Dashboard%20Aggregations%20in%20an%20International%20HIV%20Consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Katz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%5D%2C%22abstractNote%22%3A%22Online%20dashboards%20are%20valuable%20tools%20for%20gaining%20insights%20about%20population%20health%20metrics%20of%20interest%20and%20for%20disseminating%20data%20collected%20through%20research%20networks.%20The%20process%20of%20aggregating%20data%20from%20separate%20databases%20for%20use%20in%20online%20dashboards%2C%20while%20also%20ensuring%20data%20quality%2C%20is%20complex.%20We%20describe%20a%20method%20for%20integrating%20HIV%20dashboard%20aggregation%20scripts%20into%20an%20existing%20web-based%20data%20quality%20checking%20application%20and%20leveraging%20REDCap%20to%20store%20aggregated%20metrics.%22%2C%22date%22%3A%22Jun%206%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3233%5C%2FSHTI220261%22%2C%22ISSN%22%3A%221879-8365%20%28Electronic%29%200926-9630%20%28Print%29%200926-9630%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A12%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22ALEFZH9L%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22van%20der%20Hoven%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-03%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Evan%20der%20Hoven%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAllen%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECois%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Ede%20Waal%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMaartens%2C%20G.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Determining%20antenatal%20medicine%20exposures%20in%20South%20African%20women%3A%20a%20comparison%20of%20three%20methods%20of%20ascertainment.%20%3Ci%3EBMC%20Pregnancy%20Childbirth%3C%5C%2Fi%3E%2C%20%3Ci%3E22%3C%5C%2Fi%3E%20%281%29%2C%20S.%20466.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12884-022-04765-1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12884-022-04765-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determining%20antenatal%20medicine%20exposures%20in%20South%20African%20women%3A%20a%20comparison%20of%20three%20methods%20of%20ascertainment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22van%20der%20Hoven%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Cois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22de%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Maartens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Malaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Madlala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nyemba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Phelanyane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kalk%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20In%20the%20absence%20of%20clinical%20trials%2C%20data%20on%20the%20safety%20of%20medicine%20exposures%20in%20pregnancy%20are%20dependent%20on%20observational%20studies%20conducted%20after%20the%20agent%20has%20been%20licensed%20for%20use.%20This%20requires%20an%20accurate%20history%20of%20antenatal%20medicine%20use%20to%20determine%20potential%20risks.%20Medication%20use%20is%20commonly%20determined%20by%20self-report%2C%20clinician%20records%2C%20and%20electronic%20pharmacy%20data%3B%20different%20data%20sources%20may%20be%20more%20informative%20for%20different%20types%20of%20medication%20and%20resources%20may%20differ%20by%20setting.%20We%20compared%20three%20methods%20to%20determine%20antenatal%20medicine%20use%20%28self-report%2C%20clinician%20records%20and%20electronic%20pharmacy%20dispensing%20records%20%5BEDR%5D%29%20in%20women%20attending%20antenatal%20care%20at%20a%20primary%20care%20facility%20in%20Cape%20Town%2C%20South%20Africa%20in%20a%20setting%20with%20high%20HIV%20prevalence.%20METHODS%3A%20Structured%2C%20interview-administered%20questionnaires%20recorded%20self-reported%20medicine%20use.%20Data%20were%20collected%20from%20clinician%20records%20and%20EDR%20on%20the%20same%20participants.%20We%20determined%20agreement%20between%20these%20data%20sources%20using%20Cohen%27s%20kappa%20and%2C%20lacking%20a%20gold%20standard%2C%20used%20Latent%20Class%20Analysis%20to%20estimate%20sensitivity%2C%20specificity%20and%20positive%20predictive%20value%20%28PPV%29%20for%20each%20data%20source.%20RESULTS%3A%20Between%2055%25%20and%2089%25%20of%20967%20women%20had%20any%20medicine%20use%20documented%20depending%20on%20the%20data%20source%20%28median%20number%20of%20medicines%5C%2Fparticipant%20%3D%205%20%5BIQR%203-6%5D%29.%20Agreement%20between%20the%20datasets%20was%20poor%20regardless%20of%20class%20except%20for%20antiretroviral%20therapy%20%28ART%3B%20kappa%200.6-0.71%29.%20Overall%2C%20agreement%20was%20better%20between%20the%20EDR%20and%20self-report%20than%20with%20either%20dataset%20and%20the%20clinician%20records.%20Sensitivity%20and%20PPV%20were%20higher%20for%20self-report%20and%20the%20EDR%20and%20were%20similar%20for%20the%20two.%20Self-report%20was%20the%20best%20source%20for%20over-the-counter%2C%20traditional%20and%20complementary%20medicines%3B%20clinician%20records%20for%20vaccines%20and%20supplements%3B%20and%20EDR%20for%20chronic%20medicines.%20CONCLUSIONS%3A%20Medicine%20use%20in%20pregnancy%20was%20common%20and%20no%20single%20data%20source%20included%20all%20the%20medicines%20used.%20ART%20was%20the%20most%20consistently%20reported%20across%20all%20three%20datasets%20but%20otherwise%20agreement%20between%20them%20was%20poor%20and%20dependent%20on%20class.%20Using%20a%20single%20data%20collection%20method%20will%20under-estimate%20medicine%20use%20in%20pregnancy%20and%20the%20choice%20of%20data%20source%20should%20be%20guided%20by%20the%20class%20of%20the%20agents%20being%20investigated.%22%2C%22date%22%3A%22Jun%203%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12884-022-04765-1%22%2C%22ISSN%22%3A%221471-2393%20%28Electronic%29%201471-2393%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22HUVVKC7Y%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Li%20et%20al.%22%2C%22parsedDate%22%3A%222022-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELi%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBuchanan%2C%20A.%20L.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECole%2C%20S.%20R.%3C%5C%2Fspan%3E%20%282022%29.%20Generalizing%20trial%20evidence%20to%20target%20populations%20in%20non-nested%20designs%3A%20Applications%20to%20AIDS%20clinical%20trials.%20%3Ci%3EJ%20R%20Stat%20Soc%20Ser%20C%20Appl%20Stat%3C%5C%2Fi%3E%2C%20%3Ci%3E71%3C%5C%2Fi%3E%20%283%29%2C%20S.%20669%26%23x2013%3B697.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Frssc.12550%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Frssc.12550%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Generalizing%20trial%20evidence%20to%20target%20populations%20in%20non-nested%20designs%3A%20Applications%20to%20AIDS%20clinical%20trials%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Buchanan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20R.%22%2C%22lastName%22%3A%22Cole%22%7D%5D%2C%22abstractNote%22%3A%22Comparative%20effectiveness%20evidence%20from%20randomized%20trials%20may%20not%20be%20directly%20generalizable%20to%20a%20target%20population%20of%20substantive%20interest%20when%2C%20as%20in%20most%20cases%2C%20trial%20participants%20are%20not%20randomly%20sampled%20from%20the%20target%20population.%20Motivated%20by%20the%20need%20to%20generalize%20evidence%20from%20two%20trials%20conducted%20in%20the%20AIDS%20Clinical%20Trials%20Group%20%28ACTG%29%2C%20we%20consider%20weighting%2C%20regression%20and%20doubly%20robust%20estimators%20to%20estimate%20the%20causal%20effects%20of%20HIV%20interventions%20in%20a%20specified%20population%20of%20people%20living%20with%20HIV%20in%20the%20USA.%20We%20focus%20on%20a%20non-nested%20trial%20design%20and%20discuss%20strategies%20for%20both%20point%20and%20variance%20estimation%20of%20the%20target%20population%20average%20treatment%20effect.%20Specifically%20in%20the%20generalizability%20context%2C%20we%20demonstrate%20both%20analytically%20and%20empirically%20that%20estimating%20the%20known%20propensity%20score%20in%20trials%20does%20not%20increase%20the%20variance%20for%20each%20of%20the%20weighting%2C%20regression%20and%20doubly%20robust%20estimators.%20We%20apply%20these%20methods%20to%20generalize%20the%20average%20treatment%20effects%20from%20two%20ACTG%20trials%20to%20specified%20target%20populations%20and%20operationalize%20key%20practical%20considerations.%20Finally%2C%20we%20report%20on%20a%20simulation%20study%20that%20investigates%20the%20finite-sample%20operating%20characteristics%20of%20the%20generalizability%20estimators%20and%20their%20sandwich%20variance%20estimators.%22%2C%22date%22%3A%22Jun%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Frssc.12550%22%2C%22ISSN%22%3A%220035-9254%20%28Print%29%201467-9876%20%28Electronic%29%200035-9254%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A45%3A34Z%22%7D%7D%2C%7B%22key%22%3A%228NTDZHC5%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hussey%20et%20al.%22%2C%22parsedDate%22%3A%222022-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHussey%2C%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavies%2C%20M.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHeekes%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWilliamson%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EValley-Omar%2C%20Z.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Assessing%20the%20clinical%20severity%20of%20the%20Omicron%20variant%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%2C%20using%20the%20diagnostic%20PCR%20proxy%20marker%20of%20RdRp%20target%20delay%20to%20distinguish%20between%20Omicron%20and%20Delta%20infections%20-%20a%20survival%20analysis.%20%3Ci%3EInt%20J%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E118%3C%5C%2Fi%3E%2C%20S.%20150%26%23x2013%3B154.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.02.051%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.02.051%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessing%20the%20clinical%20severity%20of%20the%20Omicron%20variant%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%2C%20using%20the%20diagnostic%20PCR%20proxy%20marker%20of%20RdRp%20target%20delay%20to%20distinguish%20between%20Omicron%20and%20Delta%20infections%20-%20a%20survival%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Hussey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Williamson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Valley-Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Hardie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Korsman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Doolabh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Preiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Maponga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Iranzadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Wasserman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Boloko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Symons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Raubenheimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Schrueder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Solomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Wolter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Jassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lessells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20Y.%22%2C%22lastName%22%3A%22Hsiao%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20At%20present%2C%20it%20is%20unclear%20whether%20the%20extent%20of%20reduced%20risk%20of%20severe%20disease%20seen%20with%20SARS-Cov-2%20Omicron%20variant%20infection%20is%20caused%20by%20a%20decrease%20in%20variant%20virulence%20or%20by%20higher%20levels%20of%20population%20immunity.%20METHODS%3A%20RdRp%20target%20delay%20%28RTD%29%20in%20the%20Seegene%20Allplex%28TM%29%202019-nCoV%20PCR%20assay%20is%20a%20proxy%20marker%20for%20the%20Delta%20variant.%20The%20absence%20of%20this%20proxy%20marker%20in%20the%20transition%20period%20was%20used%20to%20identify%20suspected%20Omicron%20infections.%20Cox%20regression%20was%20performed%20for%20the%20outcome%20of%20hospital%20admission%20in%20those%20who%20tested%20positive%20for%20SARS-CoV-2%20on%20the%20Seegene%20Allplex%28TM%29%20assay%20from%20November%201%20to%20December%2014%2C%202021%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%2C%20in%20the%20public%20sector.%20Adjustments%20were%20made%20for%20vaccination%20status%20and%20prior%20diagnosis%20of%20infection.%20RESULTS%3A%20A%20total%20of%20150%20cases%20with%20RTD%20and%201486%20cases%20without%20RTD%20were%20included.%20Cases%20without%20RTD%20had%20a%20lower%20hazard%20of%20admission%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%2C%200.56%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%200.34-0.91%29.%20Complete%20vaccination%20was%20protective%20against%20admission%2C%20with%20an%20aHR%20of%200.45%20%2895%25%20CI%2C%200.26-0.77%29.%20CONCLUSION%3A%20Omicron%20has%20resulted%20in%20a%20lower%20risk%20of%20hospital%20admission%20compared%20with%20contemporaneous%20Delta%20infection%2C%20when%20using%20the%20proxy%20marker%20of%20RTD.%20Under-ascertainment%20of%20reinfections%20with%20an%20immune%20escape%20variant%20remains%20a%20challenge%20to%20accurately%20assessing%20variant%20virulence.%22%2C%22date%22%3A%22May%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2022.02.051%22%2C%22ISSN%22%3A%221878-3511%20%28Electronic%29%201201-9712%20%28Print%29%201201-9712%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A16%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22VVXTPCCD%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Crabtree-Ramirez%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECrabtree-Ramirez%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJenkins%2C%20C.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShepherd%2C%20B.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJayathilake%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVeloso%2C%20V.%20G.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Tuberculosis%20treatment%20intermittency%20in%20the%20continuation%20phase%20and%20mortality%20in%20HIV-positive%20persons%20receiving%20antiretroviral%20therapy.%20%3Ci%3EBMC%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E22%3C%5C%2Fi%3E%20%281%29%2C%20S.%20341.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-022-07330-5%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-022-07330-5%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tuberculosis%20treatment%20intermittency%20in%20the%20continuation%20phase%20and%20mortality%20in%20HIV-positive%20persons%20receiving%20antiretroviral%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Carriquiry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Koenig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22C.%20CASAnet%20Region%20of%20IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Some%20tuberculosis%20%28TB%29%20treatment%20guidelines%20recommend%20daily%20TB%20treatment%20in%20both%20the%20intensive%20and%20continuation%20phases%20of%20treatment%20in%20HIV-positive%20persons%20to%20decrease%20the%20risk%20of%20relapse%20and%20acquired%20drug%20resistance.%20However%2C%20guidelines%20vary%20across%20countries%2C%20and%20treatment%20is%20given%207%2C%205%2C%203%2C%20or%202%20days%5C%2Fweek.%20The%20effect%20of%20TB%20treatment%20intermittency%20in%20the%20continuation%20phase%20on%20mortality%20in%20HIV-positive%20persons%20on%20antiretroviral%20therapy%20%28ART%29%2C%20is%20not%20well-described.%20METHODS%3A%20We%20conducted%20an%20observational%20cohort%20study%20among%20HIV-positive%20adults%20treated%20for%20TB%20between%202000%20and%202018%20and%20after%20enrollment%20into%20the%20Caribbean%2C%20Central%2C%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%3B%20Brazil%2C%20Chile%2C%20Haiti%2C%20Honduras%2C%20Mexico%20and%20Peru%29.%20All%20received%20standard%20TB%20therapy%20%282-month%20initiation%20phase%20of%20daily%20isoniazid%2C%20rifampin%20or%20rifabutin%2C%20pyrazinamide%20%2B%5C%2F-%20ethambutol%29%20and%20continuation%20phase%20of%20isoniazid%20and%20rifampin%20or%20rifabutin%2C%20administered%20concomitantly%20with%20ART.%20Known%20timing%20of%20ART%20and%20TB%20treatment%20were%20also%20inclusion%20criteria.%20Kaplan-Meier%20and%20Cox%20proportional%20hazards%20methods%20compared%20time%20to%20death%20between%20groups.%20Missing%20model%20covariates%20were%20imputed%20via%20multiple%20imputation.%20RESULTS%3A%202303%20patients%20met%20inclusion%20criteria%3A%202003%2887%25%29%20received%20TB%20treatment%205-7%20days%5C%2Fweek%20and%20300%2813%25%29%202-3%20days%5C%2Fweek%20in%20the%20continuation%20phase.%20Intermittency%20varied%20by%20site%3A%20100%25%20of%20patients%20from%20Brazil%20and%20Haiti%20received%20continuation%20phase%20treatment%205-7%20days%5C%2Fweek%2C%20followed%20by%20Honduras%20%2891%25%29%2C%20Peru%20%2842%25%29%2C%20Mexico%20%287%25%29%2C%20and%20Chile%20%280%25%29.%20The%20crude%20risk%20of%20death%20was%20lower%20among%20those%20receiving%20treatment%205-7%20vs.%202-3%20days%5C%2Fweek%20%28HR%20%3D%200.68%3B%2095%25%20CI%20%3D%200.51-0.91%3B%20P%20%3D%200.008%29.%20After%20adjusting%20for%20age%2C%20sex%2C%20CD4%2C%20ART%20use%20at%20TB%20diagnosis%2C%20site%20of%20TB%20disease%20%28pulmonary%20vs.%20extrapulmonary%29%2C%20and%20year%20of%20TB%20diagnosis%2C%20mortality%20risk%20was%20lower%2C%20but%20not%20significantly%2C%20among%20those%20treated%205-7%20days%5C%2Fweek%20vs.%202-3%20days%5C%2Fweek%20%28HR%200.75%2C%2095%25CI%200.55-1.01%3B%20P%20%3D%200.06%29.%20After%20also%20stratifying%20by%20study%20site%2C%20there%20was%20no%20longer%20a%20protective%20effect%20%28HR%201.42%2C%2095%25CI%200.83-2.45%3B%20P%20%3D%200.20%29.%20CONCLUSIONS%3A%20TB%20treatment%205-7%20days%5C%2Fweek%20was%20associated%20with%20a%20marginally%20decreased%20risk%20of%20death%20compared%20to%20TB%20treatment%202-3%20days%5C%2Fweek%20in%20the%20continuation%20phase%20in%20multivariable%2C%20unstratified%20analyses.%20However%2C%20little%20variation%20in%20TB%20treatment%20intermittency%20within%20country%20meant%20the%20results%20could%20have%20been%20driven%20by%20other%20differences%20between%20study%20sites.%20Therefore%2C%20randomized%20trials%20are%20needed%2C%20especially%20in%20heterogenous%20regions%20such%20as%20Latin%20America.%22%2C%22date%22%3A%22Apr%205%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12879-022-07330-5%22%2C%22ISSN%22%3A%221471-2334%20%28Electronic%29%201471-2334%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A50%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22GVRPU4UF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Oyungu%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOyungu%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEl%20Kebbi%2C%20O.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVreeman%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyandiko%2C%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMonahan%2C%20P.%20O.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Predicting%20neurodevelopmental%20risk%20in%20children%20born%20to%20mothers%20living%20with%20HIV%20in%20Kenya%3A%20protocol%20for%20a%20prospective%20cohort%20study%20%28Tabiri%20Study%29.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e061051.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-061051%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-061051%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Predicting%20neurodevelopmental%20risk%20in%20children%20born%20to%20mothers%20living%20with%20HIV%20in%20Kenya%3A%20protocol%20for%20a%20prospective%20cohort%20study%20%28Tabiri%20Study%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Oyungu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22El%20Kebbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Nyandiko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20O.%22%2C%22lastName%22%3A%22Monahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Tu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Khaitan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Desta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Were%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22Carlucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20S.%22%2C%22lastName%22%3A%22McHenry%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20For%20the%20growing%20number%20of%20children%20with%20in%20utero%20and%20postpartum%20exposure%20to%20HIV%20and%5C%2For%20antiretrovirals%2C%20it%20is%20unclear%20which%20exposures%20or%20risk%20factors%20play%20a%20significant%20role%20in%20predicting%20worse%20neurodevelopmental%20outcomes.%20This%20protocol%20describes%20a%20prospective%20longitudinal%20cohort%20study%20of%20infants%20born%20to%20mothers%20living%20with%20HIV%20and%20those%20born%20to%20mothers%20without%20HIV.%20We%20will%20determine%20which%20risk%20factors%20are%20most%20predictive%20of%20child%20neurodevelopment%20at%2024%20months.%20We%20aim%20to%20create%20a%20risk%20assessment%20tool%20to%20help%20predict%20which%20children%20are%20at%20risk%20for%20worse%20neurodevelopment%20outcomes.%20METHODS%20AND%20ANALYSIS%3A%20This%20study%20leverages%20an%20existing%20Kenyan%20cohort%20to%20prospectively%20enrol%20500%20children%20born%20to%20mothers%20living%20with%20HIV%20and%20500%20to%20those%20without%20HIV%20%28n%3D1000%20total%29%20and%20follow%20them%20from%20birth%20to%20age%2024%20months.%20The%20following%20factors%20will%20be%20measured%20every%206%20months%3A%20infectious%20morbidity%20and%20biological%5C%2Fsociodemographic%5C%2Fpsychosocial%20risk%20factors.%20We%20will%20compare%20these%20factors%20between%20the%20two%20groups.%20We%20will%20then%20measure%20and%20compare%20neurodevelopment%20within%20children%20in%20both%20groups%20at%2024%20months%20of%20age%20using%20the%20Child%20Behaviour%20Checklist%20and%20the%20Bayley%20Scales%20of%20Infant%20and%20Toddler%20Development%2C%20third%20edition.%20Finally%2C%20we%20will%20use%20generalised%20linear%20mixed%20modelling%20to%20quantify%20associations%20with%20neurodevelopment%20and%20create%20a%20risk%20assessment%20tool%20for%20children%20%3C%5C%2F%3D24%20months.%20ETHICS%20AND%20DISSEMINATION%3A%20The%20study%20is%20approved%20by%20the%20Moi%20University%27s%20Institutional%20Research%20and%20Ethics%20Committee%20%28IREC%5C%2F2021%5C%2F55%3B%20Approval%20%230003892%29%2C%20Kenya%27s%20National%20Commission%20for%20Science%2C%20Technology%20and%20Innovation%20%28NACOSTI%2C%20Reference%20%23700244%29%20and%20Indiana%20University%27s%20Institutional%20Review%20Board%20%28IRB%20Protocol%20%23110990%29.%20This%20study%20carries%20minimal%20risk%20to%20the%20children%20and%20their%20mothers%2C%20and%20all%20mothers%20will%20provide%20written%20consent%20for%20participation%20in%20the%20study.%20Results%20will%20be%20disseminated%20to%20maternal%20child%20health%20clinics%20within%20Uasin%20Gishu%20County%2C%20Kenya%20and%20via%20papers%20submitted%20to%20peer-reviewed%20journals%20and%20presentation%20at%20international%20conferences.%22%2C%22date%22%3A%22Apr%204%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2022-061051%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A24%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22HP3BNVX6%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kim%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKim%2C%20H.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENance%2C%20R.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELo%20Re%2C%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESilverberg%2C%20M.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFranco%2C%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Development%20and%20Validation%20of%20a%20Model%20for%20Prediction%20of%20End-Stage%20Liver%20Disease%20in%20People%20With%20HIV.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E89%3C%5C%2Fi%3E%20%284%29%2C%20S.%20396%26%23x2013%3B404.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002886%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002886%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Development%20and%20Validation%20of%20a%20Model%20for%20Prediction%20of%20End-Stage%20Liver%20Disease%20in%20People%20With%20HIV%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20N.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20M.%22%2C%22lastName%22%3A%22Nance%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Lo%20Re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Franco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20R.%22%2C%22lastName%22%3A%22Cachay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20M.%22%2C%22lastName%22%3A%22Crane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Delaney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20M.%22%2C%22lastName%22%3A%22Kitahata%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20End-stage%20liver%20disease%20%28ESLD%29%20is%20a%20leading%20cause%20of%20non-AIDS-related%20death%20among%20people%20with%20HIV%20%28PWH%29.%20Factors%20that%20increase%20the%20progression%20of%20liver%20disease%20include%20comorbidities%20and%20HIV-specific%20factors%2C%20but%20we%20currently%20lack%20a%20tool%20to%20apply%20this%20evidence%20into%20clinical%20practice.%20METHODS%3A%20We%20developed%20and%20validated%20a%20risk%20prediction%20model%20for%20ESLD%20among%20PWH%20who%20received%20care%20in%2012%20cohorts%20of%20the%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20between%202000%20and%202016%20and%20had%20fibrosis-4%20index%20%3E%201.45.%20The%20first%20occurrence%20of%20ascites%2C%20variceal%20bleed%2C%20spontaneous%20bacterial%20peritonitis%2C%20or%20hepatic%20encephalopathy%20was%20verified%20by%20standardized%20medical%20record%20review.%20The%20Bayesian%20model%20averaging%20was%20used%20to%20select%20predictors%20among%20biomarkers%20and%20diagnoses%20and%20the%20Harrell%20C%20statistic%20to%20assess%20model%20discrimination.%20RESULTS%3A%20Among%2013%2C787%20PWH%20in%20the%20training%20set%2C%2082%25%20were%20men%20and%2054%25%20were%20Black%20with%20a%20mean%20age%20of%2048%20years.%20Three%20hundred%20ninety%20ESLD%20events%20occurred%20over%20a%20mean%205.4%20years.%20Among%20the%20ESLD%20cases%2C%2052%25%20had%20hepatitis%20C%20virus%2C%2015%25%20hepatitis%20B%20virus%2C%20and%2031%25%20alcohol%20use%20disorder.%20Twelve%20factors%20together%20predicted%20ESLD%20risk%20moderately%20well%20%28C%20statistic%200.79%2C%2095%25%20confidence%20interval%3A%200.76%20to%200.81%29%3A%20age%2C%20sex%2C%20race%5C%2Fethnicity%2C%20chronic%20hepatitis%20B%20or%20C%2C%20and%20routinely%20collected%20laboratory%20values%20reflecting%20hepatic%20impairment%20%28serum%20albumin%2C%20aspartate%20aminotransferase%2C%20total%20bilirubin%2C%20and%20platelets%29%20and%20lipid%20metabolism%20%28triglycerides%2C%20high-density%20lipoprotein%2C%20and%20total%20cholesterol%29.%20Our%20model%20performed%20well%20in%20the%20test%20set%20%28C%20statistic%200.81%2C%2095%25%20confidence%20interval%3A%200.76%20to%200.86%29.%20CONCLUSION%3A%20This%20model%20of%20readily%20accessible%20clinical%20parameters%20predicted%20ESLD%20in%20a%20large%20diverse%20population%20of%20PWH.%22%2C%22date%22%3A%22Apr%201%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000002886%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A41%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22UGGK9LMX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Staub%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStaub%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPanczak%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMatthes%2C%20K.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFloris%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBerlin%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Historically%20High%20Excess%20Mortality%20During%20the%20COVID-19%20Pandemic%20in%20Switzerland%2C%20Sweden%2C%20and%20Spain.%20%3Ci%3EAnn%20Intern%20Med%3C%5C%2Fi%3E%2C%20%3Ci%3E175%3C%5C%2Fi%3E%20%284%29%2C%20S.%20523%26%23x2013%3B532.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-3824%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-3824%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Historically%20High%20Excess%20Mortality%20During%20the%20COVID-19%20Pandemic%20in%20Switzerland%2C%20Sweden%2C%20and%20Spain%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Staub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Panczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20L.%22%2C%22lastName%22%3A%22Matthes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Floris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Berlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Junker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Weitkunat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20E.%22%2C%22lastName%22%3A%22Mamelund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Zwahlen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Riou%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Excess%20mortality%20quantifies%20the%20overall%20mortality%20impact%20of%20a%20pandemic.%20Mortality%20data%20have%20been%20accessible%20for%20many%20countries%20in%20recent%20decades%2C%20but%20few%20continuous%20data%20have%20been%20available%20for%20longer%20periods.%20OBJECTIVE%3A%20To%20assess%20the%20historical%20dimension%20of%20the%20COVID-19%20pandemic%20in%202020%20for%203%20countries%20with%20reliable%20death%20count%20data%20over%20an%20uninterrupted%20span%20of%20more%20than%20100%20years.%20DESIGN%3A%20Observational%20study.%20SETTING%3A%20Switzerland%2C%20Sweden%2C%20and%20Spain%2C%20which%20were%20militarily%20neutral%20and%20not%20involved%20in%20combat%20during%20either%20world%20war%20and%20have%20not%20been%20affected%20by%20significant%20changes%20in%20their%20territory%20since%20the%20end%20of%20the%2019th%20century.%20PARTICIPANTS%3A%20Complete%20populations%20of%20these%203%20countries.%20MEASUREMENTS%3A%20Continuous%20series%20of%20recorded%20deaths%20%28from%20all%20causes%29%20by%20month%20from%20the%20earliest%20available%20year%20%281877%20for%20Switzerland%2C%201851%20for%20Sweden%2C%20and%201908%20for%20Spain%29%20were%20jointly%20modeled%20with%20annual%20age%20group-specific%20death%20and%20total%20population%20counts%20using%20negative%20binomial%20and%20multinomial%20models%2C%20which%20accounted%20for%20temporal%20trends%20and%20seasonal%20variability%20of%20prepandemic%20years.%20The%20aim%20was%20to%20estimate%20the%20expected%20number%20of%20deaths%20in%20a%20pandemic%20year%20for%20a%20nonpandemic%20scenario%20and%20the%20difference%20in%20observed%20and%20expected%20deaths%20aggregated%20over%20the%20year.%20RESULTS%3A%20In%202020%2C%20the%20number%20of%20excess%20deaths%20recorded%20per%20100%20000%20persons%20was%20100%20%2895%25%20credible%20interval%20%5BCrI%5D%2C%2060%20to%20135%29%20for%20Switzerland%2C%2075%20%28CrI%2C%2040%20to%20105%29%20for%20Sweden%2C%20and%20155%20%28CrI%2C%20110%20to%20195%29%20for%20Spain.%20In%201918%2C%20excess%20mortality%20was%206%20to%207%20times%20higher.%20In%20all%203%20countries%2C%20the%20peaks%20of%20monthly%20excess%20mortality%20in%202020%20were%20greater%20than%20most%20monthly%20excess%20mortality%20since%201918%2C%20including%20many%20peaks%20due%20to%20seasonal%20influenza%20and%20heat%20waves%20during%20that%20period.%20LIMITATION%3A%20Historical%20vital%20statistics%20might%20be%20affected%20by%20minor%20completeness%20issues%20before%20the%20beginning%20of%20the%2020th%20century.%20CONCLUSION%3A%20In%202020%2C%20the%20COVID-19%20pandemic%20led%20to%20the%20second-largest%20infection-related%20mortality%20disaster%20in%20Switzerland%2C%20Sweden%2C%20and%20Spain%20since%20the%20beginning%20of%20the%2020th%20century.%20PRIMARY%20FUNDING%20SOURCE%3A%20Foundation%20for%20Research%20in%20Science%20and%20the%20Humanities%20at%20the%20University%20of%20Zurich%2C%20Swiss%20National%20Science%20Foundation%2C%20and%20National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7326%5C%2FM21-3824%22%2C%22ISSN%22%3A%221539-3704%20%28Electronic%29%200003-4819%20%28Print%29%200003-4819%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A46%3A29Z%22%7D%7D%2C%7B%22key%22%3A%223L3WMKHX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Walker%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWalker%2C%20T.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMiotto%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKoser%2C%20C.%20U.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFowler%2C%20P.%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKnaggs%2C%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20The%202021%20WHO%20catalogue%20of%20Mycobacterium%20tuberculosis%20complex%20mutations%20associated%20with%20drug%20resistance%3A%20A%20genotypic%20analysis.%20%3Ci%3ELancet%20Microbe%3C%5C%2Fi%3E%2C%20%3Ci%3E3%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e265%26%23x2013%3Be273.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2666-5247%2821%2900301-3%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2666-5247%2821%2900301-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%202021%20WHO%20catalogue%20of%20Mycobacterium%20tuberculosis%20complex%20mutations%20associated%20with%20drug%20resistance%3A%20A%20genotypic%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20M.%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20U.%22%2C%22lastName%22%3A%22Koser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20W.%22%2C%22lastName%22%3A%22Fowler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Knaggs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Iqbal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Hunt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Chindelevitch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Comas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Posey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20V.%22%2C%22lastName%22%3A%22Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20E.%22%2C%22lastName%22%3A%22Peto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Suresh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Uplekar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20E.%22%2C%22lastName%22%3A%22Colman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Nathanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Zignol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20S.%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22C.%20RyPTIC%20Consortium%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22Seq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Consortium%22%2C%22lastName%22%3A%22Treat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20W.%22%2C%22lastName%22%3A%22Crook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20C.%22%2C%22lastName%22%3A%22Rodwell%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Molecular%20diagnostics%20are%20considered%20the%20most%20promising%20route%20to%20achieving%20rapid%2C%20universal%20drug%20susceptibility%20testing%20for%20Mycobacterium%20tuberculosiscomplex%20%28MTBC%29.%20We%20aimed%20to%20generate%20a%20WHO%20endorsed%20catalogue%20of%20mutations%20to%20serve%20as%20a%20global%20standard%20for%20interpreting%20molecular%20information%20for%20drug%20resistance%20prediction.%20METHODS%3A%20A%20candidate%20gene%20approach%20was%20used%20to%20identify%20mutations%20as%20associated%20with%20resistance%2C%20or%20consistent%20with%20susceptibility%2C%20for%2013%20WHO%20endorsed%20anti-tuberculosis%20drugs.%2038%2C215%20MTBC%20isolates%20with%20paired%20whole-genome%20sequencing%20and%20phenotypic%20drug%20susceptibility%20testing%20data%20were%20amassed%20from%2045%20countries.%20For%20each%20mutation%2C%20a%20contingency%20table%20of%20binary%20phenotypes%20and%20presence%20or%20absence%20of%20the%20mutation%20computed%20positive%20predictive%20value%2C%20and%20Fisher%27s%20exact%20tests%20generated%20odds%20ratios%20and%20Benjamini-Hochberg%20corrected%20p-values.%20Mutations%20were%20graded%20as%20Associated%20with%20Resistance%20if%20present%20in%20at%20least%205%20isolates%2C%20if%20the%20odds%20ratio%20was%20%3E1%20with%20a%20statistically%20significant%20corrected%20p-value%2C%20and%20if%20the%20lower%20bound%20of%20the%2095%25%20confidence%20interval%20on%20the%20positive%20predictive%20value%20for%20phenotypic%20resistance%20was%20%3E25%25.%20A%20series%20of%20expert%20rules%20were%20applied%20for%20final%20confidence%20grading%20of%20each%20mutation.%20FINDINGS%3A%2015%2C667%20associations%20were%20computed%20for%2013%2C211%20unique%20mutations%20linked%20to%20one%20or%20more%20drugs.%201%2C149%5C%2F15%2C667%20%287.3%25%29%20mutations%20were%20classified%20as%20associated%20with%20phenotypic%20resistance%20and%20107%5C%2F15%2C667%20%280.7%25%29%20were%20deemed%20consistent%20with%20susceptibility.%20For%20rifampicin%2C%20isoniazid%2C%20ethambutol%2C%20fluoroquinolones%2C%20and%20streptomycin%2C%20the%20mutations%27%20pooled%20sensitivity%20was%20%3E80%25.%20Specificity%20was%20over%2095%25%20for%20all%20drugs%20except%20ethionamide%20%2891.4%25%29%2C%20moxifloxacin%20%2891.6%25%29%20and%20ethambutol%20%2893.3%25%29.%20Only%20two%20resistance%20mutations%20were%20classified%20for%20bedaquiline%2C%20delamanid%2C%20clofazimine%2C%20and%20linezolid%20as%20prevalence%20of%20phenotypic%20resistance%20was%20low%20for%20these%20drugs.%20INTERPRETATION%3A%20This%20first%20WHO%20endorsed%20catalogue%20of%20molecular%20targets%20for%20MTBC%20drug%20susceptibility%20testing%20provides%20a%20global%20standard%20for%20resistance%20interpretation.%20Its%20existence%20should%20encourage%20the%20implementation%20of%20molecular%20diagnostics%20by%20National%20Tuberculosis%20Programmes.%20FUNDING%3A%20UNITAID%2C%20Wellcome%2C%20MRC%2C%20BMGF.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2666-5247%2821%2900301-3%22%2C%22ISSN%22%3A%222666-5247%20%28Electronic%29%202666-5247%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22D9WC3N3V%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A29%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22LWYD2N35%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Coelho%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A6%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoelho%2C%20L.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJenkins%2C%20C.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShepherd%2C%20B.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPape%2C%20J.%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMejia%20Cordero%2C%20F.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Weight%20gain%20post-ART%20in%20HIV%2B%20Latinos%5C%2Fas%20differs%20in%20the%20USA%2C%20Haiti%2C%20and%20Latin%20America.%20%3Ci%3ELancet%20Reg%20Health%20Am%3C%5C%2Fi%3E%2C%20%3Ci%3E8%3C%5C%2Fi%3E%2C%20S.%20100173.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100173%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100173%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Weight%20gain%20post-ART%20in%20HIV%2B%20Latinos%5C%2Fas%20differs%20in%20the%20USA%2C%20Haiti%2C%20and%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20E.%22%2C%22lastName%22%3A%22Coelho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Mejia%20Cordero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree%20Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20R.%22%2C%22lastName%22%3A%22Koethe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Marconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20C.%22%2C%22lastName%22%3A%22Tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Willig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Colasanti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20M.%22%2C%22lastName%22%3A%22Crane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20An%20obesity%20epidemic%20has%20been%20documented%20among%20adult%20Latinos%5C%2Fas%20in%20Latin%20America%20and%20the%20United%20States%20%28US%29%3B%20however%2C%20little%20is%20known%20about%20obesity%20among%20Latinos%5C%2Fas%20with%20HIV%20%28PWH%29.%20Moreover%2C%20Latinos%5C%2Fas%20PWH%20in%20the%20US%20may%20have%20different%20weight%20trajectories%20than%20those%20in%20Latin%20America%20due%20to%20the%20cultural%20and%20environmental%20contexts.%20We%20assessed%20weight%20and%20body%20mass%20index%20%28BMI%29%20trajectories%20among%20PWH%20initiating%20antiretroviral%20therapy%20%28ART%29%20across%205%20countries%20in%20Latin%20America%20and%20the%20Caribbean%20and%20the%20US.%20METHODS%3A%20ART-nayve%20PWH%20%3E%5C%2F%3D18%20years%20old%2C%20enrolled%20in%20Brazil%2C%20Honduras%2C%20Mexico%2C%20Peru%2C%20and%20Haiti%20%28sites%20within%20CCA-SAnet%29%20and%20the%20US%20%28NA-ACCORD%29%20starting%20ART%20between%202000%20and%202017%2C%20with%20at%20least%20one%20weight%20measured%20after%20ART%20initiation%20were%20included.%20Participants%20were%20classified%20according%20to%20site%5C%2Fethnicity%20as%3A%20Latinos%5C%2Fas%20in%20US%2C%20non-Latinos%5C%2Fas%20in%20US%2C%20Haitians%2C%20and%20Latinos%5C%2Fas%20in%20Latin%20America.%20Generalized%20least%20squares%20models%20were%20used%20to%20assess%20trends%20in%20weight%20and%20BMI.%20Models%20estimating%20probabilities%20of%20becoming%20overweight%5C%2Fobese%20%28BMI%20%3E%5C%2F%3D25%20kg%5C%2Fm%282%29%29%20and%20of%20becoming%20obese%20%28BMI%20%3E%5C%2F%3D30%20kg%5C%2Fm%282%29%29%20post%20ART%20initiation%20for%20males%20and%20females%20were%20fit%20using%20generalized%20estimating%20equations%20with%20a%20logit%20link%20and%20an%20independence%20working%20correlation%20structure.%20FINDINGS%3A%20Among%2059%2C207%20PWH%2C%209%25%20were%20Latinos%5C%2Fas%20from%20Latin%20America%2C%209%25%20Latinos%5C%2Fas%20from%20the%20US%2C%2068%25%20non-Latinos%5C%2Fas%20from%20the%20US%20and%2014%25%20were%20Haitian.%20At%20ART%20initiation%2C%2029%25%20were%20overweight%20and%2014%25%20were%20obese.%20Post-ART%20weight%20and%20BMI%20increases%20were%20steeper%20for%20Latinos%5C%2Fas%20in%20Latin%20America%20compared%20with%20other%20sites%5C%2Fethnicities%3B%20however%2C%20BMI%20at%203-years%20post%20ART%20remained%20lower%20compared%20to%20Latinos%5C%2Fas%20and%20non-Latinos%5C%2Fas%20in%20the%20US.%20Among%20females%2C%20at%203-years%20post%20ART%20initiation%20the%20greatest%20adjusted%20probability%20of%20obesity%20was%20found%20among%20non-Latinas%20in%20the%20US%20%2815.2%25%29%20and%20lowest%20among%20Latinas%20in%20Latin%20America%20%288.6%25%29.%20Among%20males%2C%20while%20starting%20with%20a%20lower%20BMI%2C%20Latinos%20in%20Latin%20America%20had%20the%20greatest%20adjusted%20probability%20of%20becoming%20overweight%20or%20obese%203-years%20post-ART%20initiation.%20INTERPRETATION%3A%20In%20the%20Americas%2C%20PWH%20gain%20substantial%20weight%20after%20ART%20initiation.%20Despite%20environmental%20and%20cultural%20differences%2C%20PWH%20in%20Latin%20America%2C%20Haiti%20and%20Latinos%20and%20non-Latinos%20in%20the%20US%20share%20similar%20BMI%20trajectories%20on%20ART%20and%20high%20probabilities%20of%20becoming%20overweight%20and%20obese%20over%20time.%20Multicohort%20studies%20are%20needed%20to%20better%20understand%20the%20burden%20of%20other%20metabolic%20syndrome%20components%20in%20PWH%20across%20different%20countries.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2021.100173%22%2C%22ISSN%22%3A%222667-193X%20%28Electronic%29%202667-193X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22D9WC3N3V%22%2C%22F2Y6PLUL%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A23%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22PX7FKVW8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Caro-Vega%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECaro-Vega%2C%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERebeiro%2C%20P.%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShepherd%2C%20B.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBelaunzaran-Zamudio%2C%20P.%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECrabtree-Ramirez%2C%20B.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Clinical%20effects%20of%20durability%20of%20immunosuppression%20in%20virologically%20suppressed%20ART-initiating%20persons%20with%20HIV%20in%20Latin%20America.%20A%20retrospective%20cohort%20study.%20%3Ci%3ELancet%20Reg%20Health%20Am%3C%5C%2Fi%3E%2C%20%3Ci%3E8%3C%5C%2Fi%3E%2C%20S.%20100175.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100175%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100175%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20effects%20of%20durability%20of%20immunosuppression%20in%20virologically%20suppressed%20ART-initiating%20persons%20with%20HIV%20in%20Latin%20America.%20A%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Belaunzaran-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Padget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Clinical%20outcomes%20are%20rarely%20studied%20in%20virologically%20suppressed%20people%20living%20with%20HIV%20%28PWH%29%20and%20incomplete%20CD4%20recovery.%20To%20explore%20whether%20time%20living%20with%20severe%20immunosuppression%20predict%20clinical%20outcomes%20better%20than%20baseline%20or%20time%20updated%20CD4%2C%20we%20estimated%20the%20association%20between%20cumulative%20percentage%20of%20time%20with%20CD4%20%3C200%20cells%5C%2FmuL%20during%20viral%20suppression%20%28VS%29%20%28%25t%28CD4%3C200%29%29%2C%20and%20mortality%20and%20comorbidities%20during%202000-2019.%20METHODS%3A%20In%20a%20retrospective%20cohort%20analysis%2C%20we%20followed%20PWH%20initiating%20ART%20in%20Latin%20America%20from%20first%20VS%20%28HIV-RNA%3C200%20copies%5C%2FmuL%29%20to%20death%2C%20virological%20failure%20or%20loss%20to%20follow-up.%20We%20fit%20Cox%20models%20to%20estimate%20risk%20of%20death%20and%5C%2For%20AIDS-defining%20and%20serious%20non-AIDS-defining%20events%20%28ADE%20and%20SNADE%20-cancer%2C%20cardiovascular%2C%20liver%2C%20and%20renal%20diseases%29%20by%20%25t%28CD4%3C200%29%20%28continuous%20variable%29.%20We%20predicted%20survival%20probabilities%20for%20each%20event%20and%20calculated%20risks%20of%20hypothetical%20cases%20of%20different%20%25t%28CD4%3C200%29.%20FINDINGS%3A%20In%208%2C369%20patients%20with%2034.9%20months%20of%20follow-up%20%28median%2C%20IQR%3A%2016.7%2C%2069.1%29%2C%204%2C274%20%2851%25%29%20started%20ART%20with%20CD4%3C200%20cells%5C%2FmuL.%20Median%20%25t%28CD4%3C200%29%20was%200%25%20%28IQR%3A%200%2C%2015%25%29.%20We%20identified%20195%20%282.3%25%29%20deaths%20and%20584%20%287.2%25%29%20patients%20with%20ADE%5C%2FSNADE.%20For%20an%20increased%20%25t%28CD4%3C200%29%20of%2015%25%20%28e.g.%2C%2015%25%20vs.%200%25%29%2C%20the%20adjusted%20relative%20hazard%20%28aHR%29%20of%20death%20was%201.27%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%201.19%20-%201.35%29%2C%20of%20ADE%5C%2FSNADE%20was%201.13%20%2895%25CI%3A%201.09%20-%201.17%29%2C%20of%20SNADE%20was%200.96%20%2895%25CI%3A%200.89%20-%201.02%29%20and%20of%20death%5C%2FADE%5C%2FSNADE%20was%201.11%20%2895%25CI%3A%201.07%20-%201.14%29.%20Estimates%20were%20similar%20after%20adjusting%20for%20time%20updated%20CD4%20count.%20INTERPRETATION%3A%20In%20virologically%20suppressed%20PWH%2C%20increased%20time%20living%20with%20severe%20immunosuppression%20had%20an%20increased%20risk%20of%20death%20and%20ADE%5C%2FSNADE%20in%20this%20Latin%20American%20cohort%2C%20independently%20of%20time%20updated%20CD4%20count.%20FUNDING%3A%20This%20work%20was%20supported%20by%20the%20NIH-funded%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%2C%20U01AI069923%29%2C%20a%20member%20cohort%20of%20the%20International%20Epidemiologic%20Databases%20to%20Evaluate%20AIDS%20%28leDEA%29.%20This%20award%20is%20funded%20by%20the%20following%20institutes%3A%20Eunice%20Kennedy%20Shriver%20National%20Institute%20Of%20Child%20Health%20%26%20Human%20Development%20%28NICHD%29%2C%20National%20Cancer%20Institute%20%28NCI%29%2C%20National%20Institute%20Of%20Allergy%20And%20Infectious%20Diseases%20%28NIAID%29%2C%20National%20Institute%20Of%20Mental%20Health%20%28NIMH%29%2C%20the%20National%20Heart%2C%20Lung%2C%20and%20Blood%20Institute%20%28NHLBI%29%2C%20the%20National%20Institute%20on%20Alcohol%20Abuse%20and%20Alcoholism%20%28NIAAA%29%2C%20the%20National%20Institute%20of%20Diabetes%20and%20Digestive%20and%20Kidney%20Diseases%20%28NIDDK%29%2C%20and%20the%20Fogarty%20International%20Center%20%28FIC%29.%20Specific%20funding%20was%20provided%20from%20the%20Fogarty%20International%20Center%20%28FIC%29%20for%20lead%20author%2C%20Yanink%20Caro-Vega%2C%20for%20the%20Fogarty-IeDEA%20Mentorship%20Program%20%28FIMP%29.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2021.100175%22%2C%22ISSN%22%3A%222667-193X%20%28Electronic%29%202667-193X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A39%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22V86ICMTD%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Antimycobacterial%20Susceptibility%20Testing%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAntimycobacterial%20Susceptibility%20Testing%2C%20Group%3C%5C%2Fspan%3E%20%282022%29.%20Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment.%20%3Ci%3EEur%20Respir%20J%3C%5C%2Fi%3E%2C%20%3Ci%3E59%3C%5C%2Fi%3E%20%284%29%2C%20S.%202200166.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Group%22%2C%22lastName%22%3A%22Antimycobacterial%20Susceptibility%20Testing%22%7D%5D%2C%22abstractNote%22%3A%22Inappropriately%20high%20breakpoints%20have%20resulted%20in%20systematic%20false-susceptible%20AST%20results%20to%20anti-TB%20drugs.%20MIC%2C%20PK%5C%2FPD%20and%20clinical%20outcome%20data%20should%20be%20combined%20when%20setting%20breakpoints%20to%20minimise%20the%20emergence%20and%20spread%20of%20antimicrobial%20resistance.%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3i43wb6%5CnApproximately%2085%20000%20deaths%20globally%20in%202019%20were%20due%20to%20drug-resistant%20tuberculosis%20%28TB%29%2C%20which%20corresponds%20to%207%25%20of%20global%20deaths%20attributable%20to%20bacterial%20antimicrobial%20resistance%20%5B1%5D.%20Yet%20concerns%20have%20been%20mounting%20that%20drug-resistant%20TB%20was%20being%20underestimated%20because%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-TB%20agents%20had%20not%20kept%20up%20with%20those%20used%20for%20other%20major%20bacterial%20pathogens%20%5B2-9%5D.%20Here%2C%20we%20outline%20the%20recent%2C%20evidence-based%20initiatives%20spearheaded%20by%20the%20World%20Health%20Organization%20%28WHO%29%20and%20others%20to%20update%20breakpoints%20%28traditionally%20referred%20to%20as%20critical%20concentrations%20%28CCs%29%29%20that%20are%20used%20for%20phenotypic%20antimicrobial%20susceptibility%20testing%20%28AST%29%2C%20also%20called%20drug%20susceptibility%20testing%20in%20the%20TB%20literature.%5Cneng%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00166-2022%22%2C%22ISSN%22%3A%221399-3003%20%28Electronic%29%200903-1936%20%28Print%29%200903-1936%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A32%3A48Z%22%7D%7D%2C%7B%22key%22%3A%227LE2GH88%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Justice%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJustice%2C%20A.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGoetz%2C%20M.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStewart%2C%20C.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHogan%2C%20B.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHumes%2C%20E.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Delayed%20presentation%20of%20HIV%20among%20older%20individuals%3A%20a%20growing%20problem.%20%3Ci%3ELancet%20HIV%3C%5C%2Fi%3E%2C%20%3Ci%3E9%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e269%26%23x2013%3Be280.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2822%2900003-0%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2822%2900003-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Delayed%20presentation%20of%20HIV%20among%20older%20individuals%3A%20a%20growing%20problem%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20B.%22%2C%22lastName%22%3A%22Goetz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20N.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20C.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Humes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Rajasuriar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%5D%2C%22abstractNote%22%3A%22Late%20presentation%20for%20care%20is%20a%20major%20impediment%20to%20the%20prevention%20and%20effective%20treatment%20of%20HIV%20infection.%20Older%20individuals%20are%20at%20increased%20risk%20of%20late%20presentation%2C%20represent%20a%20growing%20proportion%20of%20people%20with%20late%20presentation%2C%20and%20might%20require%20interventions%20tailored%20to%20their%20age%20group.%20We%20provide%20a%20summary%20of%20the%20literature%20published%20globally%20between%202016-21%20%28reporting%20data%20from%201984-2018%29%20and%20quantify%20the%20association%20of%20age%20with%20delayed%20presentation.%20Using%20the%20most%20common%20definitions%20of%20late%20presentation%20and%20older%20age%20from%20these%20earlier%20studies%2C%20we%20update%20this%20work%20with%20data%20from%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%2C%20focusing%20on%20data%20from%202000-19%2C%20encompassing%20four%20continents.%20Finally%2C%20we%20consider%20how%20late%20presentation%20among%20older%20individuals%20might%20be%20more%20effectively%20addressed%20as%20electronic%20medical%20records%20become%20widely%20adopted.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2822%2900003-0%22%2C%22ISSN%22%3A%222352-3018%20%28Electronic%29%202405-4704%20%28Print%29%202352-3018%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A18%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22PWU69TDX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Enane%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEnane%2C%20L.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EApondi%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELiepmann%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EToromo%2C%20J.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOmollo%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20%26%23x201C%3BWe%20are%20not%20going%20anywhere%26%23x201D%3B%3A%20a%20qualitative%20study%20of%20Kenyan%20healthcare%20worker%20perspectives%20on%20adolescent%20HIV%20care%20engagement%20during%20the%20COVID-19%20pandemic.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e055948.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-055948%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-055948%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%27We%20are%20not%20going%20anywhere%27%3A%20a%20qualitative%20study%20of%20Kenyan%20healthcare%20worker%20perspectives%20on%20adolescent%20HIV%20care%20engagement%20during%20the%20COVID-19%20pandemic%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Apondi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Liepmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Toromo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Omollo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bakari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Scanlon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Vreeman%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Adolescents%20living%20with%20HIV%20%28ALHIV%29%20may%20be%20vulnerable%20to%20widescale%20impacts%20of%20the%20COVID-19%20pandemic%20and%20to%20health%20system%20responses%20which%20impact%20HIV%20care.%20We%20assessed%20healthcare%20worker%20%28HCW%29%20perspectives%20on%20impacts%20of%20the%20COVID-19%20pandemic%20on%20adolescent%20HIV%20care%20delivery%20and%20engagement%20in%20western%20Kenya.%20METHODS%3A%20We%20performed%20in-depth%20qualitative%20interviews%20with%20HCW%20at%2010%20clinical%20sites%20in%20the%20Academic%20Model%20Providing%20Access%20to%20Healthcare%20in%20Kenya%2C%20from%20January%20to%20March%2C%202021.%20Semistructured%20interviews%20ascertained%20pandemic-related%20impacts%20on%20adolescent%20HIV%20care%20delivery%20and%20retention.%20RESULTS%3A%20Interviews%20were%20conducted%20with%2022%20HCWs%20from%2010%20clinics.%20HCWs%20observed%20adolescent%20financial%20hardships%2C%20unmet%20basic%20needs%20and%20school%20dropouts%20during%20the%20pandemic%2C%20with%20some%20adolescents%20relocating%20to%20rural%20homes%2C%20to%20partners%20or%20to%20the%20street.%20Marked%20increases%20in%20adolescent%20pregnancies%20and%20pregnancy%20complications%20were%20described%2C%20as%20well%20as%20barriers%20to%20family%20planning%20and%20antenatal%20care.%20Transportation%20challenges%20and%20restrictions%20limited%20access%20to%20care%20and%20prompted%20provision%20of%20multi-month%20refills%2C%20refills%20at%20local%20dispensaries%20or%20transfer%20to%20local%20facilities.%20Adolescent-friendly%20services%20were%20compromised%2C%20resulting%20in%20care%20challenges%20and%20disengagement%20from%20care.%20Clinic%20capacities%20to%20respond%20to%20adolescent%20needs%20were%20limited%20by%20funding%20cuts%20to%20multidisciplinary%20staff%20and%20resources.%20HCW%20and%20youth%20peer%20mentors%20%28YPMs%29%20demonstrated%20resilience%2C%20by%20adapting%20services%2C%20taking%20on%20expanded%20roles%20and%20leveraging%20available%20resources%20to%20support%20adolescent%20retention%20and%20access%20to%20care.%20CONCLUSIONS%3A%20ALHIV%20are%20uniquely%20vulnerable%2C%20and%20adolescent-friendly%20services%20are%20essential%20to%20their%20treatment.%20The%20combined%20effects%20of%20the%20pandemic%2C%20health%20system%20changes%20and%20funding%20cuts%20compromised%20adolescent-friendly%20care%20and%20limited%20capacity%20to%20respond%20to%20adolescent%20needs.%20There%20is%20a%20need%20to%20reinforce%20adolescent-friendly%20services%20within%20programmes%20and%20funding%20structures.%20Support%20for%20expanded%20YPM%20roles%20may%20facilitate%20dedicated%2C%20scalable%20and%20effective%20adolescent-friendly%20services%2C%20which%20are%20resilient%20and%20sustainable%20in%20times%20of%20crisis.%22%2C%22date%22%3A%22Mar%2030%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2021-055948%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A33%3A54Z%22%7D%7D%2C%7B%22key%22%3A%225WY5NKVK%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Koh%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKoh%2C%20M.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMerrill%2C%20M.%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKoh%2C%20M.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStuver%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAlonso%2C%20C.%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Comparative%20outcomes%20for%20mature%20T-cell%20and%20NK%5C%2FT-cell%20lymphomas%20in%20people%20with%20and%20without%20HIV%20and%20to%20AIDS-defining%20lymphomas.%20%3Ci%3EBlood%20Adv%3C%5C%2Fi%3E%2C%20%3Ci%3E6%3C%5C%2Fi%3E%20%285%29%2C%20S.%201420%26%23x2013%3B1431.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2021006208%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2021006208%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparative%20outcomes%20for%20mature%20T-cell%20and%20NK%5C%2FT-cell%20lymphomas%20in%20people%20with%20and%20without%20HIV%20and%20to%20AIDS-defining%20lymphomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Koh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20H.%22%2C%22lastName%22%3A%22Merrill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Koh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Stuver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20M.%22%2C%22lastName%22%3A%22Foss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Epeldegui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cachay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20E.%22%2C%22lastName%22%3A%22Nijhawan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22McGinnis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20S.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20S.%22%2C%22lastName%22%3A%22Rabkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Shen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Jain%22%7D%5D%2C%22abstractNote%22%3A%22There%20are%20no%20studies%20comparing%20the%20prognosis%20for%20mature%20T-cell%20lymphoma%20%28TCL%29%20in%20people%20with%20HIV%20%28PWH%29%20to%20people%20without%20HIV%20%28PWoH%29%20and%20to%20AIDS-defining%20B-cell%20lymphomas%20%28A-BCLs%29%20in%20the%20modern%20antiretroviral%20therapy%20era.%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20and%20Comprehensive%20Oncology%20Measures%20for%20Peripheral%20T-cell%20Lymphoma%20Treatment%20are%20cohorts%20that%20enroll%20patients%20diagnosed%20with%20HIV%20and%20TCL%2C%20respectively.%20In%20our%20study%2C%2052%2C%2064%2C%20101%2C%20500%2C%20and%20246%20PWH%20with%20histologic%20confirmation%20of%20TCL%2C%20primary%20central%20nervous%20system%20lymphoma%2C%20Burkitt%27s%20lymphoma%2C%20diffuse%20large%20B-cell%20lymphoma%20%28DLBCL%29%2C%20and%20Hodgkin%27s%20lymphoma%20%28HL%29%2C%20respectively%2C%20and%20450%20TCLs%20without%20HIV%20were%20eligible%20for%20analysis.%20At%20the%20time%20of%20TCL%20diagnosis%2C%20anaplastic%20large-cell%20lymphoma%20%28ALCL%29%20was%20the%20most%20common%20TCL%20subtype%20within%20PWH.%20Although%20PWH%20with%20TCL%20diagnosed%20between%201996%20and%202009%20experienced%20a%20low%205-year%20survival%20probability%20at%200.23%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%200.13%2C%200.41%29%2C%20we%20observed%20a%20marked%20improvement%20in%20their%20survival%20when%20diagnosed%20between%202010%20and%202016%20%280.69%3B%2095%25%20CI%3A%200.48%2C%201%3B%20P%20%3D%20.04%29%20in%20contrast%20to%20TCLs%20among%20PWoH%20%280.45%3B%2095%25%20CI%3A%200.41%2C%200.51%3B%20P%20%3D%20.53%29.%20Similarly%2C%20PWH%20with%20ALCLs%20diagnosed%20between%201996%20and%202009%20were%20associated%20with%20a%20conspicuously%20inferior%205-year%20survival%20probability%20%280.17%3B%2095%25%20CI%3A%200.07%2C%200.42%29%20and%20consistently%20lagged%20behind%20A-BCL%20subtypes%20such%20as%20Burkitt%27s%20%280.43%3B%2095%25%20CI%3A0.33%2C%200.57%3B%20P%20%3D%20.09%29%20and%20DLBCL%20%280.17%3B%2095%25%20CI%3A%200.06%2C%200.46%3B%20P%20%3D%20.11%29%20and%20behind%20HL%20%280.57%3B%2095%25%20CI%3A%200.50%2C%200.65%3B%20P%20%3C%20.0001%29.%20Despite%20a%20small%20number%2C%20those%20diagnosed%20between%202010%20and%202016%20experienced%20a%20remarkable%20improvement%20in%20survival%20%280.67%3B%2095%25%20CI%3A%200.3%2C%201%29%20in%20comparison%20with%20PWoH%20%280.76%3B%2095%25%20CI%3A%200.66%2C%200.87%3B%20P%20%3D%20.58%29.%20Thus%2C%20our%20analysis%20confirms%20improved%20overall%20survival%20for%20aggressive%20B-%20and%20T-cell%20malignancies%20among%20PWH%20in%20the%20last%20decade.%22%2C%22date%22%3A%22Mar%208%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2021006208%22%2C%22ISSN%22%3A%222473-9537%20%28Electronic%29%202473-9529%20%28Print%29%202473-9529%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A39%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22JSS8DS84%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Collaborative%20Initiative%20for%20Paediatric%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A14%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECollaborative%20Initiative%20for%20Paediatric%2C%20H.%20I.%20V.%20Education%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EResearch%20Global%20Cohort%2C%20Collaboration%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJesson%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECrichton%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EQuartagno%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Growth%20and%20CD4%20patterns%20of%20adolescents%20living%20with%20perinatally%20acquired%20HIV%20worldwide%2C%20a%20CIPHER%20cohort%20collaboration%20analysis.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e25871.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25871%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25871%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Growth%20and%20CD4%20patterns%20of%20adolescents%20living%20with%20perinatally%20acquired%20HIV%20worldwide%2C%20a%20CIPHER%20cohort%20collaboration%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20I.%20V.%20Education%22%2C%22lastName%22%3A%22Collaborative%20Initiative%20for%20Paediatric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Collaboration%22%2C%22lastName%22%3A%22Research%20Global%20Cohort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Jesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Crichton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Quartagno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20J.%22%2C%22lastName%22%3A%22Abrams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Chokephaibulkit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Le%20Coeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20H.%22%2C%22lastName%22%3A%22Ake-Assi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ben-Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Van%20Dyke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Judd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mofenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Vicari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Seage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20G.%22%2C%22lastName%22%3A%22Bekker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Essajee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Gibb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Penazzato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20J.%22%2C%22lastName%22%3A%22Collins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Powis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Matshaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Thahane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Nyasulu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Lukhele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mwita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kekitiinwa-Rukyalekere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Wanless%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Goetghebuer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Warszawski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Galli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%20C.%22%2C%22lastName%22%3A%22van%20Rossum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Giaquinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Marczynska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Marques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Prata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Ene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Okhonskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Frick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Naver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kahlert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Volokha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Chappell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Marcelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lyamuya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20A.%22%2C%22lastName%22%3A%22Ogalo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20A.%22%2C%22lastName%22%3A%22Odhiambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Muhairwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Tweya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Sylla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22D%27Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Renner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Abzug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Oleske%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Purswani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Teasdale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Nuwagaba-Biribonwoha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Goodall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Leroy%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Adolescents%20living%20with%20HIV%20are%20subject%20to%20multiple%20co-morbidities%2C%20including%20growth%20retardation%20and%20immunodeficiency.%20We%20describe%20growth%20and%20CD4%20evolution%20during%20adolescence%20using%20data%20from%20the%20Collaborative%20Initiative%20for%20Paediatric%20HIV%20Education%20and%20Research%20%28CIPHER%29%20global%20project.%20METHODS%3A%20Data%20were%20collected%20between%201994%20and%202015%20from%2011%20CIPHER%20networks%20worldwide.%20Adolescents%20with%20perinatally%20acquired%20HIV%20infection%20%28APH%29%20who%20initiated%20antiretroviral%20therapy%20%28ART%29%20before%20age%2010%20years%2C%20with%20at%20least%20one%20height%20or%20CD4%20count%20measurement%20while%20aged%2010-17%20years%2C%20were%20included.%20Growth%20was%20measured%20using%20height-for-age%20Z-scores%20%28HAZ%2C%20stunting%20if%20%3C-2%20SD%2C%20WHO%20growth%20charts%29.%20Linear%20mixed-effects%20models%20were%20used%20to%20study%20the%20evolution%20of%20each%20outcome%20between%20ages%2010%20and%2017.%20For%20growth%2C%20sex-specific%20models%20with%20fractional%20polynomials%20were%20used%20to%20model%20non-linear%20relationships%20for%20age%20at%20ART%20initiation%2C%20HAZ%20at%20age%2010%20and%20time%2C%20defined%20as%20current%20age%20from%2010%20to%2017%20years%20of%20age.%20RESULTS%3A%20A%20total%20of%2020%2C939%20and%2019%2C557%20APH%20were%20included%20for%20the%20growth%20and%20CD4%20analyses%2C%20respectively.%20Half%20were%20females%2C%20two-thirds%20lived%20in%20East%20and%20Southern%20Africa%2C%20and%20median%20age%20at%20ART%20initiation%20ranged%20from%20%3C3%20years%20in%20North%20America%20and%20Europe%20to%20%3E7%20years%20in%20sub-Saharan%20African%20regions.%20At%20age%2010%2C%20stunting%20ranged%20from%206%25%20in%20North%20America%20and%20Europe%20to%2039%25%20in%20the%20Asia-Pacific%3B%2019%25%20overall%20had%20CD4%20counts%20%3C500%20cells%5C%2Fmm%283%29%20.%20Across%20adolescence%2C%20higher%20HAZ%20was%20observed%20in%20females%20and%20among%20those%20in%20high-income%20countries.%20APH%20with%20stunting%20at%20age%2010%20and%20those%20with%20late%20ART%20initiation%20%28after%20age%205%29%20had%20the%20largest%20HAZ%20gains%20during%20adolescence%2C%20but%20these%20gains%20were%20insufficient%20to%20catch-up%20with%20non-stunted%2C%20early%20ART-treated%20adolescents.%20From%20age%2010%20to%2016%20years%2C%20mean%20CD4%20counts%20declined%20from%20768%20to%20607%20cells%5C%2Fmm%283%29%20.%20This%20decline%20was%20observed%20across%20all%20regions%2C%20in%20males%20and%20females.%20CONCLUSIONS%3A%20Growth%20patterns%20during%20adolescence%20differed%20substantially%20by%20sex%20and%20region%2C%20while%20CD4%20patterns%20were%20similar%2C%20with%20an%20observed%20CD4%20decline%20that%20needs%20further%20investigation.%20Early%20diagnosis%20and%20timely%20initiation%20of%20treatment%20in%20early%20childhood%20to%20prevent%20growth%20retardation%20and%20immunodeficiency%20are%20critical%20to%20improving%20APH%20growth%20and%20CD4%20outcomes%20by%20the%20time%20they%20reach%20adulthood.%22%2C%22date%22%3A%22Mar%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25871%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A20%3A13Z%22%7D%7D%2C%7B%22key%22%3A%222Z5WU79P%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Shaikh%20et%20al.%22%2C%22parsedDate%22%3A%222022-02-01%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShaikh%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBhondoekhan%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHaberlen%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENakanishi%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoy%2C%20S.%20K.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Coronary%20artery%20plaque%20progression%20and%20cardiovascular%20risk%20scores%20in%20men%20with%20and%20without%20HIV-infection.%20%3Ci%3EAIDS%3C%5C%2Fi%3E%2C%20%3Ci%3E36%3C%5C%2Fi%3E%20%282%29%2C%20S.%20215%26%23x2013%3B224.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003093%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003093%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Coronary%20artery%20plaque%20progression%20and%20cardiovascular%20risk%20scores%20in%20men%20with%20and%20without%20HIV-infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Shaikh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Bhondoekhan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Haberlen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Nakanishi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20K.%22%2C%22lastName%22%3A%22Roy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20M.%22%2C%22lastName%22%3A%22Alla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20T.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Osawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Rahmani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Nezarat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Sheidaee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Jayawardena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Hathiramani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20J.%22%2C%22lastName%22%3A%22Palella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Witt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Ahmad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Kingsley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20S.%22%2C%22lastName%22%3A%22Post%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Budoff%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20The%20aim%20of%20this%20study%20was%20to%20assess%20the%20association%20of%20cardiovascular%20disease%20%28CVD%29%20risk%20scores%20and%20coronary%20artery%20plaque%20%28CAP%29%20progression%20in%20HIV-infected%20participants.%20METHODS%3A%20We%20studied%20men%20with%20and%20without%20HIV-infection%20enrolled%20in%20the%20Multicenter%20AIDS%20Cohort%20Study%20%28MACS%29%20CVD%20study.%20CAP%20at%20baseline%20and%20follow-up%20was%20assessed%20with%20cardiac%20computed%20tomography%20angiography%20%28CCTA%29.%20We%20examined%20the%20association%20between%20baseline%20risk%20scores%20including%20pooled%20cohort%20equation%20%28PCE%29%2C%20Framingham%20risk%20score%20%28FRS%29%2C%20and%20Data%20collect%20of%20Adverse%20effects%20of%20anti-HIV%20drugs%20equation%20%28D%3AA%3AD%29%20and%20CAP%20progression.%20RESULTS%3A%20We%20studied%20495%20men%20%28211%20HIV-uninfected%2C%20284%20HIV-infected%29.%20The%20adjusted%20odds%20ratio%20%28aOR%29%20of%20total%20plaque%20volume%20%28TPV%29%20and%20noncalcified%20plaque%20volume%20%28NCPV%29%20progression%20in%20the%20highest%20relative%20to%20lowest%20tertile%20was%209.4%20%5B95%25%20confidence%20interval%20%2895%25%20CI%29%202.4-12.1%2C%20P%20%3C%200.001%29%5D%20and%207.7%20%2895%25%20CI%203.1-19.1%2C%20P%20%3C%200.001%29%20times%20greater%2C%20respectively%2C%20among%20HIV-uninfected%20men%20in%20the%20PCE%20atherosclerotic%20cardiovascular%20disease%20%28ASCVD%29%20high%20vs.%20low-risk%20category.%20Among%20HIV-infected%20men%2C%20the%20association%20for%20TPV%20and%20NCPV%20progression%20for%20the%20same%20PCE%20risk%20categories%2C%20odds%20ratio%20%28OR%29%202.8%20%2895%25%20CI%201.4-5.8%2C%20P%20%3C%200.01%29%20and%20OR%202.4%20%2895%25%20CI%201.2-4.8%2C%20P%20%3C%200.05%29%2C%20respectively%20%28P%20values%20for%20interaction%20by%20HIV%20%3D%200.02%20and%200.08%2C%20respectively%29.%20Similar%20results%20were%20seen%20for%20the%20FRS%20risk%20scores.%20Among%20HIV-uninfected%20men%2C%20PCE%20high%20risk%20category%20identified%20the%20highest%20proportion%20of%20men%20with%20plaque%20progression%20in%20the%20highest%20tertile%2C%20although%20in%20HIV-infected%20men%2C%20high-risk%20category%20by%20D%3AA%3AD%20identified%20the%20greatest%20percentage%20of%20men%20with%20plaque%20progression%20albeit%20with%20lower%20specificity%20than%20FRS%20and%20PCE.%20CONCLUSION%3A%20PCE%20and%20FRS%20categories%20predict%20CAP%20progression%20better%20in%20HIV-uninfected%20than%20in%20HIV-infected%20men.%20Improved%20CVD%20risk%20scores%20are%20needed%20to%20identify%20high-risk%20HIV-infected%20men%20for%20more%20aggressive%20CVD%20risk%20prevention%20strategies.%22%2C%22date%22%3A%22Feb%201%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003093%22%2C%22ISSN%22%3A%221473-5571%20%28Electronic%29%200269-9370%20%28Print%29%200269-9370%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22VPFNA8BB%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Myers%20et%20al.%22%2C%22parsedDate%22%3A%222022-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMyers%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EApondi%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EToromo%2C%20J.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOmollo%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBakari%2C%20S.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20%26%23x201C%3BWho%20am%20I%20going%20to%20stay%20with%3F%20Who%20will%20accept%20me%3F%26%23x201D%3B%3A%20family-level%20domains%20influencing%20HIV%20care%20engagement%20among%20disengaged%20adolescents%20in%20Kenya.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%282%29%2C%20S.%20e25890.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25890%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25890%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5C%22Who%20am%20I%20going%20to%20stay%20with%3F%20Who%20will%20accept%20me%3F%5C%22%3A%20family-level%20domains%20influencing%20HIV%20care%20engagement%20among%20disengaged%20adolescents%20in%20Kenya%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Myers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Apondi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Toromo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Omollo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bakari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Aluoch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Sang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Njoroge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Morris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kantor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Braitstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20M.%22%2C%22lastName%22%3A%22Nyandiko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Elul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Adolescents%20living%20with%20HIV%20%28ALHIV%2C%20ages%2010-19%29%20have%20developmentally%20specific%20needs%20in%20care%2C%20and%20have%20lower%20retention%20compared%20to%20other%20age%20groups.%20Family-level%20contexts%20may%20be%20critical%20to%20adolescent%20HIV%20outcomes%2C%20but%20have%20often%20been%20overlooked.%20We%20investigated%20family-level%20factors%20underlying%20disengagement%20and%20supporting%20re-engagement%20among%20adolescents%20disengaged%20from%20HIV%20care.%20METHODS%3A%20Semi-structured%20interviews%20were%20performed%20with%2042%20disengaged%20ALHIV%2C%2032%20of%20their%20caregivers%20and%2028%20healthcare%20workers%20%28HCW%29%20in%20the%20Academic%20Model%20Providing%20Access%20to%20Healthcare%20%28AMPATH%29%20program%20in%20western%20Kenya%2C%20from%202018%20to%202020.%20Disengaged%20ALHIV%20had%20%3E%5C%2F%3D1%20visit%20within%20the%2018%20months%20prior%20to%20data%20collection%20at%20one%20of%20two%20sites%20and%20nonattendance%20%3E%5C%2F%3D60%20days%20following%20their%20last%20scheduled%20appointment.%20HCW%20were%20recruited%20from%2010%20clinics.%20Transcripts%20were%20analysed%20through%20thematic%20analysis.%20A%20conceptual%20model%20for%20family-level%20domains%20influencing%20adolescent%20HIV%20care%20engagement%20was%20developed%20from%20these%20themes.%20RESULTS%3A%20Family-level%20factors%20emerged%20as%20central%20to%20disengagement.%20ALHIV-particularly%20those%20orphaned%20by%20the%20loss%20of%20one%20or%20both%20parents-experienced%20challenges%20when%20new%20caregivers%20or%20unstable%20living%20situations%20limited%20support%20for%20HIV%20care.%20These%20challenges%20were%20compounded%20by%20anticipated%20stigma%3B%20resultant%20non-disclosure%20of%20HIV%20status%20to%20household%20members%3B%20enacted%20stigma%20in%20the%20household%2C%20with%20overwhelming%20effects%20on%20adolescents%3B%20or%20experiences%20of%20multiple%20forms%20of%20trauma%2C%20which%20undermined%20HIV%20care%20engagement.%20Some%20caregivers%20lacked%20finances%20or%20social%20support%20to%20facilitate%20care.%20Others%20did%20not%20feel%20equipped%20to%20support%20adolescent%20engagement%20or%20adherence.%20Regarding%20facilitators%20to%20re-engagement%2C%20participants%20described%20roles%20for%20household%20disclosure%3B%20and%20solidarity%20from%20caregivers%2C%20especially%20those%20also%20living%20with%20HIV.%20Family-level%20domains%20influencing%20HIV%20care%20engagement%20were%20conceptualized%20as%20follows%3A%20%281%29%20adolescent%20living%20situation%20and%20contexts%3B%20%282%29%20household%20material%20resources%20or%20poverty%3B%20%283%29%20caregiver%20capacities%20and%20skills%20to%20support%20adolescent%20HIV%20care%3B%20and%20%284%29%20HIV%20stigma%20or%20solidarity%20at%20the%20household%20level.%20CONCLUSIONS%3A%20Family-level%20factors%20are%20integral%20to%20retention%20in%20care%20for%20ALHIV.%20The%20conceptual%20model%20developed%20in%20this%20study%20for%20family-level%20influences%20on%20care%20engagement%20may%20inform%20holistic%20approaches%20to%20promote%20healthy%20outcomes%20for%20ALHIV.%20Developmentally%20appropriate%20interventions%20targeting%20household%20relationships%2C%20disclosure%2C%20HIV%20stigma%20reduction%2C%20HIV%20care%20skills%20and%20resources%2C%20and%20economic%20empowerment%20may%20promote%20adolescent%20engagement%20in%20HIV%20care.%22%2C%22date%22%3A%22Feb%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25890%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A23%3A20Z%22%7D%7D%2C%7B%22key%22%3A%222W7XGEKC%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zotova%20et%20al.%22%2C%22parsedDate%22%3A%222022-02%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZotova%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFamiliar%2C%20I.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKawende%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKasindi%2C%20F.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERavelomanana%2C%20N.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20HIV%20disclosure%20and%20depressive%20symptoms%20among%20pregnant%20women%20living%20with%20HIV%3A%20a%20cross-sectional%20study%20in%20the%20Democratic%20Republic%20of%20Congo.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%282%29%2C%20S.%20e25865.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25865%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25865%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20disclosure%20and%20depressive%20symptoms%20among%20pregnant%20women%20living%20with%20HIV%3A%20a%20cross-sectional%20study%20in%20the%20Democratic%20Republic%20of%20Congo%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Zotova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Familiar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Kawende%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20L.%22%2C%22lastName%22%3A%22Kasindi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ravelomanana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Adedimeji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20E.%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Kaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Babakazo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Disclosure%20of%20one%27s%20HIV%20status%20may%20decrease%20depression%20and%20improve%20the%20quality%20of%20life%20among%20people%20living%20with%20HIV.%20However%2C%20there%20is%20mixed%20evidence%20on%20the%20impact%20of%20disclosure%20to%20partners%20for%20pregnant%20women%20living%20with%20HIV%20%28WLHIV%29%20in%20areas%20of%20intersecting%20social%20concerns%20over%20disclosure%20and%20high%20prevalence%20of%20intimate%20partner%20violence%20%28IPV%29.%20We%20assessed%20the%20association%20between%20HIV%20disclosure%20and%20depressive%20symptoms%20among%20pregnant%20WLHIV%20in%20the%20Democratic%20Republic%20of%20Congo%20%28DRC%29%20and%20examined%20whether%20the%20knowledge%20of%20partner%27s%20status%20or%20recent%20IPV%20modified%20this%20association.%20METHODS%3A%20We%20utilized%20data%20from%20participants%20enrolled%20in%20a%20trial%20to%20evaluate%20the%20effect%20of%20continuous%20quality%20interventions%20on%20long-term%20therapy%20outcomes%20among%20HIV-positive%20pregnant%20and%20breastfeeding%20women%20in%20DRC%20%28NCT03048669%29.%20Only%20pregnant%20women%20%28n%20%3D%201392%29%20were%20included%20in%20this%20cross-sectional%20analysis.%20Between%20November%202016%20and%20June%202019%2C%20enrolled%20participants%20completed%20a%20survey%20that%20included%20the%20Patient%20Health%20Questionnaire-9%20%28PHQ-9%29%20to%20screen%20recent%20depressive%20symptoms%2C%20questions%20about%20disclosure%2C%20knowledge%20of%20partner%27s%20status%20and%20IPV.%20We%20used%20linear%20models%20to%20calculate%20crude%20and%20adjusted%20mean%20differences%20%28MDs%29%20between%20disclosure%20and%20depressive%20symptoms.%20All%20analyses%20were%20stratified%20by%20timing%20of%20HIV%20diagnosis.%20RESULTS%3A%20Disclosure%20was%20higher%20among%20participants%20diagnosed%20prior%20to%20current%20pregnancy%20%2841%25%20to%20their%20partners%20and%2024%25%20to%20family%2C%20friends%20or%20others%29%20relative%20to%20those%20diagnosed%20during%20current%20pregnancy%20%2821%25%20to%20partners%20and%2012%25%20to%20family%29.%20About%20one-quarter%20of%20women%20reported%20any%20type%20of%20IPV%20in%20the%20past%2012%20months.%20Disclosure%20to%20a%20partner%20was%20associated%20with%20lower%20depressive%20symptoms%20among%20women%20diagnosed%20prior%20to%20current%20pregnancy%20%28MD%20-0.55%3B%2095%25%20CI%3A%20-1.06%2C%20-0.04%29%20but%20the%20opposite%20was%20observed%20among%20those%20diagnosed%20during%20current%20pregnancy%20%28MD%200.5%3B%2095%25%20CI%3A%20-0.4%2C%201.4%29.%20Adjustment%20for%20IPV%2C%20knowledge%20of%20partner%27s%20status%2C%20age%2C%20number%20of%20living%20children%20and%20primigravidae%20did%20not%20change%20MDs%20substantially.%20CONCLUSIONS%3A%20Women%20in%20our%20sample%20mostly%20disclosed%20to%20partners%20despite%20high%20IPV%20burden.%20The%20observed%20association%20between%20disclosure%20to%20partners%20and%20lower%20depressive%20symptoms%20among%20women%20diagnosed%20prior%20to%20current%20pregnancy%20is%20consistent%20with%20cross-national%20evidence.%20A%20prospective%20study%20among%20pregnant%20WLHIV%20is%20needed%20to%20examine%20longitudinal%20effects%20of%20HIV%20status%20disclosure.%22%2C%22date%22%3A%22Feb%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25865%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A20%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22IJPACHVY%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sam-Agudu%20et%20al.%22%2C%22parsedDate%22%3A%222022-02%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESam-Agudu%2C%20N.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EQuakyi%2C%20N.%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMasekela%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZumla%2C%20A.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENachega%2C%20J.%20B.%3C%5C%2Fspan%3E%20%282022%29.%20Children%20and%20adolescents%20in%20African%20countries%20should%20also%20be%20vaccinated%20for%20COVID-19.%20%3Ci%3EBMJ%20Glob%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E7%3C%5C%2Fi%3E%20%282%29%2C%20S.%20e008315.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgh-2021-008315%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgh-2021-008315%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Children%20and%20adolescents%20in%20African%20countries%20should%20also%20be%20vaccinated%20for%20COVID-19%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20A.%22%2C%22lastName%22%3A%22Sam-Agudu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20K.%22%2C%22lastName%22%3A%22Quakyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Masekela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Zumla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20B.%22%2C%22lastName%22%3A%22Nachega%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Feb%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjgh-2021-008315%22%2C%22ISSN%22%3A%222059-7908%20%28Print%29%202059-7908%20%28Electronic%29%202059-7908%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A39%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22DSMSKHQ4%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thompson%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-26%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EThompson%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMpody%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESayre%2C%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERigney%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETabala%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Hepatitis%20C%20prevalence%20and%20quality%20of%20health%20services%20among%20HIV-positive%20mothers%20in%20the%20Democratic%20Republic%20of%20the%20Congo.%20%3Ci%3ESci%20Rep%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%20%281%29%2C%20S.%201384.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-022-05014-3%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-022-05014-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hepatitis%20C%20prevalence%20and%20quality%20of%20health%20services%20among%20HIV-positive%20mothers%20in%20the%20Democratic%20Republic%20of%20the%20Congo%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Mpody%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Sayre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Rigney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tabala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20L.%20R.%22%2C%22lastName%22%3A%22Ravelomanana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Malongo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Kawende%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Behets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Okitolonda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22Cqi-Pmtct%20study%20team%22%7D%5D%2C%22abstractNote%22%3A%22Hepatitis%20C%20virus%20%28HCV%29%20contributes%20to%20liver-related%20morbidity%20and%20mortality%20throughout%20Africa%20despite%20effective%20antivirals.%20HCV%20is%20endemic%20in%20the%20Democratic%20Republic%20of%20the%20Congo%20%28DRC%29%20but%20data%20on%20HCV%5C%2FHIV%20co-infection%20in%20pregnancy%20is%20limited.%20We%20estimated%20the%20prevalence%20of%20and%20risk%20factors%20for%20HCV%5C%2FHIV%20co-infection%20among%20pregnant%20women%20in%20the%20Kinshasa%20province%20of%20the%20DRC.%20This%20cross-sectional%20study%20was%20conducted%20as%20a%20sub-study%20of%20an%20ongoing%20randomized%20trial%20to%20assess%20continuous%20quality%20improvement%20interventions%20%28CQI%29%20for%20prevention%20of%20mother-to-child%20transmission%20%28PMTCT%29%20of%20HIV%20%28CQI-PMTCT%20study%2C%20NCT03048669%29.%20HIV-infected%20women%20in%20the%20CQI-PMTCT%20cohort%20were%20tested%20for%20HCV%2C%20and%20risk%20factors%20were%20evaluated%20using%20logistic%20regression.%20The%20prevalence%20of%20HCV%5C%2FHIV%20co-infection%20among%20Congolese%20women%20was%200.83%25%20%2895%25%20CI%200.43-1.23%29.%20Women%20who%20tested%20positive%20for%20HCV%20were%20younger%2C%20more%20likely%20to%20live%20in%20urban%20areas%2C%20and%20more%20likely%20to%20test%20positive%20during%20pregnancy%20versus%20postpartum.%20HCV-positive%20women%20had%20significantly%20higher%20odds%20of%20infection%20with%20hepatitis%20B%20virus%20%28HBV%29%20%28aOR%2013.87%20%5B3.29%2C58.6%5D%29.%20An%20inverse%20relationship%20was%20noted%20between%20HCV%20infection%20and%20the%20overall%20capacity%20of%20the%20health%20facility%20as%20measured%20by%20the%20service%20readiness%20index%20%28SRI%29%20%28aOR%3A0.92%20%5B0.86%2C0.98%5D%20per%20unit%20increase%29.%20Women%20who%20presented%20to%20rural%2C%20for-profit%20and%20PEPFAR-funded%20health%20facilities%20were%20more%20likely%20to%20test%20positive%20for%20HCV.%20In%20summary%2C%20this%20study%20identified%20that%20the%20prevalence%20of%20HCV%5C%2FHIV%20co-infection%20was%20%3C%201%25%20among%20Congolese%20women.%20We%20also%20identified%20HBV%20infection%20as%20a%20major%20risk%20factor%20for%20HCV%5C%2FHIV%20co-infection.%20Individuals%20with%20triple%20infection%20should%20be%20linked%20to%20care%20and%20the%20facility-related%20differences%20in%20HCV%20prevalence%20should%20be%20addressed%20in%20future%20studies.%22%2C%22date%22%3A%22Jan%2026%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-022-05014-3%22%2C%22ISSN%22%3A%222045-2322%20%28Electronic%29%202045-2322%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A46%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22JNYBYHLP%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Davies%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavies%2C%20M.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKassanjee%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERosseau%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMorden%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJohnson%2C%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Outcomes%20of%20laboratory-confirmed%20SARS-CoV-2%20infection%20in%20the%20Omicron-driven%20fourth%20wave%20compared%20with%20previous%20waves%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa.%20%3Ci%3EMedRxiv%3C%5C%2Fi%3E%2C%20S.%202022.01.12.22269148.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2022.01.12.22269148%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2022.01.12.22269148%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20of%20laboratory-confirmed%20SARS-CoV-2%20infection%20in%20the%20Omicron-driven%20fourth%20wave%20compared%20with%20previous%20waves%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rosseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Morden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Solomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20Y.%22%2C%22lastName%22%3A%22Hsiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Hussey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Meintjes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Paleker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Jacobs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Raubenheimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Dane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Bam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Preiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Pienaar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mendelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Naude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Schrueder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mnguni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20L.%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Murie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Prozesky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Mahomed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Rossouw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Wasserman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Maughan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Boloko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Taljaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Symons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ntusi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Wolter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Jassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lessells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Arendse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kariem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Moodley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Vallabhjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Wolmarans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Cloete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20We%20aimed%20to%20compare%20COVID-19%20outcomes%20in%20the%20Omicron-driven%20fourth%20wave%20with%20prior%20waves%20in%20the%20Western%20Cape%2C%20the%20contribution%20of%20undiagnosed%20prior%20infection%20to%20differences%20in%20outcomes%20in%20a%20context%20of%20high%20seroprevalence%20due%20to%20prior%20infection%2C%20and%20whether%20protection%20against%20severe%20disease%20conferred%20by%20prior%20infection%20and%5C%2For%20vaccination%20was%20maintained.%20METHODS%3A%20In%20this%20cohort%20study%2C%20we%20included%20public%20sector%20patients%20aged%20%3E%5C%2F%3D20%20years%20with%20a%20laboratory%20confirmed%20COVID-19%20diagnosis%20between%2014%20November-11%20December%202021%20%28wave%20four%29%20and%20equivalent%20prior%20wave%20periods.%20We%20compared%20the%20risk%20between%20waves%20of%20the%20following%20outcomes%20using%20Cox%20regression%3A%20death%2C%20severe%20hospitalization%20or%20death%20and%20any%20hospitalization%20or%20death%20%28all%20%3C%5C%2F%3D14%20days%20after%20diagnosis%29%20adjusted%20for%20age%2C%20sex%2C%20comorbidities%2C%20geography%2C%20vaccination%20and%20prior%20infection.%20RESULTS%3A%20We%20included%205%2C144%20patients%20from%20wave%20four%20and%2011%2C609%20from%20prior%20waves.%20Risk%20of%20all%20outcomes%20was%20lower%20in%20wave%20four%20compared%20to%20the%20Delta-driven%20wave%20three%20%28adjusted%20Hazard%20Ratio%20%28aHR%29%20%5B95%25%20confidence%20interval%20%28CI%29%5D%20for%20death%200.27%20%5B0.19%3B%200.38%5D.%20Risk%20reduction%20was%20lower%20when%20adjusting%20for%20vaccination%20and%20prior%20diagnosed%20infection%20%28aHR%3A0.41%2C%2095%25%20CI%3A%200.29%3B%200.59%29%20and%20reduced%20further%20when%20accounting%20for%20unascertained%20prior%20infections%20%28aHR%3A%200.72%29.%20Vaccine%20protection%20was%20maintained%20in%20wave%20four%20%28aHR%20for%20outcome%20of%20death%3A%200.24%3B%2095%25%20CI%3A%200.10%3B%200.58%29.%20CONCLUSIONS%3A%20In%20the%20Omicron-driven%20wave%2C%20severe%20COVID-19%20outcomes%20were%20reduced%20mostly%20due%20to%20protection%20conferred%20by%20prior%20infection%20and%5C%2For%20vaccination%2C%20but%20intrinsically%20reduced%20virulence%20may%20account%20for%20an%20approximately%2025%25%20reduced%20risk%20of%20severe%20hospitalization%20or%20death%20compared%20to%20Delta.%22%2C%22date%22%3A%22Jan%2012%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2022.01.12.22269148%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A26%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22B7GLFP6C%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nyemba%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyemba%2C%20D.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalk%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVinikoor%2C%20M.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMadlala%2C%20H.%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMubiana-Mbewe%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Growth%20patterns%20of%20infants%20with%20in-%20utero%20HIV%20and%20ARV%20exposure%20in%20Cape%20Town%2C%20South%20Africa%20and%20Lusaka%2C%20Zambia.%20%3Ci%3EBMC%20Public%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E22%3C%5C%2Fi%3E%20%281%29%2C%20S.%2055.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-021-12476-z%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-021-12476-z%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Growth%20patterns%20of%20infants%20with%20in-%20utero%20HIV%20and%20ARV%20exposure%20in%20Cape%20Town%2C%20South%20Africa%20and%20Lusaka%2C%20Zambia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20C.%22%2C%22lastName%22%3A%22Nyemba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20P.%22%2C%22lastName%22%3A%22Madlala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mubiana-Mbewe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mzumara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20B.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Powis%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Infants%20born%20HIV-exposed%20yet%20remain%20uninfected%20%28HEU%29%20are%20at%20increased%20risk%20of%20poorer%20growth%20and%20health%20compared%20to%20infants%20born%20HIV-unexposed%20%28HU%29.%20Whether%20maternal%20antiretroviral%20treatment%20%28ART%29%20in%20pregnancy%20ameliorates%20this%20risk%20of%20poorer%20growth%20is%20not%20well%20understood.%20Furthermore%2C%20whether%20risks%20are%20similar%20across%20high%20burden%20HIV%20settings%20has%20not%20been%20extensively%20explored.%20METHODS%3A%20We%20harmonized%20data%20from%20two%20prospective%20observational%20studies%20conducted%20in%20Cape%20Town%2C%20South%20Africa%2C%20and%20Lusaka%2C%20Zambia%2C%20to%20compare%20weight-for-age%20%28WAZ%29%2C%20length-for-age%20%28LAZ%29%20and%20weight-for-length%20%28WLZ%29%20Z-scores%20between%20infants%20who%20were%20HEU%20and%20HU%2C%20converting%20infant%20anthropometric%20measures%20using%20World%20Health%20Organisation%20Growth%20Standards%20adjusted%20for%20age%20and%20sex.%20Linear%20mixed%20effects%20models%20were%20fit%20to%20identify%20risk%20factors%20for%20differences%20in%20anthropometrics%20at%206-10%20weeks%20and%206%20months%20by%20infant%20HIV%20exposures%20status%20and%20by%20timing%20of%20exposure%20to%20maternal%20ART%2C%20either%20from%20conception%20or%20later%20in%20gestation.%20RESULTS%3A%20Overall%20773%20mother-infant%20pairs%20were%20included%20across%20two%20countries%3A%20women%20living%20with%20HIV%20%28WLHIV%29%2C%2051%25%20%28n%20%3D%20395%29%20with%2065%25%20on%20ART%20at%20conception%20and%2035%25%20initiating%20treatment%20in%20pregnancy.%20In%20linear%20mixed%20effects%20models%2C%20WAZ%20and%20WLZ%20at%206-10%20weeks%20were%20lower%20among%20infants%20who%20were%20HEU%20vs%20HU%20%5Bbeta%20%3D%20-%200.29%20%2895%25%20CI%3A%20-%200.46%2C%20-%200.12%29%20and%20%5Bbeta%20%3D%20-%200.42%20%2895%25%20CI%3A%20-%200.68%2C%20-%200.16%29%5D%20respectively%20after%20adjusting%20for%20maternal%20characteristics%20and%20infant%20feeding%20with%20a%20random%20intercept%20for%20country.%20At%206%20months%2C%20LAZ%20was%20lower%20%5Bbeta%20%3D%20-%200.28%20CI%3A%20-%200.50%2C%20-%200.06%29%5D%20among%20infants%20who%20were%20HEU%2C%20adjusting%20for%20the%20same%20variables%2C%20with%20no%20differences%20in%20WAZ%20and%20WLZ.%20Within%20cohort%20evaluations%20identified%20different%20results%20with%20higher%20LAZ%20among%20infants%20who%20were%20HEU%20from%20Zambia%20at%206-10%20weeks%2C%20%5Bbeta%20%3D%20%2B%200.34%20CI%3A%20%2B%200.01%2C%20%2B%200.68%29%5D%20and%20lower%20LAZ%20among%20infants%20who%20were%20HEU%20from%20South%20Africa%20%5Bbeta%20%3D%20-%200.30%20CI%3A%20-%200.59%2C%20-%200.01%29%5D%20at%206%20months%2C%20without%20other%20anthropometric%20differences%20at%20either%20site.%20CONCLUSION%3A%20Infant%20growth%20trajectories%20differed%20by%20country%2C%20highlighting%20the%20importance%20of%20studying%20contextual%20influences%20on%20outcomes%20of%20infants%20who%20were%20HEU.%22%2C%22date%22%3A%22Jan%2010%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-021-12476-z%22%2C%22ISSN%22%3A%221471-2458%20%28Electronic%29%201471-2458%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A45%3A54Z%22%7D%7D%2C%7B%22key%22%3A%228ITDMZT5%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Qian%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EQian%2C%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMoore%2C%20R.%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoburn%2C%20S.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavy-Mendez%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAkgun%2C%20K.%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Association%20of%20the%20VACS%20Index%20With%20Hospitalization%20Among%20People%20With%20HIV%20in%20the%20NA-ACCORD.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E89%3C%5C%2Fi%3E%20%281%29%2C%20S.%209%26%23x2013%3B18.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002812%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002812%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20the%20VACS%20Index%20With%20Hospitalization%20Among%20People%20With%20HIV%20in%20the%20NA-ACCORD%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Qian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20B.%22%2C%22lastName%22%3A%22Coburn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Davy-Mendez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Akgun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22McGinnis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Colasanti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20R.%22%2C%22lastName%22%3A%22Cachay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20S.%22%2C%22lastName%22%3A%22Rabkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Jacobson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20D.%22%2C%22lastName%22%3A%22Kirk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20E.%22%2C%22lastName%22%3A%22Nijhawan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20People%20with%20HIV%20%28PWH%29%20have%20a%20higher%20hospitalization%20rate%20than%20the%20general%20population.%20The%20Veterans%20Aging%20Cohort%20Study%20%28VACS%29%20Index%20at%20study%20entry%20well%20predicts%20hospitalization%20in%20PWH%2C%20but%20it%20is%20unknown%20if%20the%20time-updated%20parameter%20improves%20hospitalization%20prediction.%20We%20assessed%20the%20association%20of%20parameterizations%20of%20the%20VACS%20Index%202.0%20with%20the%205-year%20risk%20of%20hospitalization.%20SETTING%3A%20PWH%20%3E%5C%2F%3D30%20years%20old%20with%20at%20least%2012%20months%20of%20antiretroviral%20therapy%20%28ART%29%20use%20and%20contributing%20hospitalization%20data%20from%202000%20to%202016%20in%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20%28NA-ACCORD%29%20were%20included.%20Three%20parameterizations%20of%20the%20VACS%20Index%202.0%20were%20assessed%20and%20categorized%20by%20quartile%3A%20%281%29%20%5C%22baseline%5C%22%20measurement%20at%20study%20entry%3B%20%282%29%20time-updated%20measurements%3B%20and%20%283%29%20cumulative%20scores%20calculated%20using%20the%20trapezoidal%20rule.%20METHODS%3A%20Discrete-time%20proportional%20hazard%20models%20estimated%20the%20crude%20and%20adjusted%20associations%20%28and%2095%25%20confidence%20intervals%20%5BCIs%5D%29%20of%20the%20VACS%20Index%20parameterizations%20and%20all-cause%20hospitalizations.%20The%20Akaike%20information%20criterion%20%28AIC%29%20assessed%20the%20model%20fit%20with%20each%20of%20the%20VACS%20Index%20parameters.%20RESULTS%3A%20Among%207289%20patients%2C%201537%20were%20hospitalized.%20Time-updated%20VACS%20Index%20fitted%20hospitalization%20best%20with%20a%20more%20distinct%20dose-response%20relationship%20%5Bscore%20%3C43%3A%20reference%3B%20score%2043-55%3A%20aHR%20%3D%201.93%20%2895%25%20CI%3A%201.66%20to%202.23%29%3B%20score%2055-68%3A%20aHR%20%3D%203.63%20%2895%25%20CI%3A%203.12%20to%204.23%29%3B%20score%20%3E%5C%2F%3D68%3A%20aHR%20%3D%209.98%20%2895%25%20CI%3A%208.52%20to%2011.69%29%5D%20than%20study%20entry%20and%20cumulative%20VACS%20Index%20after%20adjusting%20for%20known%20risk%20factors.%20CONCLUSIONS%3A%20Time-updated%20VACS%20Index%202.0%20had%20the%20strongest%20association%20with%20hospitalization%20and%20best%20fit%20to%20the%20data.%20Health%20care%20providers%20should%20consider%20using%20it%20when%20assessing%20hospitalization%20risk%20among%20PWH.%22%2C%22date%22%3A%22Jan%201%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000002812%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A16%3A40Z%22%7D%7D%2C%7B%22key%22%3A%226LXEJH9B%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nyakato%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyakato%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESchomaker%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFatti%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETanser%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEuvrard%2C%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Virologic%20non-suppression%20and%20early%20loss%20to%20follow%20up%20among%20pregnant%20and%20non-pregnant%20adolescents%20aged%2015-19%20years%20initiating%20antiretroviral%20therapy%20in%20South%20Africa%3A%20a%20retrospective%20cohort%20study.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%281%29%2C%20S.%20e25870.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25870%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25870%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Virologic%20non-suppression%20and%20early%20loss%20to%20follow%20up%20among%20pregnant%20and%20non-pregnant%20adolescents%20aged%2015-19%20years%20initiating%20antiretroviral%20therapy%20in%20South%20Africa%3A%20a%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Nyakato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Schomaker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Tanser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Sipambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Older%20adolescents%20aged%2015-19%20years%20continue%20to%20have%20high%20rates%20of%20loss%20to%20follow%20up%20%28LTFU%29%2C%20and%20high%20rates%20of%20virologic%20non-suppression%20%28VNS%29%20compared%20to%20younger%20adolescents%20and%20adults.%20Adolescent%20females%20are%20at%20risk%20of%20pregnancy%2C%20which%20puts%20those%20living%20with%20HIV%20at%20a%20dual%20vulnerability.%20Our%20study%20assessed%20the%20factors%20associated%20with%20VNS%20and%20LTFU%20in%20older%20adolescents%20%28including%20pregnant%20females%29%20who%20initiated%20antiretroviral%20therapy%20%28ART%29%20in%20South%20Africa.%20METHODS%3A%20We%20included%20adolescents%20aged%2015-19%20years%20initiating%20ART%20between%202004%20and%202019%2C%20with%20%3E%5C%2F%3D%20one%20viral%20load%20%28VL%29%20measurement%20between%204%20and%2024.5%20months%2C%20and%20%3E%5C%2F%3D%206%20months%20follow-up%2C%20from%20six%20South%20African%20cohorts%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS-Southern%20Africa%20%28IeDEA-SA%29.%20We%20defined%20VNS%20as%20VL%20%3E%5C%2F%3D400%20copies%5C%2Fml%20and%20LTFU%20as%20not%20being%20in%20care%20for%20%3E%5C%2F%3D180%20days%20from%20ART%20start%20and%20not%20known%20as%20transferred%20out%20of%20the%20clinic%20or%20dead%20in%20the%20first%2024%20months%20on%20ART.%20We%20examined%20factors%20associated%20with%20VNS%20and%20LTFU%20using%20Fine%26Gray%20competing%20risk%20models.%20RESULTS%3A%20We%20included%20a%20total%20of%202733%20adolescents%2C%20415%20%2815.2%25%29%20males%2C%20median%20%28IQR%29%20age%20at%20ART%20start%20of%2018.6%20%2817.3%2C%2019.4%29%20years.%20Among%20females%2C%20585%5C%2F2318%20%2825.2%25%29%20were%20pregnant.%20Over%20the%2024-month%20follow-up%2C%20424%20%2815.5%25%29%20of%20all%20adolescents%20experienced%20VNS%3A%20range%20%2811.1%25%20pregnant%20females%20and%2020.5%25%20males%29.%20Over%20half%20of%20all%20adolescents%20were%20LTFU%20before%20any%20other%20event%20could%20occur.%20The%20hazard%20of%20VNS%20reduced%20with%20increasing%20age%20and%20CD4%20count%20above%20200%20cells%5C%2Fmul%20at%20ART%20initiation%20among%20all%20adolescents%20having%20adjusted%20for%20all%20measured%20patient%20characteristics%20%5Badjusted%20sub-distribution%20hazard%20ratio%20%28aSHR%29%2019%20vs.%2015%20years%3A%200.50%20%2895%25%20CI%3A%200.36%2C%200.68%29%2C%20aSHR%3A%20%3E500%20vs.%20%3C%5C%2F%3D200%20cells%5C%2Fmul%3A%200.22%20%2895%25%20CI%3A%200.16%2C%200.31%29%5D.%20The%20effect%20of%20CD4%20count%20persisted%20in%20pregnant%20females.%20Increasing%20age%20and%20CD4%20count%20%3E200%20cells%5C%2Fmul%20were%20risk%20factors%20for%20LTFU%20among%20all%20adolescents.%20CONCLUSIONS%3A%20Older%20adolescents%20had%20a%20high%20risk%20of%20LTFU%20shortly%20after%20ART%20start%20and%20a%20low%20risk%20of%20VNS%2C%20especially%20those%20initiating%20treatment%20during%20pregnancy.%20Interventions%20addressing%20adherence%20and%20retention%20should%20be%20incorporated%20into%20adolescent-friendly%20services%20to%20prevent%20VNS%20and%20LTFU%20and%20endeavour%20to%20trace%20lost%20adolescents%20as%20soon%20as%20they%20are%20identified.%22%2C%22date%22%3A%22Jan%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25870%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A33%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22ZPLWK36L%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cassidy%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECassidy%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECornell%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERuneyi%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDutyulwa%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKilani%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282022%29.%20Attrition%20from%20HIV%20care%20among%20youth%20initiating%20ART%20in%20youth-only%20clinics%20compared%20with%20general%20primary%20healthcare%20clinics%20in%20Khayelitsha%2C%20South%20Africa%3A%20a%20matched%20propensity%20score%20analysis.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E25%3C%5C%2Fi%3E%20%281%29%2C%20S.%20e25854.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25854%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25854%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Attrition%20from%20HIV%20care%20among%20youth%20initiating%20ART%20in%20youth-only%20clinics%20compared%20with%20general%20primary%20healthcare%20clinics%20in%20Khayelitsha%2C%20South%20Africa%3A%20a%20matched%20propensity%20score%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Cassidy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Runeyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Dutyulwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kilani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20T.%22%2C%22lastName%22%3A%22Duran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Zokufa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22de%20Azevedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20R.%22%2C%22lastName%22%3A%22Horsburgh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Fox%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Youth%20living%20with%20HIV%20%28YLWH%29%20are%20less%20likely%20to%20initiate%20antiretroviral%20therapy%20%28ART%29%20and%20remain%20in%20care%20than%20older%20adults.%20It%20is%20important%20to%20identify%20effective%20strategies%20to%20address%20the%20needs%20of%20this%20growing%20population%20and%20prevent%20attrition%20from%20HIV%20care.%20Since%202008%2C%20two%20clinics%20have%20offered%20youth-targeted%20services%20exclusively%20to%20youth%20aged%2012-25%20in%20Khayelitsha%2C%20a%20high%20HIV-prevalence%2C%20low-income%20area%20in%20South%20Africa.%20We%20compared%20ART%20attrition%20among%20youth%20in%20these%20two%20clinics%20to%20youth%20in%20regular%20clinics%20in%20the%20same%20area.%20METHODS%3A%20We%20conducted%20a%20propensity%20score%20matched%20cohort%20study%20of%20individuals%20aged%2012-25%20years%20initiating%20ART%20at%20eight%20primary%20care%20clinics%20in%20Khayelitsha%20between%201%20January%202008%20and%201%20April%202018.%20We%20compared%20attrition%2C%20defined%20as%20death%20or%20loss%20to%20follow-up%2C%20between%20those%20attending%20two%20youth%20clinics%20and%20those%20attending%20general%20primary%20healthcare%20clinics%2C%20using%20Cox%20proportional%20hazards%20regression.%20Follow-up%20time%20began%20at%20ART%20initiation%20and%20ended%20at%20attrition%2C%20clinic%20transfer%20or%20dataset%20closure.%20We%20conducted%20sub-analyses%20of%20patients%20attending%20adherence%20clubs.%20RESULTS%3A%20The%20distribution%20of%20age%2C%20sex%20and%20CD4%20count%20at%20ART%20initiation%20was%20similar%20across%20Youth%20Clinic%20A%20%28N%20%3D%201383%29%2C%20Youth%20Clinic%20B%20%28N%20%3D%201299%29%20and%20general%20clinics%20%28N%20%3D%203056%29.%20Youth%20at%20youth%20clinics%20were%20more%20likely%20than%20those%20at%20general%20clinics%20to%20have%20initiated%20ART%20before%20August%202011%20%28Youth%20Clinic%20A%3A%2016%25%2C%20Youth%20Clinic%20B%3A%2023%25%20and%20general%20clinics%3A%2011%25%29.%20Youth%20clinics%20were%20protective%20against%20attrition%3A%20HR%200.81%20%2895%25%20CI%3A%200.71-0.92%29%20for%20Youth%20Clinic%20A%20and%200.85%20%280.74-0.98%29%20for%20Youth%20Clinic%20B%2C%20compared%20to%20general%20clinics.%20Youth%20Clinic%20A%20club%20patients%20had%20lower%20attrition%20after%20joining%20an%20adherence%20club%20than%20general%20clinic%20patients%20in%20adherence%20clubs%20%28crude%20HR%3A%200.56%2C%2095%25%20CI%3A%200.32-0.96%3B%20adjusted%20HR%3A%200.48%2C%2095%25%20CI%3A%200.28-0.85%29%2C%20while%20Youth%20Clinic%20B%20showed%20no%20effect%20%28crude%20HR%3A%200.83%2C%2095%25%20CI%3A%200.48-1.45%3B%20adjusted%20HR%3A%201.07%2C%2095%25%20CI%3A%200.60-1.90%29.%20CONCLUSIONS%3A%20YLWH%20were%20more%20likely%20to%20be%20retained%20in%20ART%20care%20in%20two%20different%20youth-targeted%20clinics%20compared%20to%20general%20clinics%20in%20the%20same%20area.%20Our%20findings%20suggest%20that%20multiple%20approaches%20to%20making%20clinics%20more%20youth-friendly%20can%20contribute%20to%20improving%20retention%20in%20this%20important%20group.%22%2C%22date%22%3A%22Jan%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25854%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A16%3A54Z%22%7D%7D%5D%7D
Salvi, S. ; Raichur, P. ; Kadam, D. ; Sangle, S. ; Gupte, N. et al. (2022). Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India.
BMC Infect Dis ,
22 (1), S. 951.
http://doi.org/10.1186/s12879-022-07894-2 .
Bourgi, K. ; Ofner, S. ; Musick, B. ; Griffith, B. ; Diero, L. et al. (2022). Weight Gain Among Treatment-Naive Persons With HIV Receiving Dolutegravir in Kenya.
J Acquir Immune Defic Syndr ,
91 (5), S. 490–496.
http://doi.org/10.1097/QAI.0000000000003087 .
Lesko, C. R. ; Keruly, J. C. ; Moore, R. D. ; Shen, N. M. ; Pytell, J. D. et al. (2022). COVID-19 and the HIV continuum in people living with HIV enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts.
Drug Alcohol Depend ,
241 , S. 109355.
http://doi.org/10.1016/j.drugalcdep.2022.109355 .
McCann, N. C. ; Stanic, T. ; Penazzato, M. ; Flanagan, C. F. ; Abrams, E. J. et al. (2022). Prevalence of undiagnosed HIV among children in South Africa, Cote d’Ivoire and Zimbabwe: a model-based analysis to inform paediatric HIV screening programmes.
J Int AIDS Soc ,
25 (12), S. e26045.
http://doi.org/10.1002/jia2.26045 .
Chihota, B. V. ; Mandiriri, A. ; Shamu, T. ; Muula, G. ; Nyamutowa, H. et al. (2022). Metabolic syndrome among treatment-naive people living with and without HIV in Zambia and Zimbabwe: a cross-sectional analysis.
J Int AIDS Soc ,
25 (12), S. e26047.
http://doi.org/10.1002/jia2.26047 .
Brazier, E. ; Ajeh, R. ; Maruri, F. ; Musick, B. ; Freeman, A. et al. (2022). Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium.
J Int AIDS Soc ,
25 (12), S. e26036.
http://doi.org/10.1002/jia2.26036 .
Jiamsakul, A. ; Gani, Y. ; Avihingsanon, A. ; Azwa, I. ; Chaiwarith, R. et al. (2022). Brief Report: Mortality After Loss to Follow-Up-A Linkage Study of People Living With HIV in Thailand and Malaysia.
J Acquir Immune Defic Syndr ,
91 (3), S. 290–295.
http://doi.org/10.1097/QAI.0000000000003067 .
Rupasinghe, D. ; Choi, J. Y. ; Yunihastuti, E. ; Kiertiburanakul, S. ; Ross, J. et al. (2022). Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.
J Med Virol ,
94 (11), S. 5451–5464.
http://doi.org/10.1002/jmv.28019 .
Sobral, L. ; Arriaga, M. B. ; Souza, A. B. ; Araujo-Pereira, M. ; Barreto-Duarte, B. et al. (2022). Determinants of losses in the tuberculosis infection cascade of care among children and adolescent contacts of pulmonary tuberculosis cases: A Brazilian multi-centre longitudinal study.
Lancet Reg Health Am ,
15 , S. 100358.
http://doi.org/10.1016/j.lana.2022.100358 .
Bartelt, L. A. ; Markmann, A. J. ; Nelson, B. ; Keys, J. ; Root, H. et al. (2022). Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
MBio ,
13 (5), S. e0175122.
http://doi.org/10.1128/mbio.01751-22 .
Horberg, M. A. ; Watson, E. ; Bhatia, M. ; Jefferson, C. ; Certa, J. M. et al. (2022). Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparison in a matched cohort.
Nat Commun ,
13 (1), S. 5822.
http://doi.org/10.1038/s41467-022-33573-6 .
Kalua, T. ; Egger, M. ; Jahn, A. ; Chimpandule, T. ; Kolola, R. et al. (2022). HIV suppression was maintained during the COVID-19 pandemic in Malawi: a program-level cohort study.
J Clin Epidemiol ,
150 , S. 116–125.
http://doi.org/10.1016/j.jclinepi.2022.06.019 .
Marti, M. ; Zurcher, K. ; Enane, L. A. ; Diero, L. ; Marcy, O. et al. (2022). Impact of the COVID-19 pandemic on TB services at ART programmes in low- and middle-income countries: a multi-cohort survey.
J Int AIDS Soc ,
25 (10), S. e26018.
http://doi.org/10.1002/jia2.26018 .
Stalter, R. M. ; Amorim, G. ; Mocello, A. R. ; Jakait, B. ; Shepherd, B. E. et al. (2022). Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis.
J Int AIDS Soc ,
25 (9), S. e26001.
http://doi.org/10.1002/jia2.26001 .
Wada, P. Y. ; Kim, A. ; Jayathilake, K. ; Duda, S. N. ; Abo, Y. et al. (2022). Site-Level Comprehensiveness of Care Is Associated with Individual Clinical Retention Among Adults Living with HIV in International Epidemiology Databases to Evaluate AIDS, a Global HIV Cohort Collaboration, 2000-2016.
AIDS Patient Care STDS ,
36 (9), S. 343–355.
http://doi.org/10.1089/apc.2022.0042 .
Murenzi, G. ; Shumbusho, F. ; Hansen, N. ; Munyaneza, A. ; Gage, J. C. et al. (2022). Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol.
BMJ Open ,
12 (8), S. e061650.
http://doi.org/10.1136/bmjopen-2022-061650 .
Asangbeh-Kerman, S. L. ; Davidovic, M. ; Taghavi, K. ; Kachingwe, J. ; Rammipi, K. M. et al. (2022). Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies.
BMC Public Health ,
22 (1), S. 1530.
http://doi.org/10.1186/s12889-022-13827-0 .
Christ, B. ; van Dijk, J. H. ; Nyandoro, T. Y. ; Reichmuth, M. L. ; Kunzekwenyika, C. et al. (2022). Availability and experiences of differentiated antiretroviral therapy delivery at HIV care facilities in rural Zimbabwe: a mixed-method study.
J Int AIDS Soc ,
25 (8), S. e25944.
http://doi.org/10.1002/jia2.25944 .
Freeman, E. E. ; McCann, N. C. ; Semeere, A. ; Reddy, K. P. ; Laker-Oketta, M. et al. (2022). Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis.
Lancet Glob Health ,
10 (8), S. e1179–e1188.
http://doi.org/10.1016/S2214-109X(22)00242-X .
Teeraananchai, S. ; Law, M. ; Boettiger, D. ; Mata, N. ; Gupte, N. et al. (2022). Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in Asia.
J Int AIDS Soc ,
25 (8), S. e25989.
http://doi.org/10.1002/jia2.25989 .
Chihota, B. V. ; Riebensahm, C. ; Muula, G. ; Sinkala, E. ; Chilengi, R. et al. (2022). Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia.
BMJ Open Gastroenterol ,
9 (1), S. e000945.
http://doi.org/10.1136/bmjgast-2022-000945 .
Romo, M. L. ; Brazier, E. ; Mahambou-Nsonde, D. ; De Waal, R. ; Sekaggya-Wiltshire, C. et al. (2022). Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.
J Int AIDS Soc ,
25 (7), S. e25961.
http://doi.org/10.1002/jia2.25961 .
Baidya, A. ; Sangle, S. ; Marbaniang, I. ; Kulkarni, V. ; Deshpande, P. et al. (2022). Clinical and Immunological Markers of Pulmonary Impairment Among People With HIV in India.
Open Forum Infect Dis ,
9 (7), S. ofac233.
http://doi.org/10.1093/ofid/ofac233 .
Kalk, E. ; Heekes, A. ; Slogrove, A. L. ; Phelanyane, F. ; Davies, M. A. et al. (2022). Cohort profile: the Western Cape Pregnancy Exposure Registry (WCPER).
BMJ Open ,
12 (6), S. e060205.
http://doi.org/10.1136/bmjopen-2021-060205 .
Lewis, J. T. ;
Brazier, E. ;
Katz, B. ;
Nash, D. &
Duda, S. N. (2022). A Method for Generating Dashboard Aggregations in an International HIV Consortium.
Stud Health Technol Inform ,
290 , S. 1048–1049.
http://doi.org/10.3233/SHTI220261 .
van der Hoven, J. ; Allen, E. ; Cois, A. ; de Waal, R. ; Maartens, G. et al. (2022). Determining antenatal medicine exposures in South African women: a comparison of three methods of ascertainment.
BMC Pregnancy Childbirth ,
22 (1), S. 466.
http://doi.org/10.1186/s12884-022-04765-1 .
Li, F. ;
Buchanan, A. L. &
Cole, S. R. (2022). Generalizing trial evidence to target populations in non-nested designs: Applications to AIDS clinical trials.
J R Stat Soc Ser C Appl Stat ,
71 (3), S. 669–697.
http://doi.org/10.1111/rssc.12550 .
Hussey, H. ; Davies, M. A. ; Heekes, A. ; Williamson, C. ; Valley-Omar, Z. et al. (2022). Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections - a survival analysis.
Int J Infect Dis ,
118 , S. 150–154.
http://doi.org/10.1016/j.ijid.2022.02.051 .
Crabtree-Ramirez, B. ; Jenkins, C. A. ; Shepherd, B. E. ; Jayathilake, K. ; Veloso, V. G. et al. (2022). Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy.
BMC Infect Dis ,
22 (1), S. 341.
http://doi.org/10.1186/s12879-022-07330-5 .
Oyungu, E. ; El Kebbi, O. ; Vreeman, R. ; Nyandiko, W. ; Monahan, P. O. et al. (2022). Predicting neurodevelopmental risk in children born to mothers living with HIV in Kenya: protocol for a prospective cohort study (Tabiri Study).
BMJ Open ,
12 (4), S. e061051.
http://doi.org/10.1136/bmjopen-2022-061051 .
Kim, H. N. ; Nance, R. M. ; Lo Re, V. ; Silverberg, M. J. ; Franco, R. et al. (2022). Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV.
J Acquir Immune Defic Syndr ,
89 (4), S. 396–404.
http://doi.org/10.1097/QAI.0000000000002886 .
Staub, K. ; Panczak, R. ; Matthes, K. L. ; Floris, J. ; Berlin, C. et al. (2022). Historically High Excess Mortality During the COVID-19 Pandemic in Switzerland, Sweden, and Spain.
Ann Intern Med ,
175 (4), S. 523–532.
http://doi.org/10.7326/M21-3824 .
Walker, T. M. ; Miotto, P. ; Koser, C. U. ; Fowler, P. W. ; Knaggs, J. et al. (2022). The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis.
Lancet Microbe ,
3 (4), S. e265–e273.
http://doi.org/10.1016/S2666-5247(21)00301-3 .
Coelho, L. E. ; Jenkins, C. A. ; Shepherd, B. E. ; Pape, J. W. ; Mejia Cordero, F. et al. (2022). Weight gain post-ART in HIV+ Latinos/as differs in the USA, Haiti, and Latin America.
Lancet Reg Health Am ,
8 , S. 100173.
http://doi.org/10.1016/j.lana.2021.100173 .
Caro-Vega, Y. ; Rebeiro, P. F. ; Shepherd, B. E. ; Belaunzaran-Zamudio, P. F. ; Crabtree-Ramirez, B. et al. (2022). Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study.
Lancet Reg Health Am ,
8 , S. 100175.
http://doi.org/10.1016/j.lana.2021.100175 .
Antimycobacterial Susceptibility Testing, Group (2022). Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.
Eur Respir J ,
59 (4), S. 2200166.
http://doi.org/10.1183/13993003.00166-2022 .
Justice, A. C. ; Goetz, M. B. ; Stewart, C. N. ; Hogan, B. C. ; Humes, E. et al. (2022). Delayed presentation of HIV among older individuals: a growing problem.
Lancet HIV ,
9 (4), S. e269–e280.
http://doi.org/10.1016/S2352-3018(22)00003-0 .
Enane, L. A. ; Apondi, E. ; Liepmann, C. ; Toromo, J. J. ; Omollo, M. et al. (2022). “We are not going anywhere”: a qualitative study of Kenyan healthcare worker perspectives on adolescent HIV care engagement during the COVID-19 pandemic.
BMJ Open ,
12 (3), S. e055948.
http://doi.org/10.1136/bmjopen-2021-055948 .
Koh, M. J. ; Merrill, M. H. ; Koh, M. J. ; Stuver, R. ; Alonso, C. D. et al. (2022). Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas.
Blood Adv ,
6 (5), S. 1420–1431.
http://doi.org/10.1182/bloodadvances.2021006208 .
Collaborative Initiative for Paediatric, H. I. V. Education ; Research Global Cohort, Collaboration ; Jesson, J. ; Crichton, S. ; Quartagno, M. et al. (2022). Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis.
J Int AIDS Soc ,
25 (3), S. e25871.
http://doi.org/10.1002/jia2.25871 .
Shaikh, K. ; Bhondoekhan, F. ; Haberlen, S. ; Nakanishi, R. ; Roy, S. K. et al. (2022). Coronary artery plaque progression and cardiovascular risk scores in men with and without HIV-infection.
AIDS ,
36 (2), S. 215–224.
http://doi.org/10.1097/QAD.0000000000003093 .
Myers, C. ; Apondi, E. ; Toromo, J. J. ; Omollo, M. ; Bakari, S. et al. (2022). “Who am I going to stay with? Who will accept me?”: family-level domains influencing HIV care engagement among disengaged adolescents in Kenya.
J Int AIDS Soc ,
25 (2), S. e25890.
http://doi.org/10.1002/jia2.25890 .
Zotova, N. ; Familiar, I. ; Kawende, B. ; Kasindi, F. L. ; Ravelomanana, N. et al. (2022). HIV disclosure and depressive symptoms among pregnant women living with HIV: a cross-sectional study in the Democratic Republic of Congo.
J Int AIDS Soc ,
25 (2), S. e25865.
http://doi.org/10.1002/jia2.25865 .
Sam-Agudu, N. A. ;
Quakyi, N. K. ;
Masekela, R. ;
Zumla, A. &
Nachega, J. B. (2022). Children and adolescents in African countries should also be vaccinated for COVID-19.
BMJ Glob Health ,
7 (2), S. e008315.
http://doi.org/10.1136/bmjgh-2021-008315 .
Thompson, P. ; Mpody, C. ; Sayre, W. ; Rigney, C. ; Tabala, M. et al. (2022). Hepatitis C prevalence and quality of health services among HIV-positive mothers in the Democratic Republic of the Congo.
Sci Rep ,
12 (1), S. 1384.
http://doi.org/10.1038/s41598-022-05014-3 .
Davies, M. A. ; Kassanjee, R. ; Rosseau, P. ; Morden, E. ; Johnson, L. et al. (2022). Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa.
MedRxiv , S. 2022.01.12.22269148.
http://doi.org/10.1101/2022.01.12.22269148 .
Nyemba, D. C. ; Kalk, E. ; Vinikoor, M. J. ; Madlala, H. P. ; Mubiana-Mbewe, M. et al. (2022). Growth patterns of infants with in- utero HIV and ARV exposure in Cape Town, South Africa and Lusaka, Zambia.
BMC Public Health ,
22 (1), S. 55.
http://doi.org/10.1186/s12889-021-12476-z .
Qian, Y. ; Moore, R. D. ; Coburn, S. B. ; Davy-Mendez, T. ; Akgun, K. M. et al. (2022). Association of the VACS Index With Hospitalization Among People With HIV in the NA-ACCORD.
J Acquir Immune Defic Syndr ,
89 (1), S. 9–18.
http://doi.org/10.1097/QAI.0000000000002812 .
Nyakato, P. ; Schomaker, M. ; Fatti, G. ; Tanser, F. ; Euvrard, J. et al. (2022). Virologic non-suppression and early loss to follow up among pregnant and non-pregnant adolescents aged 15-19 years initiating antiretroviral therapy in South Africa: a retrospective cohort study.
J Int AIDS Soc ,
25 (1), S. e25870.
http://doi.org/10.1002/jia2.25870 .
Cassidy, T. ; Cornell, M. ; Runeyi, P. ; Dutyulwa, T. ; Kilani, C. et al. (2022). Attrition from HIV care among youth initiating ART in youth-only clinics compared with general primary healthcare clinics in Khayelitsha, South Africa: a matched propensity score analysis.
J Int AIDS Soc ,
25 (1), S. e25854.
http://doi.org/10.1002/jia2.25854 .
2021
2775998
GXCKG69T
2021
items
1
0
date
desc
https://www.iedea.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22instance%22%3A%22zotpress-21770274b54ecb5657e5808f5008ebc6%22%2C%22meta%22%3A%7B%22request_last%22%3A50%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22HRDTXHPQ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Costa%20et%20al.%22%2C%22parsedDate%22%3A%222021-12-22%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECosta%2C%20A.%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECarvalho%2C%20B.%20K.%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAraujo-Pereira%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIbiapina%2C%20H.%20N.%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESpener-Gomes%2C%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Lessons%20Learned%20from%20Implementation%20of%20an%20Interferon%20Gamma%20Release%20Assay%20to%20Screen%20for%20Latent%20Tuberculosis%20Infection%20in%20a%20Large%20Multicenter%20Observational%20Cohort%20Study%20in%20Brazil.%20%3Ci%3EMicrobiol%20Spectr%3C%5C%2Fi%3E%2C%20%3Ci%3E9%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e0116321.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FSpectrum.01163-21%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FSpectrum.01163-21%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lessons%20Learned%20from%20Implementation%20of%20an%20Interferon%20Gamma%20Release%20Assay%20to%20Screen%20for%20Latent%20Tuberculosis%20Infection%20in%20a%20Large%20Multicenter%20Observational%20Cohort%20Study%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20G.%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20K.%20S.%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Araujo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20N.%20S.%22%2C%22lastName%22%3A%22Ibiapina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Gomes-Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%20S.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20C.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Port-Brazil%20Consortium%22%2C%22lastName%22%3A%22Re%22%7D%5D%2C%22abstractNote%22%3A%22The%20interferon%20gamma%20release%20assay%20%28IGRA%29%20has%20emerged%20as%20a%20useful%20tool%20for%20identifying%20latent%20tuberculosis%20infection%20%28LTBI%29.%20This%20assay%20can%20be%20performed%20through%20testing%20platforms%20such%20as%20the%20QuantiFERON-TB%20Gold%20Plus%20%28QFT-Plus%29%20assay.%20This%20in%20vitro%20test%20has%20been%20incorporated%20into%20several%20guidelines%20worldwide%20and%20has%20recently%20been%20considered%20by%20the%20World%20Health%20Organization%20%28WHO%29%20for%20the%20diagnosis%20of%20LTBI.%20The%20possibility%20of%20systematically%20implementing%20IGRAs%20such%20as%20the%20QFT-Plus%20assay%20in%20centers%20that%20perform%20LTBI%20screening%20has%20been%20accelerated%20by%20the%20decreased%20availability%20of%20the%20tuberculin%20skin%20test%20%28TST%29%20in%20several%20countries.%20Nevertheless%2C%20the%20process%20to%20implement%20IGRA%20testing%20in%20routine%20clinical%20care%20has%20many%20gaps.%20The%20study%20utilized%20the%20expertise%20acquired%20by%20the%20laboratory%20teams%20of%20the%20Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29-Brazil%20consortium%20during%20study%20protocol%20implementation%20of%20LTBI%20screening%20of%20tuberculosis%20%28TB%29%20close%20contacts.%20RePORT-Brazil%20includes%20clinical%20research%20sites%20from%20Brazilian%20cities%20and%20is%20the%20largest%20multicenter%20cohort%20of%20TB%20close%20contacts%20in%20the%20country%20to%20date.%20Operational%20and%20logistical%20challenges%20faced%20during%20IGRA%20implementation%20in%20all%20study%20laboratories%20are%20described%2C%20as%20well%20as%20the%20solutions%20that%20were%20developed%20and%20led%20to%20the%20successful%20establishment%20of%20IGRA%20testing%20in%20RePORT-Brazil.%20The%20descriptions%20of%20the%20problems%20identified%20and%20resolved%20in%20this%20study%20can%20assist%20laboratories%20implementing%20IGRAs%2C%20in%20addition%20to%20manufacturers%20of%20IGRAs%20providing%20effective%20technical%20support.%20This%20will%20facilitate%20the%20implementation%20of%20IGRA%20testing%20in%20countries%20with%20large%20TB%20burdens%2C%20such%20as%20Brazil.%20IMPORTANCE%20The%20IGRA%20has%20emerged%20as%20a%20useful%20tool%20for%20identifying%20persons%20with%20LTBI.%20Although%20the%20implementation%20of%20IGRAs%20is%20of%20utmost%20importance%2C%20to%20our%20knowledge%20there%20is%20scarce%20information%20on%20the%20identification%20of%20logistical%20and%20technical%20challenges%20for%20systematic%20screening%20for%20LTBI%20on%20a%20large%20scale.%20Thus%2C%20the%20descriptions%20of%20the%20problems%20identified%20and%20resolved%20in%20this%20study%20can%20assist%20laboratories%20implementing%20IGRAs%2C%20in%20addition%20to%20manufacturers%20of%20IGRAs%20providing%20effective%20technical%20support.%20This%20will%20facilitate%20the%20implementation%20of%20IGRA%20testing%20in%20countries%20with%20large%20TB%20burdens%2C%20such%20as%20Brazil.%22%2C%22date%22%3A%22Dec%2022%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1128%5C%2FSpectrum.01163-21%22%2C%22ISSN%22%3A%222165-0497%20%28Electronic%29%202165-0497%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A36%3A26Z%22%7D%7D%2C%7B%22key%22%3A%227ZV5MXPB%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jesson%20et%20al.%22%2C%22parsedDate%22%3A%222021-12-14%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJesson%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEphoevi-Ga%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAke-Assi%2C%20M.%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKoumakpai%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EN%26%23x2019%3BGbeche%2C%20S.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Assessment%20of%20dietary%20diversity%20and%20nutritional%20support%20for%20children%20living%20with%20HIV%20in%20the%20IeDEA%20pediatric%20West%20African%20cohort%3A%20a%20non-comparative%2C%20feasibility%20study.%20%3Ci%3EBMC%20Nutr%3C%5C%2Fi%3E%2C%20%3Ci%3E7%3C%5C%2Fi%3E%20%281%29%2C%20S.%2083.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40795-021-00486-4%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40795-021-00486-4%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessment%20of%20dietary%20diversity%20and%20nutritional%20support%20for%20children%20living%20with%20HIV%20in%20the%20IeDEA%20pediatric%20West%20African%20cohort%3A%20a%20non-comparative%2C%20feasibility%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Jesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Ephoevi-Ga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20H.%22%2C%22lastName%22%3A%22Ake-Assi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Koumakpai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22N%27Gbeche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Dainguy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Carrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22D%27Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20T.%22%2C%22lastName%22%3A%22Eboua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Takassi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Amorissani-Folquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20West%20African%20Pediatric%20Collaboration%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Nutritional%20care%20is%20not%20optimally%20integrated%20into%20pediatric%20HIV%20care%20in%20sub-Saharan%20Africa.%20We%20assessed%20the%206-month%20effect%20of%20a%20nutritional%20support%20provided%20to%20children%20living%20with%20HIV%2C%20followed%20in%20a%20multicentric%20cohort%20in%20West%20Africa.%20METHODS%3A%20In%202014-2016%2C%20a%20nutritional%20intervention%20was%20carried%20out%20for%20children%20living%20with%20HIV%2C%20aged%20under%2010%20years%2C%20receiving%20antiretroviral%20therapy%20%28ART%29%20or%20not%2C%20in%20five%20HIV%20pediatric%20cohorts%2C%20in%20Benin%2C%20Togo%20and%20Cote%20d%27Ivoire.%20Weight%20deficiency%20was%20assessed%20using%20two%20definitions%3A%20wasting%20%28Weight%20for%20Height%20Z-score%20%5BWHZ%5D%20for%20children%3C5%20years%20old%20or%20Body-Mass-Index%20for%20Age%20%5BBAZ%5D%20for%20%3E%5C%2F%3D5%20years%29%20and%20underweight%20%28Weight%20for%20Age%20Z-score%20%5BWAZ%5D%29%20%28WHO%20child%20growth%20standards%29.%20Combining%20these%20indicators%2C%20three%20categories%20of%20nutritional%20support%20were%20defined%3A%201%5C%2F%20children%20with%20severe%20malnutrition%20%28WAZ%20and%5C%2For%20WHZ%5C%2FBAZ%20%3C-3%20Standard%20Deviations%20%5BSD%5D%29%20were%20supported%20with%20Ready-To-Use%20Therapeutic%20Food%20%28RUTF%29%2C%202%5C%2F%20those%20with%20moderate%20malnutrition%20%28WAZ%20and%5C%2For%20WHZ%5C%2FBAZ%20%3D%20%5B-3%3B-2%5B%20SD%29%20were%20supported%20with%20fortified%20blended%20flours%20produced%20locally%20in%20each%20country%2C%203%5C%2F%20those%20non%20malnourished%20%28WAZ%20and%20WHZ%5C%2FBAZ%20%3E%5C%2F%3D-2%20SD%29%20received%20nutritional%20counselling%20only.%20Children%20were%20followed%20monthly%20over%206%20months.%20Dietary%20Diversity%20Score%20%28DDS%29%20using%20a%2024h%20recall%20was%20measured%20at%20the%20first%20and%20last%20visit%20of%20the%20intervention.%20RESULTS%3A%20Overall%2C%20326%20children%20were%20included%2C%2048%25%20were%20girls.%20At%20baseline%2C%2066%25%20were%20aged%205-10%20years%2C%2091%25%20were%20on%20ART%2C%20and%2017%25%20were%20severely%20immunodeficient%20%28CD4%20%3C250%20cells%5C%2FmL%20or%20CD4%25%3C15%29.%20Twenty-nine%20%289%25%29%20were%20severely%20malnourished%2C%2063%20%2819%25%29%20moderately%20malnourished%20and%20234%20%2872%25%29%20non-malnourished.%20After%206%20months%2C%209%5C%2F29%20%2831%25%29%20and%2031%5C%2F63%20%2848%25%29%20recovered%20from%20severe%20and%20moderate%20malnutrition%20respectively.%20The%20median%20DDS%20was%208%20%28IQR%207-9%29%20in%20Cote%20d%27Ivoire%20and%20Togo%2C%206%20%28IQR%206-7%29%20in%20Benin.%20Mean%20DDS%20was%204.3%5C%2F9%20%28sd%201.2%29%20at%20first%20visit%2C%20with%20a%20lower%20score%20in%20Benin%2C%20but%20with%20no%20difference%20between%20first%20and%20last%20visit%20%28p%3D0.907%29%2C%20nor%20by%20intervention%20groups%20%28p-value%3D0.767%29.%20CONCLUSIONS%3A%20This%20intervention%20had%20a%20limited%20effect%20on%20nutritional%20recovery%20and%20dietary%20diversity%20improvement.%20Questions%20remain%20on%20determining%20appropriate%20nutritional%20products%2C%20in%20terms%20of%20adherence%2C%20proper%20use%20for%20families%20and%20adequate%20energy%20needs%20coverage%20for%20children%20living%20with%20HIV.%20TRIAL%20REGISTRATION%3A%20PACTR202001816232398%20%2C%20June%2001%2C%202020%2C%20retrospectively%20registered.%22%2C%22date%22%3A%22Dec%2014%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40795-021-00486-4%22%2C%22ISSN%22%3A%222055-0928%20%28Electronic%29%202055-0928%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A16%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22EQ3T4VIJ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Coburn%20et%20al.%22%2C%22parsedDate%22%3A%222021-12-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoburn%2C%20S.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHumes%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELang%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStewart%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHogan%2C%20B.%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20COVID-19%20infections%20post-vaccination%20by%20HIV%20status%20in%20the%20United%20States.%20%3Ci%3EMedRxiv%3C%5C%2Fi%3E%2C%20S.%202021.12.02.21267182.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2021.12.02.21267182%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2021.12.02.21267182%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22COVID-19%20infections%20post-vaccination%20by%20HIV%20status%20in%20the%20United%20States%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20B.%22%2C%22lastName%22%3A%22Coburn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Humes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20C.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20K.%22%2C%22lastName%22%3A%22Edwards%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20E.%22%2C%22lastName%22%3A%22Browne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20S.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Gordon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Certa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20R.%22%2C%22lastName%22%3A%22Jefferson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Skarbinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20A.%22%2C%22lastName%22%3A%22Leyden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20F.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20A.%20Accord%20of%20IeDEA%22%2C%22lastName%22%3A%22Corona-Infectious-Virus%20Epidemiology%20Team%20of%20the%22%7D%5D%2C%22abstractNote%22%3A%22IMPORTANCE%3A%20Recommendations%20for%20additional%20doses%20of%20COVID%20vaccine%20are%20restricted%20to%20people%20with%20HIV%20who%20have%20advanced%20disease%20or%20unsuppressed%20HIV%20viral%20load.%20Understanding%20SARS-CoV-2%20infection%20risk%20post-vaccination%20among%20PWH%20is%20essential%20for%20informing%20vaccination%20guidelines.%20OBJECTIVE%3A%20Estimate%20the%20risk%20of%20breakthrough%20infections%20among%20fully%20vaccinated%20people%20with%20%28PWH%29%20and%20without%20%28PWoH%29%20HIV%20in%20the%20US.%20DESIGN%20SETTING%20AND%20PARTICIPANTS%3A%20The%20Corona-Infectious-Virus%20Epidemiology%20Team%20%28CIVET%29-II%20cohort%20collaboration%20consists%20of%204%20longitudinal%20cohorts%20from%20integrated%20health%20systems%20and%20academic%20health%20centers.%20Each%20cohort%20identified%20individuals%20a%20per%20thousand%20yen18%20years%20old%2C%20in-care%2C%20and%20fully%20vaccinated%20for%20COVID-19%20through%2030%20June%202021.%20PWH%20were%20matched%20to%20PWoH%20on%20date%20fully%20vaccinated%2C%20age%20group%2C%20race%5C%2Fethnicity%2C%20and%20sex%20at%20birth.%20Incidence%20rates%20per%201%2C000%20person-years%20and%20cumulative%20incidence%20of%20breakthrough%20infections%20with%2095%25%20confidence%20intervals%20%28%5B%2C%5D%29%20were%20estimated%20by%20HIV%20status.%20Cox%20proportional%20hazards%20models%20estimated%20adjusted%20hazard%20ratios%20%28aHR%29%20of%20breakthrough%20infections%20by%20HIV%20status%20adjusting%20for%20demographic%20factors%2C%20prior%20COVID-19%20illness%2C%20vaccine%20type%20%28BNT162b2%2C%20%5BPfizer%5D%2C%20mRNA-1273%20%5BModerna%5D%2C%20Jansen%20Ad26.COV2.S%20%5BJ%26J%5D%29%2C%20calendar%20time%2C%20and%20cohort.%20Risk%20factors%20for%20breakthroughs%20among%20PWH%2C%20were%20also%20investigated.%20EXPOSURE%3A%20HIV%20infection.%20OUTCOME%3A%20COVID-19%20breakthrough%20infections%2C%20defined%20as%20laboratory%20evidence%20of%20SARS-CoV-2%20infection%20or%20COVID-19%20diagnosis%20after%20an%20individual%20was%20fully%20vaccinated.%20RESULTS%3A%20Among%20109%2C599%20individuals%20%2831%2C840%20PWH%20and%2077%2C759%20PWoH%29%2C%20the%20rate%20of%20breakthrough%20infections%20was%20higher%20in%20PWH%20versus%20PWoH%3A%2044%20%5B41%2C%2048%5D%20vs.%2031%20%5B29%2C%2033%5D%20per%201%2C000%20person-years.%20Cumulative%20incidence%20at%20210%20days%20after%20date%20fully%20vaccinated%20was%20low%2C%20albeit%20higher%20in%20PWH%20versus%20PWoH%20overall%20%282.8%25%20versus%202.1%25%2C%20log-rank%20p%3C0.001%2C%20risk%20difference%3D0.7%25%20%5B0.4%25%2C%201.0%25%5D%29%20and%20within%20each%20vaccine%20type.%20Breakthrough%20infection%20risk%20was%2041%25%20higher%20in%20PWH%20versus%20PWoH%20%28aHR%3D1.41%20%5B1.28%2C%201.56%5D%29.%20Among%20PWH%2C%20younger%20age%20%2818-24%20versus%2045-54%29%2C%20history%20of%20COVID-19%20prior%20to%20fully%20vaccinated%20date%2C%20and%20J%26J%20vaccination%20%28versus%20Pfizer%29%20were%20associated%20with%20increased%20risk%20of%20breakthroughs.%20There%20was%20no%20association%20of%20breakthrough%20with%20HIV%20viral%20load%20suppression%20or%20CD4%20count%20among%20PWH.%20CONCLUSIONS%20AND%20RELEVANCE%3A%20COVID-19%20vaccination%20is%20effective%20against%20infection%20with%20SARS-CoV-2%20strains%20circulating%20through%2030%20Sept%202021.%20PWH%20have%20an%20increased%20risk%20of%20breakthrough%20infections%20compared%20to%20PWoH.%20Recommendations%20for%20additional%20vaccine%20doses%20should%20be%20expanded%20to%20all%20PWH.%22%2C%22date%22%3A%22Dec%205%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2021.12.02.21267182%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22XDJEW7C4%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Robertson%20et%20al.%22%2C%22parsedDate%22%3A%222021-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERobertson%2C%20M.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIrvine%2C%20M.%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPenrose%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHarriman%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBraunstein%2C%20S.%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Mortality%20among%20clients%20in%20the%20New%20York%20city%20HIV%20Care%20Coordination%20Program%20%28CCP%29%3A%20incidence%20and%20associated%20clinical%20factors.%20%3Ci%3EAnn%20Epidemiol%3C%5C%2Fi%3E%2C%20%3Ci%3E64%3C%5C%2Fi%3E%2C%20S.%20161%26%23x2013%3B166.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annepidem.2021.10.001%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annepidem.2021.10.001%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mortality%20among%20clients%20in%20the%20New%20York%20city%20HIV%20Care%20Coordination%20Program%20%28CCP%29%3A%20incidence%20and%20associated%20clinical%20factors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20M.%22%2C%22lastName%22%3A%22Robertson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20K.%22%2C%22lastName%22%3A%22Irvine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Penrose%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Harriman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20L.%22%2C%22lastName%22%3A%22Braunstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20We%20examined%20psychosocial%20factors%20%28housing%2C%20drug%20use%2C%20incarceration%20history%20or%20mental%20health%29%20and%20care%20factors%20%28comorbidities%20and%20acute%20care%29%20associated%20with%20all-cause%20and%20HIV-related%20mortality%20while%20enrolled%20in%20the%20New%20York%20City%20Ryan%20White%20HIV%20Care%20Coordination%20Program%20%28CCP%29%2C%20an%20intensive%20case%20management%20program%20for%20people%20with%20barriers%20to%20HIV%20care%20and%20treatment.%20METHODS%3A%20We%20used%20hazards%20regression%20%28HR%29%20to%20understand%20factors%20associated%20with%20mortality.%20RESULTS%3A%208%2C135%20people%20%2813%2C479.4%20person%20years%20%5BPY%5D%29%20enrolled%20in%20the%20CCP%20from%20March%202011%20to%20December%202016.%20The%20all-cause%20mortality%20rate%20while%20enrolled%20was%2028.8%20per%201000%20PY%20%28N%5Cu202f%3D%5Cu202f388%29%2C%20with%2043%25%20of%20deaths%20%28N%5Cu202f%3D%5Cu202f167%29%20related%20to%20HIV%20%2812.4%20per%201000%20PY%29.%20Controlling%20for%20demographics%20and%20clinical%20status%2C%20the%20variables%20associated%20with%20increased%20hazards%20of%20all-cause%20mortality%20included%20hospitalizations%20or%20emergency-department%20visits%20prior%20to%20enrollment%20%28aHR%28Hospitalizations%29%3A%202.54%3B%2095%25%20Confidence%20Interval%202.07-3.11%20and%20aHR%28ED%29%3A%201.54%3B%201.24-1.92%29%20or%20a%20diabetes%20or%20Hepatitis%20C%20diagnosis%20at%20enrollment%20%28aHR%28Diabetes%29%3A%201.80%3B%201.36-2.37%20and%20aHR%28HCV%29%3A%201.78%3B%201.37-2.30%29.%20These%20factors%20also%20increased%20the%20hazards%20of%20HIV-related%20mortality.%20CONCLUSIONS%3A%20CCP%20and%20similar%20case%20management%20programs%20should%20systematically%20screen%20enrolling%20clients%20for%20a%20history%20of%20acute%20care%20and%20comorbidities%2C%20as%20they%20may%20be%20important%20markers%20of%20need%20for%20more%20intensive%20engagement%20and%20follow-up%20to%20prevent%20death.%22%2C%22date%22%3A%22Dec%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annepidem.2021.10.001%22%2C%22ISSN%22%3A%221873-2585%20%28Electronic%29%201047-2797%20%28Print%29%201047-2797%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A48%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22T2Z5M8SR%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lancaster%20et%20al.%22%2C%22parsedDate%22%3A%222021-12%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELancaster%2C%20K.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERemch%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDzudie%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAjeh%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAdedimeji%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Heavy%20episodic%20drinking%20and%20HIV%20disclosure%20by%20HIV%20treatment%20status%20among%20People%20with%20HIV%20in%20IeDEA%20Cameroon.%20%3Ci%3EInt%20J%20Drug%20Policy%3C%5C%2Fi%3E%2C%20%3Ci%3E98%3C%5C%2Fi%3E%2C%20S.%20103431.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.drugpo.2021.103431%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.drugpo.2021.103431%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Heavy%20episodic%20drinking%20and%20HIV%20disclosure%20by%20HIV%20treatment%20status%20among%20People%20with%20HIV%20in%20IeDEA%20Cameroon%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20E.%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Remch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dzudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Adedimeji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20W.%22%2C%22lastName%22%3A%22Yone-Pefura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nsame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Heavy%20alcohol%20use%20is%20common%20among%20people%20with%20HIV%20%28PWH%29%2C%20leading%20to%20sub-optimal%20HIV%20care%20outcomes.%20Yet%2C%20heavy%20episodic%20drinking%20%28HED%29%20is%20not%20routinely%20addressed%20within%20most%20HIV%20clinics%20in%20sub-Saharan%20Africa.%20HIV%20disclosure%20may%20provide%20social%20support%2C%20potentially%20reducing%20HED%20to%20cope%20with%20HIV.%20We%20examined%20the%20prevalence%20of%20HED%20and%20HIV%20disclosure%20by%20antiretroviral%20treatment%20%28ART%29%20status%20among%20PWH%20receiving%20HIV%20care%20in%20Cameroon.%20METHODS%3A%20We%20analyzed%20routine%20HIV%20clinical%20data%20augmented%20with%20systematic%20alcohol%20use%20data%20among%20adult%20PWH%20receiving%20HIV%20care%20in%20three%20regional%20hospitals%20from%20January%202016%20to%20March%202020.%20Recent%20HED%20prevalence%20was%20examined%20across%20PWH%20by%20ART%20status%3A%20those%20not%20on%20ART%2C%20recent%20ART%20initiators%20%28ART%20initiation%20%3C%5C%2F%3D30%20days%20prior%29%2C%20and%20ART%20users%20%28ART%20initiation%20%3E30%20days%20prior%29%3B%20and%20by%20gender.%20We%20used%20log-binomial%20regression%20to%20estimate%20prevalence%20differences%20%28PD%29%20between%20HIV%20disclosure%20and%20recent%20HED%20by%20ART%20status.%20RESULTS%3A%20Among%2012%2C517%20PWH%20in%20care%2C%2016.4%25%20%2895%25CI%3A%2015.7%2C%2017.0%29%20reported%20recent%20HED.%20HED%20was%20reported%20among%2021.2%25%20%2895%25CI%3A%2016.0%2C%2026.3%29%20of%20those%20not%20on%20ART%2C%2024.5%25%20%2895%25CI%3A%2023.1%2C%2026.0%29%20of%20recent%20ART%20initiators%2C%20and%2012.9%25%20%2895%25CI%3A%2012.2%2C%2013.6%29%20of%20ART%20users.%20Regardless%20of%20ART%20status%2C%20men%20were%20more%20likely%20than%20women%20to%20report%20HED.%20Those%20who%20disclosed%20HIV%20status%20had%20a%20lower%20HED%20prevalence%20than%20those%20who%20had%20not%20disclosed%20%28aPD%3A%20-0.07%3B%2095%25CI%3A%20-0.10%2C%20-0.05%29%20and%20not%20modified%20by%20gender.%20CONCLUSION%3A%20The%20prevalence%20of%20recent%20HED%20was%20high%20among%20PWH%20in%20care.%20HED%20prevalence%20was%20highest%20among%20men%20and%20recent%20ART%20initiators.%20Longitudinal%20analyses%20should%20explore%20how%20HIV%20disclosure%20may%20support%20PWH%20in%20reducing%20or%20abstaining%20from%20HED%20through%20social%20support.%20Systematic%20HED%20screening%20and%20referral%20to%20care%20should%20be%20included%20in%20routine%20HIV%20clinical%20care%2C%20particularly%20for%20men%2C%20to%20improve%20engagement%20in%20the%20HIV%20care%20continuum%20in%20Cameroon.%22%2C%22date%22%3A%22Dec%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.drugpo.2021.103431%22%2C%22ISSN%22%3A%221873-4758%20%28Electronic%29%200955-3959%20%28Print%29%200955-3959%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A20%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22G2FSDMXA%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parcesepe%20et%20al.%22%2C%22parsedDate%22%3A%222021-11%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EParcesepe%2C%20A.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFiliatreau%2C%20L.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEbasone%2C%20P.%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDzudie%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPence%2C%20B.%20W.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Mental%20health%20and%20initiation%20of%20antiretroviral%20treatment%20at%20enrolment%20into%20HIV%20care%20in%20Cameroon%20under%20a%20national%20%26%23x201C%3Btreat%20all%26%23x201D%3B%20policy%3A%20a%20cross-sectional%20analysis.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E24%3C%5C%2Fi%3E%20%2811%29%2C%20S.%20e25842.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25842%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25842%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mental%20health%20and%20initiation%20of%20antiretroviral%20treatment%20at%20enrolment%20into%20HIV%20care%20in%20Cameroon%20under%20a%20national%20%5C%22treat%20all%5C%22%20policy%3A%20a%20cross-sectional%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20M.%22%2C%22lastName%22%3A%22Filiatreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20V.%22%2C%22lastName%22%3A%22Ebasone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dzudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20W.%22%2C%22lastName%22%3A%22Pence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Wainberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Pefura-Yone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Rapid%20antiretroviral%20treatment%20%28ART%29%20initiation%20reduces%20time%20from%20HIV%20infection%20to%20viral%20suppression%2C%20decreasing%20HIV%20transmission%20risk.%20Mental%20health%20symptoms%20may%20influence%20timing%20of%20ART%20initiation.%20This%20study%20estimated%20the%20prevalence%20of%20ART%20initiation%20at%20enrolment%20into%20HIV%20care%20and%20the%20relationship%20between%20mental%20health%20and%20ART%20initiation%20at%20enrolment%20into%20HIV%20care.%20METHODS%3A%20We%20conducted%20interviews%20with%20426%20individuals%20initiating%20HIV%20care%20in%20Cameroon%20between%20June%202019%20and%20March%202020%20to%20estimate%20the%20association%20between%20mental%20health%20and%20timing%20of%20ART%20initiation.%20Depression%20%28Patient%20Health%20Questionnaire-9%3B%20cut-point%2010%29%2C%20anxiety%20%28Generalized%20Anxiety%20Disorder-7%3B%20cut-point%2010%29%2C%20post-traumatic%20stress%20disorder%20%28PTSD%29%20%28PTSD%20Checklist%20for%20DSM-5%3B%20cut-point%2031%29%20and%20harmful%20alcohol%20use%20%28Alcohol%20Use%20Disorders%20Identification%20Test%3B%20cut-point%2016%29%20were%20dichotomized%20to%20represent%20those%20with%20and%20without%20each%20exposure%20at%20first%20HIV%20care%20appointment.%20Date%20of%20ART%20initiation%20%28date%20ART%20prescribed%29%20was%20ascertained%20from%20medical%20records.%20Separate%20multivariable%20log-binomial%20regression%20models%20were%20used%20to%20estimate%20the%20association%20between%20mental%20health%20exposures%20and%20ART%20initiation%20at%20enrolment%20into%20care.%20RESULTS%20AND%20DISCUSSION%3A%20Overall%2C%2087%25%20initiated%20ART%20at%20enrolment%20into%20HIV%20care.%20Approximately%2020%25%20reported%20depressive%20symptoms%2C%2015%25%20reported%20PTSD%20symptoms%2C%2012%25%20reported%20anxiety%20symptoms%20and%2013%25%20reported%20harmful%20alcohol%20use.%20In%20multivariable%20analyses%2C%20individuals%20with%20moderate%20to%20severe%20depressive%20symptoms%20had%201.7%20%2895%25%20confidence%20interval%20%5BCI%5D%201.1%2C%202.7%29%20times%20the%20prevalence%20of%20not%20initiating%20ART%20at%20enrolment%20into%20HIV%20care%20compared%20to%20those%20with%20no%20or%20mild%20depressive%20symptoms.%20Those%20with%20symptoms%20of%20PTSD%2C%20compared%20to%20those%20without%2C%20had%201.9%20%2895%25%20CI%201.2%2C%202.9%29%20times%20the%20prevalence%20of%20not%20initiating%20ART%20at%20enrolment%20into%20HIV%20care.%20Symptoms%20of%20anxiety%20or%20harmful%20drinking%20were%20not%20associated%20with%20ART%20initiation%20at%20enrolment%20into%20HIV%20care%20in%20multivariable%20models.%20CONCLUSIONS%3A%20Symptoms%20of%20depression%20and%20PTSD%20were%20associated%20with%20lower%20prevalence%20of%20ART%20initiation%20at%20enrolment%20into%20HIV%20care%20among%20this%20sample%20of%20individuals%20initiating%20HIV%20care%20in%20Cameroon%20under%20a%20%5C%22treat%20all%5C%22%20policy.%20Research%20should%20examine%20barriers%20to%20timely%20ART%20initiation%2C%20whether%20incorporating%20mental%20health%20services%20into%20HIV%20care%20improves%20timely%20ART%20initiation%2C%20and%20whether%20untreated%20symptoms%20of%20depression%20and%20PTSD%20drive%20suboptimal%20HIV%20care%20outcomes.%22%2C%22date%22%3A%22Nov%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25842%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A34%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22YR2TD7UX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thompson%20et%20al.%22%2C%22parsedDate%22%3A%222021-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EThompson%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMorgan%2C%20C.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENgimbi%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMwandagalirwa%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERavelomanana%2C%20N.%20L.%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Arresting%20vertical%20transmission%20of%20hepatitis%20B%20virus%20%28AVERT-HBV%29%20in%20pregnant%20women%20and%20their%20neonates%20in%20the%20Democratic%20Republic%20of%20the%20Congo%3A%20a%20feasibility%20study.%20%3Ci%3ELancet%20Glob%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E9%3C%5C%2Fi%3E%20%2811%29%2C%20S.%20e1600%26%23x2013%3Be1609.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2214-109X%2821%2900304-1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2214-109X%2821%2900304-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Arresting%20vertical%20transmission%20of%20hepatitis%20B%20virus%20%28AVERT-HBV%29%20in%20pregnant%20women%20and%20their%20neonates%20in%20the%20Democratic%20Republic%20of%20the%20Congo%3A%20a%20feasibility%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20E.%22%2C%22lastName%22%3A%22Morgan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Ngimbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Mwandagalirwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20L.%20R.%22%2C%22lastName%22%3A%22Ravelomanana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tabala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Fathy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Kawende%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Muwonga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Misingi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Mbendi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Luhata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Jhaveri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Cloherty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Kaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20B.%22%2C%22lastName%22%3A%22Parr%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Hepatitis%20B%20virus%20%28HBV%29%20remains%20endemic%20throughout%20sub-Saharan%20Africa%20despite%20the%20widespread%20availability%20of%20effective%20childhood%20vaccines.%20In%20the%20Democratic%20Republic%20of%20the%20Congo%2C%20HBV%20treatment%20and%20birth-dose%20vaccination%20programmes%20are%20not%20established.%20We%2C%20therefore%2C%20aimed%20to%20evaluate%20the%20feasibility%20and%20acceptability%20of%20adding%20HBV%20testing%20and%20treatment%20of%20pregnant%20women%20as%20well%20as%20the%20birth-dose%20vaccination%20of%20HBV-exposed%20infants%20to%20the%20HIV%20prevention%20of%20mother-to-child%20transmission%20programme%20infrastructure%20in%20the%20Democratic%20Republic%20of%20the%20Congo.%20METHODS%3A%20We%20did%20a%20feasibility%20study%20in%20two%20maternity%20centres%20in%20Kinshasa%3A%20Binza%20and%20Kingasani.%20Using%20the%20already%20established%20HIV%20prevention%20of%20mother-to-child%20transmission%20programme%20at%20these%20two%20maternity%20centres%2C%20we%20screened%20pregnant%20women%20for%20HBV%20infection%20at%20routine%20prenatal%20care%20registration.%20Those%20who%20tested%20positive%20and%20had%20a%20gestational%20age%20of%2024%20weeks%20or%20less%20were%20included%20in%20this%20study.%20Eligible%20pregnant%20women%20with%20a%20high%20viral%20load%20%28%3E%5C%2F%3D200%20000%20IU%5C%2FmL%20or%20HBeAg%20positivity%2C%20or%20both%29%20were%20considered%20as%20having%20HBV%20of%20high%20risk%20of%20mother-to-child%20transmission%20and%20initiated%20on%20oral%20tenofovir%20disoproxil%20fumarate%20%28300%20mg%5C%2Fday%29%20between%2028%20weeks%20and%2032%20weeks%20of%20gestation%20and%20continued%20through%2012%20weeks%20post%20partum.%20All%20HBV-exposed%20infants%20received%20a%20birth-dose%20of%20monovalent%20HBV%20vaccine%20%28Euvax-B%20Pediatric%3A%20Sanofi%20Pasteur%2C%20Seoul%2C%20South%20Korea%3B%200.5%20mL%29%20within%2024%20h%20of%20life.%20All%20women%20were%20followed%20up%20for%2024%20weeks%20post%20partum%2C%20when%20they%20completed%20an%20exit%20questionnaire%20that%20assessed%20the%20acceptability%20of%20study%20procedures.%20The%20primary%20outcomes%20were%20the%20feasibility%20of%20screening%20pregnant%20women%20to%20identify%20those%20at%20high%20risk%20for%20HBV%20mother-to-child%20transmission%20and%20to%20provide%20them%20with%20antiviral%20prophylaxis%2C%20the%20feasibility%20of%20administrating%20the%20birth-dose%20vaccine%20to%20exposed%20infants%2C%20and%20the%20acceptability%20of%20this%20prevention%20programme.%20This%20study%20is%20registered%20with%20ClinicalTrials.gov%2C%20NCT03567382.%20FINDINGS%3A%20Between%20Sept%2024%2C%202018%2C%20and%20Feb%2022%2C%202019%2C%204016%20women%20were%20approached%20and%20screened.%20Of%20these%20pregnant%20women%2C%20109%20%282.7%25%29%20were%20positive%20for%20HBsAg.%20Of%20the%20109%20women%2C%2091%20%2883%25%29%20met%20the%20eligibility%20criteria%20for%20participation.%20However%2C%20only%20data%20from%2090%20women-excluding%20one%20woman%20who%20had%20a%20false%20pregnancy-were%20included%20in%20the%20study%20analysis.%20The%20median%20overall%20age%20of%20the%20enrolled%20women%20was%2031%20years%20%28IQR%2025-34%29%20and%20the%20median%20overall%20gestational%20age%20was%2019%20weeks%20%2815-22%29.%20Ten%20%2811%25%29%20of%2091%20women%20evaluated%20had%20high-risk%20HBV%20infection.%20Nine%20%2890%25%29%20of%20the%20ten%20pregnant%20women%20with%20high-risk%20HBV%20infection%20received%20tenofovir%20disoproxil%20fumarate%20and%20one%20%2810%25%29%20refused%20therapy%20and%20withdrew%20from%20the%20study%3B%20five%20%2856%25%29%20of%20the%20nine%20women%20achieved%20viral%20suppression%20%28ie%2C%20%3C200%20000%20IU%5C%2FmL%29%20on%20tenofovir%20disoproxil%20fumarate%20therapy%20by%20the%20time%20of%20delivery%20and%20the%20remaining%20four%20%2844%25%29%20had%20decreased%20viral%20loads%20from%20enrolment%20to%20delivery.%20A%20total%20of%2088%20infants%20were%20born%20to%20the%2090%20enrolled%20women.%20Of%20the%2088%20infants%2C%2060%20%2868%25%29%20received%20a%20birth-dose%20vaccine%3B%20of%20these%2C%2046%20%2877%25%29%20received%20a%20timely%20birth-dose%20vaccine.%20No%20cases%20of%20HBV%20mother-to-child%20transmission%20were%20observed.%20No%20serious%20adverse%20events%20associated%20with%20tenofovir%20disoproxil%20fumarate%20nor%20with%20the%20birth-dose%20vaccine%20were%20reported.%20Only%20one%20%2811%25%29%20of%20nine%20women%20reported%20dizziness%20during%20the%20course%20of%20tenofovir%20disoproxil%20fumarate%20therapy.%20The%20study%20procedures%20were%20considered%20highly%20acceptable%20%28%3E80%25%29%20among%20mothers.%20INTERPRETATION%3A%20Adding%20HBV%20screening%20and%20treatment%20of%20pregnant%20women%20and%20infant%20birth-dose%20vaccination%20to%20existing%20HIV%20prevention%20of%20mother-to-child%20transmission%20platforms%20is%20feasible%20in%20countries%20such%20as%20the%20Democratic%20Republic%20of%20the%20Congo.%20Birth-dose%20vaccination%20against%20HBV%20infection%20integrated%20within%20the%20current%20Expanded%20Programme%20on%20Immunisation%20and%20HIV%20prevention%20of%20mother-to-child%20transmission%20programme%20could%20accelerate%20progress%20toward%20HBV%20elimination%20in%20Africa.%20FUNDING%3A%20Gillings%20Innovation%20Laboratory%20award%20and%20the%20National%20Institutes%20of%20Health.%20TRANSLATIONS%3A%20For%20the%20French%20and%20Lingala%20translations%20of%20the%20abstract%20see%20Supplementary%20Materials%20section.%22%2C%22date%22%3A%22Nov%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2214-109X%2821%2900304-1%22%2C%22ISSN%22%3A%222214-109X%20%28Electronic%29%202214-109X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A16%3A02Z%22%7D%7D%2C%7B%22key%22%3A%225XU8JFME%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Irvine%20et%20al.%22%2C%22parsedDate%22%3A%222021-10-12%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIrvine%2C%20M.%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERobertson%2C%20M.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENash%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKulkarni%2C%20S.%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBraunstein%2C%20S.%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20HIV%20Care%20Coordination%20promotes%20care%20re-engagement%20and%20viral%20suppression%20among%20people%20who%20have%20been%20out%20of%20HIV%20medical%20care%3A%20an%20observational%20effectiveness%20study%20using%20a%20surveillance-based%20contemporaneous%20comparison%20group.%20%3Ci%3EAIDS%20Res%20Ther%3C%5C%2Fi%3E%2C%20%3Ci%3E18%3C%5C%2Fi%3E%20%281%29%2C%20S.%2070.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12981-021-00398-0%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12981-021-00398-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20Care%20Coordination%20promotes%20care%20re-engagement%20and%20viral%20suppression%20among%20people%20who%20have%20been%20out%20of%20HIV%20medical%20care%3A%20an%20observational%20effectiveness%20study%20using%20a%20surveillance-based%20contemporaneous%20comparison%20group%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20K.%22%2C%22lastName%22%3A%22Irvine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20M.%22%2C%22lastName%22%3A%22Robertson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20G.%22%2C%22lastName%22%3A%22Kulkarni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20L.%22%2C%22lastName%22%3A%22Braunstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Levin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Medical%20care%20re-engagement%20is%20critical%20to%20suppressing%20viral%20load%20and%20preventing%20HIV%20transmission%2C%20morbidity%20and%20mortality%2C%20yet%20few%20rigorous%20intervention%20studies%20address%20this%20outcome.%20We%20assessed%20the%20effectiveness%20of%20a%20Ryan%20White%20Part%20A-funded%20HIV%20Care%20Coordination%20Program%20relative%20to%20%27usual%20care%2C%27%20for%20short-term%20care%20re-engagement%20and%20viral%20suppression%20among%20people%20without%20recent%20HIV%20medical%20care.%20METHODS%3A%20The%20Care%20Coordination%20Program%20was%20launched%20in%202009%20at%2028%20hospitals%2C%20health%20centers%2C%20and%20community-based%20organizations%20in%20New%20York%20City.%20Designed%20for%20people%20with%20HIV%20%28PWH%29%20experiencing%20or%20at%20risk%20for%20poor%20HIV%20outcomes%2C%20the%20Care%20Coordination%20Program%20provides%20long-term%2C%20comprehensive%20medical%20case%20management%20utilizing%20interdisciplinary%20teams%2C%20structured%20health%20education%20and%20patient%20navigation.%20The%20intervention%20was%20implemented%20as%20a%20safety-net%20services%20program%2C%20without%20a%20designated%20comparison%20group.%20To%20evaluate%20it%20retrospectively%2C%20we%20created%20an%20observational%2C%20matched%20cohort%20of%20clients%20and%20controls.%20Using%20the%20HIV%20surveillance%20registry%2C%20we%20identified%20individuals%20meeting%20program%20eligibility%20criteria%20from%20December%201%2C%202009%20to%20March%2031%2C%202013%20and%20excluded%20those%20dying%20prior%20to%2012%20months%20of%20follow-up.%20We%20then%20matched%20clients%20to%20controls%20on%20baseline%20status%20%28lacking%20evidence%20of%20viral%20suppression%2C%20consistently%20suppressed%2C%20inconsistently%20suppressed%2C%20or%20newly%20diagnosed%20in%20the%20past%2012%20months%29%2C%20start%20of%20follow-up%20and%20propensity%20score.%20For%20this%20analysis%2C%20we%20limited%20to%20those%20out%20of%20care%20at%20baseline%20%28defined%20as%20having%20no%20viral%20load%20test%20in%20the%2012%20months%20pre-enrollment%29%20and%20still%20residing%20within%20jurisdiction%20%28defined%20as%20having%20a%20viral%20load%20or%20CD4%20test%20reported%20to%20local%20surveillance%20and%20dated%20within%20the%2012-month%20follow-up%20period%29.%20Using%20a%20GEE%20model%20with%20binary%20error%20distribution%20and%20logit%20link%2C%20we%20compared%20odds%20of%20care%20re-engagement%20%28defined%20as%20having%20%3E%5C%2F%3D%202%20laboratory%20events%20%3E%5C%2F%3D%2090%20days%20apart%29%20and%20viral%20suppression%20%28defined%20as%20having%20HIV%20RNA%20%3C%5C%2F%3D%20200%20copies%5C%2FmL%20on%20the%20most%20recent%20viral%20load%20test%29%20at%2012-month%20follow-up.%20RESULTS%3A%20Among%20326%20individuals%20out%20of%20care%20at%20baseline%2C%2087.2%25%20of%20clients%20and%2048.2%25%20of%20controls%20achieved%20care%20re-engagement%20%28Odds%20Ratio%3A%204.53%3B%2095%25CI%202.66%2C%207.71%29%3B%2058.3%25%20of%20clients%20and%2049.3%25%20of%20controls%20achieved%20viral%20suppression%20%28Odds%20Ratio%3A%202.05%3B%2095%25CI%201.30%2C%203.23%29.%20CONCLUSIONS%3A%20HIV%20Care%20Coordination%20shows%20evidence%20of%20effectiveness%20for%20care%20and%20treatment%20re-engagement.%22%2C%22date%22%3A%22Oct%2012%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12981-021-00398-0%22%2C%22ISSN%22%3A%221742-6405%20%28Electronic%29%201742-6405%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A46%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22FTS7EN6W%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Riou%20et%20al.%22%2C%22parsedDate%22%3A%222021-10-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERiou%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDupont%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBertagnolio%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGupta%2C%20R.%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKouyos%2C%20R.%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Drivers%20of%20HIV-1%20drug%20resistance%20to%20non-nucleoside%20reverse-transcriptase%20inhibitors%20%28NNRTIs%29%20in%20nine%20southern%20African%20countries%3A%20a%20modelling%20study.%20%3Ci%3EBMC%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%20%281%29%2C%20S.%201042.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-021-06757-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-021-06757-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Drivers%20of%20HIV-1%20drug%20resistance%20to%20non-nucleoside%20reverse-transcriptase%20inhibitors%20%28NNRTIs%29%20in%20nine%20southern%20African%20countries%3A%20a%20modelling%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Riou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Dupont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bertagnolio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20K.%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Kouyos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22L.%20Althaus%20C%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20The%20rise%20of%20HIV-1%20drug%20resistance%20to%20non-nucleoside%20reverse-transcriptase%20inhibitors%20%28NNRTI%29%20threatens%20antiretroviral%20therapy%27s%20long-term%20success%20%28ART%29.%20NNRTIs%20will%20remain%20an%20essential%20drug%20for%20the%20management%20of%20HIV-1%20due%20to%20safety%20concerns%20associated%20with%20integrase%20inhibitors.%20We%20fitted%20a%20dynamic%20transmission%20model%20to%20historical%20data%20from%202000%20to%202018%20in%20nine%20countries%20of%20southern%20Africa%20to%20understand%20the%20mechanisms%20that%20have%20shaped%20the%20HIV-1%20epidemic%20and%20the%20rise%20of%20pretreatment%20NNRTI%20resistance.%20METHODS%3A%20We%20included%20data%20on%20HIV-1%20prevalence%2C%20ART%20coverage%2C%20HIV-related%20mortality%2C%20and%20survey%20data%20on%20pretreatment%20NNRTI%20resistance%20from%20nine%20southern%20Africa%20countries%20from%20a%20systematic%20review%2C%20UNAIDS%20and%20World%20Bank.%20Using%20a%20Bayesian%20hierarchical%20framework%2C%20we%20developed%20a%20dynamic%20transmission%20model%20linking%20data%20on%20the%20HIV-1%20epidemic%20to%20survey%20data%20on%20NNRTI%20drug%20resistance%20in%20each%20country.%20We%20estimated%20the%20proportion%20of%20resistance%20attributable%20to%20unregulated%2C%20off-programme%20use%20of%20ART.%20We%20examined%20each%20national%20ART%20programme%27s%20vulnerability%20to%20NNRTI%20resistance%20by%20defining%20a%20fragility%20index%3A%20the%20ratio%20of%20the%20rate%20of%20NNRTI%20resistance%20emergence%20during%20first-line%20ART%20over%20the%20rate%20of%20switching%20to%20second-line%20ART.%20We%20explored%20associations%20between%20fragility%20and%20characteristics%20of%20the%20health%20system%20of%20each%20country.%20RESULTS%3A%20The%20model%20reliably%20described%20the%20dynamics%20of%20the%20HIV-1%20epidemic%20and%20NNRTI%20resistance%20in%20each%20country.%20Predicted%20levels%20of%20resistance%20in%202018%20ranged%20between%203.3%25%20%2895%25%20credible%20interval%201.9-7.1%29%20in%20Mozambique%20and%2025.3%25%20%2817.9-33.8%29%20in%20Eswatini.%20The%20proportion%20of%20pretreatment%20NNRTI%20resistance%20attributable%20to%20unregulated%20antiretroviral%20use%20ranged%20from%206%25%20%282-14%29%20in%20Eswatini%20to%2064%25%20%2826-85%29%20in%20Mozambique.%20The%20fragility%20index%20was%20low%20in%20Botswana%20%280.01%3B%200.0-0.11%29%20but%20high%20in%20Namibia%20%280.48%3B%200.16-10.17%29%2C%20Eswatini%20%280.64%3B%200.23-11.8%29%20and%20South%20Africa%20%281.21%3B%200.83-9.84%29.%20The%20combination%20of%20high%20fragility%20of%20ART%20programmes%20and%20high%20ART%20coverage%20levels%20was%20associated%20with%20a%20sharp%20increase%20in%20pretreatment%20NNRTI%20resistance.%20CONCLUSIONS%3A%20This%20comparison%20of%20nine%20countries%20shows%20that%20pretreatment%20NNRTI%20resistance%20can%20be%20controlled%20despite%20high%20ART%20coverage%20levels.%20This%20was%20the%20case%20in%20Botswana%2C%20Mozambique%2C%20and%20Zambia%2C%20most%20likely%20because%20of%20better%20HIV%20care%20delivery%2C%20including%20rapid%20switching%20to%20second-line%20ART%20of%20patients%20failing%20first-line%20ART.%22%2C%22date%22%3A%22Oct%207%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12879-021-06757-6%22%2C%22ISSN%22%3A%221471-2334%20%28Electronic%29%201471-2334%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A42%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22274VWRZX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22McGinnis%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcGinnis%2C%20K.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESkanderson%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJustice%2C%20A.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAkgun%2C%20K.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETate%2C%20J.%20P.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20HIV%20care%20using%20differentiated%20service%20delivery%20during%20the%20COVID-19%20pandemic%3A%20a%20nationwide%20cohort%20study%20in%20the%20US%20Department%20of%20Veterans%20Affairs.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E24%20Suppl%206%3C%5C%2Fi%3E%20%28Suppl%206%29%2C%20S.%20e25810.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25810%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25810%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20care%20using%20differentiated%20service%20delivery%20during%20the%20COVID-19%20pandemic%3A%20a%20nationwide%20cohort%20study%20in%20the%20US%20Department%20of%20Veterans%20Affairs%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22McGinnis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Skanderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Akgun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Tate%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22King%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Rentsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Marconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Hsieh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Ruser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Kidwai-Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Yousefzadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Erdos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20S.%22%2C%22lastName%22%3A%22Park%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20The%20Department%20of%20Veterans%20Affairs%20%28VA%29%20is%20the%20largest%20provider%20of%20HIV%20care%20in%20the%20United%20States.%20Changes%20in%20healthcare%20delivery%20became%20necessary%20with%20the%20COVID-19%20pandemic.%20We%20compared%20HIV%20healthcare%20delivery%20during%20the%20first%20year%20of%20the%20COVID-19%20pandemic%20to%20a%20prior%20similar%20calendar%20period.%20METHODS%3A%20We%20included%2027%2C674%20people%20with%20HIV%20%28PWH%29%20enrolled%20in%20the%20Veterans%20Aging%20Cohort%20Study%20prior%20to%201%20March%202019%2C%20with%20%3E%5C%2F%3D1%20healthcare%20encounter%20from%201%20March%202019%20to%2029%20February%202020%20%282019%29%20and%5C%2For%201%20March%202020%20to%2028%20February%202021%20%282020%29.%20We%20counted%20monthly%20general%20medicine%5C%2Finfectious%20disease%20%28GM%5C%2FID%29%20clinic%20visits%20and%20HIV-1%20RNA%20viral%20load%20%28VL%29%20tests.%20We%20determined%20the%20percentage%20with%20%3E%5C%2F%3D1%20clinic%20visit%20%28in-person%20vs.%20telephone%5C%2Fvideo%20%5Bvirtual%5D%29%20and%20%3E%5C%2F%3D1%20VL%20test%20%28detectable%20vs.%20suppressed%29%20for%202019%20and%202020.%20Using%20pharmacy%20records%2C%20we%20summarized%20antiretroviral%20%28ARV%29%20medication%20refill%20length%20%28%3C90%20vs.%20%3E%5C%2F%3D90%20days%29%20and%20monthly%20ARV%20coverage.%20RESULTS%3A%20Most%20patients%20had%20%3E%5C%2F%3D1%20GM%5C%2FID%20visit%20in%202019%20%2896%25%29%20and%202020%20%2895%25%29.%20For%202019%2C%2027%25%20of%20visits%20were%20virtual%20compared%20to%2064%25%20in%202020.%20In%202019%2C%2082%25%20had%20VL%20measured%20compared%20to%2074%25%20in%202020.%20Of%20those%20with%20VL%20measured%2C%2092%25%20and%2091%25%20had%20suppressed%20VL%20in%202019%20and%202020.%20ARV%20refills%20for%20%3E%5C%2F%3D90%20days%20increased%20from%2039%25%20in%202019%20to%2051%25%20in%202020.%20ARV%20coverage%20was%20similar%20for%20all%20months%20of%202019%20and%202020%20ranging%20from%2076%25%20to%2080%25%20except%20for%20March%202019%20%2872%25%29.%20Women%20were%20less%20likely%20than%20men%20to%20be%20on%20ARVs%20or%20to%20have%20a%20VL%20test%20in%20both%20years.%20CONCLUSIONS%3A%20During%20the%20COVID-19%20pandemic%2C%20the%20VA%20increased%20the%20use%20of%20virtual%20visits%20and%20longer%20ARV%20refills%2C%20while%20maintaining%20a%20high%20percentage%20of%20patients%20with%20suppressed%20VL%20among%20those%20with%20VL%20measured.%20Despite%20decreased%20in-person%20services%20during%20the%20pandemic%2C%20access%20to%20ARVs%20was%20not%20disrupted.%20More%20follow-up%20time%20is%20needed%20to%20determine%20whether%20overall%20health%20was%20impacted%20by%20the%20use%20of%20differentiated%20service%20delivery%20and%20to%20evaluate%20whether%20a%20long-term%20shift%20to%20increased%20virtual%20healthcare%20could%20be%20beneficial%2C%20particularly%20for%20PWH%20in%20rural%20areas%20or%20with%20transportation%20barriers.%20Programmes%20to%20increase%20ARV%20use%20and%20VL%20testing%20for%20women%20are%20needed.%22%2C%22date%22%3A%22Oct%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25810%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A46%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22TK4X5ZP8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Amorim%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAmorim%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETao%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELotspeich%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShaw%2C%20P.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELumley%2C%20T.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Two-Phase%20Sampling%20Designs%20for%20Data%20Validation%20in%20Settings%20with%20Covariate%20Measurement%20Error%20and%20Continuous%20Outcome.%20%3Ci%3EJ%20R%20Stat%20Soc%20Ser%20A%20Stat%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E184%3C%5C%2Fi%3E%20%284%29%2C%20S.%201368%26%23x2013%3B1389.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Frssa.12689%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Frssa.12689%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Two-Phase%20Sampling%20Designs%20for%20Data%20Validation%20in%20Settings%20with%20Covariate%20Measurement%20Error%20and%20Continuous%20Outcome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Tao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Lotspeich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Lumley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22Measurement%20errors%20are%20present%20in%20many%20data%20collection%20procedures%20and%20can%20harm%20analyses%20by%20biasing%20estimates.%20To%20correct%20for%20measurement%20error%2C%20researchers%20often%20validate%20a%20subsample%20of%20records%20and%20then%20incorporate%20the%20information%20learned%20from%20this%20validation%20sample%20into%20estimation.%20In%20practice%2C%20the%20validation%20sample%20is%20often%20selected%20using%20simple%20random%20sampling%20%28SRS%29.%20However%2C%20SRS%20leads%20to%20inefficient%20estimates%20because%20it%20ignores%20information%20on%20the%20error-prone%20variables%2C%20which%20can%20be%20highly%20correlated%20to%20the%20unknown%20truth.%20Applying%20and%20extending%20ideas%20from%20the%20two-phase%20sampling%20literature%2C%20we%20propose%20optimal%20and%20nearly-optimal%20designs%20for%20selecting%20the%20validation%20sample%20in%20the%20classical%20measurement-error%20framework.%20We%20target%20designs%20to%20improve%20the%20efficiency%20of%20model-based%20and%20design-based%20estimators%2C%20and%20show%20how%20the%20resulting%20designs%20compare%20to%20each%20other.%20Our%20results%20suggest%20that%20sampling%20schemes%20that%20extract%20more%20information%20from%20the%20error-prone%20data%20are%20substantially%20more%20efficient%20than%20SRS%2C%20for%20both%20design-%20and%20model-based%20estimators.%20The%20optimal%20procedure%2C%20however%2C%20depends%20on%20the%20analysis%20method%2C%20and%20can%20differ%20substantially.%20This%20is%20supported%20by%20theory%20and%20simulations.%20We%20illustrate%20the%20various%20designs%20using%20data%20from%20an%20HIV%20cohort%20study.%22%2C%22date%22%3A%22Oct%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Frssa.12689%22%2C%22ISSN%22%3A%220964-1998%20%28Print%29%201467-985X%20%28Electronic%29%200964-1998%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A51%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22SZWKFUXW%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stover%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStover%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGlaubius%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKassanjee%2C%20R.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDugdale%2C%20C.%20M.%3C%5C%2Fspan%3E%20%282021%29.%20Updates%20to%20the%20Spectrum%5C%2FAIM%20model%20for%20the%20UNAIDS%202020%20HIV%20estimates.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E24%20Suppl%205%3C%5C%2Fi%3E%20%28Suppl%205%29%2C%20S.%20e25778.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25778%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25778%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Updates%20to%20the%20Spectrum%5C%2FAIM%20model%20for%20the%20UNAIDS%202020%20HIV%20estimates%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Stover%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Glaubius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Dugdale%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20The%20Spectrum%5C%2FAIM%20model%20is%20used%20by%20national%20HIV%20programs%20and%20UNAIDS%20to%20prepare%20annual%20estimates%20of%20key%20HIV%20indicators.%20This%20article%20describes%20key%20updates%20to%20paediatric%20and%20adult%20models%20for%20the%202021%20round%20of%20HIV%20estimates.%20METHODS%3A%20Potential%20updates%20to%20Spectrum%20arise%20due%20to%20newly%20available%20data%2C%20new%20analyses%20of%20existing%20data%2C%20and%20the%20need%20for%20new%20issues%20to%20be%20addressed.%20Updates%20are%20guided%20by%20experts%20through%20the%20UNAIDS%20Reference%20Group%20on%20Estimates%2C%20Modelling%20and%20Projections.%20Changes%20are%20tested%20and%20assessed%20for%20impact%20before%20being%20accepted%20into%20the%20final%20model.%20RESULTS%3A%20Spectrum%20tracks%20children%20living%20with%20HIV%20by%20CD4%25%20for%20ages%200-4%20and%20CD4%20count%20for%20ages%205-14.%20Data%20from%20IeDEA%20treatment%20sites%20have%20been%20used%20to%20map%20the%20transition%20from%20CD4%25%20to%20CD4%20count%20at%20age%205.%20Breastfeeding%20patterns%20in%20sub-Saharan%20Africa%20have%20been%20updated%20with%20the%20latest%20survey%20data%20and%20estimates%20of%20continuation%20on%20antiretroviral%20therapy%20%28ART%29%20with%20breastfeeding%20have%20been%20revised%20based%20on%20recent%20studies.%20Model%20assumptions%20about%20the%20CD4%20counts%20of%20people%20who%20drop%20out%20of%20ART%20have%20been%20revised%20to%20account%20for%20CD4%20count%20increases%20while%20on%20treatment.%20If%20available%2C%20monthly%20data%20on%20numbers%20on%20ART%20can%20now%20be%20used%20to%20estimate%20the%20effects%20of%20COVID-19-related%20disruptions%20during%202020.%20CONCLUSIONS%3A%20These%20changes%20are%20intended%20to%20provide%20more%20accurate%20estimates%20of%20HIV%20burden.%20The%20effects%20of%20these%20changes%20on%20paediatric%20indicators%20are%20small%20except%20in%20countries%20with%20new%20surveys%20that%20might%20have%20updated%20patterns%20of%20breastfeeding.%20Changes%20to%20the%20adult%20model%20have%20little%20effect%20on%20total%20new%20infections.%20AIDS-related%20deaths%20will%20be%20somewhat%20lower%20in%20countries%20that%20have%20data%20on%20ART%20drop%20out%20but%20might%20be%20increased%20by%20HIV%20care%20disruptions%20due%20to%20COVID-19.%20The%20updated%20model%20uses%20newly%20available%20data%20to%20improve%20the%20estimation%20of%20paediatric%20and%20adult%20HIV%20indicators.%22%2C%22date%22%3A%22Sep%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25778%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A51%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22H7GYRRYL%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jaquet%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJaquet%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuula%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEkouevi%2C%20D.%20K.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWandeler%2C%20G.%3C%5C%2Fspan%3E%20%282021%29.%20Elimination%20of%20Viral%20Hepatitis%20in%20Low%20and%20Middle-Income%20Countries%3A%20Epidemiological%20Research%20Gaps.%20%3Ci%3ECurr%20Epidemiol%20Rep%3C%5C%2Fi%3E%2C%20%3Ci%3E8%3C%5C%2Fi%3E%20%283%29%2C%20S.%2089%26%23x2013%3B96.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40471-021-00273-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40471-021-00273-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Elimination%20of%20Viral%20Hepatitis%20in%20Low%20and%20Middle-Income%20Countries%3A%20Epidemiological%20Research%20Gaps%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20K.%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Wandeler%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%20OF%20REVIEW%3A%20The%20purpose%20of%20our%20review%20was%20to%20summarize%20current%20recommendations%20on%20testing%20strategies%2C%20antiviral%20therapy%20eligibility%20and%20monitoring%2C%20and%20prevention%20of%20mother-to-child%20transmission%20of%20chronic%20hepatitis%20B%20virus%20%28HBV%29%20and%20hepatitis%20C%20virus%20%28HCV%29%20infections%2C%20and%20to%20highlight%20major%20research%20gaps%20in%20low%20and%20middle-income%20countries%20%28LMIC%29%2C%20with%20a%20particular%20focus%20on%20sub-Saharan%20Africa%20%28SSA%29.%20RECENT%20FINDINGS%3A%20While%20data%20on%20the%20prevalence%20of%20HBV%20and%20HCV%20infections%20in%20LMIC%20are%20increasing%2C%20current%20knowledge%20on%20liver-related%20complications%20as%20well%20as%20on%20treatment%20outcomes%20remains%20limited.%20Furthermore%2C%20very%20little%20information%20is%20available%20on%20the%20feasibility%20and%20cost-effectiveness%20of%20large-scale%20testing%20and%20management%20strategies%20in%20high-prevalence%20settings.%20The%20availability%20of%20policy-relevant%20data%20is%20particularly%20scarce%20in%20SSA%2C%20which%20accounts%20for%20a%20significant%20part%20of%20the%20global%20burden%20of%20chronic%20viral%20hepatitis.%20SUMMARY%3A%20Current%20recommendations%20on%20the%20management%20and%20monitoring%20of%20chronic%20viral%20hepatitis%20rely%20mainly%20on%20data%20from%20high-income%20settings.%20The%20global%20elimination%20of%20viral%20hepatitis%20will%20only%20be%20achieved%20if%20prevention%2C%20testing%2C%20and%20treatment%20strategies%20tailored%20to%20specific%20LMIC%20are%20implemented.%20In%20order%20to%20inform%20scalable%20and%20cost-effective%20interventions%2C%20dedicated%20research%20initiatives%20have%20to%20be%20undertaken.%20Future%20studies%20will%20have%20to%20include%20the%20evaluation%20of%20innovative%20testing%20strategies%2C%20the%20validation%20of%20simplified%20methods%20to%20diagnose%20liver%20cirrhosis%20and%20hepatocellular%20carcinoma%2C%20and%20the%20monitoring%20of%20long-term%20treatment%20outcomes%20and%20toxicity.%20In%20addition%2C%20national%20plans%20to%20achieve%20the%20elimination%20of%20HBV%20mother-to-child%20transmission%20are%20urgently%20needed%2C%20including%20effective%20ways%20to%20test%20pregnant%20women%2C%20treat%20those%20who%20are%20eligible%2C%20and%20ensure%20birth%20dose%20vaccination%20is%20given%20to%20all%20newborns.%22%2C%22date%22%3A%22Sep%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs40471-021-00273-6%22%2C%22ISSN%22%3A%222196-2995%20%28Print%29%202196-2995%20%28Electronic%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A44%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22EZQ7V2ZQ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wei%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWei%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGaisa%2C%20M.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ED%26%23x2019%3BSouza%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EXia%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGiuliano%2C%20A.%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Epidemiology%20of%20anal%20human%20papillomavirus%20infection%20and%20high-grade%20squamous%20intraepithelial%20lesions%20in%2029%20900%20men%20according%20to%20HIV%20status%2C%20sexuality%2C%20and%20age%3A%20a%20collaborative%20pooled%20analysis%20of%2064%20studies.%20%3Ci%3ELancet%20HIV%3C%5C%2Fi%3E%2C%20%3Ci%3E8%3C%5C%2Fi%3E%20%289%29%2C%20S.%20e531%26%23x2013%3Be543.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2821%2900108-9%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2821%2900108-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Epidemiology%20of%20anal%20human%20papillomavirus%20infection%20and%20high-grade%20squamous%20intraepithelial%20lesions%20in%2029%20900%20men%20according%20to%20HIV%20status%2C%20sexuality%2C%20and%20age%3A%20a%20collaborative%20pooled%20analysis%20of%2064%20studies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Wei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20M.%22%2C%22lastName%22%3A%22Gaisa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22D%27Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Xia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20R.%22%2C%22lastName%22%3A%22Giuliano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20E.%22%2C%22lastName%22%3A%22Hawes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20H.%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20G.%22%2C%22lastName%22%3A%22Dona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20E.%22%2C%22lastName%22%3A%22Goldstone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20F.%22%2C%22lastName%22%3A%22Schim%20van%20der%20Loeff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Neukam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Meites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20M.%22%2C%22lastName%22%3A%22Poynten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Dai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20D.%22%2C%22lastName%22%3A%22Combes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Wieland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Burgos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20J.%22%2C%22lastName%22%3A%22Wilkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Hernandez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Iribarren%20Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Hidalgo-Tenorio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Valencia%20Arredondo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20G.%22%2C%22lastName%22%3A%22Nyitray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Wentzensen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20P.%22%2C%22lastName%22%3A%22Chow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Smelov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20G.%22%2C%22lastName%22%3A%22Nowak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Phanuphak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20L.%22%2C%22lastName%22%3A%22Woo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Hu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Schofield%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20J.%22%2C%22lastName%22%3A%22Woestenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20T.%22%2C%22lastName%22%3A%22Chikandiwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Hickey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22de%20Pokomandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Pere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Del%20Pino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20P.%22%2C%22lastName%22%3A%22Ortiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Charnot-Katsikas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X.%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Chariyalertsak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Strong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Ong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Yunihastuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Etienney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20M.%22%2C%22lastName%22%3A%22Ferre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Zou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Segondy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Chinyowa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20J.%22%2C%22lastName%22%3A%22Alberts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20M.%22%2C%22lastName%22%3A%22Clifford%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Robust%20age-specific%20estimates%20of%20anal%20human%20papillomavirus%20%28HPV%29%20and%20high-grade%20squamous%20intraepithelial%20lesions%20%28HSIL%29%20in%20men%20can%20inform%20anal%20cancer%20prevention%20efforts.%20We%20aimed%20to%20evaluate%20the%20age-specific%20prevalence%20of%20anal%20HPV%2C%20HSIL%2C%20and%20their%20combination%2C%20in%20men%2C%20stratified%20by%20HIV%20status%20and%20sexuality.%20METHODS%3A%20We%20did%20a%20systematic%20review%20for%20studies%20on%20anal%20HPV%20infection%20in%20men%20and%20a%20pooled%20analysis%20of%20individual-level%20data%20from%20eligible%20studies%20across%20four%20groups%3A%20HIV-positive%20men%20who%20have%20sex%20with%20men%20%28MSM%29%2C%20HIV-negative%20MSM%2C%20HIV-positive%20men%20who%20have%20sex%20with%20women%20%28MSW%29%2C%20and%20HIV-negative%20MSW.%20Studies%20were%20required%20to%20inform%20on%20type-specific%20HPV%20infection%20%28at%20least%20HPV16%29%2C%20detected%20by%20use%20of%20a%20PCR-based%20test%20from%20anal%20swabs%2C%20HIV%20status%2C%20sexuality%20%28MSM%2C%20including%20those%20who%20have%20sex%20with%20men%20only%20or%20also%20with%20women%2C%20or%20MSW%29%2C%20and%20age.%20Authors%20of%20eligible%20studies%20with%20a%20sample%20size%20of%20200%20participants%20or%20more%20were%20invited%20to%20share%20deidentified%20individual-level%20data%20on%20the%20above%20four%20variables.%20Authors%20of%20studies%20including%2040%20or%20more%20HIV-positive%20MSW%20or%2040%20or%20more%20men%20from%20Africa%20%28irrespective%20of%20HIV%20status%20and%20sexuality%29%20were%20also%20invited%20to%20share%20these%20data.%20Pooled%20estimates%20of%20anal%20high-risk%20HPV%20%28HR-HPV%2C%20including%20HPV16%2C%2018%2C%2031%2C%2033%2C%2035%2C%2039%2C%2045%2C%2051%2C%2052%2C%2056%2C%2058%2C%2059%2C%20and%2068%29%2C%20and%20HSIL%20or%20worse%20%28HSIL%2B%29%2C%20were%20compared%20by%20use%20of%20adjusted%20prevalence%20ratios%20%28aPRs%29%20from%20generalised%20linear%20models.%20FINDINGS%3A%20The%20systematic%20review%20identified%2093%20eligible%20studies%2C%20of%20which%2064%20contributed%20data%20on%2029%20900%20men%20to%20the%20pooled%20analysis.%20Among%20HIV-negative%20MSW%20anal%20HPV16%20prevalence%20was%201.8%25%20%2891%20of%205190%29%20and%20HR-HPV%20prevalence%20was%206.9%25%20%28345%20of%205003%29%3B%20among%20HIV-positive%20MSW%20the%20prevalences%20were%208.7%25%20%2859%20of%20682%29%20and%2026.9%25%20%28179%20of%20666%29%3B%20among%20HIV-negative%20MSM%20they%20were%2013.7%25%20%281455%20of%2010%20617%29%20and%2041.2%25%20%283798%20of%209215%29%2C%20and%20among%20HIV-positive%20MSM%2028.5%25%20%283819%20of%2013%20411%29%20and%2074.3%25%20%288765%20of%2011%20803%29.%20In%20HIV-positive%20MSM%2C%20HPV16%20prevalence%20was%205.6%25%20%28two%20of%2036%29%20among%20those%20age%2015-18%20years%20and%2028.8%25%20%28141%20of%20490%29%20among%20those%20age%2023-24%20years%20%28p%28trend%29%3D0.0091%29%3B%20prevalence%20was%2031.7%25%20%281057%20of%203337%29%20among%20those%20age%2025-34%20years%20and%2022.8%25%20%28451%20of%201979%29%20among%20those%20age%2055%20and%20older%20%28p%28trend%29%3C0.0001%29.%20HPV16%20prevalence%20in%20HIV-negative%20MSM%20was%206.7%25%20%2815%20of%20223%29%20among%20those%20age%2015-18%20and%2013.9%25%20%28166%20of%201192%29%20among%20those%20age%2023-24%20years%20%28p%28trend%29%3D0.0076%29%3B%20the%20prevalence%20plateaued%20thereafter%20%28p%28trend%29%3D0.72%29.%20Similar%20age-specific%20patterns%20were%20observed%20for%20HR-HPV.%20No%20significant%20differences%20for%20HPV16%20or%20HR-HPV%20were%20found%20by%20age%20for%20either%20HIV-positive%20or%20HIV-negative%20MSW.%20HSIL%2B%20detection%20ranged%20from%207.5%25%20%2812%20of%20160%29%20to%2054.5%25%20%2861%20of%20112%29%20in%20HIV-positive%20MSM%3B%20after%20adjustment%20for%20heterogeneity%2C%20HIV%20was%20a%20significant%20predictor%20of%20HSIL%2B%20%28aPR%201.54%2C%2095%25%20CI%201.36-1.73%29%2C%20HPV16-positive%20HSIL%2B%20%281.66%2C%201.36-2.03%29%2C%20and%20HSIL%2B%20in%20HPV16-positive%20MSM%20%281.19%2C%201.04-1.37%29.%20Among%20HPV16-positive%20MSM%2C%20HSIL%2B%20prevalence%20increased%20with%20age.%20INTERPRETATION%3A%20High%20anal%20HPV%20prevalence%20among%20young%20HIV-positive%20and%20HIV-negative%20MSM%20highlights%20the%20benefits%20of%20gender-neutral%20HPV%20vaccination%20before%20sexual%20activity%20over%20catch-up%20vaccination.%20HIV-positive%20MSM%20are%20a%20priority%20for%20anal%20cancer%20screening%20research%20and%20initiatives%20targeting%20HPV16-positive%20HSIL%2B.%20FUNDING%3A%20International%20Agency%20for%20Research%20on%20Cancer.%22%2C%22date%22%3A%22Sep%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2821%2900108-9%22%2C%22ISSN%22%3A%222352-3018%20%28Electronic%29%202405-4704%20%28Print%29%202352-3018%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A44%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22CWGWA9SX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Edwards%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEdwards%2C%20J.%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECole%2C%20S.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBreger%2C%20T.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERudolph%2C%20J.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFiliatreau%2C%20L.%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Mortality%20Among%20Persons%20Entering%20HIV%20Care%20Compared%20With%20the%20General%20U.S.%20Population%26%23x202F%3B%3A%20An%20Observational%20Study.%20%3Ci%3EAnn%20Intern%20Med%3C%5C%2Fi%3E%2C%20%3Ci%3E174%3C%5C%2Fi%3E%20%289%29%2C%20S.%201197%26%23x2013%3B1206.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-0065%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-0065%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mortality%20Among%20Persons%20Entering%20HIV%20Care%20Compared%20With%20the%20General%20U.S.%20Population%20%3A%20An%20Observational%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20K.%22%2C%22lastName%22%3A%22Edwards%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20R.%22%2C%22lastName%22%3A%22Cole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20L.%22%2C%22lastName%22%3A%22Breger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Rudolph%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20M.%22%2C%22lastName%22%3A%22Filiatreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Buchacz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Humes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22D%27Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20C.%22%2C%22lastName%22%3A%22Mathews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20I.%22%2C%22lastName%22%3A%22Hall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Marconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20D.%22%2C%22lastName%22%3A%22Lima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22Bosch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Saag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Eron%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Understanding%20advances%20in%20the%20care%20and%20treatment%20of%20adults%20with%20HIV%20as%20well%20as%20remaining%20gaps%20requires%20comparing%20differences%20in%20mortality%20between%20persons%20entering%20care%20for%20HIV%20and%20the%20general%20population.%20OBJECTIVE%3A%20To%20assess%20the%20extent%20to%20which%20mortality%20among%20persons%20entering%20HIV%20care%20in%20the%20United%20States%20is%20elevated%20over%20mortality%20among%20matched%20persons%20in%20the%20general%20U.S.%20population%20and%20trends%20in%20this%20difference%20over%20time.%20DESIGN%3A%20Observational%20cohort%20study.%20SETTING%3A%20Thirteen%20sites%20from%20the%20U.S.%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design.%20PARTICIPANTS%3A%2082%20766%20adults%20entering%20HIV%20clinical%20care%20between%201999%20and%202017%20and%20a%20subset%20of%20the%20U.S.%20population%20matched%20on%20calendar%20time%2C%20age%2C%20sex%2C%20race%5C%2Fethnicity%2C%20and%20county%20using%20U.S.%20mortality%20and%20population%20data%20compiled%20by%20the%20National%20Center%20for%20Health%20Statistics.%20MEASUREMENTS%3A%20Five-year%20all-cause%20mortality%2C%20estimated%20using%20the%20Kaplan-Meier%20estimator%20of%20the%20survival%20function.%20RESULTS%3A%20Overall%205-year%20mortality%20among%20persons%20entering%20HIV%20care%20was%2010.6%25%2C%20and%20mortality%20among%20the%20matched%20U.S.%20population%20was%202.9%25%2C%20for%20a%20difference%20of%207.7%20%2895%25%20CI%2C%207.4%20to%207.9%29%20percentage%20points.%20This%20difference%20decreased%20over%20time%2C%20from%2011.1%20percentage%20points%20among%20those%20entering%20care%20between%201999%20and%202004%20to%202.7%20percentage%20points%20among%20those%20entering%20care%20between%202011%20and%202017.%20LIMITATION%3A%20Matching%20on%20available%20covariates%20may%20have%20failed%20to%20account%20for%20differences%20in%20mortality%20that%20were%20due%20to%20sociodemographic%20factors%20rather%20than%20consequences%20of%20HIV%20infection%20and%20other%20modifiable%20factors.%20CONCLUSION%3A%20Mortality%20among%20persons%20entering%20HIV%20care%20decreased%20dramatically%20between%201999%20and%202017%2C%20although%20those%20entering%20care%20remained%20at%20modestly%20higher%20risk%20for%20death%20in%20the%20years%20after%20starting%20care%20than%20comparable%20persons%20in%20the%20general%20U.S.%20population.%20PRIMARY%20FUNDING%20SOURCE%3A%20National%20Institutes%20of%20Health.%22%2C%22date%22%3A%22Sep%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7326%5C%2FM21-0065%22%2C%22ISSN%22%3A%221539-3704%20%28Electronic%29%200003-4819%20%28Print%29%200003-4819%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A34%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22HSLNCL77%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Souza%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESouza%2C%20A.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EArriaga%2C%20M.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAmorim%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAraujo-Pereira%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENogueira%2C%20B.%20M.%20F.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Determinants%20of%20losses%20in%20the%20latent%20tuberculosis%20infection%20cascade%20of%20care%20in%20Brazil.%20%3Ci%3EBMJ%20Glob%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E6%3C%5C%2Fi%3E%20%289%29%2C%20S.%20e005969.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgh-2021-005969%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgh-2021-005969%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determinants%20of%20losses%20in%20the%20latent%20tuberculosis%20infection%20cascade%20of%20care%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Araujo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20M.%20F.%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Silva%20J.%20R.%22%2C%22lastName%22%3A%22Lapa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Port%20Brazil%20consortium%22%2C%22lastName%22%3A%22Re%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Factors%20associated%20with%20losses%20in%20the%20latent%20tuberculosis%20infection%20%28LTBI%29%20cascade%20of%20care%20in%20contacts%20of%20patients%20with%20tuberculosis%20%28TB%29%20were%20investigated%20in%20a%20multicentre%20prospective%20cohort%20from%20highly%20endemic%20regions%20in%20Brazil.%20METHODS%3A%20Close%20contacts%20of%201187%20patients%20with%20culture-confirmed%20pulmonary%20TB%20were%20prospectively%20studied%20between%202015%20and%202019%2C%20with%20follow-up%20of%206-24%20months.%20Data%20on%20TB%20screening%20by%20clinical%20investigation%2C%20radiographic%20examination%20and%20interferon-gamma%20release%20assay%20%28IGRA%29%20were%20collected.%20Multivariable%20regressions%20were%20used%20to%20identify%20determinants%20of%20losses%20in%20the%20LTBI%20cascade.%20RESULTS%3A%20Among%204145%20TB%20contacts%20initially%20identified%2C%201901%20were%20examined%20%2854%25%20loss%29.%20Among%20those%20examined%2C%20933%20were%20people%20living%20with%20HIV%2C%20%3C%5C%2F%3D5%20years%20old%20and%5C%2For%20had%20positive%20IGRA%20results%2C%20and%20therefore%20had%20a%20recommendation%20to%20start%20TB%20preventive%20treatment%20%28TPT%29.%20Of%20those%2C%20454%20%2823%25%29%20initiated%20treatment%2C%20and%20247%20%2854%25%20of%20those%20initiating%3B%2026%25%20of%20those%20in%20whom%20treatment%20was%20recommended%29%20completed%20TPT.%20Multivariable%20regression%20analysis%20revealed%20that%20living%20with%20HIV%2C%20illiteracy%20and%20black%5C%2Fpardo%20%28brown%29%20race%20were%20independently%20associated%20with%20losses%20in%20the%20cascade.%20CONCLUSION%3A%20There%20were%20losses%20at%20all%20LTBI%20cascade%20stages%2C%20but%20particularly%20at%20the%20initial%20screening%20and%20examination%20steps.%20Close%20contacts%20of%20low%20socioeconomic%20status%20and%20living%20with%20HIV%20were%20at%20heightened%20risk%20of%20not%20completing%20the%20LTBI%20cascade%20of%20care%20in%20Brazil.%22%2C%22date%22%3A%22Sep%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjgh-2021-005969%22%2C%22ISSN%22%3A%222059-7908%20%28Print%29%202059-7908%20%28Electronic%29%202059-7908%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A41%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22HVPBERBS%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Boni%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoni%2C%20S.%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGnahatin%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EComoe%2C%20J.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETchounga%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEkouevi%2C%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Barriers%20and%20facilitators%20in%20cervical%20cancer%20screening%20uptake%20in%20Abidjan%2C%20Cote%20d%26%23x2019%3BIvoire%20in%202018%3A%20a%20cross-sectional%20study.%20%3Ci%3EBMC%20Cancer%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%20%281%29%2C%20S.%20952.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-021-08650-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-021-08650-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Barriers%20and%20facilitators%20in%20cervical%20cancer%20screening%20uptake%20in%20Abidjan%2C%20Cote%20d%27Ivoire%20in%202018%3A%20a%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20P.%22%2C%22lastName%22%3A%22Boni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Gnahatin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20C.%22%2C%22lastName%22%3A%22Comoe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Tchounga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Horo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Adoubi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jaquet%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUNDS%3A%20Cervical%20cancer%20%28CC%29%20incidence%20remains%20unacceptably%20high%20in%20Cote%20d%27Ivoire.%20In%20an%20effort%20to%20prevent%20this%20malignant%20condition%2C%20a%20national%20CC%20screening%20program%20has%20been%20scaled%20up%20in%20the%20country.%20This%20study%20aimed%20at%20assessing%20CC%20screening%20uptake%20and%20its%20associated%20factors%20in%20Abidjan%20in%202018.%20METHODS%3A%20A%20cross-sectional%20survey%20was%20conducted%20from%20July%20to%20September%202018%20in%20the%20main%20healthcare%20facilities%20of%20three%20randomly%20selected%20out%20of%20the%20eight%20health%20districts%20of%20Abidjan.%20During%20the%20study%20period%2C%20a%20standardized%20questionnaire%20was%20administrated%20by%20research%20assistants%20to%20all%20women%20aged%2025%20to%2055%20years%20old%2C%20attending%20the%20three%20participating%20facilities.%20Demographics%2C%20knowledge%20on%20CC%2C%20personal%20history%20of%20CC%20screening%20and%20reasons%20for%20not%20attending%20CC%20screening%20were%20collected.%20A%20logistic%20regression%20model%20was%20computed%20to%20document%20factors%20associated%20with%20reported%20CC%20screening%20uptake.%20RESULTS%3A%20A%20total%20of%201158%20women%20with%20a%20median%20age%20of%2032%20years%20%28IQR%20%5B27-36%5D%29%2C%20including%20364%20%2831.4%25%29%20with%20no%20formal%20education%20were%20included.%20Of%20those%20participants%2C%20786%20%2867.9%25%29%20had%20ever%20heard%20about%20CC.%20CC%20screening%20uptake%20at%20least%20once%20was%20reported%20by%207.5%25%20%5B95%25%20CI%3A%206.0-9.0%5D%20participants.%20In%20multivariable%20analysis%2C%20being%20%3E%5C%2F%3D45%20years%20%28aOR%3A%206.2%20%5B2.3-17.2%5D%29%2C%20having%20a%20university%20level%20%28aOR%3A%202.8%20%5B1.2-6.6%5D%29%20%28versus%20non%20formal%20education%29%20and%20access%20to%20mass%20campaign%20information%20%28aOR%3A%2018.2%20%5B8.5-39.1%5D%29%20were%20associated%20with%20a%20reported%20CC%20screening%20uptake.%20The%20main%20reported%20barriers%20to%20CC%20screening%20were%20unawareness%20towards%20CC%20screening%20%2875.5%25%29%2C%20negligence%20%2820.5%25%29%2C%20fear%20of%20CC%20detection%20%283.9%25%29%20and%20fear%20of%20additional%20costs%20%283.3%25%29.%20CONCLUSION%3A%20CC%20screening%20uptake%20remains%20low%20despite%20current%20initiatives%20to%20support%20awareness%20and%20prevention%20in%20Abidjan.%20Awareness%20campaigns%20need%20to%20be%20massively%20increased%20with%20the%20adjunction%20of%20tailored%20messages%20based%20on%20the%20level%20of%20women%27s%20education%20to%20enhance%20the%20CC%20screening%20coverage%20and%20reach%20the%20WHO%20goal%20of%20CC%20elimination%20by%202030.%22%2C%22date%22%3A%22Aug%2025%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-021-08650-6%22%2C%22ISSN%22%3A%221471-2407%20%28Electronic%29%201471-2407%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22WEB8KW8I%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Davy-Mendez%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-16%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavy-Mendez%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENapravnik%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEron%2C%20J.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECole%2C%20S.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Evan%20Duin%2C%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Current%20and%20Past%20Immunodeficiency%20Are%20Associated%20With%20Higher%20Hospitalization%20Rates%20Among%20Persons%20on%20Virologically%20Suppressive%20Antiretroviral%20Therapy%20for%20up%20to%2011%20Years.%20%3Ci%3EJ%20Infect%20Dis%3C%5C%2Fi%3E%2C%20%3Ci%3E224%3C%5C%2Fi%3E%20%284%29%2C%20S.%20657%26%23x2013%3B666.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiaa786%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiaa786%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Current%20and%20Past%20Immunodeficiency%20Are%20Associated%20With%20Higher%20Hospitalization%20Rates%20Among%20Persons%20on%20Virologically%20Suppressive%20Antiretroviral%20Therapy%20for%20up%20to%2011%20Years%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Davy-Mendez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Eron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20R.%22%2C%22lastName%22%3A%22Cole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22van%20Duin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20A.%22%2C%22lastName%22%3A%22Wohl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20C.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20C.%22%2C%22lastName%22%3A%22Mathews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20B.%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Colasanti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Buchacz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20G.%20A.%22%2C%22lastName%22%3A%22Nanditha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Nijhawan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20A.%22%2C%22lastName%22%3A%22Berry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%20Cohort%20Collaboration%20on%20Research%22%2C%22lastName%22%3A%22North%20American%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22Design%20of%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Persons%20with%20human%20immunodeficiency%20virus%20%28PWH%29%20with%20persistently%20low%20CD4%20counts%20despite%20efficacious%20antiretroviral%20therapy%20could%20have%20higher%20hospitalization%20risk.%20METHODS%3A%20In%206%20US%20and%20Canadian%20clinical%20cohorts%2C%20PWH%20with%20virologic%20suppression%20for%20%3E%5C%2F%3D1%20year%20in%202005-2015%20were%20followed%20until%20virologic%20failure%2C%20loss%20to%20follow-up%2C%20death%2C%20or%20study%20end.%20Stratified%20by%20early%20%28years%202-5%29%20and%20long-term%20%28years%206-11%29%20suppression%20and%20lowest%20presuppression%20CD4%20count%20%3C200%20and%20%3E%5C%2F%3D200%20cells%5C%2FmicroL%2C%20Poisson%20regression%20models%20estimated%20hospitalization%20incidence%20rate%20ratios%20%28aIRRs%29%20comparing%20patients%20by%20time-updated%20CD4%20count%20category%2C%20adjusted%20for%20cohort%2C%20age%2C%20gender%2C%20calendar%20year%2C%20suppression%20duration%2C%20and%20lowest%20presuppression%20CD4%20count.%20RESULTS%3A%20The%206997%20included%20patients%20%2819%20980%20person-years%29%20were%2081%25%20cisgender%20men%20and%2040%25%20white.%20Among%20patients%20with%20lowest%20presuppression%20CD4%20count%20%3C200%20cells%5C%2FmuL%20%2844%25%29%2C%20patients%20with%20current%20CD4%20count%20200-350%20vs%20%3E500%20cells%5C%2FmuL%20had%20aIRRs%20of%201.44%20during%20early%20suppression%20%2895%25%20confidence%20interval%20%5BCI%5D%2C%201.01-2.06%29%2C%20and%201.67%20%2895%25%20CI%2C%201.03-2.72%29%20during%20long-term%20suppression.%20Among%20patients%20with%20lowest%20presuppression%20CD4%20count%20%3E%5C%2F%3D200%20%2856%25%29%2C%20patients%20with%20current%20CD4%20351-500%20vs%20%3E500%20cells%5C%2FmuL%20had%20an%20aIRR%20of%201.22%20%2895%25%20CI%2C%20.93-1.60%29%20during%20early%20suppression%20and%202.09%20%2895%25%20CI%2C%201.18-3.70%29%20during%20long-term%20suppression.%20CONCLUSIONS%3A%20Virologically%20suppressed%20patients%20with%20lower%20CD4%20counts%20experienced%20higher%20hospitalization%20rates%20and%20could%20potentially%20benefit%20from%20targeted%20clinical%20management%20strategies.%22%2C%22date%22%3A%22Aug%2016%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Finfdis%5C%2Fjiaa786%22%2C%22ISSN%22%3A%221537-6613%20%28Electronic%29%200022-1899%20%28Print%29%200022-1899%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A41%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22GVGYAEKG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Freeman%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-15%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFreeman%2C%20E.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESemeere%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMcMahon%2C%20D.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EByakwaga%2C%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELaker-Oketta%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Beyond%20T%20Staging%20in%20the%20%26%23x201C%3BTreat-All%26%23x201D%3B%20Era%3A%20Severity%20and%20Heterogeneity%20of%20Kaposi%20Sarcoma%20in%20East%20Africa.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E87%3C%5C%2Fi%3E%20%285%29%2C%20S.%201119%26%23x2013%3B1127.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002699%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002699%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Beyond%20T%20Staging%20in%20the%20%5C%22Treat-All%5C%22%20Era%3A%20Severity%20and%20Heterogeneity%20of%20Kaposi%20Sarcoma%20in%20East%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20E.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%22%2C%22lastName%22%3A%22McMahon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Laker-Oketta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Regan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Wenger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kasozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ssemakadde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bwana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kanyesigye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Kadama-Makanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Rotich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Kisuya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20V.%22%2C%22lastName%22%3A%22Bassett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Busakhala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Martin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Although%20many%20patients%20with%20Kaposi%20sarcoma%20%28KS%29%20in%20sub-Saharan%20Africa%20are%20diagnosed%20with%20AIDS%20Clinical%20Trials%20Group%20%28ACTG%29%20T1%20disease%2C%20T1%20staging%20insufficiently%20captures%20clinical%20heterogeneity%20of%20advanced%20KS.%20Using%20a%20representative%20community-based%20sample%2C%20we%20detailed%20disease%20severity%20at%20diagnosis%20to%20inform%20KS%20staging%20and%20treatment%20in%20sub-Saharan%20Africa.%20METHODS%3A%20We%20performed%20rapid%20case%20ascertainment%20on%20people%20living%20with%20HIV%2C%20aged%2018%20years%20or%20older%2C%20newly%20diagnosed%20with%20KS%20from%202016%20to%202019%20at%203%20clinic%20sites%20in%20Kenya%20and%20Uganda%20to%20ascertain%20disease%20stage%20as%20close%20as%20possible%20to%20diagnosis.%20We%20reported%20KS%20severity%20using%20ACTG%20and%20WHO%20staging%20criteria%20and%20detailed%20measurements%20that%20are%20not%20captured%20in%20the%20current%20staging%20systems.%20RESULTS%3A%20We%20performed%20rapid%20case%20ascertainment%20within%201%20month%20for%20241%20adults%20newly%20diagnosed%20with%20KS%20out%20of%20389%20adult%20patients%20with%20suspected%20KS.%20The%20study%20was%2068%25%20men%20with%20median%20age%2035%20years%20and%20median%20CD4%20count%20239.%20Most%20of%20the%20patients%20had%20advanced%20disease%2C%20with%2082%25%20qualifying%20as%20ACTG%20T1%20and%2064%25%20as%20WHO%20severe%5C%2Fsymptomatic%20KS.%20The%20most%20common%20ACTG%20T1%20qualifiers%20were%20edema%20%2879%25%29%2C%20tumor-associated%20ulceration%20%2824%25%29%2C%20extensive%20oral%20KS%20%289%25%29%2C%20pulmonary%20KS%20%287%25%29%2C%20and%20gastrointestinal%20KS%20%284%25%29.%20There%20was%20marked%20heterogeneity%20within%20T1%20KS%2C%20with%2025%25%20of%20patients%20having%202%20T1%20qualifying%20symptoms%20and%203%25%20having%203%20or%20more.%20CONCLUSION%3A%20Most%20of%20the%20patients%20newly%20diagnosed%20with%20KS%20had%20advanced%20stage%20disease%2C%20even%20in%20the%20current%20antiretroviral%20therapy%20%5C%22treat-all%5C%22%20era.%20We%20observed%20great%20clinical%20heterogeneity%20among%20advanced%20stage%20patients%2C%20leading%20to%20questions%20about%20whether%20all%20patients%20with%20advanced%20KS%20require%20the%20same%20treatment%20strategy.%22%2C%22date%22%3A%22Aug%2015%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000002699%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A02Z%22%7D%7D%2C%7B%22key%22%3A%229Z4972PZ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Haas%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-07%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHaas%2C%20A.%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKunzekwenyika%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHossmann%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EManzero%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Evan%20Dijk%2C%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Symptoms%20of%20common%20mental%20disorders%20and%20adherence%20to%20antiretroviral%20therapy%20among%20adults%20living%20with%20HIV%20in%20rural%20Zimbabwe%3A%20a%20cross-sectional%20study.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E11%3C%5C%2Fi%3E%20%287%29%2C%20S.%20e049824.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-049824%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-049824%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Symptoms%20of%20common%20mental%20disorders%20and%20adherence%20to%20antiretroviral%20therapy%20among%20adults%20living%20with%20HIV%20in%20rural%20Zimbabwe%3A%20a%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Hossmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Manzero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22van%20Dijk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Manhibi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Verhey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Limacher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22von%20Groote%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Manda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Hobbins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Chibanda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20Southern%20Africa%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20examine%20the%20proportion%20of%20people%20living%20with%20HIV%20who%20screen%20positive%20for%20common%20mental%20disorders%20%28CMD%29%20and%20the%20associations%20between%20CMD%20and%20self-reported%20adherence%20to%20antiretroviral%20therapy%20%28ART%29.%20SETTING%3A%20Sixteen%20government-funded%20health%20facilities%20in%20the%20rural%20Bikita%20district%20of%20Zimbabwe.%20DESIGN%3A%20Cross-sectional%20study.%20PARTICIPANTS%3A%20HIV-positive%20non-pregnant%20adults%2C%20aged%2018%20years%20or%20older%2C%20who%20lived%20in%20Bikita%20district%20and%20had%20received%20ART%20for%20at%20least%206%20months.%20OUTCOME%20MEASURES%3A%20The%20primary%20outcome%20was%20the%20proportion%20of%20participants%20screening%20positive%20for%20CMD%20defined%20as%20a%20Shona%20Symptoms%20Questionnaire%20score%20of%209%20or%20greater.%20Secondary%20outcomes%20were%20the%20proportion%20of%20participants%20reporting%20suicidal%20ideation%2C%20perceptual%20symptoms%20and%20suboptimal%20ART%20adherence%20and%20adjusted%20prevalence%20ratios%20%28aPR%29%20for%20factors%20associated%20with%20CMD%2C%20suicidal%20ideation%2C%20perceptual%20symptoms%20and%20suboptimal%20ART%20adherence.%20RESULTS%3A%20Out%20of%203480%20adults%2C%2018.8%25%20%2895%25%20CI%2014.8%25%20to%2023.7%25%29%20screened%20positive%20for%20CMD%2C%202.7%25%20%2895%25%20CI%201.5%25%20to%204.7%25%29%20reported%20suicidal%20ideations%2C%20and%201.5%25%20%2895%25%20CI%200.9%25%20to%202.6%25%29%20reported%20perceptual%20symptoms.%20Positive%20CMD%20screens%20were%20more%20common%20in%20women%20%28aPR%201.67%2C%2095%25%20CI%201.19%20to%202.35%29%20than%20in%20men%20and%20were%20more%20common%20in%20adults%20aged%2040-49%20years%20%28aPR%201.47%2C%2095%25%20CI%201.16%20to%201.85%29%20or%20aged%2050-59%20years%20%28aPR%201.51%2C%2095%25%20CI%201.05%20to%202.17%29%20than%20in%20those%2060%20years%20or%20older.%20Positive%20CMD%20screen%20was%20associated%20with%20suboptimal%20adherence%20%28aPR%201.53%3B%2095%25%20CI%201.37%20to%201.70%29.%20CONCLUSIONS%3A%20A%20substantial%20proportion%20of%20people%20living%20with%20HIV%20in%20rural%20Zimbabwe%20are%20affected%20by%20CMD.%20There%20is%20a%20need%20to%20integrate%20mental%20health%20services%20and%20HIV%20programmes%20in%20rural%20Zimbabwe.%20TRIAL%20REGISTRATION%20NUMBER%3A%20NCT03704805.%22%2C%22date%22%3A%22Jul%207%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2021-049824%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A29%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22SWFV4HUK%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Somerville%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESomerville%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJenkins%2C%20C.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECarlucci%2C%20J.%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPerson%2C%20A.%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMachado%2C%20D.%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Outcomes%20After%20Second-Line%20Antiretroviral%20Therapy%20in%20Children%20Living%20With%20HIV%20in%20Latin%20America.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E87%3C%5C%2Fi%3E%20%283%29%2C%20S.%20993%26%23x2013%3B1001.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002678%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002678%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20After%20Second-Line%20Antiretroviral%20Therapy%20in%20Children%20Living%20With%20HIV%20in%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Somerville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22Carlucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20K.%22%2C%22lastName%22%3A%22Person%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20T.%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20K.%22%2C%22lastName%22%3A%22Friedman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Little%20is%20known%20about%20the%20long-term%20outcomes%20of%20children%20living%20with%20HIV%20in%20Latin%20America.%20Few%20studies%20have%20examined%20antiretroviral%20therapy%20%28ART%29%20regimen%20switches%20in%20the%20years%20after%20the%20introduction%20of%20ART%20in%20this%20population.%20This%20study%20aimed%20to%20assess%20clinical%20outcomes%20among%20children%20who%20started%20second-line%20ART%20in%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology.%20METHODS%3A%20Children%20%28%3C18%20years%20old%29%20with%20HIV%20who%20switched%20to%20second-line%20ART%20at%20sites%20within%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20were%20included.%20The%20cumulative%20incidence%20and%20relative%20hazards%20of%20virologic%20failure%20while%20on%20second-line%20ART%2C%20loss%20to%20follow-up%2C%20additional%20major%20ART%20regimen%20changes%2C%20and%20all-cause%20mortality%20were%20evaluated%20using%20competing%20risks%20methods%20and%20Cox%20models.%20RESULTS%3A%20A%20total%20of%20672%20children%20starting%20second-line%20ART%20were%20included.%20Three%20years%20after%20starting%20second-line%20ART%2C%20the%20cumulative%20incidence%20of%20death%20was%200.10%20%5B95%25%20confidence%20interval%20%28CI%29%200.08%20to%200.13%5D%2C%20loss%20to%20follow-up%20was%200.14%20%2895%25%20CI%3A%200.11%20to%200.17%29%2C%20and%20major%20regimen%20change%20was%200.19%20%2895%25%20CI%3A%200.15%20to%200.22%29.%20Of%20those%20changing%20regimens%2C%2035%25%20were%20due%20to%20failure%20and%2011%25%20due%20to%20toxicities%5C%2Fside%20effects.%20Among%20the%20312%20children%20with%20viral%20load%20data%2C%20the%20cumulative%20incidence%20of%20virologic%20failure%20at%203%20years%20was%200.62%20%2895%25%20CI%3A%200.56%20to%200.68%29%3B%20time%20to%20virologic%20failure%20and%20regimen%20change%20were%20uncorrelated%20%28rank%20correlation%20-0.001%3B%2095%25%20CI%20-0.18%20to%200.17%29.%20CONCLUSIONS%3A%20Poor%20outcomes%20after%20starting%20second-line%20ART%20in%20Latin%20America%20were%20common.%20The%20high%20incidence%20of%20virologic%20failure%20and%20its%20poor%20correlation%20with%20changing%20regimens%20was%20particularly%20worrisome.%20Additional%20efforts%20are%20needed%20to%20ensure%20children%20receive%20optimal%20ART%20regimens.%22%2C%22date%22%3A%22Jul%201%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000002678%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A35%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22RX7PRK3H%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Davy-Mendez%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDavy-Mendez%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENapravnik%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEron%2C%20J.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECole%2C%20S.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVan%20Duin%2C%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Racial%2C%20ethnic%2C%20and%20gender%20disparities%20in%20hospitalizations%20among%20persons%20with%20HIV%20in%20the%20United%20States%20and%20Canada%2C%202005-2015.%20%3Ci%3EAIDS%3C%5C%2Fi%3E%2C%20%3Ci%3E35%3C%5C%2Fi%3E%20%288%29%2C%20S.%201229%26%23x2013%3B1239.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000002876%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000002876%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Racial%2C%20ethnic%2C%20and%20gender%20disparities%20in%20hospitalizations%20among%20persons%20with%20HIV%20in%20the%20United%20States%20and%20Canada%2C%202005-2015%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Davy-Mendez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Eron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20R.%22%2C%22lastName%22%3A%22Cole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Van%20Duin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20A.%22%2C%22lastName%22%3A%22Wohl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Gebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Poteat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20G.%20A.%22%2C%22lastName%22%3A%22Nanditha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20A.%22%2C%22lastName%22%3A%22Berry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%20Cohort%20Collaboration%20on%20Research%22%2C%22lastName%22%3A%22North%20American%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%22%2C%22lastName%22%3A%22Design%20of%20Ie%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20examine%20recent%20trends%20and%20differences%20in%20all-cause%20and%20cause-specific%20hospitalization%20rates%20by%20race%2C%20ethnicity%2C%20and%20gender%20among%20persons%20with%20HIV%20%28PWH%29%20in%20the%20United%20States%20and%20Canada.%20DESIGN%3A%20HIV%20clinical%20cohort%20consortium.%20METHODS%3A%20We%20followed%20PWH%20at%20least%2018%20years%20old%20in%20care%202005-2015%20in%20six%20clinical%20cohorts.%20We%20used%20modified%20Clinical%20Classifications%20Software%20to%20categorize%20hospital%20discharge%20diagnoses.%20Incidence%20rate%20ratios%20%28IRR%29%20were%20estimated%20using%20Poisson%20regression%20with%20robust%20variances%20to%20compare%20racial%20and%20ethnic%20groups%2C%20stratified%20by%20gender%2C%20adjusted%20for%20cohort%2C%20calendar%20year%2C%20injection%20drug%20use%20history%2C%20and%20annually%20updated%20age%2C%20CD4%2B%2C%20and%20HIV%20viral%20load.%20RESULTS%3A%20Among%2027%20085%20patients%20%28122%20566%20person-years%29%2C%2080%25%20were%20cisgender%20men%2C%201%25%20transgender%2C%2043%25%20White%2C%2033%25%20Black%2C%2017%25%20Hispanic%20of%20any%20race%2C%20and%201%25%20Indigenous.%20Unadjusted%20all-cause%20hospitalization%20rates%20were%20higher%20for%20Black%20%5BIRR%201.46%2C%2095%25%20confidence%20interval%20%28CI%29%201.32-1.61%5D%20and%20Indigenous%20%281.99%2C%201.44-2.74%29%20versus%20White%20cisgender%20men%2C%20and%20for%20Indigenous%20versus%20White%20cisgender%20women%20%282.55%2C%201.68-3.89%29.%20Unadjusted%20AIDS-related%20hospitalization%20rates%20were%20also%20higher%20for%20Black%2C%20Hispanic%2C%20and%20Indigenous%20versus%20White%20cisgender%20men%20%28all%20P%20%3C%200.05%29.%20Transgender%20patients%20had%201.50%20times%20%281.05-2.14%29%20and%20cisgender%20women%201.37%20times%20%281.26-1.48%29%20the%20unadjusted%20hospitalization%20rate%20of%20cisgender%20men.%20In%20adjusted%20analyses%2C%20among%20both%20cisgender%20men%20and%20women%2C%20Black%20patients%20had%20higher%20rates%20of%20cardiovascular%20and%20renal%5C%2Fgenitourinary%20hospitalizations%20compared%20to%20Whites%20%28all%20P%20%3C%200.05%29.%20CONCLUSION%3A%20Black%2C%20Hispanic%2C%20Indigenous%2C%20women%2C%20and%20transgender%20PWH%20in%20the%20United%20States%20and%20Canada%20experienced%20substantially%20higher%20hospitalization%20rates%20than%20White%20patients%20and%20cisgender%20men%2C%20respectively.%20Disparities%20likely%20have%20several%20causes%2C%20including%20differences%20in%20virologic%20suppression%20and%20chronic%20conditions%20such%20as%20diabetes%20and%20renal%20disease.%22%2C%22date%22%3A%22Jul%201%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000002876%22%2C%22ISSN%22%3A%221473-5571%20%28Electronic%29%200269-9370%20%28Print%29%200269-9370%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A25%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22RNKDWEN7%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tafadzwa%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-29%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETafadzwa%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJulien%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELina%2C%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEliane%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFrederique%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Spatiotemporal%20modelling%20and%20mapping%20of%20cervical%20cancer%20incidence%20among%20HIV%20positive%20women%20in%20South%20Africa%3A%20a%20nationwide%20study.%20%3Ci%3EInt%20J%20Health%20Geogr%3C%5C%2Fi%3E%2C%20%3Ci%3E20%3C%5C%2Fi%3E%20%281%29%2C%20S.%2030.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12942-021-00283-z%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12942-021-00283-z%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Spatiotemporal%20modelling%20and%20mapping%20of%20cervical%20cancer%20incidence%20among%20HIV%20positive%20women%20in%20South%20Africa%3A%20a%20nationwide%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Tafadzwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Julien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Lina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Eliane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Frederique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Leigh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Elvira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Victor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20M.%22%2C%22lastName%22%3A%22Mazvita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Matthias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Julia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Garyfallos%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Disparities%20in%20invasive%20cervical%20cancer%20%28ICC%29%20incidence%20exist%20globally%2C%20particularly%20in%20HIV%20positive%20women%20who%20are%20at%20elevated%20risk%20compared%20to%20HIV%20negative%20women.%20We%20aimed%20to%20determine%20the%20spatial%2C%20temporal%2C%20and%20spatiotemporal%20incidence%20of%20ICC%20and%20the%20potential%20risk%20factors%20among%20HIV%20positive%20women%20in%20South%20Africa.%20METHODS%3A%20We%20included%20ICC%20cases%20in%20women%20diagnosed%20with%20HIV%20from%20the%20South%20African%20HIV%20cancer%20match%20study%20during%202004-2014.%20We%20used%20the%20Thembisa%20model%2C%20a%20mathematical%20model%20of%20the%20South%20African%20HIV%20epidemic%20to%20estimate%20women%20diagnosed%20with%20HIV%20per%20municipality%2C%20age%20group%20and%20calendar%20year.%20We%20fitted%20Bayesian%20hierarchical%20models%2C%20using%20a%20reparameterization%20of%20the%20Besag-York-Mollie%20to%20capture%20spatial%20autocorrelation%2C%20to%20estimate%20the%20spatiotemporal%20distribution%20of%20ICC%20incidence%20among%20women%20diagnosed%20with%20HIV.%20We%20also%20examined%20the%20association%20of%20deprivation%2C%20access%20to%20health%20%28using%20the%20number%20of%20health%20facilities%20per%20municipality%29%20and%20urbanicity%20with%20ICC%20incidence.%20We%20corrected%20our%20estimates%20to%20account%20for%20ICC%20case%20underascertainment%2C%20missing%20data%20and%20data%20errors.%20RESULTS%3A%20We%20included%2017%2C821%20ICC%20cases%20and%20demonstrated%20a%20decreasing%20trend%20in%20ICC%20incidence%2C%20from%20306%20to%20312%20in%202004%20and%20from%20160%20to%20191%20in%202014%20per%20100%2C000%20person-years%20across%20all%20municipalities%20and%20corrections.%20The%20spatial%20relative%20rate%20%28RR%29%20ranged%20from%200.27%20to%204.43%20in%20the%20model%20without%20any%20covariates.%20In%20the%20model%20adjusting%20for%20covariates%2C%20the%20most%20affluent%20municipalities%20had%20a%20RR%20of%203.18%20%2895%25%20Credible%20Interval%201.82%2C%205.57%29%20compared%20to%20the%20least%20affluent%20ones%2C%20and%20municipalities%20with%20better%20access%20to%20health%20care%20had%20a%20RR%20of%201.52%20%281.03%2C%202.27%29%20compared%20to%20municipalities%20with%20worse%20access%20to%20health.%20CONCLUSIONS%3A%20The%20results%20show%20an%20increased%20incidence%20of%20cervical%20cancer%20in%20affluent%20municipalities%20and%20in%20those%20with%20more%20health%20facilities.%20This%20is%20likely%20driven%20by%20better%20access%20to%20health%20care%20in%20more%20affluent%20areas.%20More%20efforts%20should%20be%20made%20to%20ensure%20equitable%20access%20to%20health%20services%2C%20including%20mitigating%20physical%20barriers%2C%20such%20as%20transportation%20to%20health%20centres%20and%20strengthening%20of%20screening%20programmes.%22%2C%22date%22%3A%22Jun%2029%202021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12942-021-00283-z%22%2C%22ISSN%22%3A%221476-072X%20%28Electronic%29%201476-072X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A28%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22USJPABM5%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Filiatreau%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-05%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFiliatreau%2C%20L.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEbasone%2C%20P.%20V.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDzudie%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAjeh%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPence%2C%20B.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Correlates%20of%20self-reported%20history%20of%20mental%20health%20help-seeking%3A%20a%20cross-sectional%20study%20among%20individuals%20with%20symptoms%20of%20a%20mental%20or%20substance%20use%20disorder%20initiating%20care%20for%20HIV%20in%20Cameroon.%20%3Ci%3EBMC%20Psychiatry%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%20%281%29%2C%20S.%20293.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12888-021-03306-y%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12888-021-03306-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Correlates%20of%20self-reported%20history%20of%20mental%20health%20help-seeking%3A%20a%20cross-sectional%20study%20among%20individuals%20with%20symptoms%20of%20a%20mental%20or%20substance%20use%20disorder%20initiating%20care%20for%20HIV%20in%20Cameroon%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20M.%22%2C%22lastName%22%3A%22Filiatreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20V.%22%2C%22lastName%22%3A%22Ebasone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dzudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Pence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Wainberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Pefura-Yone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nsame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Mental%20health%20and%20substance%20use%20disorders%20%28MSDs%29%20increase%20the%20risk%20of%20poor%20human%20immunodeficiency%20virus%20%28HIV%29%20care%20outcomes%20among%20people%20living%20with%20HIV%20%28PLWH%29.%20Receipt%20of%20mental%20health%20care%20may%20improve%20these%20adverse%20outcomes.%20We%20aimed%20to%20identify%20correlates%20of%20prior%20mental%20health%20help-seeking%20among%20PLWH%20with%20symptoms%20of%20an%20MSD%20in%20Cameroon.%20METHODS%3A%20We%20characterize%20prior%20mental%20health%20help-seeking%20from%20formal%20%28mental%20health%20specialist%5C%2Fgeneral%20medical%20provider%29%20and%20informal%20%28traditional%20healer%5C%2Freligious%20leader%29%20sources%20among%20161%20people%20with%20symptoms%20of%20depression%20%28Patient%20Health%20Questionnaire-9%20scores%3E%209%29%2C%20anxiety%20%28General%20Anxiety%20Disorder-7%20scores%3E%209%29%2C%20probable%20post-traumatic%20stress%20disorder%20%28PTSD%20Checklist%20for%20DSM-5%20scores%3E%2030%29%2C%20or%20possible%20alcohol%20use%20disorder%20%28Alcohol%20Use%20Disorders%20Identification%20Test%20scores%3E%5C%2F%3D16%29%20who%20were%20newly%20entering%20HIV%20care%20at%20three%20healthcare%20facilities%20in%20Cameroon%20between%20June%202019%20and%20March%202020.%20Help-seeking%20was%20defined%20as%20ever%20speaking%20to%20a%20formal%20or%20informal%20source%20about%20emotional%20problems%2C%20sadness%2C%20or%20the%20way%20they%20were%20feeling%20or%20behaving.%20We%20estimated%20the%20association%20between%20sociodemographic%20and%20psychosocial%20measures%20and%20lifetime%20mental%20health%20help-seeking%20from%20each%20type%20of%20source%20using%20log-binomial%20regression.%20RESULTS%3A%20Overall%2C%2055.3%25%20of%20161%20PLWH%20with%20MSD%20symptoms%20reported%20prior%20mental%20health%20help-seeking%2C%20with%2024.2%25%20and%2046.0%25%20seeking%20help%20from%20formal%20and%20informal%20sources%2C%20respectively.%20Religious%20leaders%20were%20the%20most%20common%20source%20of%20help%20%2840.4%25%29%2C%20followed%20by%20general%20medical%20professionals%20%2822.4%25%29%2C%20traditional%20healers%20%2816.8%25%29%2C%20and%20mental%20health%20specialists%20%287.4%25%29.%20Individuals%20with%20higher%20depressive%2C%20anxiety%2C%20and%20trauma%20symptom%20severity%20scores%20were%20more%20likely%20to%20have%20sought%20help%20than%20those%20with%20lower%20scores.%20Individuals%20with%20possible%20alcohol%20use%20disorder%20were%20the%20least%20likely%20to%20have%20sought%20help.%20Prior%20help-seeking%20was%20more%20common%20among%20those%20reporting%20a%20higher%20number%20of%20lifetime%20traumatic%20events%20%28prevalence%20ratio%20%5BPR%5D%3A%201.06%3B%2095%25%20confidence%20interval%20%5BCI%5D%3A%201.01%2C%201.11%29%20and%20those%20with%20a%20history%20of%20emotional%20intimate%20partner%20violence%20%28PR%3A%201.34%3B%2095%25%20CI%3A%201.01%2C%201.80%29.%20CONCLUSIONS%3A%20Prior%20mental%20health%20help-seeking%20was%20associated%20with%20psychosocial%20stressors.%20Help-seeking%20from%20informal%20networks%20was%20more%20common%20than%20formal%20help-seeking.%20Training%20in%20the%20provision%20of%20evidence-based%20mental%20health%20support%20for%20informal%20networks%20could%20improve%20access%20to%20mental%20health%20care%20for%20PLWH%20with%20MSDs%20in%20Cameroon.%22%2C%22date%22%3A%22Jun%205%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12888-021-03306-y%22%2C%22ISSN%22%3A%221471-244X%20%28Electronic%29%201471-244X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22RLU2TWQ7%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Onovo%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-24%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOnovo%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalaiwo%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKatbi%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOgorry%2C%20O.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJaquet%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Geographical%20Disparities%20in%20HIV%20Seroprevalence%20Among%20Men%20Who%20Have%20Sex%20with%20Men%20and%20People%20Who%20Inject%20Drugs%20in%20Nigeria%3A%20Exploratory%20Spatial%20Data%20Analysis.%20%3Ci%3EJMIR%20Public%20Health%20Surveill%3C%5C%2Fi%3E%2C%20%3Ci%3E7%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e19587.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2196%5C%2F19587%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2196%5C%2F19587%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Geographical%20Disparities%20in%20HIV%20Seroprevalence%20Among%20Men%20Who%20Have%20Sex%20with%20Men%20and%20People%20Who%20Inject%20Drugs%20in%20Nigeria%3A%20Exploratory%20Spatial%20Data%20Analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Onovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kalaiwo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Katbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Ogorry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Keiser%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20assessment%20of%20geographical%20heterogeneity%20of%20HIV%20among%20men%20who%20have%20sex%20with%20men%20%28MSM%29%20and%20people%20who%20inject%20drugs%20%28PWID%29%20can%20usefully%20inform%20targeted%20HIV%20prevention%20and%20care%20strategies.%20OBJECTIVE%3A%20We%20aimed%20to%20measure%20HIV%20seroprevalence%20and%20identify%20hotspots%20of%20HIV%20infection%20among%20MSM%20and%20PWID%20in%20Nigeria.%20METHODS%3A%20We%20included%20all%20MSM%20and%20PWID%20accessing%20HIV%20testing%20services%20across%207%20prioritized%20states%20%28Lagos%2C%20Nasarawa%2C%20Akwa%20Ibom%2C%20Cross%20Rivers%2C%20Rivers%2C%20Benue%2C%20and%20the%20Federal%20Capital%20Territory%29%20in%203%20geographic%20regions%20%28North%20Central%2C%20South%20South%2C%20and%20South%20West%29%20between%20October%201%2C%202016%2C%20and%20September%2030%2C%202017.%20We%20extracted%20data%20from%20national%20testing%20registers%2C%20georeferenced%20all%20HIV%20test%20results%20aggregated%20at%20the%20local%20government%20area%20level%2C%20and%20calculated%20HIV%20seroprevalence.%20We%20calculated%20and%20compared%20HIV%20seroprevalence%20from%20our%20study%20to%20the%202014%20integrated%20biological%20and%20behavioural%20surveillance%20survey%20and%20used%20global%20spatial%20autocorrelation%20and%20hotspot%20analysis%20to%20highlight%20patterns%20of%20HIV%20infection%20and%20identify%20areas%20of%20significant%20clustering%20of%20HIV%20cases.%20RESULTS%3A%20MSM%20and%20PWID%20had%20HIV%20seroprevalence%20rates%20of%2012.14%25%20%283209%5C%2F26%2C423%29%20and%2011.88%25%20%281126%5C%2F9474%29%2C%20respectively.%20Global%20spatial%20autocorrelation%20Moran%20I%20statistics%20revealed%20a%20clustered%20distribution%20of%20HIV%20infection%20among%20MSM%20and%20PWID%20with%20a%20%3C5%25%20and%20%3C1%25%20likelihood%20that%20this%20clustered%20pattern%20could%20be%20due%20to%20chance%2C%20respectively.%20Significant%20clusters%20of%20HIV%20infection%20%28Getis-Ord-Gi%2A%20statistics%29%20confined%20to%20the%20North%20Central%20and%20South%20South%20regions%20were%20identified%20among%20MSM%20and%20PWID.%20Compared%20to%20the%202014%20integrated%20biological%20and%20behavioural%20surveillance%20survey%2C%20our%20results%20suggest%20an%20increased%20HIV%20seroprevalence%20among%20PWID%20and%20a%20substantial%20decrease%20among%20MSM.%20CONCLUSIONS%3A%20This%20study%20identified%20geographical%20areas%20to%20prioritize%20for%20control%20of%20HIV%20infection%20among%20MSM%20and%20PWID%2C%20thus%20demonstrating%20that%20geographical%20information%20system%20technology%20is%20a%20useful%20tool%20to%20inform%20public%20health%20planning%20for%20interventions%20targeting%20epidemic%20control%20of%20HIV%20infection.%22%2C%22date%22%3A%22May%2024%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.2196%5C%2F19587%22%2C%22ISSN%22%3A%222369-2960%20%28Electronic%29%202369-2960%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A45%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22HRLWA789%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nyemba%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENyemba%2C%20D.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKalk%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMadlala%2C%20H.%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMalaba%2C%20T.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESlogrove%2C%20A.%20L.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Lower%20birth%20weight-for-age%20and%20length-for-age%20z-scores%20in%20infants%20with%20in-utero%20HIV%20and%20ART%20exposure%3A%20a%20prospective%20study%20in%20Cape%20Town%2C%20South%20Africa.%20%3Ci%3EBMC%20Pregnancy%20Childbirth%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%20%281%29%2C%20S.%20354.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12884-021-03836-z%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12884-021-03836-z%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lower%20birth%20weight-for-age%20and%20length-for-age%20z-scores%20in%20infants%20with%20in-utero%20HIV%20and%20ART%20exposure%3A%20a%20prospective%20study%20in%20Cape%20Town%2C%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20C.%22%2C%22lastName%22%3A%22Nyemba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20P.%22%2C%22lastName%22%3A%22Madlala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Malaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Powis%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Successful%20scale-up%20of%20antiretroviral%20therapy%20%28ART%29%20during%20pregnancy%20has%20minimized%20infant%20HIV%20acquisition%2C%20and%20over%201%20million%20infants%20are%20born%20HIV-exposed%20but%20uninfected%20%28HEU%29%2C%20with%20an%20increasing%20proportion%20also%20exposed%20in%20utero%20to%20maternal%20ART.%20While%20benefits%20of%20ART%20in%20pregnancy%20outweigh%20risks%2C%20some%20studies%20have%20reported%20associations%20between%20in%20utero%20ART%20exposure%20and%20impaired%20fetal%20growth%2C%20highlighting%20the%20need%20to%20identify%20the%20safest%20ART%20regimens%20for%20use%20in%20pregnancy.%20METHODS%3A%20We%20compared%20birth%20anthropometrics%20of%20infants%20who%20were%20HEU%20with%20those%20HIV-unexposed%20%28HU%29%20in%20Cape%20Town%2C%20South%20Africa.%20Pregnant%20women%20had%20gestational%20age%20assessed%20by%20ultrasound%20at%20enrolment.%20Women%20living%20with%20HIV%20were%20on%20ART%20%28predominately%20tenofovir-emtricitabine-efavirenz%29%20either%20prior%20to%20conception%20or%20initiated%20during%20pregnancy.%20Birth%20weights%20and%20lengths%20were%20converted%20to%20weight-for-age%20%28WAZ%29%20and%20length-for-age%20%28LAZ%29%20z-scores%20using%20Intergrowth-21st%20software.%20Linear%20regression%20was%20used%20to%20compare%20mean%20z-scores%20adjusting%20for%20maternal%20and%20pregnancy%20characteristics.%20RESULTS%3A%20Among%20888%20infants%2C%2049%25%20%28n%20%3D%20431%29%20were%20HEU%20and%2051%25%20%28n%20%3D%20457%29%20HU.%20Of%20431%20HEU%20infants%2C%2062%25%20%28n%20%3D%20268%29%20were%20exposed%20to%20HIV%20and%20antiretrovirals%20%28ARVs%29%20from%20conception%20and%2038%25%20%28n%20%3D%20163%29%20were%20exposed%20to%20ARVs%20during%20gestation%20but%20after%20conception%20%28median%20fetal%20ARV%20exposure%20of%2021%20weeks%20%5BIQR%3B%2017-26%5D%29.%20In%20univariable%20analysis%2C%20infants%20who%20were%20HEU%20had%20lower%20mean%20WAZ%20compared%20with%20HU%20%5Bbeta%20%3D%20-%200.15%20%2895%25%20Confidence%20Interval%20%28CI%29%3A%20-%200.28%2C%20-%200.020%29%5D.%20After%20adjustment%20for%20maternal%20age%2C%20gravidity%2C%20alcohol%20use%2C%20marital%20and%20employment%20status%20the%20effect%20remained%20%5Badjusted%20beta%20-%200.14%20%2895%25CI%3A%20-%200.28%2C%20-%200.01%5D.%20Similar%20differences%20were%20noted%20for%20mean%20LAZ%20in%20univariable%20%5Bbeta%20-%200.20%20%2895%25CI%3A%20-%200.42%2C%20-%200.01%5D%20but%20not%20multivariable%20analyses%20%5Badjusted%20beta%20-%200.18%20%2895%25CI%3A%20-%200.41%2C%20%2B%200.04%5D%20after%20adjusting%20for%20the%20same%20variables.%20Mean%20WAZ%20and%20LAZ%20did%20not%20vary%20by%20in%20utero%20ARV%20exposure%20duration%20among%20infants%20who%20were%20HEU.%20CONCLUSION%3A%20In%20a%20cohort%20with%20high%20prevalence%20of%20ART%20exposure%20in%20pregnancy%2C%20infants%20who%20were%20HEU%20had%20lower%20birth%20WAZ%20compared%20with%20those%20HU.%20Studies%20designed%20to%20identify%20the%20mechanisms%20and%20clinical%20significance%20of%20these%20disparities%2C%20and%20to%20establish%20the%20safest%20ART%20for%20use%20in%20pregnancy%20are%20urgently%20needed.%22%2C%22date%22%3A%22May%204%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12884-021-03836-z%22%2C%22ISSN%22%3A%221471-2393%20%28Electronic%29%201471-2393%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A37%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22M58IDJ9L%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Coburn%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoburn%2C%20S.%20B.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShiels%2C%20M.%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESilverberg%2C%20M.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHorberg%2C%20M.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGill%2C%20M.%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Secular%20Trends%20in%20Breast%20Cancer%20Risk%20Among%20Women%20With%20HIV%20Initiating%20ART%20in%20North%20America.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E87%3C%5C%2Fi%3E%20%281%29%2C%20S.%20663%26%23x2013%3B670.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002627%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002627%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Secular%20Trends%20in%20Breast%20Cancer%20Risk%20Among%20Women%20With%20HIV%20Initiating%20ART%20in%20North%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20B.%22%2C%22lastName%22%3A%22Coburn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20S.%22%2C%22lastName%22%3A%22Shiels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20T.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Visvanathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20E.%22%2C%22lastName%22%3A%22Connor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Marcus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20C.%22%2C%22lastName%22%3A%22Mathews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20S.%22%2C%22lastName%22%3A%22Rabkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22D%27Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Lau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%20Cohort%20Collaboration%20on%20Research%22%2C%22lastName%22%3A%22North%20American%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22Design%20of%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Studies%20suggest%20lower%20risk%20of%20breast%20cancer%20in%20women%20with%20HIV%20versus%20without%20HIV.%20These%20estimates%20may%20be%20biased%20by%20lower%20life%20expectancy%20and%20younger%20age%20distribution%20of%20women%20with%20HIV.%20Our%20analysis%20evaluated%20this%20bias%20and%20characterized%20secular%20trends%20in%20breast%20cancer%20among%20women%20with%20HIV%20initiating%20antiretroviral%20therapy.%20We%20hypothesized%20breast%20cancer%20risk%20would%20increase%20over%20time%20as%20mortality%20decreased.%20SETTING%3A%20Women%20with%20HIV%20prescribed%20antiretroviral%20therapy%20in%20the%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20%28NA-ACCORD%29%20from%201997%20through%202016.%20METHODS%3A%20We%20estimated%20breast%20cancer%20hazard%20%28cause-specific%20hazard%20ratios%29%20and%20cumulative%20incidence%20accounting%20for%20competing%20risks%20%28subdistribution%20hazard%20ratios%29%20to%20assess%20changes%20in%20breast%20cancer%20risk%20over%20time.%20This%20was%20assessed%20overall%20%281997-2016%29%20and%20within%5C%2Facross%20calendar%20periods.%20Analyses%20were%20adjusted%20for%20race%5C%2Fethnicity%20and%20inverse%20probability%20weighted%20for%20cohort.%20Cumulative%20incidence%20was%20graphically%20assessed%20by%20calendar%20period%20and%20race%5C%2Fethnicity.%20RESULTS%3A%20We%20observed%2011%2C587%20women%20during%201997-2016%2C%20contributing%2063%20incident%20breast%20cancer%20diagnoses%20and%201%2C353%20deaths%20%5B73%2C445%20person-years%20%28median%20follow-up%20%3D%204.5%20years%29%5D.%20Breast%20cancer%20cumulative%20incidence%20was%203.2%25%20for%201997-2016.%20We%20observed%20no%20secular%20trends%20in%20breast%20cancer%20hazard%20or%20cumulative%20incidence.%20There%20were%20annual%20declines%20in%20the%20hazard%20and%20cumulative%20incidence%20of%20death%20%28cause-specific%20hazard%20ratios%20and%20subdistribution%20hazard%20ratios%3A%200.89%2C%2095%25%20confidence%20interval%3A%200.87%20to%200.91%29%20which%20remained%20within%20and%20across%20calendar%20periods.%20CONCLUSIONS%3A%20These%20findings%20contradict%20the%20hypothesis%20of%20increasing%20breast%20cancer%20risk%20with%20declining%20mortality%20over%20time%20among%20women%20with%20HIV%2C%20suggesting%20limited%20impact%20of%20changing%20mortality%20on%20breast%20cancer%20risk.%20Additional%20inquiry%20is%20merited%20as%20survival%20improves%20among%20women%20with%20HIV.%22%2C%22date%22%3A%22May%201%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000002627%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A27%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22Q86DM8E3%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Han%20et%20al.%22%2C%22parsedDate%22%3A%222021-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHan%2C%20W.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJiamsakul%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESalleh%2C%20N.%20A.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChoi%2C%20J.%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHuy%2C%20B.%20V.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20HIV%20treatment%20outcomes%20among%20people%20who%20acquired%20HIV%20via%20injecting%20drug%20use%20in%20the%20Asia-Pacific%20region%3A%20a%20longitudinal%20cohort%20study.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E24%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e25736.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25736%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25736%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20treatment%20outcomes%20among%20people%20who%20acquired%20HIV%20via%20injecting%20drug%20use%20in%20the%20Asia-Pacific%20region%3A%20a%20longitudinal%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20M.%22%2C%22lastName%22%3A%22Han%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20A.%20M.%22%2C%22lastName%22%3A%22Salleh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20V.%22%2C%22lastName%22%3A%22Huy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Yunihastuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20P.%22%2C%22lastName%22%3A%22Merati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20M.%22%2C%22lastName%22%3A%22Gani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chaiwarith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20T.%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ditangco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Sangle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22Treat%20Asia%20HIV%20Observational%20Database%20of%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20Asia-Pacific%20Group%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Data%20on%20HIV%20treatment%20outcomes%20in%20people%20who%20inject%20drugs%20%28PWID%29%20in%20the%20Asia-Pacific%20are%20sparse%20despite%20the%20high%20burden%20of%20drug%20use.%20We%20assessed%20immunological%20and%20virological%20responses%2C%20AIDS-defining%20events%20and%20mortality%20among%20PWID%20receiving%20antiretroviral%20therapy%20%28ART%29.%20METHODS%3A%20We%20investigated%20HIV%20treatment%20outcomes%20among%20people%20who%20acquired%20HIV%20via%20injecting%20drug%20use%20in%20the%20TREAT%20Asia%20HIV%20Observational%20Database%20%28TAHOD%29%20between%20January%202003%20and%20March%202019.%20Trends%20in%20CD4%20count%20and%20viral%20suppression%20%28VS%2C%20HIV%20viral%20load%20%3C1000%20copies%5C%2FmL%29%20were%20assessed.%20Factors%20associated%20with%20mean%20CD4%20changes%20were%20analysed%20using%20repeated%20measures%20linear%20regression%2C%20and%20combined%20AIDS%20event%20and%20mortality%20were%20analysed%20using%20survival%20analysis.%20RESULTS%3A%20Of%20622%20PWID%20from%2012%20countries%20in%20the%20Asia-Pacific%2C%2093%25%20were%20male%20and%20the%20median%20age%20at%20ART%20initiation%20was%2031%20years%20%28IQR%2C%2028%20to%2034%29.%20The%20median%20pre-ART%20CD4%20count%20was%2071%20cells%5C%2FmicroL.%20CD4%20counts%20increased%20over%20time%2C%20with%20a%20mean%20difference%20of%20401%20%2895%25%20CI%2C%20372%20to%20457%29%20cells%5C%2FmicroL%20at%20year-10%20%28n%20%3D%2078%29.%20Higher%20follow-up%20HIV%20viral%20load%20and%20pre-ART%20CD4%20counts%20were%20associated%20with%20smaller%20increases%20in%20CD4%20counts.%20Among%20361%20PWID%20with%20%3E%5C%2F%3D1%20viral%20load%20after%20six%20months%20on%20ART%2C%20proportions%20with%20VS%20were%2082%25%2C%2088%25%20and%2093%25%20at%202-%2C%205-%20and%2010-years%20following%20ART%20initiation.%20There%20were%2052%20new%20AIDS-defining%20events%20and%2050%20deaths%20during%203347%20person-years%20of%20follow-up%20%28PYS%29%20%28incidence%203.05%5C%2F100%20PYS%2C%2095%25%20CI%2C%202.51%20to%203.70%29.%20Previous%20AIDS%20or%20TB%20diagnosis%2C%20lower%20current%20CD4%20count%20and%20adherence%20%3C95%25%20were%20associated%20with%20combined%20new%20AIDS-defining%20event%20and%20death.%20CONCLUSIONS%3A%20Despite%20improved%20outcomes%20over%20time%2C%20our%20findings%20highlight%20the%20need%20for%20rapid%20ART%20initiation%20and%20adherence%20support%20among%20PWID%20within%20Asian%20settings.%22%2C%22date%22%3A%22May%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25736%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A51%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22LJ8B66T6%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tiendrebeogo%20et%20al.%22%2C%22parsedDate%22%3A%222021-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETiendrebeogo%2C%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMessou%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EArikawa%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEkouevi%2C%20D.%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETanon%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Ten-year%20attrition%20and%20antiretroviral%20therapy%20response%20among%20HIV-positive%20adults%3A%20a%20sex-based%20cohort%20analysis%20from%20eight%20West%20African%20countries.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E24%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e25723.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25723%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25723%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ten-year%20attrition%20and%20antiretroviral%20therapy%20response%20among%20HIV-positive%20adults%3A%20a%20sex-based%20cohort%20analysis%20from%20eight%20West%20African%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Arikawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20K.%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Tanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Kwaghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Balestre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20D.%22%2C%22lastName%22%3A%22Zannou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Poda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Dabis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Becquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20West%20Africa%20Collaboration%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Sex%20differences%20have%20already%20been%20reported%20in%20sub-Saharan%20Africa%20for%20attrition%20and%20immunological%20response%20after%20antiretroviral%20therapy%20%28ART%29%20initiation%2C%20but%20follow-up%20was%20usually%20limited%20to%20the%20first%20two%20to%20three%20years%20after%20ART%20initiation.%20We%20evaluated%20sex%20differences%20on%20the%20same%20outcomes%20in%20the%2010%20years%20following%20ART%20initiation%20in%20West%20African%20adults.%20METHODS%3A%20We%20used%20cohort%20data%20of%20patients%20included%20in%20the%20IeDEA%20West%20Africa%20collaboration%2C%20who%20initiated%20ART%20between%202002%20and%202014.%20We%20modelled%20no-follow-up%20and%2010-year%20attrition%20risks%2C%20and%20immunological%20response%20by%20sex%20using%20logistic%20regression%20analysis%2C%20survival%20analysis%20with%20random%20effect%20and%20linear%20mixed%20models%20respectively.%20RESULTS%3A%20A%20total%20of%2071%2C283%20patients%20%2865.8%25%20women%29%20contributed%20to%20310%2C007%20person-years%20of%20follow-up%20in%2016%20clinics%20in%20eight%20West%20African%20countries.%20The%20cumulative%20attrition%20incidence%20at%2010-year%20after%20ART%20initiation%20reached%2075%25%20and%2068%25%20for%20men%20and%20women%20respectively.%20Being%20male%20was%20associated%20with%20an%20increased%20risk%20of%20no%20follow-up%20after%20starting%20ART%20%285.1%25%20vs.%204.0%25%2C%20adjusted%20Odds%20Ratio%3A%201.25%20%5B95%25%20CI%3A%201.15%20to%201.35%5D%29%20and%20of%2010-year%20attrition%20throughout%20the%2010-year%20period%20following%20ART%20initiation%3A%20adjusted%20Hazard%20Ratios%20were%201.22%20%5B95%25%20CI%3A%201.17%20to%201.27%5D%2C%201.08%20%5B95%25%20CI%3A%201.04%20to%201.12%5D%20and%201.04%20%5B95%25%20CI%3A%201.01%20to%201.08%5D%20during%20year%201%2C%20years%202%20to%204%20and%205%20to%2010%20respectively.%20A%20better%20immunological%20response%20was%20achieved%20by%20women%20than%20men%3A%20monthly%20CD4%20gain%20was%2030.2%20and%2028.3%20cells%5C%2FmL%20in%20the%20first%20four%20months%20and%202.6%20and%201.9%20cells%5C%2FmuL%20thereafter.%20Ultimately%2C%20women%20reached%20the%20average%20threshold%20of%20500%20CD4%20cells%5C%2FmuL%20in%20their%20sixth%20year%20of%20follow-up%2C%20whereas%20men%20failed%20to%20reach%20it%20even%20at%20the%20end%20of%20the%2010-year%20follow-up%20period.%20The%20proportion%20of%20patients%20reaching%20the%20threshold%20was%20much%20higher%20in%20women%20than%20in%20men%20after%2010%20years%20since%20ART%20initiation%20%2865%25%20vs.%2044%25%29.%20CONCLUSIONS%3A%20In%20West%20Africa%2C%20attrition%20is%20unacceptably%20high%20in%20both%20sexes.%20Men%20are%20more%20vulnerable%20than%20women%20on%20both%20attrition%20and%20immunological%20response%20to%20ART%20in%20the%2010%20years%20following%20ART%20initiation.%20Innovative%20tracing%20strategies%20that%20are%20sex-adapted%20are%20needed%20for%20patients%20in%20care%20to%20monitor%20attrition%2C%20detect%20early%20high-risk%20groups%20so%20that%20they%20can%20stay%20in%20care%20with%20a%20durably%20controlled%20infection.%22%2C%22date%22%3A%22May%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25723%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A29%3A29Z%22%7D%7D%2C%7B%22key%22%3A%223S3R5MNY%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fouda%20et%20al.%22%2C%22parsedDate%22%3A%222021-05%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFouda%2C%20G.%20G.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKwiek%2C%20J.%20J.%3C%5C%2Fspan%3E%20%26amp%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYotebieng%2C%20M.%3C%5C%2Fspan%3E%20%282021%29.%20Safety%20of%20Breastfeeding%20by%20Mothers%20With%20COVID-19%3A%20New%20Evidence%20From%20Israel.%20%3Ci%3EPediatrics%3C%5C%2Fi%3E%2C%20%3Ci%3E147%3C%5C%2Fi%3E%20%285%29.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1542%5C%2Fpeds.2020-049772%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1542%5C%2Fpeds.2020-049772%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Safety%20of%20Breastfeeding%20by%20Mothers%20With%20COVID-19%3A%20New%20Evidence%20From%20Israel%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20G.%20A.%22%2C%22lastName%22%3A%22Fouda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Kwiek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22May%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1542%5C%2Fpeds.2020-049772%22%2C%22ISSN%22%3A%221098-4275%20%28Electronic%29%200031-4005%20%28Print%29%200031-4005%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A27%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22V9WKSHVK%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Yohannes%20et%20al.%22%2C%22parsedDate%22%3A%222021-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EYohannes%2C%20N.%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJenkins%2C%20C.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EClouse%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECortes%2C%20C.%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMejia%20Cordero%2C%20F.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Timing%20of%20HIV%20diagnosis%20relative%20to%20pregnancy%20and%20postpartum%20HIV%20care%20continuum%20outcomes%20among%20Latin%20American%20women%2C%202000%20to%202017.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E24%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e25740.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25740%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25740%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Timing%20of%20HIV%20diagnosis%20relative%20to%20pregnancy%20and%20postpartum%20HIV%20care%20continuum%20outcomes%20among%20Latin%20American%20women%2C%202000%20to%202017%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20T.%22%2C%22lastName%22%3A%22Yohannes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Clouse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Mejia%20Cordero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20K.%22%2C%22lastName%22%3A%22Friedman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20HIV%20incidence%20among%20women%20of%20reproductive%20age%20and%20vertical%20HIV%20transmission%20rates%20remain%20high%20in%20Latin%20America.%20We%2C%20therefore%2C%20quantified%20HIV%20care%20continuum%20barriers%20and%20outcomes%20among%20pregnant%20women%20living%20with%20HIV%20%28WLWH%29%20in%20Latin%20America.%20METHODS%3A%20WLWH%20%28aged%20%3E%5C%2F%3D16%20years%29%20enrolling%20at%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%20sites%20from%202000%20to%202017%20who%20had%20HIV%20diagnosis%2C%20pregnancy%20and%20delivery%20dates%20contributed.%20Logistic%20regression%20produced%20adjusted%20odds%20ratios%20%28aOR%29%20and%2095%25%20confidence%20intervals%20%28CI%29%20for%20retention%20in%20care%20%28%3E%5C%2F%3D2%20visits%20%3E%5C%2F%3D3%20months%20apart%29%20and%20virological%20suppression%20%28viral%20load%20%3C200%20copies%5C%2FmL%29%2012%20months%20after%20pregnancy%20outcome.%20Cumulative%20incidences%20of%20loss%20to%20follow-up%20%28LTFU%29%20postpartum%20were%20estimated%20using%20Cox%20regression.%20Evidence%20of%20HIV%20status%20at%20pregnancy%20confirmation%20was%20the%20exposure.%20Covariates%20included%20pregnancy%20outcome%20%28born%20alive%20vs.%20others%29%3B%20AIDS%20diagnosis%20prior%20to%20delivery%3B%20CD4%2C%20age%2C%20HIV-1%20RNA%20and%20cART%20regimen%20at%20first%20delivery%20and%20CCASAnet%20country.%20RESULTS%3A%20Among%20579%20WLWH%2C%20median%20postpartum%20follow-up%20was%204.34%20years%20%28IQR%201.91%2C%207.35%29%3B%20459%20%2879%25%29%20were%20HIV-diagnosed%20before%20pregnancy%20confirmation%2C%20445%20%2877%25%29%20retained%20in%20care%20and%20259%20%2845%25%29%20virologically%20suppressed%20at%2012%20months%20of%20postpartum.%20Cumulative%20incidence%20of%20LTFU%20was%2021%25%20by%2012%20months%20and%2040%25%20by%20five%20years%20postpartum.%20Those%20HIV-diagnosed%20during%20pregnancy%20had%20lower%20odds%20of%20retention%20%28aOR%20%3D%200.58%2C%2095%25%20CI%3A%200.35%20to%200.97%29%20and%20virological%20suppression%20%28aOR%20%3D%200.50%2C%2095%25%20CI%3A%200.31%20to%200.82%29%20versus%20those%20HIV-diagnosed%20before.%20CONCLUSION%3A%20HIV%20diagnosis%20during%20pregnancy%20was%20associated%20with%20poorer%2012-month%20retention%20and%20virological%20suppression.%20Young%20women%20should%20be%20tested%20and%20linked%20to%20HIV%20care%20earlier%20to%20narrow%20these%20disparities.%22%2C%22date%22%3A%22May%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25740%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A31%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22KCP8KSCP%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ross%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-24%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoss%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurenzi%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHill%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERemera%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIngabire%2C%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Reducing%20time%20to%20differentiated%20service%20delivery%20for%20newly%20diagnosed%20people%20living%20with%20HIV%20in%20Kigali%2C%20Rwanda%3A%20study%20protocol%20for%20a%20pilot%2C%20unblinded%2C%20randomised%20controlled%20study.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E11%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e047443.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2020-047443%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2020-047443%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Reducing%20time%20to%20differentiated%20service%20delivery%20for%20newly%20diagnosed%20people%20living%20with%20HIV%20in%20Kigali%2C%20Rwanda%3A%20study%20protocol%20for%20a%20pilot%2C%20unblinded%2C%20randomised%20controlled%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Hill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Remera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Ingabire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Umwiza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Muhoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20S.%22%2C%22lastName%22%3A%22Habimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Mugwaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anastos%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Current%20HIV%20guidelines%20recommend%20differentiated%20service%20delivery%20%28DSD%29%20models%20that%20allow%20for%20fewer%20health%20centre%20visits%20for%20clinically%20stable%20people%20living%20with%20HIV%20%28PLHIV%29.%20Newly%20diagnosed%20PLHIV%20may%20require%20more%20intensive%20care%20early%20in%20their%20treatment%20course%2C%20yet%20frequent%20appointments%20can%20be%20burdensome%20to%20patients%20and%20health%20systems.%20Determining%20the%20optimal%20parameters%20for%20defining%20clinical%20stability%20and%20transitioning%20to%20less%20frequent%20appointments%20could%20decrease%20patient%20burden%20and%20health%20system%20costs.%20The%20objectives%20of%20this%20pilot%20study%20are%20to%20explore%20the%20feasibility%20and%20acceptability%20of%20%281%29%20reducing%20the%20time%20to%20DSD%20from%2012%20to%206%20months%20after%20antiretroviral%20therapy%20%28ART%29%20initiation%2Cand%20%282%29%20reducing%20the%20number%20of%20suppressed%20viral%20loads%20required%20to%20enter%20DSD%20from%20two%20to%20one.%20METHODS%20AND%20ANALYSES%3A%20The%20present%20study%20is%20a%20pilot%2C%20unblinded%20trial%20taking%20place%20in%20three%20health%20facilities%20in%20Kigali%2C%20Rwanda.%20Current%20Rwandan%20guidelines%20require%20PLHIV%20to%20be%20on%20ART%20for%20%3E%5C%2F%3D12%20months%20with%20two%20consecutive%20suppressed%20viral%20loads%20in%20order%20to%20transition%20to%20less%20frequent%20appointments.%20We%20will%20randomise%2090%20participants%20to%20one%20of%20three%20arms%3A%20entry%20into%20DSD%20at%206%20months%20after%20one%20suppressed%20viral%20load%20%28n%3D30%29%2C%20entry%20into%20DSD%20at%206%20months%20after%20two%20suppressed%20viral%20loads%20%28n%3D30%29%20or%20current%20standard%20of%20care%20%28n%3D30%29.%20We%20will%20measure%20feasibility%20and%20acceptability%20of%20this%20intervention%3B%20clinical%20outcomes%20include%20viral%20suppression%20at%2012%20months%20%28primary%20outcome%29%20and%20appointment%20attendance%20%28secondary%20outcome%29.%20ETHICS%20AND%20DISSEMINATION%3A%20This%20clinical%20trial%20was%20approved%20by%20the%20institutional%20review%20board%20of%20Albert%20Einstein%20College%20of%20Medicine%20and%20by%20the%20Rwanda%20National%20Ethics%20Committee.%20Findings%20will%20be%20disseminated%20through%20conferences%20and%20peer-reviewed%20publications%2C%20as%20well%20as%20meetings%20with%20stakeholders.%20TRIAL%20REGISTRATION%20NUMBER%3A%20NCT04567693.%22%2C%22date%22%3A%22Apr%2024%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2020-047443%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A25%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22Y8U2SGES%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Olali%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-15%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOlali%2C%20A.%20Z.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESharma%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShi%2C%20Q.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHoover%2C%20D.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWeber%2C%20K.%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Change%20in%20Circulating%20Undercarboxylated%20Osteocalcin%20%28ucOCN%29%20Is%20Associated%20With%20Fat%20Accumulation%20in%20HIV-Seropositive%20Women.%20%3Ci%3EJ%20Acquir%20Immune%20Defic%20Syndr%3C%5C%2Fi%3E%2C%20%3Ci%3E86%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e139%26%23x2013%3Be145.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002617%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002617%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Change%20in%20Circulating%20Undercarboxylated%20Osteocalcin%20%28ucOCN%29%20Is%20Associated%20With%20Fat%20Accumulation%20in%20HIV-Seropositive%20Women%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20Z.%22%2C%22lastName%22%3A%22Olali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q.%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Hoover%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Weber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22French%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20S.%22%2C%22lastName%22%3A%22McKay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20C.%22%2C%22lastName%22%3A%22Tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Al-Harthi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20T.%22%2C%22lastName%22%3A%22Yin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Ross%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Bone%20mineral%20density%20loss%20and%20fat%20accumulation%20are%20common%20in%20people%20living%20with%20HIV.%20The%20bone-derived%20hormone%2C%20undercarboxylated%20osteocalcin%20%28ucOCN%29%20regulates%20fat%20metabolism.%20We%20investigated%20the%20relationship%20between%20ucOCN%20change%20and%20body%20fat%20change%20among%20perimenopausal%5C%2Fpostmenopausal%20HIV-seronegative%20and%20HIV-seropositive%20women%20on%20long-term%20antiretrovirals.%20METHODS%3A%20Perimenopausal%20and%20postmenopausal%20women%20enrolled%20in%20the%20Women%27s%20Interagency%20HIV%20Study%20MSK%20substudy%20underwent%20trunk%20and%20total%20fat%20assessment%20by%20dual%20energy%20x-ray%20absorptiometry%20%28DXA%29%20at%20study%20enrollment%20%28index%20visit%29%20and%20again%202%20years%20later.%20Circulating%20ucOCN%20and%20cOCN%20were%20also%20measured%20at%20the%20index%20and%202-year%20visits.%20The%20correlation%20between%20the%202-year%20change%20in%20ucOCN%20and%20cOCN%20and%20change%20in%20trunk%20and%20total%20fat%20was%20assessed%20as%20a%20function%20of%20HIV%20serostatus%20using%20linear%20regression%20modeling.%20Multivariate%20linear%20regression%20assessed%20the%20association%20between%20ucOCN%20and%20cOCN%20change%20and%20total%20and%20trunk%20fat%20change%20after%20adjusting%20for%20sociodemographic%20variables.%20Linear%20regression%20models%20restricted%20to%20HIV-seropositive%20women%20were%20performed%20to%20examine%20the%20contributions%20of%20HIV-specific%20factors%20%28index%20CD4%20count%2C%20viral%20load%2C%20and%20combined%20antiretroviral%20therapy%20use%29%20on%20the%20associations.%20RESULTS%3A%20Increased%20ucOCN%20over%20the%202-year%20follow-up%20was%20associated%20with%20less%20trunk%20and%20total%20fat%20accumulation%20in%20models%20adjusting%20for%20HIV%20serostatus%20and%20participants%20sociodemographics%2C%20whereas%20there%20was%20no%20association%20with%20cOCN%20and%20the%20fat%20parameters.%20None%20of%20the%20HIV-specific%20factors%20evaluated%20influenced%20the%20association%20between%20ucOCN%20and%20fat%20parameters.%20CONCLUSION%3A%20The%20current%20study%20suggests%20that%20increases%20in%20ucOCN%20are%20associated%20with%20decreased%20fat%20accumulation%20in%20HIV-seronegative%20and%20HIV-seropositive%20postmenopausal%20women%20on%20long-term%20antiretroviral%20therapy.%22%2C%22date%22%3A%22Apr%2015%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000002617%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A38%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22SV4RT3L7%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Enane%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEnane%2C%20L.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EApondi%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOmollo%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EToromo%2C%20J.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBakari%2C%20S.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20%26%23x201C%3BI%20just%20keep%20quiet%20about%20it%20and%20act%20as%20if%20everything%20is%20alright%26%23x201D%3B%20-%20The%20cascade%20from%20trauma%20to%20disengagement%20among%20adolescents%20living%20with%20HIV%20in%20western%20Kenya.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E24%3C%5C%2Fi%3E%20%284%29%2C%20S.%20e25695.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25695%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25695%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5C%22I%20just%20keep%20quiet%20about%20it%20and%20act%20as%20if%20everything%20is%20alright%5C%22%20-%20The%20cascade%20from%20trauma%20to%20disengagement%20among%20adolescents%20living%20with%20HIV%20in%20western%20Kenya%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Apondi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Omollo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Toromo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bakari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Aluoch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Morris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kantor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Braitstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20D.%22%2C%22lastName%22%3A%22Fortenberry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20M.%22%2C%22lastName%22%3A%22Nyandiko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Elul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Vreeman%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20There%20are%20approximately%201.7%20million%20adolescents%20living%20with%20HIV%20%28ALHIV%2C%20ages%2010%20to%2019%29%20globally%2C%20including%20110%2C000%20in%20Kenya.%20While%20ALHIV%20experience%20poor%20retention%20in%20care%2C%20limited%20data%20exist%20on%20factors%20underlying%20disengagement.%20We%20investigated%20the%20burden%20of%20trauma%20among%20disengaged%20ALHIV%20in%20western%20Kenya%2C%20and%20its%20potential%20role%20in%20HIV%20care%20disengagement.%20METHODS%3A%20We%20performed%20in-depth%20qualitative%20interviews%20with%20ALHIV%20who%20had%20disengaged%20from%20care%20at%20two%20sites%2C%20their%20caregivers%20and%20healthcare%20workers%20%28HCW%29%20at%2010%20sites%2C%20from%202018%20to%202020.%20Disengagement%20was%20defined%20as%20not%20attending%20clinic%20%3E%5C%2F%3D60%20days%20past%20a%20missed%20scheduled%20visit.%20ALHIV%20and%20their%20caregivers%20were%20traced%20through%20phone%20calls%20and%20home%20visits.%20Interviews%20ascertained%20barriers%20and%20facilitators%20to%20adolescent%20retention%20in%20HIV%20care.%20Dedicated%20questions%20elicited%20narratives%20surrounding%20traumatic%20experiences%2C%20and%20the%20ways%20in%20which%20these%20did%20or%20did%20not%20impact%20retention%20in%20care.%20Through%20thematic%20analysis%2C%20a%20conceptual%20model%20emerged%20for%20a%20cascade%20from%20adolescent%20experience%20of%20trauma%20to%20disengagement%20from%20HIV%20care.%20RESULTS%3A%20Interviews%20were%20conducted%20with%2042%20disengaged%20ALHIV%2C%2034%20caregivers%20and%2028%20HCW.%20ALHIV%20experienced%20a%20high%20burden%20of%20trauma%20from%20a%20range%20of%20stressors%2C%20including%20experiences%20at%20HIV%20disclosure%20or%20diagnosis%2C%20the%20loss%20of%20parents%2C%20enacted%20stigma%20and%20physical%20or%20sexual%20violence.%20A%20confluence%20of%20factors%20-%20trauma%2C%20stigma%20and%20isolation%2C%20and%20lack%20of%20social%20support%20-%20led%20to%20hopelessness%20and%20depression.%20These%20factors%20compounded%20each%20other%2C%20and%20resulted%20in%20complex%20mental%20health%20burdens%2C%20poor%20antiretroviral%20adherence%20and%20care%20disengagement.%20HCW%20approaches%20aligned%20with%20the%20factors%20in%20this%20model%2C%20suggesting%20that%20these%20areas%20represent%20targets%20for%20intervention%20and%20provision%20of%20trauma-informed%20care.%20CONCLUSIONS%3A%20Trauma%20is%20a%20major%20factor%20underlying%20disengagement%20from%20HIV%20care%20among%20Kenyan%20adolescents.%20We%20describe%20a%20cascade%20of%20factors%20representing%20areas%20for%20intervention%20to%20support%20mental%20health%20and%20retention%20in%20HIV%20care.%20These%20include%20not%20only%20the%20provision%20of%20mental%20healthcare%2C%20but%20also%20preventing%20or%20addressing%20violence%2C%20trauma%20and%20stigma%2C%20and%20reinforcing%20social%20and%20familial%20support%20surrounding%20vulnerable%20adolescents.%20In%20this%20conceptualization%2C%20supporting%20retention%20in%20HIV%20care%20requires%20a%20trauma-informed%20approach%2C%20both%20in%20the%20individualized%20care%20of%20ALHIV%20and%20in%20the%20development%20of%20strategies%20and%20policies%20to%20support%20adolescent%20health%20outcomes.%22%2C%22date%22%3A%22Apr%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25695%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A47%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22EJA4YBWS%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Peetluk%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-02%22%2C%22numChildren%22%3A216%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPeetluk%2C%20L.%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERidolfi%2C%20F.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERebeiro%2C%20P.%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELiu%2C%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERolla%2C%20V.%20C.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Systematic%20review%20of%20prediction%20models%20for%20pulmonary%20tuberculosis%20treatment%20outcomes%20in%20adults.%20%3Ci%3EBMJ%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E11%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e044687.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2020-044687%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2020-044687%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Systematic%20review%20of%20prediction%20models%20for%20pulmonary%20tuberculosis%20treatment%20outcomes%20in%20adults%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20S.%22%2C%22lastName%22%3A%22Peetluk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20M.%22%2C%22lastName%22%3A%22Ridolfi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20systematically%20review%20and%20critically%20evaluate%20prediction%20models%20developed%20to%20predict%20tuberculosis%20%28TB%29%20treatment%20outcomes%20among%20adults%20with%20pulmonary%20TB.%20DESIGN%3A%20Systematic%20review.%20DATA%20SOURCES%3A%20PubMed%2C%20Embase%2C%20Web%20of%20Science%20and%20Google%20Scholar%20were%20searched%20for%20studies%20published%20from%201%20January%201995%20to%209%20January%202020.%20STUDY%20SELECTION%20AND%20DATA%20EXTRACTION%3A%20Studies%20that%20developed%20a%20model%20to%20predict%20pulmonary%20TB%20treatment%20outcomes%20were%20included.%20Study%20screening%2C%20data%20extraction%20and%20quality%20assessment%20were%20conducted%20independently%20by%20two%20reviewers.%20Study%20quality%20was%20evaluated%20using%20the%20Prediction%20model%20Risk%20Of%20Bias%20Assessment%20Tool.%20Data%20were%20synthesised%20with%20narrative%20review%20and%20in%20tables%20and%20figures.%20RESULTS%3A%2014%20739%20articles%20were%20identified%2C%20536%20underwent%20full-text%20review%20and%2033%20studies%20presenting%2037%20prediction%20models%20were%20included.%20Model%20outcomes%20included%20death%20%28n%3D16%2C%2043%25%29%2C%20treatment%20failure%20%28n%3D6%2C%2016%25%29%2C%20default%20%28n%3D6%2C%2016%25%29%20or%20a%20composite%20outcome%20%28n%3D9%2C%2025%25%29.%20Most%20models%20%28n%3D30%2C%2081%25%29%20measured%20discrimination%20%28median%20c-statistic%3D0.75%3B%20IQR%3A%200.68-0.84%29%2C%20and%2017%20%2846%25%29%20reported%20calibration%2C%20often%20the%20Hosmer-Lemeshow%20test%20%28n%3D13%29.%20Nineteen%20%2851%25%29%20models%20were%20internally%20validated%2C%20and%20six%20%2816%25%29%20were%20externally%20validated.%20Eighteen%20%2854%25%29%20studies%20mentioned%20missing%20data%2C%20and%20of%20those%2C%20half%20%28n%3D9%29%20used%20complete%20case%20analysis.%20The%20most%20common%20predictors%20included%20age%2C%20sex%2C%20extrapulmonary%20TB%2C%20body%20mass%20index%2C%20chest%20X-ray%20results%2C%20previous%20TB%20and%20HIV.%20Risk%20of%20bias%20varied%20across%20studies%2C%20but%20all%20studies%20had%20high%20risk%20of%20bias%20in%20their%20analysis.%20CONCLUSIONS%3A%20TB%20outcome%20prediction%20models%20are%20heterogeneous%20with%20disparate%20outcome%20definitions%2C%20predictors%20and%20methodology.%20We%20do%20not%20recommend%20applying%20any%20in%20clinical%20settings%20without%20external%20validation%2C%20and%20encourage%20future%20researchers%20adhere%20to%20guidelines%20for%20developing%20and%20reporting%20of%20prediction%20models.%20TRIAL%20REGISTRATION%3A%20The%20study%20was%20registered%20on%20the%20international%20prospective%20register%20of%20systematic%20reviews%20PROSPERO%20%28CRD42020155782%29.%22%2C%22date%22%3A%22Mar%202%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2020-044687%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A29%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22I5YBV5LQ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Boettiger%20et%20al.%22%2C%22parsedDate%22%3A%222021-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBoettiger%2C%20D.%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENewall%2C%20A.%20T.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPhillips%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBendavid%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELaw%2C%20M.%20G.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Cost-effectiveness%20of%20statins%20for%20primary%20prevention%20of%20atherosclerotic%20cardiovascular%20disease%20among%20people%20living%20with%20HIV%20in%20the%20United%20States.%20%3Ci%3EJ%20Int%20AIDS%20Soc%3C%5C%2Fi%3E%2C%20%3Ci%3E24%3C%5C%2Fi%3E%20%283%29%2C%20S.%20e25690.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25690%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25690%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cost-effectiveness%20of%20statins%20for%20primary%20prevention%20of%20atherosclerotic%20cardiovascular%20disease%20among%20people%20living%20with%20HIV%20in%20the%20United%20States%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20C.%22%2C%22lastName%22%3A%22Boettiger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20T.%22%2C%22lastName%22%3A%22Newall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Bendavid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20G.%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Ryom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Reiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mocroft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Weber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22El-Sadr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22d%27Arminio%20Monforte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22de%20Wit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Pradier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20I.%22%2C%22lastName%22%3A%22Hatleberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Lundgren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Sabin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22Kahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20S.%22%2C%22lastName%22%3A%22Kazi%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Expanding%20statin%20use%20may%20help%20to%20alleviate%20the%20excess%20burden%20of%20atherosclerotic%20cardiovascular%20disease%20in%20people%20living%20with%20HIV%20%28PLHIV%29.%20Pravastatin%20and%20pitavastatin%20are%20preferred%20agents%20due%20to%20their%20lack%20of%20substantial%20interaction%20with%20antiretroviral%20therapy.%20We%20aimed%20to%20evaluate%20the%20cost-effectiveness%20of%20pravastatin%20and%20pitavastatin%20for%20the%20primary%20prevention%20of%20atherosclerotic%20cardiovascular%20disease%20among%20PLHIV%20in%20the%20United%20States.%20METHODS%3A%20We%20developed%20a%20microsimulation%20model%20that%20randomly%20selected%20%28with%20replacement%29%20individuals%20from%20the%20Data-collection%20on%20Adverse%20Effects%20of%20Anti-HIV%20Drugs%20study%20with%20follow-up%20between%202013%20and%202016.%20Our%20study%20population%20was%20PLHIV%20aged%2040%20to%2075%20years%2C%20stable%20on%20antiretroviral%20therapy%2C%20and%20not%20currently%20using%20lipid-lowering%20therapy.%20Direct%20medical%20costs%20and%20quality-adjusted%20life-years%20%28QALYs%29%20were%20assigned%20in%20annual%20cycles%20and%20discounted%20at%203%25%20per%20year.%20We%20assumed%20a%20willingness-to-pay%20threshold%20of%20%24100%2C000%5C%2FQALY%20gained.%20The%20interventions%20assessed%20were%20as%20follows%3A%20%281%29%20treating%20no%20one%20with%20statins%3B%20%282%29%20treating%20everyone%20with%20generic%20pravastatin%2040%20mg%5C%2Fday%20%28drug%20cost%20%24236%5C%2Fyear%29%20and%20%283%29%20treating%20everyone%20with%20branded%20pitavastatin%204%20mg%5C%2Fday%20%28drug%20cost%20%242%2C828%5C%2Fyear%29.%20The%20model%20simulated%20each%20individual%27s%20probability%20of%20experiencing%20atherosclerotic%20cardiovascular%20disease%20over%2020%20years.%20RESULTS%3A%20Persons%20receiving%20pravastatin%20accrued%200.024%20additional%20QALYs%20compared%20with%20those%20not%20receiving%20a%20statin%2C%20at%20an%20incremental%20cost%20of%20%241338%2C%20giving%20an%20incremental%20cost-effectiveness%20ratio%20of%20%2456%2C000%5C%2FQALY%20gained.%20Individuals%20receiving%20pitavastatin%20accumulated%200.013%20additional%20QALYs%20compared%20with%20those%20using%20pravastatin%2C%20at%20an%20additional%20cost%20of%20%2418%2C251%2C%20giving%20an%20incremental%20cost-effectiveness%20ratio%20of%20%241%2C444%2C000%5C%2FQALY%20gained.%20These%20findings%20were%20most%20sensitive%20to%20the%20pill%20burden%20associated%20with%20daily%20statin%20administration%2C%20statin%20costs%2C%20statin%20efficacy%20and%20baseline%20atherosclerotic%20cardiovascular%20disease%20risk.%20In%20probabilistic%20sensitivity%20analysis%2C%20no%20statin%20was%20optimal%20in%205.2%25%20of%20simulations%2C%20pravastatin%20was%20optimal%20in%2094.8%25%20of%20simulations%20and%20pitavastatin%20was%20never%20optimal.%20CONCLUSIONS%3A%20Pravastatin%20was%20projected%20to%20be%20cost-effective%20compared%20with%20no%20statin.%20With%20substantial%20price%20reduction%2C%20pitavastatin%20may%20be%20cost-effective%20compared%20with%20pravastatin.%20These%20findings%20bode%20well%20for%20the%20expanded%20use%20of%20statins%20among%20PLHIV%20in%20the%20United%20States.%20To%20gain%20greater%20confidence%20in%20our%20conclusions%20it%20is%20important%20to%20generate%20strong%2C%20HIV-specific%20estimates%20on%20the%20efficacy%20of%20statins%20and%20the%20quality-of-life%20burden%20associated%20with%20taking%20an%20additional%20daily%20pill.%22%2C%22date%22%3A%22Mar%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25690%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%228IRGNQWZ%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A40%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22K6FNXUMX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Murenzi%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-19%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMurenzi%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ETuyisenge%2C%20P.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKanyabwisha%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMunyaneza%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMuhoza%2C%20B.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Type-specific%20persistence%2C%20clearance%20and%20incidence%20of%20high-risk%20HPV%20among%20screen-positive%20Rwandan%20women%20living%20with%20HIV.%20%3Ci%3EInfect%20Agent%20Cancer%3C%5C%2Fi%3E%2C%20%3Ci%3E16%3C%5C%2Fi%3E%20%281%29%2C%20S.%2016.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13027-021-00355-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13027-021-00355-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Type-specific%20persistence%2C%20clearance%20and%20incidence%20of%20high-risk%20HPV%20among%20screen-positive%20Rwandan%20women%20living%20with%20HIV%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Tuyisenge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Kanyabwisha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Muhoza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Kubwimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Murangwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mutesa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20E.%22%2C%22lastName%22%3A%22Castle%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Persistent%20infection%20with%20high-risk%20human%20papillomavirus%20%28hrHPV%29%20is%20a%20critical%20step%20in%20cervical%20carcinogenesis.%20We%20report%20on%20type-specific%20hrHPV%20persistence%2C%20clearance%20and%20incidence%20among%20screen-positive%20Rwandan%20women%20living%20with%20HIV%20%28WLWH%29.%20METHODS%3A%20This%20was%20a%20nested%20analysis%20from%20a%20large%20cervical%20cancer%20screening%20study%20of%20~%205000%20Rwandan%20WLWH.%20Women%20who%20tested%20positive%20for%20hrHPV%20and%5C%2For%20visual%20inspection%20with%20acetic%20acid%20were%20referred%20to%20colposcopy.%20For%20a%20subset%20of%20women%20%28n%20%3D%20298%29%20who%20were%20%3E%5C%2F%3D%206%20months%20delayed%20in%20receiving%20colposcopy%2C%20we%20tested%20their%20screening%20and%20colposcopy%20visit%20specimens%20using%20the%20AmpFire%20HPV%20genotyping%20assay%20that%20tests%2014%20hrHPV%20types%20%2816%2C%2018%2C%2031%2C%2033%2C%2035%2C%2039%2C%2045%2C%2051%2C%2052%2C%2056%2C%2058%2C%2059%2C%2066%2C%20and%2068%29%20individually.%20RESULTS%3A%20The%20mean%2C%20median%20%28interquartile%20range%20%5BIQR%5D%29%20and%20range%20of%20time%20between%20the%20screening%20and%20colposcopy%20visits%20were%20644%2C%20650%20%28490-820.5%29%20and%20197-1161%20days%2C%20respectively.%20Mean%2C%20median%20%28IQR%29%20and%20range%20of%20age%20at%20the%20screening%20visit%20were%2038%2C%2037%20%2834-43%29%20and%2030-54%20years%2C%20respectively.%20Two-hundred%20eighty-three%20%2895.0%25%29%20had%20CD4%20count%20%28cells%20per%20mm%283%29%29%20data%20available%20at%20baseline%20with%20mean%2C%20median%20%28IQR%29%20and%20range%20of%20592%2C%20513%20%28346-717%29%20and%200-7290%2C%20respectively.%20Two-hundred%20thirty-five%20WLWH%20were%20positive%20for%20at%20least%20one%20hrHPV%20type%20at%20the%20screening%20visit%2C%20of%20whom%2050.2%25%20had%20at%20least%20one%20HPV%20type-specific%20infection%20persist%3B%2037.2%25%20of%20all%20HPV%20infections%20detected%20at%20the%20screening%20visit%20persisted.%20Compared%20to%20all%20other%20HPV%20types%20in%20aggregate%2C%20HPV16%20%28vs.%20non-HPV16%20types%29%20%2847.7%25%2C%20p%20%3D%200.03%29%20and%20HPV33%20%28vs.%20non-HPV33%20types%29%20%2856.7%25%2C%20p%20%3D%200.03%29%20were%20significantly%20more%20likely%2C%20and%20HPV39%20%28vs.%20non-HPV39%20types%29%20%286.7%25%2C%20p%20%3D%200.01%29%2C%20HPV51%20%28vs.%20non-HPV51%20types%29%20%2815.6%25%2C%20p%20%3C%200.01%29%2C%20and%20HPV66%20%28vs.%20non-HPV66%20types%20%2817.9%25%2C%20p%20%3D%200.04%29%20were%20significantly%20less%20likely%2C%20to%20persist.%20Lower%20CD4%20counts%20were%20associated%20with%20having%20any%20persistent%20hrHPV%20infection%20%28p%28trend%29%20%3D%200.04%29%20and%20multiple%20persistent%20hrHPV%20infections%20%28p%28trend%29%20%3D%200.04%29.%20CONCLUSION%3A%20There%20is%20a%20significant%20proportion%20of%20WLWH%20with%20persistent%20hrHPV%20infection%2C%20emphasizing%20the%20need%20to%20vaccinate%20them%20against%20HPV%20prior%20to%20becoming%20sexually%20active.%22%2C%22date%22%3A%22Feb%2019%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13027-021-00355-6%22%2C%22ISSN%22%3A%221750-9378%20%28Print%29%201750-9378%20%28Electronic%29%201750-9378%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A51%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22NM9WNZK6%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rodrigues%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-19%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERodrigues%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStruchiner%2C%20C.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECoelho%2C%20L.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EVeloso%2C%20V.%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGrinsztejn%2C%20B.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Late%20initiation%20of%20antiretroviral%20therapy%3A%20inequalities%20by%20educational%20level%20despite%20universal%20access%20to%20care%20and%20treatment.%20%3Ci%3EBMC%20Public%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%20%281%29%2C%20S.%20389.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-021-10421-8%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-021-10421-8%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Late%20initiation%20of%20antiretroviral%20therapy%3A%20inequalities%20by%20educational%20level%20despite%20universal%20access%20to%20care%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20J.%22%2C%22lastName%22%3A%22Struchiner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20E.%22%2C%22lastName%22%3A%22Coelho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Late%20antiretroviral%20treatment%20initiation%20for%20HIV%20disease%20worsens%20health%20outcomes%20and%20contributes%20to%20ongoing%20transmission.%20We%20investigated%20whether%20socioeconomic%20inequalities%20exist%20in%20access%20to%20treatment%20in%20a%20setting%20with%20universal%20access%20to%20care%20and%20treatment.%20METHODS%3A%20This%20study%20investigated%20the%20association%20of%20educational%20level%2C%20used%20as%20a%20proxy%20for%20socioeconomic%20status%2C%20with%20late%20treatment%20initiation%20and%20treatment%20initiation%20with%20advanced%20disease.%20Study%20participants%20included%20adults%20%28%3E%5C%2F%3D25%20years%29%20who%20started%20treatment%20from%202005%20to%202018%20at%20Instituto%20Nacional%20de%20Infectologia%20Evandro%20Chagas%20of%20Fundacao%20Oswaldo%20Cruz%20%28INI%5C%2FFIOCRUZ%29%2C%20Rio%20de%20Janeiro%2C%20Brazil.%20Educational%20level%20was%20categorized%20following%20UNESCO%27s%20International%20Standard%20Classification%20of%20Education%3A%20incomplete%20basic%20education%2C%20basic%20education%2C%20secondary%20level%2C%20and%20tertiary%20level.%20We%20defined%20late%20treatment%20initiation%20as%20those%20initiating%20treatment%20with%20a%20CD4%20%3C%20350%20cells%5C%2FmL%20or%20an%20AIDS-defining%20event%2C%20and%20treatment%20initiation%20with%20advanced%20disease%20as%20those%20initiating%20treatment%20with%20a%20CD4%20%3C%20200%20cells%5C%2FmL%20or%20an%20AIDS-defining%20event.%20A%20directed%20acyclic%20graph%20%28DAG%29%20was%20constructed%20to%20represent%20the%20theoretical-operational%20model%20and%20to%20understand%20the%20involvement%20of%20covariates.%20Logistic%20regression%20models%20were%20used%20to%20estimate%20the%20adjusted%20odds%20ratios%20%28aOR%29%20and%2095%25%20confidence%20intervals%20%2895%25CI%29.%20Multiple%20imputation%20using%20a%20chained%20equations%20approach%20was%20used%20to%20treat%20missing%20values%20and%20non-linear%20terms%20for%20continuous%20variables%20were%20tested.%20RESULTS%3A%20In%20total%2C%203226%20individuals%20composed%20the%20study%20population%3A%20876%20%2827.4%25%29%20had%20incomplete%20basic%20education%2C%20540%20%2816.9%25%29%20basic%2C%201251%20%2839.2%25%29%20secondary%20level%2C%20and%20525%20%2816.4%25%29%20tertiary%20level.%20Late%20treatment%20initiation%20was%20observed%20for%202076%20%2864.4%25%29%20while%20treatment%20initiation%20with%20advanced%20disease%20was%20observed%20for%201423%20%2844.1%25%29.%20Compared%20to%20tertiary%20level%20of%20education%2C%20incomplete%20basic%2C%20basic%20and%20secondary%20level%20increased%20the%20odds%20of%20late%20treatment%20initiation%20by%2089%25%20%28aOR%3A1.89%2095%25CI%3A1.47-2.43%29%2C%2061%25%20%28aOR%3A1.61%2095%25CI%3A1.23-2.10%29%2C%20and%2035%25%20%28aOR%3A1.35%2095%25CI%3A1.09-1.67%29.%20Likewise%2C%20the%20odds%20of%20treatment%20initiation%20with%20advanced%20disease%20was%202.5-fold%20%28aOR%3A2.53%2095%25CI%3A1.97-3.26%29%2C%202-fold%20%28aOR%3A2.07%2095%25CI%3A1.59-2.71%29%2C%201.5-fold%20%28aOR%3A1.51%2095%25CI%3A1.21-1.88%29%20higher%20for%20those%20with%20incomplete%20basic%2C%20basic%20and%20secondary%20level%20education%20compared%20to%20tertiary%20level.%20CONCLUSION%3A%20Despite%20universal%20access%20to%20HIV%20care%20and%20antiretroviral%20treatment%2C%20late%20treatment%20initiation%20and%20social%20inequalities%20persist.%20Lower%20educational%20level%20significantly%20increased%20the%20odds%20of%20both%20outcomes%2C%20reinforcing%20the%20existence%20of%20barriers%20to%20%5C%22universal%5C%22%20antiretroviral%20treatment.%22%2C%22date%22%3A%22Feb%2019%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-021-10421-8%22%2C%22ISSN%22%3A%221471-2458%20%28Electronic%29%201471-2458%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A37%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22KUMQVQQU%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Adedimeji%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-18%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAdedimeji%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAjeh%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPierz%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENkeng%2C%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENdenkeh%2C%20J.%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Challenges%20and%20opportunities%20associated%20with%20cervical%20cancer%20screening%20programs%20in%20a%20low%20income%2C%20high%20HIV%20prevalence%20context.%20%3Ci%3EBMC%20Womens%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%20%281%29%2C%20S.%2074.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12905-021-01211-w%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12905-021-01211-w%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Challenges%20and%20opportunities%20associated%20with%20cervical%20cancer%20screening%20programs%20in%20a%20low%20income%2C%20high%20HIV%20prevalence%20context%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Adedimeji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Pierz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Nkeng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Ndenkeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Fuhngwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nsame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Nji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dzudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20E.%22%2C%22lastName%22%3A%22Castle%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Cervical%20cancer%20is%20a%20leading%20cause%20of%20death%20among%20Cameroon%20women.%20The%20burden%20of%20cervical%20cancer%20is%20in%20part%20traceable%20to%20the%20inadequate%20understanding%20of%20socio-contextual%20determinants%20of%20access%20to%20screening%20and%20prevention%20opportunities.%20We%20explored%20multilevel%20individual%2C%20community%20and%20structural%20factors%20that%20facilitate%20or%20inhibit%20cervical%20cancer%20prevention%20in%20women%20at%20risk%20in%20a%20low-income%2C%20high%20HIV%20prevalence%20context.%20METHODS%3A%20We%20utilized%20an%20exploratory%20qualitative%20approach%20to%20obtain%20data%20through%20focus%20group%20discussions%20and%20in-depth%20interviews%20from%20May%20to%20August%2C%202018.%20A%20two-stage%20purposive%20sampling%20strategy%20was%20used%20to%20select%2080%20women%20and%2020%20men%20who%20participated%20in%208%20focus%20group%20discussions%20and%208%20in-depth%20interviews.%20The%20socio-ecological%20model%20guided%20data%20analyses%20to%20identify%20micro-%2C%20meso-%2C%20and%20macro-level%20determinants%20of%20cervical%20cancer%20screening.%20RESULTS%3A%20Micro-level%20factors%20including%20lack%20of%20awareness%20and%20knowledge%20about%20cervical%20cancer%2C%20lack%20of%20access%20to%20information%2C%20excessive%20cost%20of%20cervical%20cancer%20screening%2C%20low%20risk%20perceptions%2C%20and%20poor%20health%20seeking%20behaviors%20were%20major%20barriers%20for%20women%20seeking%20cervical%20cancer%20screening.%20Meso-level%20factors%2C%20such%20as%20social%20networks%2C%20socio-cultural%20norms%2C%20perceptions%20of%20the%20role%20of%20men%20and%20HIV-related%20stigma%20when%20screening%20is%20integrated%20into%20HIV%20care%2C%20also%20engender%20negative%20attitudes%20and%20behaviors.%20Macro-level%20barriers%20to%20cervical%20cancer%20screening%20included%20poorly%20equipped%20health%20facilities%20and%20a%20lack%20of%20national%20cancer%20prevention%20policies%20and%20programs.%20CONCLUSION%3A%20In%20the%20context%20of%20the%20call%20for%20elimination%20of%20cervical%20cancer%20as%20a%20public%20health%20problem%2C%20our%20findings%20highlight%20challenges%20and%20opportunities%20that%20should%20be%20considered%20when%20implementing%20interventions%20to%20increase%20uptake%20of%20cervical%20cancer%20screening%20in%20low-middle%20income%20settings.%22%2C%22date%22%3A%22Feb%2018%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12905-021-01211-w%22%2C%22ISSN%22%3A%221472-6874%20%28Electronic%29%201472-6874%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A38%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22LX3VI6KM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Markmann%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMarkmann%2C%20A.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGiallourou%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBhowmik%2C%20D.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHou%2C%20Y.%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELerner%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Sex%20disparities%20and%20neutralizing%20antibody%20durability%20to%20SARS-CoV-2%20infection%20in%20convalescent%20individuals.%20%3Ci%3EMedRxiv%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2021.02.01.21250493%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2021.02.01.21250493%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sex%20disparities%20and%20neutralizing%20antibody%20durability%20to%20SARS-CoV-2%20infection%20in%20convalescent%20individuals%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20J.%22%2C%22lastName%22%3A%22Markmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Giallourou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Bhowmik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Hou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lerner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Premkumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Root%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22van%20Duin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Napravnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20D.%22%2C%22lastName%22%3A%22Graham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q.%22%2C%22lastName%22%3A%22Guerra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Raut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20J.%22%2C%22lastName%22%3A%22Petropoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Wrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cornaby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Schmitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Kuruc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Weiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Baric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22de%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Margolis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Bartelt%22%7D%5D%2C%22abstractNote%22%3A%22The%20coronavirus%20disease%202019%20%28COVID-19%29%20pandemic%2C%20caused%20by%20severe%20acute%20respiratory%20syndrome-related%20coronavirus-2%20%28SARS-CoV-2%29%20has%20now%20caused%20over%202%20million%20deaths%20worldwide%20and%20continues%20to%20expand.%20Currently%2C%20much%20is%20unknown%20about%20functionally%20neutralizing%20human%20antibody%20responses%20and%20durability%20to%20SARS-CoV-2.%20Using%20convalescent%20sera%20collected%20from%20101%20COVID-19%20recovered%20individuals%2021-212%20days%20after%20symptom%20onset%20with%20forty-eight%20additional%20longitudinal%20samples%2C%20we%20measured%20functionality%20and%20durability%20of%20serum%20antibodies.%20We%20also%20evaluated%20associations%20between%20individual%20demographic%20and%20clinical%20parameters%20with%20functional%20neutralizing%20antibody%20responses%20to%20COVID-19.%20We%20found%20robust%20antibody%20durability%20out%20to%20six%20months%2C%20as%20well%20as%20significant%20positive%20associations%20with%20the%20magnitude%20of%20the%20neutralizing%20antibody%20response%20and%20male%20sex.%20We%20also%20show%20that%20SARS-CoV-2%20convalescent%20neutralizing%20antibodies%20are%20higher%20in%20individuals%20with%20cardio-metabolic%20comorbidities.%20SIGNIFICANCE%3A%20In%20this%20study%20we%20found%20that%20neutralizing%20antibody%20responses%20in%20COVID-19%20convalescent%20individuals%20vary%20in%20magnitude%20but%20are%20durable%20and%20correlate%20well%20with%20RBD%20Ig%20binding%20antibody%20levels%20compared%20to%20other%20SARS-CoV-2%20antigen%20responses.%20In%20our%20cohort%2C%20higher%20neutralizing%20antibody%20titers%20are%20independently%20and%20significantly%20associated%20with%20male%20sex%20compared%20to%20female%20sex.%20We%20also%20show%20for%20the%20first%20time%2C%20that%20higher%20convalescent%20antibody%20titers%20in%20male%20donors%20are%20associated%20with%20increased%20age%20and%20symptom%20grade.%20Furthermore%2C%20cardio-metabolic%20co-morbidities%20are%20associated%20with%20higher%20antibody%20titers%20independently%20of%20sex.%20Here%2C%20we%20present%20an%20in-depth%20evaluation%20of%20serologic%2C%20demographic%2C%20and%20clinical%20correlates%20of%20functional%20antibody%20responses%20and%20durability%20to%20SARS-CoV-2.%22%2C%22date%22%3A%22Feb%203%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2021.02.01.21250493%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A49%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22UZRQGREZ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Collins%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECollins%2C%20L.%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EColasanti%2C%20J.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENguyen%2C%20M.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMoran%2C%20C.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ELahiri%2C%20C.%20D.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20The%20COVID-19%20pandemic%20as%20a%20catalyst%20for%20differentiated%20care%20models%20to%20end%20the%20HIV%20epidemic%20in%20the%20United%20States%3A%20applying%20lessons%20from%20high-burden%20settings.%20%3Ci%3EAIDS%3C%5C%2Fi%3E%2C%20%3Ci%3E35%3C%5C%2Fi%3E%20%282%29%2C%20S.%20337%26%23x2013%3B341.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000002746%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000002746%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20COVID-19%20pandemic%20as%20a%20catalyst%20for%20differentiated%20care%20models%20to%20end%20the%20HIV%20epidemic%20in%20the%20United%20States%3A%20applying%20lessons%20from%20high-burden%20settings%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20F.%22%2C%22lastName%22%3A%22Collins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Colasanti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20A.%22%2C%22lastName%22%3A%22Moran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Lahiri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20C.%22%2C%22lastName%22%3A%22Marconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20S.%22%2C%22lastName%22%3A%22Armstrong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Sarita%20Shah%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Feb%202%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000002746%22%2C%22ISSN%22%3A%221473-5571%20%28Electronic%29%200269-9370%20%28Print%29%200269-9370%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A30%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22XSADN6CR%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sun%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESun%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EAlthoff%2C%20K.%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJing%2C%20Y.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHorberg%2C%20M.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBuchacz%2C%20K.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Trends%20in%20Hepatocellular%20Carcinoma%20Incidence%20and%20Risk%20Among%20Persons%20With%20HIV%20in%20the%20US%20and%20Canada%2C%201996-2015.%20%3Ci%3EJAMA%20Netw%20Open%3C%5C%2Fi%3E%2C%20%3Ci%3E4%3C%5C%2Fi%3E%20%282%29%2C%20S.%20e2037512.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamanetworkopen.2020.37512%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamanetworkopen.2020.37512%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Trends%20in%20Hepatocellular%20Carcinoma%20Incidence%20and%20Risk%20Among%20Persons%20With%20HIV%20in%20the%20US%20and%20Canada%2C%201996-2015%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Sun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Jing%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Buchacz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20S.%22%2C%22lastName%22%3A%22Rabkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Goedert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Sigel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cachay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20K.%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20N.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Lo%20Re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20G.%22%2C%22lastName%22%3A%22Peters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20J.%22%2C%22lastName%22%3A%22Achenbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20E.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20M.%22%2C%22lastName%22%3A%22Crane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20M.%22%2C%22lastName%22%3A%22Kitahata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20D.%22%2C%22lastName%22%3A%22Kirk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%20Cohort%20Collaboration%20on%20Research%22%2C%22lastName%22%3A%22North%20American%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%22%2C%22lastName%22%3A%22Design%20of%20Ie%22%7D%5D%2C%22abstractNote%22%3A%22IMPORTANCE%3A%20People%20with%20HIV%20%28PWH%29%20are%20often%20coinfected%20with%20hepatitis%20B%20virus%20%28HBV%29%20and%5C%2For%20hepatitis%20C%20virus%20%28HCV%29%2C%20leading%20to%20increased%20risk%20of%20developing%20hepatocellular%20carcinoma%20%28HCC%29%2C%20but%20few%20cohort%20studies%20have%20had%20sufficient%20power%20to%20describe%20the%20trends%20of%20HCC%20incidence%20and%20risk%20among%20PWH%20in%20the%20combination%20antiretroviral%20therapy%20%28cART%29%20era.%20OBJECTIVE%3A%20To%20determine%20the%20temporal%20trends%20of%20HCC%20incidence%20rates%20%28IRs%29%20and%20to%20compare%20rates%20by%20risk%20factors%20among%20PWH%20in%20the%20cART%20era.%20DESIGN%2C%20SETTING%2C%20AND%20PARTICIPANTS%3A%20This%20cohort%20study%20used%20data%20from%20the%20North%20American%20AIDS%20Cohort%20Collaboration%20on%20Research%20and%20Design%20%28NA-ACCORD%29%20study%2C%20which%20was%20conducted%20between%201996%20and%202015.%20NA-ACCORD%20pooled%20individual-level%20data%20from%2022%20HIV%20clinical%20and%20interval%20cohorts%20of%20PWH%20in%20the%20US%20and%20Canada.%20PWH%20aged%2018%20years%20or%20older%20with%20available%20CD4%20cell%20counts%20and%20HIV%20RNA%20data%20were%20enrolled.%20Data%20analyses%20were%20completed%20in%20March%202020.%20EXPOSURES%3A%20HBV%20infection%20was%20defined%20as%20detection%20of%20either%20HBV%20surface%20antigen%2C%20HBV%20e%20antigen%2C%20or%20HBV%20DNA%20in%20serum%20or%20plasma%20any%20time%20during%20observation.%20HCV%20infection%20was%20defined%20by%20detection%20of%20anti-HCV%20seropositivity%2C%20HCV%20RNA%2C%20or%20detectable%20genotype%20in%20serum%20or%20plasma%20at%20any%20time%20under%20observation.%20MAIN%20OUTCOMES%20AND%20MEASURES%3A%20HCC%20diagnoses%20were%20identified%20on%20the%20basis%20of%20review%20of%20medical%20records%20or%20cancer%20registry%20linkage.%20RESULTS%3A%20Of%20109%5Cu202f283%20PWH%20with%20723%5Cu202f441%20person-years%20of%20follow-up%2C%20the%20median%20%28interquartile%20range%29%20age%20at%20baseline%20was%2043%20%2836-51%29%20years%2C%2093%5Cu202f017%20%2885.1%25%29%20were%20male%2C%2044%5Cu202f752%20%2840.9%25%29%20were%20White%2C%2044%5Cu202f322%20%2840.6%25%29%20were%20Black%2C%2021%5Cu202f343%20%2819.5%25%29%20had%20HCV%20coinfection%2C%206348%20%285.8%25%29%20had%20HBV%20coinfection%2C%20and%202082%20%281.9%25%29%20had%20triple%20infection%3B%20451%20individuals%20received%20a%20diagnosis%20of%20HCC%20by%202015.%20Between%20the%20early%20%281996-2000%29%20and%20modern%20%282006-2015%29%20cART%20eras%2C%20the%20crude%20HCC%20IR%20increased%20from%200.28%20to%200.75%20case%20per%201000%20person-years.%20HCC%20IRs%20remained%20constant%20among%20HIV-monoinfected%20persons%20or%20those%20coinfected%20with%20HBV%2C%20but%20from%201996%20to%202015%2C%20IRs%20increased%20among%20PWH%20coinfected%20with%20HCV%20%28from%200.34%20cases%5C%2F1000%20person-years%20in%201996%20to%202.39%20cases%5C%2F1000%20person-years%20in%202015%29%20or%20those%20with%20triple%20infection%20%28from%200.65%20cases%5C%2F1000%20person-years%20in%201996%20to%204.49%20cases%5C%2F1000%20person-years%20in%202015%29.%20Recent%20HIV%20RNA%20levels%20greater%20than%20or%20equal%20to%20500%20copies%5C%2FmL%20%28IR%20ratio%2C%201.8%3B%2095%25%20CI%2C%201.4-2.4%29%20and%20CD4%20cell%20counts%20less%20than%20or%20equal%20to%20500%20cells%5C%2FmuL%20%28IR%20ratio%2C%201.3%3B%2095%25%20CI%2C%201.0-1.6%29%20were%20associated%20with%20higher%20HCC%20risk%20in%20the%20modern%20cART%20era.%20People%20who%20injected%20drugs%20had%20higher%20HCC%20risk%20compared%20with%20men%20who%20had%20sex%20with%20men%20%28IR%20ratio%2C%202.0%3B%2095%25%20CI%2C%201.3-2.9%29%2C%20adjusted%20for%20HBV-HCV%20coinfection.%20CONCLUSIONS%20AND%20RELEVANCE%3A%20HCC%20rates%20among%20PWH%20increased%20significantly%20over%20time%20from%201996%20to%202015.%20PWH%20coinfected%20with%20viral%20hepatitis%2C%20those%20with%20higher%20HIV%20RNA%20levels%20or%20lower%20CD4%20cell%20counts%2C%20and%20those%20who%20inject%20drugs%20had%20higher%20HCC%20risk.%22%2C%22date%22%3A%22Feb%201%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1001%5C%2Fjamanetworkopen.2020.37512%22%2C%22ISSN%22%3A%222574-3805%20%28Electronic%29%202574-3805%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A50%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22UJTH39X9%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ujeneza%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-14%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EUjeneza%2C%20E.%20L.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENdifon%2C%20W.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ESawry%2C%20S.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFatti%2C%20G.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERiou%2C%20J.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20A%20mechanistic%20model%20for%20long-term%20immunological%20outcomes%20in%20South%20African%20HIV-infected%20children%20and%20adults%20receiving%20ART.%20%3Ci%3EELife%3C%5C%2Fi%3E%2C%20%3Ci%3E10%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7554%5C%2FeLife.42390%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7554%5C%2FeLife.42390%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20mechanistic%20model%20for%20long-term%20immunological%20outcomes%20in%20South%20African%20HIV-infected%20children%20and%20adults%20receiving%20ART%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20L.%22%2C%22lastName%22%3A%22Ujeneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Ndifon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Sawry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Riou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Nieuwoudt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20Southern%20Africa%20collaboration%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22Long-term%20effects%20of%20the%20growing%20population%20of%20HIV-treated%20people%20in%20Southern%20Africa%20on%20individuals%20and%20the%20public%20health%20sector%20at%20large%20are%20not%20yet%20understood.%20This%20study%20proposes%20a%20novel%20%27ratio%27%20model%20that%20relates%20CD4%2B%20T-cell%20counts%20of%20HIV-infected%20individuals%20to%20the%20CD4%2B%20count%20reference%20values%20from%20healthy%20populations.%20We%20use%20mixed-effects%20regression%20to%20fit%20the%20model%20to%20data%20from%201616%20children%20%28median%20age%204.3%20years%20at%20ART%20initiation%29%20and%2014%2C542%20adults%20%28median%20age%2036%20years%20at%20ART%20initiation%29.%20We%20found%20that%20the%20scaled%20carrying%20capacity%2C%20maximum%20CD4%2B%20count%20relative%20to%20an%20HIV-negative%20individual%20of%20similar%20age%2C%20and%20baseline%20scaled%20CD4%2B%20counts%20were%20closer%20to%20healthy%20values%20in%20children%20than%20in%20adults.%20Post-ART%20initiation%2C%20CD4%2B%20growth%20rate%20was%20inversely%20correlated%20with%20baseline%20CD4%2B%20T-cell%20counts%2C%20and%20consequently%20higher%20in%20adults%20than%20children.%20Our%20results%20highlight%20the%20impacts%20of%20age%20on%20dynamics%20of%20the%20immune%20system%20of%20healthy%20and%20HIV-infected%20individuals.%5CnThe%20human%20immunodeficiency%20virus%20%28HIV%29%20remains%20an%20ongoing%20global%20pandemic.%20There%20is%20currently%20no%20cure%20for%20HIV%2C%20but%20antiretroviral%20therapies%20can%20keep%20the%20virus%20in%20check%20and%20allow%20individuals%20with%20HIV%20to%20live%20longer%2C%20healthier%20lives.%20These%20drugs%20work%20in%20two%20ways.%20They%20block%20the%20ability%20of%20the%20virus%20to%20multiply%20and%20they%20allow%20numbers%20of%20an%20important%20type%20of%20infection-fighting%20cell%20called%20CD4%2B%20T%20cells%20to%20rebound.%20As%20more%20patients%20with%20HIV%20survive%20and%20transition%20from%20one%20life%20stage%20to%20the%20next%2C%20it%20is%20critical%20to%20understand%20how%20long-term%20antiretroviral%20therapies%20will%20affect%20normal%20age-related%20changes%20in%20their%20immune%20systems.%20The%20health%20of%20an%20immune%20system%20can%20be%20evaluated%20by%20looking%20at%20the%20number%20of%20CD4%2B%20T%20cells%20an%20individual%20has%2C%20though%20this%20will%20vary%20by%20age%20and%20location.%20Clinicians%20use%20the%20same%20metrics%20to%20assess%20the%20immune%20health%20of%20individuals%20with%20HIV%2C%20however%2C%20as%20they%20age%2C%20it%20becomes%20a%20challenge%20to%20identify%20if%20a%20patient%27s%20immune%20system%20recovers%20normally%20or%20insufficiently.%20Thus%2C%20learning%20more%20about%20age-related%20differences%20in%20CD4%2B%20T%20cells%20in%20people%20living%20with%20HIV%20may%20help%20improve%20their%20care.%20Using%20data%20from%201%2C616%20children%20and%2014%2C542%20adults%20from%20South%20Africa%2C%20Ujeneza%20et%20al.%20created%20a%20simple%20mathematical%20model%20that%20can%20compare%20the%20immune%20system%20of%20person%20with%20HIV%20with%20the%20immune%20system%20of%20a%20similarly%20aged%20healthy%20individual.%20The%20model%20shows%20that%20among%20individuals%20with%20HIV%20receiving%20antiretroviral%20therapies%2C%20children%20have%20CD4%2B%20T-cell%20numbers%20that%20are%20closest%20to%20the%20numbers%20seen%20in%20healthy%20individuals%20of%20the%20same%20age.%20This%20suggests%20that%20children%20may%20be%20more%20able%20to%20recover%20immune%20system%20function%20than%20adults%20after%20beginning%20treatment.%20Children%20also%20start%20antiretroviral%20therapies%20before%20their%20immune%20system%20has%20been%20severely%20damaged%2C%20while%20adults%20tend%20to%20start%20treatment%20much%20later%20when%20they%20have%20fewer%20CD4%2B%20T%20cells%20left.%20Ujeneza%20et%20al.%20show%20that%20the%20fewer%20CD4%2B%20T%20cells%20a%20person%20has%20when%20they%20start%20treatment%2C%20the%20faster%20the%20number%20of%20these%20cells%20grows%20after%20starting%20treatment.%20This%20suggests%20that%20the%20more%20damaged%20the%20immune%20system%20is%2C%20the%20harder%20it%20works%20to%20recover.%20This%20reinforces%20the%20need%20to%20identify%20people%20infected%20with%20HIV%20as%20soon%20as%20possible%20through%20testing%20and%20to%20begin%20treatment%20promptly.%20The%20new%20model%20may%20help%20clinicians%20and%20policy%20makers%20develop%20screening%20and%20treatment%20protocols%20tailored%20to%20the%20specific%20needs%20of%20children%20and%20adults%20living%20with%20HIV.%5Cneng%22%2C%22date%22%3A%22Jan%2014%202021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.7554%5C%2FeLife.42390%22%2C%22ISSN%22%3A%222050-084X%20%28Electronic%29%202050-084X%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A12%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22FBRAQRTQ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pereira%20et%20al.%22%2C%22parsedDate%22%3A%222021-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPereira%2C%20G.%20F.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKim%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EJalil%2C%20E.%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFernandes%20Fonseca%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EShepherd%2C%20B.%20E.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Dolutegravir%20and%20pregnancy%20outcomes%20in%20women%20on%20antiretroviral%20therapy%20in%20Brazil%3A%20a%20retrospective%20national%20cohort%20study.%20%3Ci%3ELancet%20HIV%3C%5C%2Fi%3E%2C%20%3Ci%3E8%3C%5C%2Fi%3E%20%281%29%2C%20S.%20e33%26%23x2013%3Be41.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2820%2930268-X%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2820%2930268-X%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dolutegravir%20and%20pregnancy%20outcomes%20in%20women%20on%20antiretroviral%20therapy%20in%20Brazil%3A%20a%20retrospective%20national%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20F.%20M.%22%2C%22lastName%22%3A%22Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20M.%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Fernandes%20Fonseca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Rick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20C.%22%2C%22lastName%22%3A%22Pimenta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Beber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20G.%22%2C%22lastName%22%3A%22Correa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Schwartz%20Benzaken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dolutegravir%22%2C%22lastName%22%3A%22National%20Cohort%20Study%20of%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brazil%22%2C%22lastName%22%3A%22Pregnancy%20Outcomes%20in%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Dolutegravir%20has%20been%20widely%20available%20in%20Brazil%20since%202017.%20Following%20the%20signal%20that%20infants%20born%20to%20women%20with%20dolutegravir%20exposure%20at%20conception%20in%20Botswana%20had%20a%20higher%20risk%20of%20neural%20tube%20defects%20%28NTDs%29%2C%20public%20health%20leaders%20initiated%20a%20national%20investigation%20to%20evaluate%20periconception%20dolutegravir%20exposure%20among%20all%20pregnant%20Brazilian%20women%20with%20HIV%20and%20its%20potential%20association%20with%20risk%20of%20NTDs%2C%20stillbirth%2C%20or%20miscarriage%20before%2022%20weeks%20%28also%20called%20spontaneous%20abortion%29.%20METHODS%3A%20In%20this%20retrospective%2C%20observational%2C%20national%2C%20cohort%20study%2C%20we%20identified%20all%20women%20with%20pregnancies%20and%20possible%20dolutegravir%20exposure%20within%208%20weeks%20of%20estimated%20date%20of%20conception%20between%20Jan%201%2C%202017%2C%20and%20May%2031%2C%202018%2C%20and%20approximately%203%3A1%20matched%20pregnant%20women%20exposed%20to%20efavirenz%20between%20Jan%201%2C%202015%2C%20and%20May%2031%2C%202018%2C%20using%20the%20Brazilian%20antiretroviral%20therapy%20database.%20We%20did%20detailed%20chart%20reviews%20for%20identified%20women.%20The%20primary%20outcomes%20were%20NTD%20and%20a%20composite%20measure%20of%20NTD%2C%20stillbirth%2C%20or%20miscarriage.%20NTD%20incidences%20were%20calculated%20with%2095%25%20CI.%20The%20composite%20outcome%20was%20examined%20with%20logistic%20regression%20using%20propensity%20score%20matching%20weights%20to%20balance%20confounders.%20FINDINGS%3A%20Of%201427%20included%20women%2C%20382%20were%20exposed%20to%20dolutegravir%20within%208%20weeks%20of%20estimated%20date%20of%20conception.%20During%20pregnancy%2C%20183%20%2848%25%29%20of%20382%20dolutegravir-exposed%20and%20465%20%2844%25%29%20of%201045%20efavirenz-exposed%20women%20received%20folic%20acid%20supplementation.%20There%20were%201452%20birth%20outcomes.%20There%20were%20no%20NTDs%20in%20either%20dolutegravir-exposed%20%280%2C%2095%25%20CI%200-0.0010%29%20or%20efavirenz-exposed%20groups%20%280%2C%2095%25%20CI%200-0.0036%29.%20There%20were%2023%20%286%25%29%20stillbirths%20or%20miscarriages%20in%20384%20dolutegravir-exposed%20fetuses%20and%2028%20%283%25%29%20in%20the%201068%20efavirenz-exposed%20fetuses%20%28p%3D0.0037%29.%20Logistic%20regression%20models%20did%20not%20consistently%20indicate%20an%20association%20between%20dolutegravir%20exposure%20and%20risk%20of%20stillbirths%20or%20miscarriages.%20After%20study%20closure%2C%20two%20confirmed%20NTD%20outcomes%20in%20fetuses%20with%20periconception%20dolutegravir%20exposure%20were%20reported%20to%20public%20health%20officials.%20An%20updated%20estimate%20of%20NTD%20incidence%20incorporating%20these%20cases%20and%20the%20estimated%20number%20of%20additional%20dolutegravir-exposed%20pregnancies%20between%20Jan%201%2C%202015%20and%20Feb%2028%2C%202019%2C%20is%200.0018%20%2895%25%20CI%200.0005-0.0067%29.%20INTERPRETATION%3A%20Neither%20dolutegravir%20nor%20efavirenz%20exposure%20was%20associated%20with%20NTDs%20in%20our%20national%20cohort%3B%20incidence%20of%20NTDs%20is%20probably%20well%20under%201%25%20in%20dolutegravir-exposed%20HIV-positive%20women%20but%20still%20slightly%20above%20HIV-uninfected%20women%20%280.06%25%29%20in%20Brazil.%20FUNDING%3A%20The%20Brazilian%20Ministry%20of%20Health%20and%20the%20United%20States%27%20National%20Institutes%20of%20Health.%22%2C%22date%22%3A%22Jan%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2820%2930268-X%22%2C%22ISSN%22%3A%222352-3018%20%28Electronic%29%202405-4704%20%28Print%29%202352-3018%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22F2Y6PLUL%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A42%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22EIRV47MW%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Osman%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EOsman%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMeehan%2C%20S.%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3Evon%20Delft%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDu%20Preez%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EDunbar%2C%20R.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Early%20mortality%20in%20tuberculosis%20patients%20initially%20lost%20to%20follow%20up%20following%20diagnosis%20in%20provincial%20hospitals%20and%20primary%20health%20care%20facilities%20in%20Western%20Cape%2C%20South%20Africa.%20%3Ci%3EPLoS%20One%3C%5C%2Fi%3E%2C%20%3Ci%3E16%3C%5C%2Fi%3E%20%286%29%2C%20S.%20e0252084.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0252084%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0252084%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Early%20mortality%20in%20tuberculosis%20patients%20initially%20lost%20to%20follow%20up%20following%20diagnosis%20in%20provincial%20hospitals%20and%20primary%20health%20care%20facilities%20in%20Western%20Cape%2C%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Osman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20A.%22%2C%22lastName%22%3A%22Meehan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22von%20Delft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Du%20Preez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Dunbar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20M.%22%2C%22lastName%22%3A%22Marx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Welte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Naidoo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Hesseling%22%7D%5D%2C%22abstractNote%22%3A%22In%20South%20Africa%2C%20low%20tuberculosis%20%28TB%29%20treatment%20coverage%20and%20high%20TB%20case%20fatality%20remain%20important%20challenges.%20Following%20TB%20diagnosis%2C%20patients%20must%20link%20with%20a%20primary%20health%20care%20%28PHC%29%20facility%20for%20initiation%20or%20continuation%20of%20antituberculosis%20treatment%20and%20TB%20registration.%20We%20aimed%20to%20evaluate%20mortality%20among%20TB%20patients%20who%20did%20not%20link%20to%20a%20TB%20treatment%20facility%20for%20TB%20treatment%20within%2030%20days%20of%20their%20TB%20diagnosis%2C%20i.e.%20who%20were%20%5C%22initial%20loss%20to%20follow-up%20%28ILTFU%29%5C%22%20in%20Cape%20Town%2C%20South%20Africa.%20We%20prospectively%20included%20all%20patients%20with%20a%20routine%20laboratory%20or%20clinical%20diagnosis%20of%20TB%20made%20at%20PHC%20or%20hospital%20level%20in%20Khayelitsha%20and%20Tygerberg%20sub-districts%20in%20Cape%20Town%2C%20using%20routine%20TB%20data%20from%20an%20integrated%20provincial%20health%20data%20centre%20between%20October%202018%20and%20March%202020.%20Overall%2C%2074%25%20%2810%2C208%5C%2F13%2C736%29%20of%20TB%20patients%20were%20diagnosed%20at%20PHC%20facilities%20and%20ILTFU%20was%2020.0%25%20%282%2C742%5C%2F13%2C736%29.%20Of%20ILTFU%20patients%2C%2017.1%25%20%28468%5C%2F2%2C742%29%20died%2C%20with%2069.7%25%20%28326%5C%2F468%29%20of%20deaths%20occurring%20within%2030%20days%20of%20diagnosis.%20Most%20ILTFU%20deaths%20%2885.5%25%3B%20400%5C%2F468%29%20occurred%20in%20patients%20diagnosed%20in%20hospital.%20Multivariable%20logistic%20regression%20identified%20increasing%20age%2C%20HIV%20positive%20status%2C%20and%20hospital-based%20TB%20diagnosis%20%28higher%20in%20the%20absence%20of%20TB%20treatment%20initiation%20and%20being%20ILTFU%29%20as%20predictors%20of%20mortality.%20Although%20hospitals%20account%20for%20a%20modest%20proportion%20of%20diagnosed%20TB%20patients%20they%20have%20high%20TB-associated%20mortality.%20A%20hospital-based%20TB%20diagnosis%20is%20a%20critical%20opportunity%20to%20identify%20those%20at%20high%20risk%20of%20early%20and%20overall%20mortality.%20Interventions%20to%20diagnose%20TB%20before%20hospital%20admission%2C%20improve%20linkage%20to%20TB%20treatment%20following%20diagnosis%2C%20and%20reduce%20mortality%20in%20hospital-diagnosed%20TB%20patients%20should%20be%20prioritised.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0252084%22%2C%22ISSN%22%3A%221932-6203%20%28Electronic%29%201932-6203%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22BBUNSKWT%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hussey%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHussey%2C%20H.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EZinyakatira%2C%20N.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMorden%2C%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIsmail%2C%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EPaleker%2C%20M.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20Higher%20COVID-19%20mortality%20in%20low-income%20communities%20in%20the%20City%20of%20Cape%20Town%20-%20a%20descriptive%20ecological%20study.%20%3Ci%3EGates%20Open%20Res%3C%5C%2Fi%3E%2C%20%3Ci%3E5%3C%5C%2Fi%3E%2C%20S.%2090.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.12688%5C%2Fgatesopenres.13288.1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.12688%5C%2Fgatesopenres.13288.1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Higher%20COVID-19%20mortality%20in%20low-income%20communities%20in%20the%20City%20of%20Cape%20Town%20-%20a%20descriptive%20ecological%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Hussey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Zinyakatira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Morden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Paleker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Bam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22London%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%5D%2C%22abstractNote%22%3A%22Background%20Cape%20Town%2C%20a%20South%20African%20city%20with%20high%20levels%20of%20economic%20inequality%2C%20has%20gone%20through%20two%20COVID-19%20waves.%20There%20is%20evidence%20globally%20that%20low-income%20communities%20experience%20higher%20levels%20of%20morbidity%20and%20mortality%20during%20the%20pandemic.%20Methods%20Age-standardized%20COVID-19%20mortality%20in%20the%20eight%20sub-districts%20of%20Cape%20Town%20was%20compared%20by%20economic%20indicators%20taken%20from%20the%20most%20recent%20Census%20%28unemployment%20rate%2C%20monthly%20income%29.%20Results%20The%20overall%20Standardized%20Death%20Rate%20%28SDR%29%20for%20COVID-19%20in%20Cape%20Town%20was%201%20640%20per%20million%2C%20but%20there%20was%20wide%20variation%20across%20the%20different%20sub-districts.%20A%20linear%20relationship%20was%20seen%20between%20sub-districts%20with%20high%20poverty%20and%20high%20COVID-19%20SDRs.%20Conclusions%20Low-income%20communities%20in%20Cape%20Town%20experienced%20higher%20levels%20of%20COVID-19%20mortality.%20As%20we%20continue%20to%20contend%20with%20COVID-19%2C%20these%20communities%20need%20to%20be%20prioritized%20for%20access%20to%20quality%20health%20care.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.12688%5C%2Fgatesopenres.13288.1%22%2C%22ISSN%22%3A%222572-4754%20%28Electronic%29%202572-4754%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A46%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22K9QSJC4F%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kammers%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EKammers%2C%20K.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChen%2C%20A.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMonaco%2C%20D.%20R.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHudelson%2C%20S.%20E.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGrant-McAuley%2C%20W.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20HIV%20Antibody%20Profiles%20in%20HIV%20Controllers%20and%20Persons%20With%20Treatment-Induced%20Viral%20Suppression.%20%3Ci%3EFront%20Immunol%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%2C%20S.%20740395.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2021.740395%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2021.740395%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20Antibody%20Profiles%20in%20HIV%20Controllers%20and%20Persons%20With%20Treatment-Induced%20Viral%20Suppression%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Kammers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Monaco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20E.%22%2C%22lastName%22%3A%22Hudelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Grant-McAuley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Alter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20G.%22%2C%22lastName%22%3A%22Deeks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20S.%22%2C%22lastName%22%3A%22Morrison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Eller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20N.%22%2C%22lastName%22%3A%22Blankson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Laeyendecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Ruczinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20H.%22%2C%22lastName%22%3A%22Eshleman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20B.%22%2C%22lastName%22%3A%22Larman%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Low%20HIV%20viral%20load%20is%20associated%20with%20delayed%20disease%20progression%20and%20reduced%20HIV%20transmission.%20HIV%20controllers%20suppress%20viral%20load%20to%20low%20levels%20in%20the%20absence%20of%20antiretroviral%20treatment%20%28ART%29.%20We%20used%20an%20antibody%20profiling%20system%2C%20VirScan%2C%20to%20compare%20antibody%20reactivity%20and%20specificity%20in%20HIV%20controllers%2C%20non-controllers%20with%20treatment-induced%20viral%20suppression%2C%20and%20viremic%20non-controllers.%20METHODS%3A%20The%20VirScan%20library%20contains%203%2C384%20phage-displayed%20peptides%20spanning%20the%20HIV%20proteome.%20Antibody%20reactivity%20to%20these%20peptides%20was%20measured%20in%20plasma%20from%20a%20Discovery%20Cohort%20that%20included%2013%20elite%20controllers%2C%2027%20viremic%20controllers%2C%2012%20viremic%20non-controllers%2C%20and%2021%20non-controllers%20who%20were%20virally%20suppressed%20on%20ART.%20Antibody%20reactivity%20to%20selected%20peptides%20was%20also%20assessed%20in%20an%20independent%20cohort%20of%2029%20elite%20controllers%20and%2037%20non-controllers%20who%20were%20virally%20suppressed%20on%20ART%20%28Validation%20Cohort%29%20and%20in%20a%20longitudinal%20cohort%20of%20non-controllers.%20RESULTS%3A%20In%20the%20Discovery%20Cohort%2C%2062%20peptides%20were%20preferentially%20targeted%20in%20HIV%20controllers%20compared%20to%20non-controllers%20who%20were%20virally%20suppressed%20on%20ART.%20These%20specificities%20were%20not%20significantly%20different%20when%20comparing%20controllers%20versus%20viremic%20non-controllers.%20Aggregate%20reactivity%20to%20these%20peptides%20was%20also%20high%20in%20elite%20controllers%20from%20the%20independent%20Validation%20Cohort.%20The%2062%20peptides%20formed%20seven%20clusters%20of%20homologous%20epitopes%20in%20env%2C%20gag%2C%20integrase%2C%20and%20vpu.%20Reactivity%20to%20one%20of%20these%20clusters%20located%20in%20gag%20p17%20was%20inversely%20correlated%20with%20viral%20load%20set%20point%20in%20an%20independent%20cohort%20of%20non-controllers.%20CONCLUSIONS%3A%20Antibody%20reactivity%20was%20low%20in%20non-controllers%20suppressed%20on%20ART%2C%20but%20remained%20high%20in%20viremic%20controllers%20despite%20viral%20suppression.%20Antibodies%20in%20controllers%20and%20viremic%20non-controllers%20were%20directed%20against%20epitopes%20in%20diverse%20HIV%20proteins%3B%20higher%20reactivity%20against%20p17%20peptides%20was%20associated%20with%20lower%20viral%20load%20set%20point.%20Further%20studies%20are%20needed%20to%20determine%20if%20these%20antibodies%20play%20a%20role%20in%20regulation%20of%20HIV%20viral%20load.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2021.740395%22%2C%22ISSN%22%3A%221664-3224%20%28Electronic%29%201664-3224%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22YAE5EUBI%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A46%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22Z72V3S9P%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ross%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERoss%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EIngabire%2C%20C.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EUmwiza%2C%20F.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EGasana%2C%20J.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMunyaneza%2C%20A.%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282021%29.%20How%20early%20is%20too%20early%3F%20Challenges%20in%20ART%20initiation%20and%20engaging%20in%20HIV%20care%20under%20Treat%20All%20in%20Rwanda-A%20qualitative%20study.%20%3Ci%3EPLoS%20One%3C%5C%2Fi%3E%2C%20%3Ci%3E16%3C%5C%2Fi%3E%20%285%29%2C%20S.%20e0251645.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0251645%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0251645%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22How%20early%20is%20too%20early%3F%20Challenges%20in%20ART%20initiation%20and%20engaging%20in%20HIV%20care%20under%20Treat%20All%20in%20Rwanda-A%20qualitative%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Ingabire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Umwiza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Gasana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nsanzimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Remera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Akiyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Adedimeji%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20HIV%20treatment%20guidelines%20recommend%20that%20all%20people%20living%20with%20HIV%20%28PLWH%29%20initiate%20antiretroviral%20therapy%20%28ART%29%20as%20soon%20as%20possible%20after%20diagnosis%20%28Treat%20All%29.%20As%20Treat%20All%20is%20more%20widely%20implemented%2C%20an%20increasing%20proportion%20of%20PLWH%20are%20likely%20to%20initiate%20ART%20when%20they%20are%20asymptomatic%2C%20and%20they%20may%20view%20the%20relative%20benefits%20and%20risks%20of%20ART%20differently%20than%20those%20initiating%20at%20more%20advanced%20disease%20stages.%20To%20date%2C%20patient%20perspectives%20of%20initiating%20care%20under%20Treat%20All%20in%20sub-Saharan%20Africa%20have%20not%20been%20well%20described.%20METHODS%3A%20From%20September%202018%20to%20March%202019%2C%20we%20conducted%20individual%2C%20semi-structured%2C%20qualitative%20interviews%20with%2037%20patients%20receiving%20HIV%20care%20in%20two%20health%20centers%20in%20Kigali%2C%20Rwanda.%20Data%20were%20analyzed%20using%20a%20mixed%20deductive%20and%20inductive%20thematic%20analysis%20approach%20to%20describe%20perceived%20barriers%20to%2C%20facilitators%20of%20and%20acceptability%20of%20initiating%20and%20adhering%20to%20ART%20rapidly%20under%20Treat%20All.%20RESULTS%3A%20Of%2037%20participants%2C%2027%20were%20women%20and%20the%20median%20age%20was%2031%20years.%20Participants%20described%20feeling%20traumatized%20and%20overwhelmed%20by%20their%20HIV%20diagnosis%2C%20resulting%20in%20difficulty%20accepting%20their%20HIV%20status.%20Most%20were%20prescribed%20ART%20soon%20after%20diagnosis%2C%20yet%20fear%20of%20lifelong%20medication%20and%20severe%20side%20effects%20in%20the%20immediate%20period%20after%20initiating%20ART%20led%20to%20challenges%20adhering%20to%20therapy.%20Moreover%2C%20because%20many%20PLWH%20initiated%20ART%20while%20healthy%2C%20taking%20medications%20and%20attending%20appointments%20were%20visible%20signals%20of%20HIV%20status%20and%20highly%20stigmatizing.%20Nonetheless%2C%20many%20participants%20expressed%20enthusiasm%20for%20Treat%20All%20as%20a%20program%20that%20improved%20health%20as%20well%20as%20health%20equity.%20CONCLUSION%3A%20For%20newly-diagnosed%20PLWH%20in%20Rwanda%2C%20initiating%20ART%20rapidly%20under%20Treat%20All%20presents%20logistical%20and%20emotional%20challenges%20despite%20the%20perceived%20benefits.%20Our%20findings%20suggest%20that%20optimizing%20early%20engagement%20in%20HIV%20care%20under%20Treat%20All%20requires%20early%20and%20ongoing%20intervention%20to%20reduce%20trauma%20and%20stigma%2C%20and%20promote%20both%20individual%20and%20community%20benefits%20of%20ART.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0251645%22%2C%22ISSN%22%3A%221932-6203%20%28Electronic%29%201932-6203%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A47%3A38Z%22%7D%7D%5D%7D
Costa, A. G. ; Carvalho, B. K. S. ; Araujo-Pereira, M. ; Ibiapina, H. N. S. ; Spener-Gomes, R. et al. (2021). Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil.
Microbiol Spectr ,
9 (3), S. e0116321.
http://doi.org/10.1128/Spectrum.01163-21 .
Jesson, J. ; Ephoevi-Ga, A. ; Ake-Assi, M. H. ; Koumakpai, S. ; N’Gbeche, S. et al. (2021). Assessment of dietary diversity and nutritional support for children living with HIV in the IeDEA pediatric West African cohort: a non-comparative, feasibility study.
BMC Nutr ,
7 (1), S. 83.
http://doi.org/10.1186/s40795-021-00486-4 .
Coburn, S. B. ; Humes, E. ; Lang, R. ; Stewart, C. ; Hogan, B. C. et al. (2021). COVID-19 infections post-vaccination by HIV status in the United States.
MedRxiv , S. 2021.12.02.21267182.
http://doi.org/10.1101/2021.12.02.21267182 .
Robertson, M. M. ; Irvine, M. K. ; Penrose, K. ; Harriman, G. ; Braunstein, S. L. et al. (2021). Mortality among clients in the New York city HIV Care Coordination Program (CCP): incidence and associated clinical factors.
Ann Epidemiol ,
64 , S. 161–166.
http://doi.org/10.1016/j.annepidem.2021.10.001 .
Lancaster, K. E. ; Remch, M. ; Dzudie, A. ; Ajeh, R. ; Adedimeji, A. et al. (2021). Heavy episodic drinking and HIV disclosure by HIV treatment status among People with HIV in IeDEA Cameroon.
Int J Drug Policy ,
98 , S. 103431.
http://doi.org/10.1016/j.drugpo.2021.103431 .
Parcesepe, A. M. ; Filiatreau, L. M. ; Ebasone, P. V. ; Dzudie, A. ; Pence, B. W. et al. (2021). Mental health and initiation of antiretroviral treatment at enrolment into HIV care in Cameroon under a national “treat all” policy: a cross-sectional analysis.
J Int AIDS Soc ,
24 (11), S. e25842.
http://doi.org/10.1002/jia2.25842 .
Thompson, P. ; Morgan, C. E. ; Ngimbi, P. ; Mwandagalirwa, K. ; Ravelomanana, N. L. R. et al. (2021). Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study.
Lancet Glob Health ,
9 (11), S. e1600–e1609.
http://doi.org/10.1016/S2214-109X(21)00304-1 .
Irvine, M. K. ; Robertson, M. M. ; Nash, D. ; Kulkarni, S. G. ; Braunstein, S. L. et al. (2021). HIV Care Coordination promotes care re-engagement and viral suppression among people who have been out of HIV medical care: an observational effectiveness study using a surveillance-based contemporaneous comparison group.
AIDS Res Ther ,
18 (1), S. 70.
http://doi.org/10.1186/s12981-021-00398-0 .
Riou, J. ; Dupont, C. ; Bertagnolio, S. ; Gupta, R. K. ; Kouyos, R. D. et al. (2021). Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study.
BMC Infect Dis ,
21 (1), S. 1042.
http://doi.org/10.1186/s12879-021-06757-6 .
McGinnis, K. A. ; Skanderson, M. ; Justice, A. C. ; Akgun, K. M. ; Tate, J. P. et al. (2021). HIV care using differentiated service delivery during the COVID-19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs.
J Int AIDS Soc ,
24 Suppl 6 (Suppl 6), S. e25810.
http://doi.org/10.1002/jia2.25810 .
Amorim, G. ; Tao, R. ; Lotspeich, S. ; Shaw, P. A. ; Lumley, T. et al. (2021). Two-Phase Sampling Designs for Data Validation in Settings with Covariate Measurement Error and Continuous Outcome.
J R Stat Soc Ser A Stat Soc ,
184 (4), S. 1368–1389.
http://doi.org/10.1111/rssa.12689 .
Stover, J. ;
Glaubius, R. ;
Kassanjee, R. &
Dugdale, C. M. (2021). Updates to the Spectrum/AIM model for the UNAIDS 2020 HIV estimates.
J Int AIDS Soc ,
24 Suppl 5 (Suppl 5), S. e25778.
http://doi.org/10.1002/jia2.25778 .
Jaquet, A. ;
Muula, G. ;
Ekouevi, D. K. &
Wandeler, G. (2021). Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps.
Curr Epidemiol Rep ,
8 (3), S. 89–96.
http://doi.org/10.1007/s40471-021-00273-6 .
Wei, F. ; Gaisa, M. M. ; D’Souza, G. ; Xia, N. ; Giuliano, A. R. et al. (2021). Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies.
Lancet HIV ,
8 (9), S. e531–e543.
http://doi.org/10.1016/S2352-3018(21)00108-9 .
Edwards, J. K. ; Cole, S. R. ; Breger, T. L. ; Rudolph, J. E. ; Filiatreau, L. M. et al. (2021). Mortality Among Persons Entering HIV Care Compared With the General U.S. Population : An Observational Study.
Ann Intern Med ,
174 (9), S. 1197–1206.
http://doi.org/10.7326/M21-0065 .
Souza, A. B. ; Arriaga, M. B. ; Amorim, G. ; Araujo-Pereira, M. ; Nogueira, B. M. F. et al. (2021). Determinants of losses in the latent tuberculosis infection cascade of care in Brazil.
BMJ Glob Health ,
6 (9), S. e005969.
http://doi.org/10.1136/bmjgh-2021-005969 .
Boni, S. P. ; Gnahatin, F. ; Comoe, J. C. ; Tchounga, B. ; Ekouevi, D. et al. (2021). Barriers and facilitators in cervical cancer screening uptake in Abidjan, Cote d’Ivoire in 2018: a cross-sectional study.
BMC Cancer ,
21 (1), S. 952.
http://doi.org/10.1186/s12885-021-08650-6 .
Davy-Mendez, T. ; Napravnik, S. ; Eron, J. J. ; Cole, S. R. ; van Duin, D. et al. (2021). Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years.
J Infect Dis ,
224 (4), S. 657–666.
http://doi.org/10.1093/infdis/jiaa786 .
Freeman, E. E. ; Semeere, A. ; McMahon, D. E. ; Byakwaga, H. ; Laker-Oketta, M. et al. (2021). Beyond T Staging in the “Treat-All” Era: Severity and Heterogeneity of Kaposi Sarcoma in East Africa.
J Acquir Immune Defic Syndr ,
87 (5), S. 1119–1127.
http://doi.org/10.1097/QAI.0000000000002699 .
Haas, A. D. ; Kunzekwenyika, C. ; Hossmann, S. ; Manzero, J. ; van Dijk, J. et al. (2021). Symptoms of common mental disorders and adherence to antiretroviral therapy among adults living with HIV in rural Zimbabwe: a cross-sectional study.
BMJ Open ,
11 (7), S. e049824.
http://doi.org/10.1136/bmjopen-2021-049824 .
Somerville, K. ; Jenkins, C. A. ; Carlucci, J. G. ; Person, A. K. ; Machado, D. M. et al. (2021). Outcomes After Second-Line Antiretroviral Therapy in Children Living With HIV in Latin America.
J Acquir Immune Defic Syndr ,
87 (3), S. 993–1001.
http://doi.org/10.1097/QAI.0000000000002678 .
Davy-Mendez, T. ; Napravnik, S. ; Eron, J. J. ; Cole, S. R. ; Van Duin, D. et al. (2021). Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015.
AIDS ,
35 (8), S. 1229–1239.
http://doi.org/10.1097/QAD.0000000000002876 .
Tafadzwa, D. ; Julien, R. ; Lina, B. ; Eliane, R. ; Frederique, C. et al. (2021). Spatiotemporal modelling and mapping of cervical cancer incidence among HIV positive women in South Africa: a nationwide study.
Int J Health Geogr ,
20 (1), S. 30.
http://doi.org/10.1186/s12942-021-00283-z .
Filiatreau, L. M. ; Ebasone, P. V. ; Dzudie, A. ; Ajeh, R. ; Pence, B. et al. (2021). Correlates of self-reported history of mental health help-seeking: a cross-sectional study among individuals with symptoms of a mental or substance use disorder initiating care for HIV in Cameroon.
BMC Psychiatry ,
21 (1), S. 293.
http://doi.org/10.1186/s12888-021-03306-y .
Onovo, A. ; Kalaiwo, A. ; Katbi, M. ; Ogorry, O. ; Jaquet, A. et al. (2021). Geographical Disparities in HIV Seroprevalence Among Men Who Have Sex with Men and People Who Inject Drugs in Nigeria: Exploratory Spatial Data Analysis.
JMIR Public Health Surveill ,
7 (5), S. e19587.
http://doi.org/10.2196/19587 .
Nyemba, D. C. ; Kalk, E. ; Madlala, H. P. ; Malaba, T. R. ; Slogrove, A. L. et al. (2021). Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa.
BMC Pregnancy Childbirth ,
21 (1), S. 354.
http://doi.org/10.1186/s12884-021-03836-z .
Coburn, S. B. ; Shiels, M. S. ; Silverberg, M. J. ; Horberg, M. A. ; Gill, M. J. et al. (2021). Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America.
J Acquir Immune Defic Syndr ,
87 (1), S. 663–670.
http://doi.org/10.1097/QAI.0000000000002627 .
Han, W. M. ; Jiamsakul, A. ; Salleh, N. A. M. ; Choi, J. Y. ; Huy, B. V. et al. (2021). HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asia-Pacific region: a longitudinal cohort study.
J Int AIDS Soc ,
24 (5), S. e25736.
http://doi.org/10.1002/jia2.25736 .
Tiendrebeogo, T. ; Messou, E. ; Arikawa, S. ; Ekouevi, D. K. ; Tanon, A. et al. (2021). Ten-year attrition and antiretroviral therapy response among HIV-positive adults: a sex-based cohort analysis from eight West African countries.
J Int AIDS Soc ,
24 (5), S. e25723.
http://doi.org/10.1002/jia2.25723 .
Fouda, G. G. A. ;
Kwiek, J. J. &
Yotebieng, M. (2021). Safety of Breastfeeding by Mothers With COVID-19: New Evidence From Israel.
Pediatrics ,
147 (5).
http://doi.org/10.1542/peds.2020-049772 .
Yohannes, N. T. ; Jenkins, C. A. ; Clouse, K. ; Cortes, C. P. ; Mejia Cordero, F. et al. (2021). Timing of HIV diagnosis relative to pregnancy and postpartum HIV care continuum outcomes among Latin American women, 2000 to 2017.
J Int AIDS Soc ,
24 (5), S. e25740.
http://doi.org/10.1002/jia2.25740 .
Ross, J. ; Murenzi, G. ; Hill, S. ; Remera, E. ; Ingabire, C. et al. (2021). Reducing time to differentiated service delivery for newly diagnosed people living with HIV in Kigali, Rwanda: study protocol for a pilot, unblinded, randomised controlled study.
BMJ Open ,
11 (4), S. e047443.
http://doi.org/10.1136/bmjopen-2020-047443 .
Olali, A. Z. ; Sharma, A. ; Shi, Q. ; Hoover, D. R. ; Weber, K. M. et al. (2021). Change in Circulating Undercarboxylated Osteocalcin (ucOCN) Is Associated With Fat Accumulation in HIV-Seropositive Women.
J Acquir Immune Defic Syndr ,
86 (5), S. e139–e145.
http://doi.org/10.1097/QAI.0000000000002617 .
Enane, L. A. ; Apondi, E. ; Omollo, M. ; Toromo, J. J. ; Bakari, S. et al. (2021). “I just keep quiet about it and act as if everything is alright” - The cascade from trauma to disengagement among adolescents living with HIV in western Kenya.
J Int AIDS Soc ,
24 (4), S. e25695.
http://doi.org/10.1002/jia2.25695 .
Peetluk, L. S. ; Ridolfi, F. M. ; Rebeiro, P. F. ; Liu, D. ; Rolla, V. C. et al. (2021). Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults.
BMJ Open ,
11 (3), S. e044687.
http://doi.org/10.1136/bmjopen-2020-044687 .
Boettiger, D. C. ; Newall, A. T. ; Phillips, A. ; Bendavid, E. ; Law, M. G. et al. (2021). Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States.
J Int AIDS Soc ,
24 (3), S. e25690.
http://doi.org/10.1002/jia2.25690 .
Murenzi, G. ; Tuyisenge, P. ; Kanyabwisha, F. ; Munyaneza, A. ; Muhoza, B. et al. (2021). Type-specific persistence, clearance and incidence of high-risk HPV among screen-positive Rwandan women living with HIV.
Infect Agent Cancer ,
16 (1), S. 16.
http://doi.org/10.1186/s13027-021-00355-6 .
Rodrigues, A. ; Struchiner, C. J. ; Coelho, L. E. ; Veloso, V. G. ; Grinsztejn, B. et al. (2021). Late initiation of antiretroviral therapy: inequalities by educational level despite universal access to care and treatment.
BMC Public Health ,
21 (1), S. 389.
http://doi.org/10.1186/s12889-021-10421-8 .
Adedimeji, A. ; Ajeh, R. ; Pierz, A. ; Nkeng, R. ; Ndenkeh, J. J. et al. (2021). Challenges and opportunities associated with cervical cancer screening programs in a low income, high HIV prevalence context.
BMC Womens Health ,
21 (1), S. 74.
http://doi.org/10.1186/s12905-021-01211-w .
Markmann, A. J. ; Giallourou, N. ; Bhowmik, D. R. ; Hou, Y. J. ; Lerner, A. et al. (2021). Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals.
MedRxiv .
http://doi.org/10.1101/2021.02.01.21250493 .
Collins, L. F. ; Colasanti, J. A. ; Nguyen, M. L. ; Moran, C. A. ; Lahiri, C. D. et al. (2021). The COVID-19 pandemic as a catalyst for differentiated care models to end the HIV epidemic in the United States: applying lessons from high-burden settings.
AIDS ,
35 (2), S. 337–341.
http://doi.org/10.1097/QAD.0000000000002746 .
Sun, J. ; Althoff, K. N. ; Jing, Y. ; Horberg, M. A. ; Buchacz, K. et al. (2021). Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015.
JAMA Netw Open ,
4 (2), S. e2037512.
http://doi.org/10.1001/jamanetworkopen.2020.37512 .
Ujeneza, E. L. ; Ndifon, W. ; Sawry, S. ; Fatti, G. ; Riou, J. et al. (2021). A mechanistic model for long-term immunological outcomes in South African HIV-infected children and adults receiving ART.
ELife ,
10 .
http://doi.org/10.7554/eLife.42390 .
Pereira, G. F. M. ; Kim, A. ; Jalil, E. M. ; Fernandes Fonseca, F. ; Shepherd, B. E. et al. (2021). Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
Lancet HIV ,
8 (1), S. e33–e41.
http://doi.org/10.1016/S2352-3018(20)30268-X .
Osman, M. ; Meehan, S. A. ; von Delft, A. ; Du Preez, K. ; Dunbar, R. et al. (2021). Early mortality in tuberculosis patients initially lost to follow up following diagnosis in provincial hospitals and primary health care facilities in Western Cape, South Africa.
PLoS One ,
16 (6), S. e0252084.
http://doi.org/10.1371/journal.pone.0252084 .
Hussey, H. ; Zinyakatira, N. ; Morden, E. ; Ismail, M. ; Paleker, M. et al. (2021). Higher COVID-19 mortality in low-income communities in the City of Cape Town - a descriptive ecological study.
Gates Open Res ,
5 , S. 90.
http://doi.org/10.12688/gatesopenres.13288.1 .
Kammers, K. ; Chen, A. ; Monaco, D. R. ; Hudelson, S. E. ; Grant-McAuley, W. et al. (2021). HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression.
Front Immunol ,
12 , S. 740395.
http://doi.org/10.3389/fimmu.2021.740395 .
Ross, J. ; Ingabire, C. ; Umwiza, F. ; Gasana, J. ; Munyaneza, A. et al. (2021). How early is too early? Challenges in ART initiation and engaging in HIV care under Treat All in Rwanda-A qualitative study.
PLoS One ,
16 (5), S. e0251645.
http://doi.org/10.1371/journal.pone.0251645 .
2020
Tchounga, Boris K.; Charpentier, Charlotte; Coffie, Patrick A.; Dabis, François; Descamps, Diane et al. (2020). Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d’Ivoire West Africa. PloS One , 15 (8), S. e0236642–e0236642. http://doi.org/10.1371/journal.pone.0236642 .
Safe, Izabella P.; Amaral, Eduardo P.; Araújo-Pereira, Mariana; Lacerda, Marcus V. G.; Printes, Vitoria S. et al. (2020). Adjunct N-Acetylcysteine Treatment in Hospitalized Patients With HIV-Associated Tuberculosis Dampens the Oxidative Stress in Peripheral Blood: Results From the RIPENACTB Study Trial. Frontiers in Immunology , 11 , S. 602589. http://doi.org/10.3389/fimmu.2020.602589 .
Raichur, Priyanka; Salvi, Sonali Pankaj; Sangle, Shashikala; Chavan, Amol; Nimkar, Smita et al. (2020). Trends and Sex Differences in Access to HIV Care with Scale Up of National HIV Treatment Guidelines in Pune, India. Journal of the International Association of Providers of AIDS Care , 19 . http://doi.org/10.1177/2325958220931735 .
Pillay, Tameryn; Cornell, Morna; Fox, Matthew P.; Euvrard, Jonathan; Fatti, Geoffrey et al. (2020). Recording of HIV viral loads and viral suppression in South African patients receiving antiretroviral treatment: a multicentre cohort study. Antiviral Therapy . doi:Publisher: International Medical Press.
Oh, Eric J.; Shepherd, Bryan E.; Lumley, Thomas & Shaw, Pamela A. (2020). Raking and regression calibration: Methods to address bias from correlated covariate and time-to-event error. Statistics in Medicine . http://doi.org/10.1002/sim.8793 .
Nimkar, Smita; Kinikar, Aarti; Chavan, Amol; Sangle, Shashikala; Rewari, Bharatbhushan et al. (2020). High prevalence of late presentation of ART-naïve perinatally infected children for care in Pune, India. AIDS Care – Psychological and Socio-Medical Aspects of AIDS/HIV . http://doi.org/10.1080/09540121.2020.1727407 .
Musayón-Oblitas, Flor Yesenia; Cárcamo, Cesar Paul; Gimbel, Sarah; Zarate, Juan Ignacio Echevarria & Espinoza, Ana Beatriz Graña (2020). Validation of a counseling guide for adherence to antiretroviral therapy using implementation science. Revista Latino-Americana de Enfermagem , 28 , S. e3228–e3228. http://doi.org/10.1590/1518-8345.3117.3228 .
Johnson, Leigh F.; Patrick, Mark; Stephen, Cindy; Patten, Gabriela; Dorrington, Rob E. et al. (2020). Steep Declines in Pediatric AIDS Mortality in South Africa, Despite Poor Progress Toward Pediatric Diagnosis and Treatment Targets. Pediatric Infectious Disease Journal , 39 (9), S. 843–848. http://doi.org/10.1097/inf.0000000000002680 .
Jacob, Nisha; Rice, Brian; Kalk, Emma; Heekes, Alexa; Morgan, Jennie et al. (2020). Consolidating strategic information to monitor progress against the UNAIDS 90-90-90 targets: evaluating the operational feasibility of an electronic HIV testing register in Cape Town, South Africa. BMC Health Services Research , 20 (1), S. 720–720. http://doi.org/10.1186/s12913-020-05517-7 .
Jacob, Nisha; Rice, Brian; Kalk, Emma; Heekes, Alexa; Morgan, Jennie et al. (2020). Utility of digitising point of care HIV test results to accurately measure, and improve performance towards, the UNAIDS 90-90-90 targets. PloS One , 15 (6), S. e0235471–e0235471. http://doi.org/10.1371/journal.pone.0235471 .
Giganti, Mark J.; Shaw, Pamela A.; Chen, Guanhua; Bebawy, Sally S.; Turner, Megan M. et al. (2020). Accounting for dependent errors in predictors and time-to-event outcomes using electronic health records, validation samples and multiple imputation. Annals of Applied Statistics , 14 (2), S. 1045–1061. http://doi.org/10.1214/20-AOAS1343 .
Edwards, Jessie K.; Lesko, Catherine R.; Herce, Michael E.; Murenzi, Gad; Twizere, Christella et al. (2020). Gone But Not Lost: Implications for Estimating HIV Care Outcomes When Loss to Clinic Is Not Loss to Care. Epidemiology , 31 (4), S. 570–577. http://doi.org/10.1097/EDE.0000000000001201 .
Chimbetete, Cleophas; Shamu, Tinei & Keiser, Olivia (2020). Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes. PloS One , 15 (3), S. e0228601. http://doi.org/10.1371/journal.pone.0228601 .
Castle, Philip E.; Ajeh, Rogers; Dzudie, Anastase; Kendowo, Ernestine; Fuhngwa, Norbert et al. (2020). A comparison of screening tests for detection of high-grade cervical abnormalities in women living with HIV from Cameroon. Infectious Agents and Cancer , 15 , S. 45. http://doi.org/10.1186/s13027-020-00311-w .
Boettiger, David C.; Escuder, Maria Mercedes; Law, Matthew G.; Veloso, Valdiléa; Souza, Rosa A. et al. (2020). Cardiovascular disease among people living with HIV in Brazil. Tropical Medicine and International Health . http://doi.org/10.1111/tmi.13405 .
Bijker, Rimke; Kiertiburanakul, Sasisopin; Kumarasamy, Nagalingeswaran; Pujari, Sanjay; Sun, Ly P. et al. (2020). Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART. Antiviral Therapy . http://doi.org/10.3851/imp3358 .
Belaunzaran-Zamudio, Pablo F.; Caro-Vega, Yanink; Giganti, Mark J.; Castilho, Jessica L.; Crabtree-Ramirez, Brenda E. et al. (2020). Frequency of non-communicable diseases in people 50 years of age and older receiving HIV care in Latin America. PloS One , 15 (6), S. e0233965–e0233965. http://doi.org/10.1371/journal.pone.0233965 .
Barreto-Duarte, Beatriz; Sterling, Timothy R.; Fiske, Christina T.; Almeida, Alexandre; Nochowicz, Cynthia H. et al. (2020). Increased Frequency of Memory CD4+ T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis. Frontiers in Immunology , 11 , S. 605338. http://doi.org/10.3389/fimmu.2020.605338 .
Tsondai, Priscilla R.; Braithwaite, Kate; Fatti, Geoffrey; Bolton Moore, Carolyn; Chimbetete, Cleophas et al. (2020). Characteristics and outcomes of adolescents living with perinatally acquired HIV within Southern Africa. AIDS (London, England) , 34 (15), S. 2275–2284. http://doi.org/10.1097/QAD.0000000000002683 .
Taghavi, Katayoun; Rohner, Eliane; Basu, Partha; Low, Nicola; Rutjes, Anne et al. (2020). Screening test accuracy of portable devices that can be used to perform colposcopy for detecting CIN2+ in low- and middle-income countries: a systematic review and meta-analysis. BMC Women’s Health , 20 (1). http://doi.org/10.1186/s12905-020-01121-3 .
Penn-Nicholson, Adam; Mbandi, Stanley Kimbung; Thompson, Ethan; Mendelsohn, Simon C.; Suliman, Sara et al. (2020). RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports , 10 (1). http://doi.org/10.1038/s41598-020-65043-8 .
Oliveira-de-Souza, Deivide; Vinhaes, Caian L.; Arriaga, María B.; Kumar, Nathella Pavan; Queiroz, Artur T. L. et al. (2020). Aging increases the systemic molecular degree of inflammatory perturbation in patients with tuberculosis. Scientific Reports , 10 (1). http://doi.org/10.1038/s41598-020-68255-0 .
Marbaniang, Ivan; Sangle, Shashikala; Nimkar, Smita; Zarekar, Kanta; Salvi, Sonali et al. (2020). The burden of anxiety among people living with HIV during the COVID-19 pandemic in Pune, India. BMC Public Health , 20 (1). http://doi.org/10.1186/s12889-020-09656-8 .
Kim, H. Nina (2020). Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy. Current Hepatology Reports , 19 (4), S. 345–353. http://doi.org/10.1007/s11901-020-00541-x .
Hauser, Anthony; Kusejko, Katharina; Johnson, Leigh F.; Günthard, Huldrych F.; Riou, Julien et al. (2020). Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. PLOS Medicine , 17 (12), S. e1003397–e1003397. http://doi.org/10.1371/journal.pmed.1003397 .
Haas, Andreas D.; Technau, Karl‐Günter; Pahad, Shenaaz; Braithwaite, Kate; Madzivhandila, Mampho et al. (2020). Mental health, substance use and viral suppression in adolescents receiving ART at a paediatric HIV clinic in South Africa. Journal of the International AIDS Society , 23 (12). http://doi.org/10.1002/jia2.25644 .
Bernard, Charlotte; Font, Hélène; Diallo, Zélica; Ahonon, Richard; Tine, Judicaël Malick et al. (2020). Prevalence and factors associated with severe depressive symptoms in older west African people living with HIV. BMC Psychiatry , 20 (1), S. 442–442. http://doi.org/10.1186/s12888-020-02837-0 .
Anderegg, Nanina; Hector, Jonas; Jefferys, Laura F.; Burgos-Soto, Juan; Hobbins, Michael A. et al. (2020). Loss to follow-up correction increased mortality estimates in HIV–positive people on antiretroviral therapy in Mozambique. Journal of Clinical Epidemiology , 128 , S. 83–92. http://doi.org/10.1016/j.jclinepi.2020.08.012 .
Taghavi, Katayoun; Moono, Misinzo; Mwanahamuntu, Mulindi; Basu, Partha; Limacher, Andreas et al. (2020). Screening test accuracy to improve detection of precancerous lesions of the cervix in women living with HIV: a study protocol. BMJ Open , 10 (12), S. e037955. http://doi.org/10.1136/bmjopen-2020-037955 .
Petoumenos, Kathy; Kuwanda, Locadiah; Ryom, Lene; Mocroft, Amanda; Reiss, Peter et al. (2020). Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D: A: D study. Journal of Acquired Immune Deficiency Syndromes (1999) , Publish Ahead of Print . http://doi.org/10.1097/QAI.0000000000002603 .
Desmonde, Sophie; Ciaranello, Andrea L.; Malateste, Karen; Musick, Beverly; Patten, Gabriela et al. (2020). Age-specific mortality rate ratios in adolescents and youth aged 10–24 years living with perinatally versus non-perinatally-acquired HIV. AIDS , Publish Ahead of Print . http://doi.org/10.1097/QAD.0000000000002765 .
Han, Win Min; Bijker, Rimke; Chandrasekaran, Ezhilarasi; Pujari, Sanjay; Ng, Oon Tek et al. (2020). Validation of the D: A: D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacific. Journal of Acquired Immune Deficiency Syndromes (1999) , 85 (4), S. 489–497. http://doi.org/10.1097/QAI.0000000000002464 .
Giganti, Mark J. & Shepherd, Bryan E. (2020). Multiple-Imputation Variance Estimation in Studies With Missing or Misclassified Inclusion Criteria. American Journal of Epidemiology , 189 (12), S. 1628–1632. http://doi.org/10.1093/aje/kwaa153 .
Tao, Ran; Lotspeich, Sarah C.; Amorim, Gustavo; Shaw, Pamela A. & Shepherd, Bryan E. (2020). Efficient semiparametric inference for two-phase studies with outcome and covariate measurement errors. Statistics in Medicine , S. sim.8799-sim.8799. http://doi.org/10.1002/sim.8799 .
Ross, J.; Jiamsakul, A.; Kumarasamy, N.; Azwa, I.; Merati, T. P. et al. (2020). Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific. HIV Medicine , S. hiv.13006-hiv.13006. http://doi.org/10.1111/hiv.13006 .
Mpofu, Philani B.; Bakoyannis, Giorgos; Yiannoutsos, Constantin T.; Mwangi, Ann W. & Mburu, Margaret (2020). A pseudo‐likelihood method for estimating misclassification probabilities in competing‐risks settings when true‐event data are partially observed. Biometrical Journal , 62 (7), S. 1747–1768. http://doi.org/10.1002/bimj.201900198 .
Han, W. M.; Jiamsakul, A.; Jantarapakde, J.; Yunihastuti, E.; Choi, J. Y. et al. (2020). Association of body mass index with immune recovery, virological failure and cardiovascular disease risk among people living with HIV. HIV Medicine . http://doi.org/10.1111/hiv.13017 .
Reichmuth, Martina L.; Hömke, Rico; Zürcher, Kathrin; Sander, Peter; Avihingsanon, Anchalee et al. (2020). Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients. Antimicrobial Agents and Chemotherapy , 64 (11). http://doi.org/10.1128/AAC.00513-20 .
Rebeiro, Peter F.; Duda, Stephany N.; Wools-Kaloustian, Kara K.; Nash, Denis & Althoff, Keri N. (2020). Implications of COVID-19 for HIV Research: data sources, indicators and longitudinal analyses. Journal of the International AIDS Society , 23 (10), S. e25627–e25627. http://doi.org/10.1002/jia2.25627 .
Patsis, Ioannis; Goodrich, Suzanne; Yiannoutsos, Constantin T.; Brown, Steven A.; Musick, Beverly S. et al. (2020). Lower rates of ART initiation and decreased retention among ART-naïve patients who consume alcohol enrolling in HIV care and treatment programs in Kenya and Uganda. PLoS ONE , 15 (10 October 2020). http://doi.org/10.1371/journal.pone.0240654 .
Haas, Andreas D.; Ruffieux, Yann; van den Heuvel, Leigh Luella; Lund, Crick; Boulle, Andrew et al. (2020). Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records. The Lancet Global Health , 8 (10), S. e1326–e1334. http://doi.org/10.1016/S2214-109X(20)30279-5 .
Desmonde, Sophie; Neilan, Anne M.; Musick, Beverly; Patten, Gabriela; Chokephaibulkit, Kulkanya et al. (2020). Time-varying age- and CD4-stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric IeDEA Gl. Journal of the International AIDS Society , 23 (10), S. e25617–e25617. http://doi.org/10.1002/jia2.25617 .
Arikawa, Shino; Dumazert, Patricia; Messou, Eugène; Burgos-Soto, Juan; Tiendrebeogo, Thierry et al. (2020). Childbearing desire and reproductive behaviors among women living with HIV: A cross-sectional study in Abidjan, Côte d’Ivoire. PLoS ONE , 15 (10 October). http://doi.org/10.1371/journal.pone.0239859 .
Demitto, Fernanda O.; Araújo-Pereira, Mariana; Schmaltz, Carolina A.; Sant’Anna, Flávia M.; Arriaga, María B. et al. (2020). Impact of Persistent Anemia on Systemic Inflammation and Tuberculosis Outcomes in Persons Living With HIV. Frontiers in Immunology , 11 . http://doi.org/10.3389/fimmu.2020.588405 .
Bakoyannis, Giorgos; Diero, Lameck; Mwangi, Ann; Wools-Kaloustian, Kara K. & Yiannoutsos, Constantin T. (2020). A semiparametric method for the analysis of outcomes during a gap in HIV care under incomplete outcome ascertainment. Statistical Communications in Infectious Diseases , 12 (Suppl 1), S. 20190013. http://doi.org/10.1515/scid-2019-0013 .
Zürcher, Kathrin; Morrow, Carl; Riou, Julien; Ballif, Marie; Koch, Anastasia Sideris et al. (2020). Novel approach to estimate tuberculosis transmission in primary care clinics in sub-Saharan Africa: protocol of a prospective study. BMJ Open , 10 (8), S. e036214–e036214. http://doi.org/10.1136/bmjopen-2019-036214 .
Yunihastuti, Evy; Teeratakulpisarn, Nipat; Jeo, Wifanto Saditya; Nilasari, Hanny; Rachmadi, Lisnawati et al. (2020). Incidence, clearance, persistence and factors related with high-risk anal HPV persistence in South-East Asian MSM and transgender women. AIDS (London, England) . http://doi.org/10.1097/QAD.0000000000002654 .
Sohn, Annette H.; Lumbiganon, Pagakrong; Kurniati, Nia; Lapphra, Keswadee; Law, Matthew et al. (2020). Determining standardized causes of death of infants, children, and adolescents living with HIV in Asia. AIDS (London, England) , 34 (10), S. 1527–1537. http://doi.org/10.1097/QAD.0000000000002583 .
Seth, Divya; Williams, Victoria L.; McMahon, Devon E.; Regan, Susan; Busakhala, Naftali et al. (2020). The role of dermatology in Kaposi sarcoma diagnosis across three regions in sub-Saharan Africa. Journal of the American Academy of Dermatology . http://doi.org/10.1016/j.jaad.2020.07.114 .
Parcesepe, Angela M.; Lancaster, Kathryn; Edelman, E. Jennifer; DeBoni, Raquel; Ross, Jeremy et al. (2020). Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017. PLoS ONE , 15 (8 August), S. e0237772–e0237772. http://doi.org/10.1371/journal.pone.0237772 .
Marbaniang, Ivan; Sangle, Shashikala; Nimkar, Smita; Zarekar, Kanta; Salvi, Sonali et al. (2020). The Burden of Anxiety During the COVID-19 Pandemic Among People Living with HIV (PLHIV) in Pune, India. Research Square . http://doi.org/10.21203/rs.3.rs-45412/v1 .
Boulle, Andrew; Davies, Mary-Ann; Hussey, Hannah; Ismail, Muzzammil; Morden, Erna et al. (2020). Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clinical Infectious Diseases . http://doi.org/10.1093/cid/ciaa1198 .
Zaniewski, Elizabeth; Dao Ostinelli, Cam H.; Chammartin, Frédérique; Maxwell, Nicola; Davies, Mary-Ann et al. (2020). Trends in CD4 and viral load testing 2005 to 2018: multi-cohort study of people living with HIV in Southern Africa. Journal of the International AIDS Society , 23 (7), S. e25546–e25546. http://doi.org/10.1002/jia2.25546 .
Tchounga, Boris; Horo, Apollinaire; Boni, Simon; Tanon, Aristophane; Folquet, Madeleine Amorissani et al. (2020). Human papilloma viruses infection among adolescent females perinatally infected with HIV in Côte d’Ivoire. Sexually Transmitted Infections , S. sextrans-2019-054420. http://doi.org/10.1136/sextrans-2019-054420 .
Sudjaritruk, Tavitiya; Teeraananchai, Sirinya; Kariminia, Azar; Lapphra, Keswadee; Kumarasamy, Nagalingeswaran et al. (2020). Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study. Journal of the International AIDS Society , 23 (7). http://doi.org/10.1002/jia2.25550 .
Patten, Gabriela; Puthanakit, Thanyawee; McGowan, Catherine C.; Wools-Kaloustian, Kara; Hazra, Rohan et al. (2020). Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium. Journal of the International AIDS Society , 23 (7). http://doi.org/10.1002/jia2.25580 .
Chan, Andrew T.; Drew, David A.; Nguyen, Long H.; Joshi, Amit D.; Ma, Wenjie et al. (2020). The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action. Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology , 29 (7), S. 1283–1289. http://doi.org/10.1158/1055-9965.EPI-20-0606 .
Adedimeji, Adebola; Ajeh, Rogers; Dzudie, Anastase; Kendowo, Ernestine; Fuhngwa, Norbert et al. (2020). Cervical human papillomavirus DNA detection in women living with HIV and HIV-uninfected women living in Limbe, Cameroon. Journal of Clinical Virology , 128 . http://doi.org/10.1016/j.jcv.2020.104445 .
Loiseau, Chloé; Brites, Daniela; Reinhard, Miriam; Zürcher, Kathrin; Borrell, Sonia et al. (2020). HIV coinfection is associated with low fitness rpoB variants in rifampicin-resistant Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy . http://doi.org/10.1128/AAC.00782-20 .
Duda, Stephany N.; Musick, Beverly S.; Davies, Mary-Ann; Sohn, Annette H.; Ledergerber, Bruno et al. (2020). The IeDEA Data Exchange Standard: a common data model for global HIV cohort collaboration (preprint). Health Informatics. https://doi.org/10.1101/2020.07.22.20159921
Tchakounte Youngui, Boris; Coffie, Patrick; Messou, Eugène; Poda, Armel; Fortes Deguenonvo, Louise et al. (2020). Incidence of Tuberculosis During the First Year of Antiretroviral Treatment in West African HIV-Infected Adults. Open Forum Infectious Diseases , 7 (6). http://doi.org/10.1093/ofid/ofaa203 .
Ross, Jonathan; Ribakare, Muhayimpundu; Remera, Eric; Murenzi, Gad; Munyaneza, Athanase et al. (2020). High levels of viral load monitoring and viral suppression under Treat All in Rwanda – a cross‐sectional study. Journal of the International AIDS Society , 23 (6). http://doi.org/10.1002/jia2.25543 .
Rebeiro, Peter F.; Cohen, Mollie J.; Ewing, Heather M.; Figueiredo, Marina Cruvinel; Peetluk, Lauren Saag et al. (2020). Knowledge and stigma of latent tuberculosis infection in Brazil: implications for tuberculosis prevention strategies. BMC Public Health , 20 (1), S. 897–897. http://doi.org/10.1186/s12889-020-09053-1 .
Osler, Meg; Cornell, Morna; Ford, Nathan; Hilderbrand, Katherine; Goemaere, Eric et al. (2020). Population-wide differentials in HIV service access and outcomes in the Western Cape for men as compared to women, South Africa: 2008 to 2018: a cohort analysis. Journal of the International AIDS Society , 23 Suppl 2 (S2), S. e25530–e25530. http://doi.org/10.1002/jia2.25530 .
Makusha, Tawanda; van Rooyen, Heidi & Cornell, Morna (2020). Reframing the approach to heterosexual men in the HIV epidemic in sub-Saharan Africa. Journal of the International AIDS Society , 23 Suppl 2 (S2), S. e25510–e25510. http://doi.org/10.1002/jia2.25510 .
Johnson, Leigh F.; Mutemaringa, Themba; Mutemaringa, Themba; Heekes, Alexa; Heekes, Alexa et al. (2020). Effect of HIV Infection and Antiretroviral Treatment on Pregnancy Rates in the Western Cape Province of South Africa. Journal of Infectious Diseases , 221 (12), S. 1953–1962. http://doi.org/10.1093/infdis/jiz362 .
Dovel, Kathryn; Dworkin, Shari L.; Cornell, Morna; Coates, Thomas J. & Yeatman, Sara (2020). Gendered health institutions: examining the organization of health services and men’s use of HIV testing in Malawi. Journal of the International AIDS Society , 23 (S2). http://doi.org/10.1002/jia2.25517 .
Boettiger, David C.; Newall, Anthony T.; Chattranukulchai, Pairoj; Chaiwarith, Romanee; Khusuwan, Suwimon et al. (2020). Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. Journal of the International AIDS Society , 23 Suppl 1 (S1), S. e25494–e25494. http://doi.org/10.1002/jia2.25494 .
Bartlett, Adam W.; Sudjaritruk, Tavitiya; Mohamed, Thahira J.; Anugulruengkitt, Suvaporn; Kumarasamy, Nagalingeswaran et al. (2020). Identification, management and outcomes of combination antiretroviral treatment failure in adolescents with perinatal HIV infection in Asia. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America . http://doi.org/10.1093/cid/ciaa872 .
Nyakato, Patience; Davies, Mary Ann; Technau, Karl Gunter; Fatti, Geoffrey; Rabie, Helena et al. (2020). Virologic response to efavirenz-based firstline antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. PLoS ONE , 15 (5). http://doi.org/10.1371/journal.pone.0233693 .
Kehoe, Kathleen; Boulle, Andrew; Tsondai, Priscilla R.; Euvrard, Jonathan; Davies, Mary Ann et al. (2020). Long‐term virologic responses to antiretroviral therapy among HIV‐positive patients entering adherence clubs in Khayelitsha, Cape Town, South Africa: a longitudinal analysis. Journal of the International AIDS Society , 23 (5). http://doi.org/10.1002/jia2.25476 .
Jesson, Julie; Desmonde, Sophie; Yiannoutsos, Constantin T.; Patten, Gabriela; Malateste, Karen et al. (2020). Weight-for-age distributions among children with HIV on antiretroviral therapy in the International epidemiology Databases to Evaluate AIDS (IeDEA) multiregional consortium. BMC Research Notes , 13 (1), S. 249–249. http://doi.org/10.1186/s13104-020-05081-7 .
Harezlak, Jaroslaw; Sarwat, Samiha; Wools-Kaloustian, Kara; Schomaker, Michael; Balestre, Eric et al. (2020). PS-SiZer map to investigate significant features of body-weight profile changes in HIV infected patients in the IeDEA Collaboration. PLoS ONE , 15 (5). http://doi.org/10.1371/journal.pone.0220165 .
Chammartin, Frédérique; Dao Ostinelli, Cam Ha; Anastos, Kathryn; Jaquet, Antoine; Brazier, Ellen et al. (2020). International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019. BMJ Open , 10 (5). http://doi.org/10.1136/bmjopen-2019-035246 .
Calkins, Keri L.; Chander, Geetanjali; Joshu, Corinne E.; Visvanathan, Kala; Fojo, Anthony T. et al. (2020). A comparison of cancer stage at diagnosis and treatment initiation between enrollees in an urban HIV clinic and SEER. Cancer Causes and Control , 31 (5), S. 511–516. http://doi.org/10.1007/s10552-020-01289-x .
Bell Gorrod, Helen; Court, Richard; Schomaker, Michael; Maartens, Gary & Murphy, Richard A. (2020). Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999) , 84 (1), S. 107–113. http://doi.org/10.1097/QAI.0000000000002313 .
Yumo, Habakkuk A.; Ajeh, Rogers A.; Sieleunou, Isidore; Ndenkeh, Jackson N.; Jordan, Michael R. et al. (2020). Parental and child-level predictors of HIV testing uptake, seropositivity and treatment initiation among children and adolescents in Cameroon. PLoS ONE , 15 (4). http://doi.org/10.1371/journal.pone.0230988 .
Teeraananchai, Sirinya; Kerr, Stephen J.; Gandhi, Monica; Do, Viet Chau; Van Nguyen, Lam et al. (2020). Determinants of Viral Resuppression or Persistent Virologic Failure After Initial Failure With Second-Line Antiretroviral Treatment Among Asian Children and Adolescents With HIV. Journal of the Pediatric Infectious Diseases Society , 9 (2), S. 253–256. http://doi.org/10.1093/jpids/piz034 .
Patel, Kunjal; Smith, Colette; Collins, Intira Jeannie; Goodall, Ruth; Abrams, Elaine J. et al. (2020). Outcomes of second-line antiretroviral therapy among children living with HIV: a global cohort analysis. Journal of the International AIDS Society , 23 (4). http://doi.org/10.1002/jia2.25477 .
Lotspeich, Sarah C.; Giganti, Mark J.; Maia, Marcelle; Vieira, Renalice; Machado, Daisy Maria et al. (2020). Self-audits as alternatives to travel-audits for improving data quality in the Caribbean, Central and South America network for HIV epidemiology. Journal of Clinical and Translational Science , 4 (2), S. 125–132. http://doi.org/10.1017/cts.2019.442 .
Bourgi, Kassem; Jenkins, Cathy A.; Rebeiro, Peter F.; Palella, Frank; Moore, Richard D. et al. (2020). Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. Journal of the International AIDS Society , 23 (4).